# Hospital Outpatient Quality Reporting Specifications Manual Release Notes Version: 13.0a

Release Notes Completed: December 2, 2019

# **Guidelines for Using Release Notes**

Release Notes provide modifications to the Hospital Outpatient Quality Reporting (OQR) Specifications Manual. They are provided as a reference tool and are not intended to be used to program abstraction tools. Please refer to the Hospital OQR Specifications Manual for the complete and current technical specifications and abstraction information.

The notes are organized to follow the order of the Table of Contents. Within each topic section, a row represents a change that begins with general changes and is followed by data elements in alphabetical order. The **implementation date is 01/01/2020** unless otherwise specified. The row headings are described below:

- Impacts—used to identify which portion(s) of the Manual Section is impacted by the changes listed. Examples are Alphabetical Data Element List, Alphabetical Data Dictionary, Measure Information Form (MIF), and Flowchart (Algorithm). If any changes are made to a data element, the measure(s) affected are identified also.
- Rationale—provided for the change being made.
- **Description of Changes** used to identify the section within the document where the change occurs (e.g., Definition, Data Collection Question, Allowable Value, and Denominator Data elements).

Data elements that cross multiple measures and contain the same changes will be consolidated into one row. If those changes do not apply to all of the measures listed in the Impacts row, the Description of Changes row will identify what measures are applicable.

Release Notes version 13.0a—The notes in the tables below are organized to follow the Table of Contents in the Specifications Manual. The implementation date is 01/01/2020 unless otherwise specified.

# Section 1.7: Measures Submitted via a Web-Based Tool

**Impacts: OP-33** 

**Rationale:** In the CY2020 OPPS/ASC Final Rule OP-33 was finalized for removal from the Outpatient Quality Reporting Program beginning with calendar year 2022 payment determination and subsequent years.

# **Description of Change(s):**

**Remove** OP-33: External Beam Radiotherapy for Bone Metastases.

# **Section 2: Data Dictionary**

**Impacts:** Initial ECG Interpretation

**Rationale:** This update adds "likely" as an acceptable qualifier term to disregard an inclusion term when present (neither Inclusion nor Exclusion). The qualifier terms for disregarding the findings are not all-inclusive to allow abstractors to use synonymous terms.

# **Description of Change(s):**

# **Initial ECG Interpretation**

**Add** "likely" as an acceptable qualifier term to disregard an inclusion term when present. **Add** that this list is not all-inclusive.

Impacts: Date Last Known Well

**Rationale:** Two additional signs and symptoms of stroke were added to the *Date Last Known Well* data element Inclusion Guidelines for Abstraction following expert input.

# **Description of Change(s):**

# Date Last Known Well

**Add** syncope and seizure to the Inclusion Guidelines for Abstraction.

# **Appendices**

# Appendix A: ICD-10-CM Diagnosis and CPT® Code Tables

**Impacts:** ICD-10-CM Diagnosis and CPT® Code Tables

Rationale: Include the most up to date codes to the OQR Specifications Manual

#### **Description of Change(s):**

Include the current codes for effective dates January 1, 2020 through September 30, 2020 to the Specifications Manual.

# Hospital Outpatient Quality Reporting Specifications Manual Release Notes Version: 13.0

Release Notes Completed: June 1, 2019

# **Guidelines for Using Release Notes**

Release Notes provide modifications to the Hospital Outpatient Quality Reporting (OQR) Specifications Manual. They are provided as a reference tool and are not intended to be used as program abstraction tools. Please refer to the Hospital OQR Specifications Manual for the complete and current technical specifications and abstraction information.

The notes are organized to follow the order of the Table of Contents. Within each topic section, a row represents a change that begins with general changes and is followed by data elements in alphabetical order. The **implementation date is 01/01/2020** unless otherwise specified. The row headings are described below:

- Impacts used to identify which portion(s) of the Manual Section is impacted by the changes listed. Examples are Alphabetical Data Element List, Alphabetical Data Dictionary, Measure Information Form (MIF), and Flowchart (Algorithm). If any changes are made to a data element, the measure(s) affected are identified also.
- **Rationale** provided for the change being made.
- **Description of Changes** used to identify the section within the document where the change occurs (e.g., Definition, Data Collection Question, Allowable Value, and Denominator Data elements).

Data elements that cross multiple measures and contain the same changes will be consolidated into one row. If those changes do not apply to all of the measures listed in the Impacts row, the Description of Changes row will identify what measures are applicable.

Release Notes version 13.0 – The notes in the tables below are organized to follow the Table of Contents in the Specifications Manual. The **implementation date is 01/01/2020** unless otherwise specified.

# **Table of Contents**

**Impacts:** Table of Contents

**Rationale:** As a result of the 2019 OPPS/ASC Final Rule, OP-5 has been removed beginning with CY 2021 payment determination. Removal of this measure, which is also the Chest Pain Measure Set, also impacts section numbering to the Specifications Manual.

# **Description of Change(s):**

Table of Contents

**Remove:** 

All references to OP-5

**Remove:** 

Section 1.2 Chest Pain (CP)

Change:

Section numbering to reflect removal of Chest Pain Measure Set

# **Outpatient Delivery Settings**

Impacts: AMI and Chest Pain Measure Sets

**Rationale:** As a result of the 2019 OPPS/ASC Final Rule, OP-5 has been removed beginning with CY 2021 payment determination.

# **Description of Change(s):**

**Outpatient Delivery Settings** 

**Remove:** 

OP-5 from the AMI Measure Set

Remove:

Chest Pain (CP) Measure Set

#### **Section 1.1: Acute Myocardial Infarction (AMI)**

**Impacts:** OP-5 Median Time to ECG

**Rationale:** In the 2019 OPPS/ASC Final Rule it was finalized to remove OP-5 from the OQR program beginning with CY 2021 payment determination and subsequent years.

#### **Description of Change(s):**

Measure Short Name

Remove: OP-5 Median Time to ECG

Measure Information Form

**Remove:** OP-5 Median Time to ECG

Hospital OOR Specifications Manual

Encounter dates 01-01-20 (1Q20) through 12-31-20 (4Q20) v13.0a

CPT® only copyright 2019 American Medical Association. All rights reserved.

# **Section 2: Data Dictionary**

Impacts: OP-5 Median Time to ECG

**Rationale:** In the 2019 OPPS/ASC Final Rule it was finalized to remove OP-5 from the OQR program beginning with CY 2021 payment determination and subsequent years. There are five data elements collected for OP-5 exclusively that are to be removed.

# **Description of Change(s):**

Alphabetical Data Element List

Remove: ECG, ECG Date, ECG Time, Probable Cardiac Chest Pain, and ICD-10-CM Other Diagnosis

Codes from list.

Remove: All references to OP-5

# **Section 4: Population and Sampling Specifications**

**Impacts:** OP-5 Median Time to ECG

Rationale:

**Description of Change(s):** 

Table 1: HOP Measure Sets and Measure Populations

Remove: OP-5 and Chest Pain

Sample Size Examples

Remove: OP-5 and Chest Pain

# Hospital Outpatient Quality Reporting Specifications Manual

# Version 13.0a

Encounter Dates: 01-01-20 (1Q20) through 12-31-20 (4Q20)

OMB# 0938-1109 Expiration Date 01/31/2022

# **Table of Contents**

Acknowledgement	iii
Program Background	iv
Using the Manual	vi
Outpatient Delivery Settingsvi	iii
Section 1: Measure Information Forms	
MIF Format Overview1-	-1
<b>Note:</b> Each measure set section below includes the measure-specific Measure Information Forms (MIFs) and Algorithms	
Section 1.1: Acute Myocardial Infarction (AMI) – OP-2 and OP-3	
General Data Element List	-7 -8 10
Section 1.2: ED-Throughput – OP-18 and OP-22	
General Data Element List	23
Specific Data Element List	
OP-18: Median Time from ED Arrival to ED Departure for Discharged ED Patients	
Section 1.3: Stroke – OP-23	
General Data Element List	34
Specific Data Element List	
Population Algorithm	
Section 1.4: Imaging Efficiency – OP-8, OP-10, OP-13	
OP-8: MRI Lumbar Spine for Low Back Pain	17
Section 1.5: Measures Submitted via a Web-Based Tool – OP-29 and OP-31	
OP-29: Appropriate Follow-up Interval for Normal Colonoscopy in Average Risk Patients1-4 OP-31: Cataracts – Improvement in Patient's Visual Function within 90 Days Following Cataract	
Surgery 1-5	١ (

Section 1.6: Outcome Claims-Based Measures	
OP-32: Facility 7-Day Risk-Standardized Hospital Visit Rate after Outpatient Colonoscopy	1-53
OP-35: Admissions and Emergency Department (ED) Visits for Patients Receiving Outpatient	1.50
Chemotherapy	
OP-36: Hospital Visits after Hospital Outpatient Surgery	1-63
Section 2: Data Dictionary	
Introduction	
Interpretation of Data Dictionary Terms	
Data Dictionary Terms	2-70
General Abstraction Guidelines	
Alphabetical Data Element List	
Alphabetical Data Dictionary	2-76
Section 3: Missing and Invalid Data	
Introduction	3-130
Data Collection and the Unable to be Determined (UTD) Allowable Value	3-130
Missing and Invalid Data	3-131
Abstraction Software Skip Logic and Missing Data	3-131
Section 4: Population and Sampling Specifications	
Introduction	4-132
Order of Data Flow	4-133
Sample Size Requirements	4-135
Sampling Approaches	4-138
Transmission of Outpatient Population and Sample Data Elements	4-140
Section 5: Hospital Outpatient Quality Measure Data Transmission	
Introduction	5-142
Guidelines for Submission of Data	5-142
Transmission Data Element List	5-150
Transmission Data Element Pages	5-151
Transmission Data Processing Flow	5-159
Section 6: Tools and Resources	6-165
Appendices	
Appendix A: ICD-10-CM Diagnosis and CPT® Code Tables	A-i
Table 1.0: E/M Codes for Emergency Department Encounters	
Table 1.1: Acute Myocardial Infarction (AMI) Diagnosis Codes	
Table 7.01: Mental Disorders	
Table 8.0: Ischemic and Hemorrhagic Stroke	
Appendix B: Glossary of Terms	
Appendix C: Medication Tables	

# Acknowledgement

The *Hospital Outpatient Quality Reporting (OQR) Specifications Manual* was developed by the Centers for Medicare & Medicaid Services (CMS) to provide a uniform set of quality measures to be implemented in hospital outpatient settings. The primary purpose of these measures is to promote high quality care for patients receiving services in hospital outpatient settings.

No royalty or use fee is required for copying or reprinting this manual, but the following are required as a condition of usage: 1) disclosure that the *Hospital OQR Specifications Manual* is periodically updated and that the version being copied or reprinted may not be up-to-date when used unless the copier or printer has verified the version to be up-to-date and affirms that, and 2) users participating in the Hospital Outpatient Quality Reporting Program (Hospital OQR Program) are required to update their software and associated documentation based on the published manual production timelines.

Example Acknowledgement: The *Hospital OQR Specifications Manual* [Version xx, Month, Year] is periodically updated by the Centers for Medicare & Medicaid Services. Users of the *Hospital OQR Specifications Manual* must update their software and associated documentation based on the published manual production timelines.

*CPT*<sup>®</sup> only copyright 2019 American Medical Association. All rights reserved. *CPT*<sup>®</sup> is a registered trademark of the American Medical Association.

Applicable FARS\DFARS Restrictions Apply to Government Use.

Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT®, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.

The International Classification of Diseases, 11<sup>th</sup> Revision, Clinical Modification (ICD-10-CM) is published by the United States Government. A CD-ROM, which may be purchased through the Government Printing Office, is the only official Federal government version of the ICD-10-CM. ICD-10-CM is an official Health Insurance Portability and Accountability Act standard.

#### **IMPORTANT SUBMISSION ALERT!!**

At this time, for submission of the Hospital Outpatient measures to CMS under the Hospital Outpatient Quality Reporting Program (Hospital OQR Program), files must meet the specifications in this CMS manual only. Otherwise, the files will be rejected as not meeting CMS quality data submission requirements for receiving the full payment update.

Providers who are planning to also submit data for the Hospital Outpatient measures to The Joint Commission must refer to the transmission section separately issued by The Joint Commission. This is important because, at this time, CMS can only accept files which meet the CMS transmission manual specifications, and such files cannot contain the additional Joint Commission transmission data elements (e.g., vendor tracking ID, measure category assignment, measurement value).

# **Program Background**

#### **CMS Quality Initiatives**

# Background

In November 2001, Health & Human Services' (HHS) Secretary Tommy G. Thompson announced The Quality Initiative, his commitment to assure quality healthcare for all Americans through published consumer information coupled with healthcare quality improvement support through Medicare's Quality Improvement Organizations (QIOs). The Quality Initiative was launched nationally in 2002 as the Nursing Home Quality Initiative (NHQI) and expanded in 2003 with the Home Health Quality Initiative (HHQI) and the Hospital Quality Initiative (HQI). These initiatives are part of a comprehensive look at quality of care that includes hospitals, nursing homes, home health agencies, and physician offices. These efforts have continued to expand under subsequent Secretaries through support and expansion of activities to support healthcare transparency and value-driven healthcare.

The Medicare Improvements and Extension Act under Division B of title I of the Tax Relief and Health Care Act (MIEA-TRHCA) of 2006 (Pub. L. 109-432), enacted on December 20, 2006, made changes in the Outpatient Prospective Payment System (OPPS). The Centers for Medicare & Medicaid Services (CMS) is now statutorily required to have a program under which hospitals will report data on the quality of hospital outpatient care using standardized measures to receive the full annual update to the OPPS payment rate, effective for payment beginning in calendar year (CY) 2009. The OPPS Final Rule (42 CFR Parts 410, 411, 412, 413, 416, 419, and 489) is accessible at <a href="http://www.ecfr.gov">http://www.ecfr.gov</a>. The program established under the OPPS Final Rule and supported by this manual is the Hospital Outpatient Quality Reporting Program (Hoppital OQR Program) formally known as the Hospital Outpatient Quality Data Reporting Program (HOP QDRP). The measures described in this manual will expand as additional priority areas for quality improvement in hospital outpatient settings are identified and will be designed to evaluate the diversity of services and clinical topics provided to adult patients in hospital outpatient settings.

# **Objective**

The Hospital OQR Program uses a variety of tools to stimulate and support a significant improvement in the quality of hospital outpatient care. This initiative aims to refine and standardize hospital outpatient data collection, data transmission, and performance measures in order to construct one robust, prioritized, and standard quality outpatient measure set for hospitals. The goal is for all private and public purchasers, oversight and accrediting entities, and payers and providers of hospital outpatient care to use these same measures in their national public reporting activities. Quality improvement support, collaborations, standardization, and assuring compliance with Medicare Conditions of Participation (CoPs) are important additional tools in achieving this objective.

#### **Related National Activities**

#### National Quality Forum

The NQF has approved a set of national voluntary consensus standards for measuring the quality of hospital care. These measures will permit consumers, providers, purchasers, and quality improvement professionals to evaluate and compare the quality of care in a variety of healthcare settings across the nation by using a standard set of measures. Measures that are endorsed by NQF are denoted as such on the measure information forms.

# Hospital Inpatient Quality Reporting (IQR) Program

The Hospital IQR Program is intended to equip consumers with quality of care information to make more informed decisions about healthcare options. It is also intended to encourage hospitals and clinicians to improve the quality of inpatient care provided to all patients. The hospital quality of care information gathered through the program is available to consumers on the Hospital Compare website.

The Hospital IQR Program requires submission of data for specific quality measures for health conditions common among people with Medicare, which typically results in hospitalization.

# Measures Management System

The Measures Management System (MMS) is a set of processes and decision criteria used by CMS to oversee the development, implementation, and maintenance of healthcare quality measures. CMS recognizes the need for quality measures of the highest caliber, maintained throughout their life cycle to ensure they retain the highest level of scientific soundness, importance, feasibility, and usability. Through the use of a standardized process with broadly recognized criteria, the MMS ensures that CMS will have a coherent, transparent system for measuring the quality of care delivered to its beneficiaries.

# Paperwork Reduction Act (PRA)

PRA Disclosure Statement

According to the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. The valid OMB control number for this information collection is **0938-1109**. The time required to complete this information collection is estimated to average 15 minutes per response, including the time to review instructions, search existing data resources, gather the data needed, and complete and review the information collection. If you have comments concerning the accuracy of the time estimate(s) or suggestions for improving this form, please write to CMS, 7500 Security Boulevard, Attn: PRA Reports Clearance Officer, Mail Stop C4-26-05, Baltimore, MD 21244-1650.

Expiration Date: 01-31-2022

# Using the Manual

This portion of the manual provides a brief overview of the information contained within each section. It is intended as a quick reference to assist in the implementation of the Hospital Outpatient measures. The sections of this manual are interrelated and are most useful when considered together.

#### Section 1 – Measurement Information

This section contains a Measure Information Form (MIF) for each Hospital Outpatient measure. MIFs describe the purpose, use, and clinical rationale for specific measures. They also identify population assessed by the measure and how improvement in a measure would be demonstrated.

Detailed analytical algorithms are included with each MIF. The algorithms are used to calculate performance measurement rates for each of the measures. Each algorithm contains detailed steps regarding information used in the rate calculation. They specify when and how exclusion and inclusion criteria are applied for the specified measure.

# Section 2 – Data Dictionary

This section describes the patient-level data elements required to capture and calculate individual measurements; it specifies those data elements that must be collected for each patient that falls into any of the selected populations and those data elements needed for a specific measure.

# Section 3 – Missing and Invalid Data

This section addresses how to approach missing and invalid data. Missing data refer to data elements, required for calculating a Hospital Outpatient measure, that have no values present for one or more encounters. Invalid data refer to data element values, required for calculating a hospital outpatient measure, that fall outside of the range of allowable values defined for that data element. Reducing missing and invalid data minimizes the bias to a measure rate because records with missing or invalid data cannot be included in the calculation of the observed measure rate. This section describes preventing missing and invalid data in detail.

# Section 4 – Population and Sampling Specifications

This section provides guidance on defining the hospital's outpatient population and information on the order of data flow. Defining the population is the first step to estimate a hospital's performance. A population is generally defined as a collection of patients sharing a common set of universally measured characteristics, such as an International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Principal Diagnosis or Current Procedural Terminology (CPT®) Codes. The outpatient population and diagnosis/CPT® codes meet this description for the Hospital Outpatient measures. Additional information regarding population and sampling are found in this section.

# Section 5 – Hospital Outpatient Department Quality Measure Data Transmission

This section provides guidelines for transmitting Hospital Outpatient measure data. It highlights the unique data transmission specifications for Hospital Outpatient measure data for the CMS Clinical Data Warehouse. It is divided into three parts: Guidelines for Submission of Data, Transmission Data Element List, and Transmission Data Processing Flow. This section provides specific information regarding data transmission.

# Section 6 - Tools and Resources

This section provides additional resources for abstracting measures and data elements.

# Appendix A – ICD-10-CM Diagnosis and CPT® Code Tables

For many of the measures, eligibility for inclusion or exclusion in the outpatient population of interest is defined by the presence of certain ICD-10-CM diagnosis codes and CPT® codes including Evaluation and Management (E/M) codes within the patient-level record. Appendix A contains the code tables that define the populations for all measures. There is a description of the codes, as defined in the applicable coding manual, and a shortened description that may be used in a data abstraction tool. The Measure Information section also refers to the codes or tables provided in this section. The code tables in this Appendix are evaluated periodically and modified as indicated.

# Appendix B – Glossary of Terms

# **Appendix C – Medication Tables**

Several of the Hospital Outpatient measures address the use and timing of certain medications. This appendix contains tables with the specific names that may be associated with medication categories (e.g., trade names). These tables are provided to facilitate appropriate data collection of applicable medications. These tables are not meant to be an inclusive list of all available therapeutic agents; rather, they represent current information available at the time of publication.

# Appendix D - Preview Section

The preview section is intended to provide an overview of future updates. The information provided in a Preview Section **should not** be programmed or submitted. Placement in this appendix does not assume that the information will be implemented in a future manual.

# **Outpatient Delivery Settings**

		Acute Myocardial Infarction (AMI)
Measures:	OP-2	Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival
	OP-3	Median Time to Transfer to Another Facility for Acute Coronary Intervention

		ED-Throughput
Measures:	OP-18	Median Time from ED Arrival to ED Departure for Discharged ED Patients
	OP-22	Left Without Being Seen

Stroke		
Measure:	OP-23	Head CT or MRI Scan Results for Acute Ischemic Stroke or Hemorrhagic Stroke Patients who Received Head CT or MRI Scan Interpretation Within 45 Minutes of ED Arrival

Imaging Efficiency		
Measures:	OP-8	MRI Lumbar Spine for Low Back Pain
	OP-10	Abdomen CT – Use of Contrast Material
	OP-13 Cardiac Imaging for Preoperative Risk Assessment for Non-Cardiac Low-Risk	
		Surgery

Measures Submitted via a Web-Based Tool		
Measures:	OP-29	Appropriate Follow-up Interval for Normal Colonoscopy in Average Risk Patients
	OP-31	Cataracts – Improvement in Patient's Visual Function within 90 Days Following Cataract Surgery

Outcome			
Measures:	OP-32	OP-32 Facility 7-Day Risk-Standardized Hospital Visit Rate after Outpatient	
		Colonoscopy	
	OP-35	Admissions and Emergency Department (ED) Visits for Patients Receiving	
		Outpatient Chemotherapy	
	OP-36	Hospital Visits after Hospital Outpatient surgery	

# **Measure Information Forms**

#### Overview

Below is a defined overview of the Measure Information Form (MIF) and Flowchart (Algorithm) Formats:

**Note**: An algorithm provides the logical steps, data element evaluation, arithmetic calculations, and data manipulation steps that are required to calculate a given measure. The algorithms and data elements needed to calculate each of the measures are identified in the MIF.

**Measure Set** – The specific national Hospital Outpatient quality measure set to which an individual measure belongs (e.g., Acute Myocardial Infarction, ED-Throughput).

**Set Measure ID** # – A unique alphanumeric identifier assigned to a measure. Information associated with a measure is identified by this unique alphanumeric number (i.e., OP-2, OP-3, etc.).

**Performance Measure Name** – A brief title that uniquely identifies the measure.

**Description** – A brief explanation of the measure's focus, such as the activity or the area on which the measure centers attention (e.g., median time from ED arrival to ED departure time for discharged ED patients).

**Rationale** – The reason for performing a specified process to improve the quality of care outcome. This may include specific literature references, evidence-based information, expert consensus, etc.

**Type of Measure** – Indicates what is being evaluated by the measure.

- **Process:** A measure used to assess a goal-directed, interrelated series of actions, events, mechanisms, or steps, such as a measure of performance that describes what is done to, for, or by patients, as in performance of a procedure.
- **Outcome:** A measure that indicates the result of performance (or non-performance) of a function(s) or process(es).
- **Structural:** A measure used to assess the characteristics and capacity of the provider to deliver quality healthcare.
- **Measures Submitted via a Web-Based Tool:** A measure used to assess a goal-directed, interrelated series of actions, events, mechanisms, or steps with data entry achieved through the secure side of QualityNet.org.

**Improvement Noted As** – Describes how improvement would be indicated by the measure.

- An increase in the rate/score/number of occurrences.
- A decrease in the rate/score/number of occurrences.
- Either an increase or a decrease in the rate/score/number of occurrences, depending upon the context of the measure (e.g., utilization).

**Numerator Statement** – Represents the portion of the denominator that satisfies the conditions of the performance measure.

- **Included Population in Numerator:** Specific information describing the population(s) comprising the numerator, not contained in the numerator statement, or not applicable.
- Excluded Population in Numerator: Specific information describing the population(s) that should not be included in the numerator, or none.
- **Data Elements:** Those data elements necessary or required to determine (or establish) the numerator.

**Note:** If the measure is reported as a rate (proportion or ratio), the Numerator and Denominator Statements are completed. If a performance measure does not have both a numerator and a denominator, then a Continuous Variable Statement is completed.

**Denominator Statement** – Represents the population evaluated by the performance measure.

- **Included Population in Denominator:** Specific information describing the population(s) comprising the denominator, not contained in the denominator statement, or not applicable.
- Excluded Population in Denominator: Specific information describing the population(s) that should not be included in the denominator, or none.
- Data Elements: Those data elements required to determine (or establish) the denominator.

**Note:** If the measure is reported as a rate (proportion or ratio), the Numerator and Denominator Statements are completed. If a performance measure does not have both a numerator and a denominator, then a Continuous Variable Statement is completed.

**Continuous Variable Statement** – Describes an aggregate data measure in which the value of each measurement can fall anywhere along a continuous scale.

- **Included Population in Continuous Variable:** Specific information describing the population(s) comprising the performance measure, not contained in the Continuous Variable Statement, or not applicable.
- Excluded Population in Continuous Variable: Specific information describing the population(s) that should not be included in the performance measure, or none.
- **Data Elements:** Those data elements required to determine (or establish) the measure for a continuous variable.

**Note:** If a measure is reported as a central tendency, the Continuous Variable Statement is completed. This item is only completed when the performance measure does not have numerator and denominator statements.

**Risk Adjustment** – Indicates whether a measure is subject to the statistical process for reducing, removing, or clarifying the influences of confounding factors to allow more useful comparisons.

**Data Collection Approach** – Recommended timing for when data should be collected for a measure. Data collection approaches include retrospective, concurrent, prospective, or Medicare Claims data collection.

- Retrospective data collection: Involves collecting data for events that have already occurred.
- Concurrent data collection: The process of gathering data on how a process works or is working while a patient is in active treatment.
- **Prospective data collection:** Data collection in anticipation of an event or occurrence.
- **Medicare Claims data collection:** The use of data that is administratively derived from CMS claims and does not require abstraction.

**Data Accuracy** – Recommendations to reduce identifiable data errors, to the extent possible.

**Measure Analysis Suggestions** – Recommendations to assist in the process of interpreting data and drawing valid conclusions.

**Sampling** – Indicates whether a measure can be sampled. Sampling is a process of selecting a representative part of the population in order to estimate the hospital's performance without collecting data for its entire population.

**Data Reported As** – Indicates how data will be reported for a measure.

- Aggregate rate generated from count data reported as a proportion.
- Aggregate rate generated from count data reported as a ratio.
- Aggregate measures of central tendency.
- Claims data reported as condition-specific, hospital-specific, or risk-standardized.

**Selected References** – Specific literature references that are used to support the importance of the performance measure.

# **Algorithm Introduction**

Each measure set's initial patient population and associated measures are described by a unique algorithm. An algorithm is a predefined set of rules that helps to break down complex processes into simple, repetitive steps.

Initial Patient Population algorithms evaluate and identify which episode of care (EOC) records are in the measure set's population and are eligible to be sampled.

Measure algorithms serve two purposes. First, they evaluate and identify which EOC records contain missing and/or invalid data that will prohibit the ability to properly evaluate the measure. Second, they determine if:

- For rate-based measures, the patient's EOC record belongs in the measure population described by the denominator, and if the patient experienced the event described in the numerator.
- For continuous variable measures, the patient's EOC record belongs in the patient population described in the measure's statement and, if so, to define and calculate the measurement value.

This section contains some standard flowcharting conventions used to develop each algorithm:

- **Flow lines:** Used to guide the reader to different parts of the algorithm, with arrows denoting the direction of movement. Generally, movement is from the top to the bottom of the chart.
- Symbols: Used in each algorithm are described later in this section under Flowchart Symbols.
- **Temporary variables:** Within algorithms are noted in the variable key at the top of each page.

# **Flowchart Symbols** Start/Stop (ovals) denotes the beginning or end of an algorithm. Diamonds represent "If...Then" decision points for logic tests and comparisons. Two or three flow lines exit the decision point to reflect alternative actions based upon an evaluation of the condition(s) stated around the decision point. Rectangles or process boxes show when computation or manipulation of the data are required, such as a calculation or summarization. Circle or "On-page" connectors, labeled with a letter, show a link to sections of the algorithm which are continued on the same page. Five-sided or "Off-page" connectors, labeled with a letter, show a link to sections of the algorithm which are continued on different pages. Note: Both circular, "On-page," and five-sided, "Off-page," connectors containing the letters B, D, E, X, or Y lead to measure Outcome Boxes. Outcome Boxes represent the result of data passed through the algorithm. Connectors extending from outcome boxes lead to the end of the algorithm or to risk adjustment procedures, where applicable. This symbol is also used to identify the strata within a stratified measure. Symbol to represent comments ("note") that should be taken into account when programming the flowchart. The open rectangle symbol is placed alongside the Process box to which they are applicable. Comments are used to expand upon information contained within the process box, such as how to properly calculate age. Comments are never the sole location where processing logic is provided. Start/Return symbols denote the beginning and end of a sub-routine. Algorithms that use this symbol are called from another algorithm, and the data processing flow returns to the calling algorithm when the "Return" is encountered. See the Initial Patient Population Algorithms and Transmission Data Processing Flows for an example of the usage of this symbol.

# **Measure Category Assignments**

Measure Category Assignments are calculated measure results for each EOC that is processed through a measure algorithm.

The following are the possible Measure Category Assignments:

# **B** Not in Measure Population

• For rate-based and continuous variable measures: Record is not a member of the measure's population.

# **D** In Measure Population (used for reporting)

- For rate-based measures: Record is a member of the measure's population, and there has not been an occurrence of the measure.
- For continuous variable measures: Record is a member of the measure's population and has sufficient, accurate, and valid data to compute the measurement.

# **D(#)** In Measure Population (used to identify stratified populations of specific measures)

- For rate-based measures: Record is a member of the measure's population, and there has not been an occurrence of the measure.
- For continuous variable measures: Record is a member of the measure's population and has sufficient, accurate, and valid data to compute the measurement.

# **E** In Numerator Population

- For rate-based measures: Record is a member of the measure's population, and there has been an occurrence of the measure.
- For continuous variable measures: Does not apply.

# **X** Data Are Missing

• For rate-based and continuous variable measures: Data are missing that are required to calculate the measure. The record will be rejected when transmitted.

# Y<sup>1</sup> Unable to Determine (UTD) (Allowable Value Does Not Allow Calculation of the Measure)

- For rate-based measures: Does not apply
- For continuous variable measures: Record contains a Date, Time, or Numeric data element with a value of 'UTD.'

# **Hospital Outpatient Quality Measures Acute Myocardial Infarction (AMI)**

Set Measure ID #	Measure Short Name	
OP-2	Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival	
OP-3	Median Time to Transfer to Another Facility for Acute Coronary Intervention	

# **OP Acute Myocardial Infarction General Data Element List**

<b>General Data Element Name</b>	Collected For:
Arrival Time	All Records
Birthdate	All Records
CMS Certification Number ‡, †	All Records
First Name	All Records
Hispanic Ethnicity	All Records
Last Name	All Records
National Provider Identifier ‡, †	Optional for All Records
Outpatient Encounter Date	All Records
Patient Identifier	All Records
Payment Source	All Records
Physician 1	Optional for All Records
Physician 2	Optional for All Records
Postal Code	All Records
Race	All Records
Sex	All Records

<sup>&</sup>lt;sup>‡</sup>Transmission Data Element

<sup>&</sup>lt;sup>†</sup>Defined in the Transmission Data Element List within the Hospital Outpatient Measure Data Transmission section of this manual.

# **OP Acute Myocardial Infarction Specific Data Element List**

OP AMI Data Element Name	Collected For:
Discharge Code	OP-2, OP-3
E/M Code	OP-2, OP-3
ED Departure Date	OP-3
ED Departure Time	OP-3
Fibrinolytic Administration	OP-2, OP-3
Fibrinolytic Administration Date	OP-2
Fibrinolytic Administration Time	OP-2
ICD-10-CM Principal Diagnosis Code	OP-2, OP-3
Initial ECG Interpretation	OP-2, OP-3
Reason for Delay in Fibrinolytic Therapy	OP-2
Reason for Not Administering Fibrinolytic Therapy	OP-3
Transfer for Acute Coronary Intervention	OP-3

# OP-2 and OP-3 Hospital Outpatient Emergency Department AMI Population


# **Acute Myocardial Infarction**

The population of the OP-2 and OP-3 AMI measures is identified using 5 data elements:

- E/M Code
- Discharge Code
- Outpatient Encounter Date
- Birthdate
- ICD-10-CM Principal Diagnosis Code

Patients seen in a Hospital Emergency Department (*E/M Code* in Appendix A, OP Table 1.0) are included in the OP-2 and OP-3 AMI Hospital Outpatient Population and are eligible to be sampled if they have:

- Discharged/transferred to a short-term general hospital for inpatient care or to a federal healthcare facility (*Discharge Code*), and
- A Patient Age on Outpatient Encounter Date (Outpatient Encounter Date Birthdate)  $\geq$  18 years, and
- An ICD-10-CM Principal Diagnosis Code for AMI defined in Appendix A, OP Table 1.1.



# Algorithm Narrative for OP-2 and OP-3: AMI Hospital Outpatient Population

- 1. Start AMI Hospital Outpatient Measure Set Population Logic (cases eligible for OP-2 and OP-3).
- 2. Start processing all cases that have successfully reached the point in the data processing flow which call this Initial Patient Population Algorithm. Do not process cases that have been rejected before this point in the Data Processing Flow: Clinical in the Data Transmission section.

#### 3. Check E/M Code

- a. If *E/M Code* is not in Appendix A, OP Table 1.0, patient is not in the Outpatient AMI Population. Patient is not in the AMI Hospital Outpatient Measure Population for OP-2 and OP-3. Patient is not eligible to be sampled for the AMI Hospital Outpatient Measure Set. Set the OP Population Reject Case Flag to Yes. Return to Transmission Data Processing Flow: Clinical in the Data Transmission section.
- b. If E/M Code is in Appendix A, OP Table 1.0, continue processing and proceed to Discharge Code.

#### 4. Check Discharge Code

- a. If Discharge Code equals 1, 2, 3, 4b, 4c, 5, 6, 7, or 8 (Discharge Status code values would = 01, 03, 04, 05, 06, 07, 09, 20, 21, 41, 50, 51, 61, 62, 63, 64, 65, 66, 70), patient is not in the Outpatient AMI Population. Patient is not in the AMI Hospital Outpatient Measure Population for OP-2 and OP-3. Patient is not eligible to be sampled for the AMI Hospital Outpatient Measure Set. Set the OP Population Reject Case Flag to Yes. Return to Transmission Data Processing Flow: Clinical in the Data Transmission section.
- b. If *Discharge Code* equals 4a or 4d (Discharge Status code values would = 02 or 43), continue processing and proceed to Patient Age on *Outpatient Encounter Date*.
- 5. Calculate Patient Age on *Outpatient Encounter Date*. Patient age, in years, is equal to the *Outpatient Encounter Date* minus the *Birthdate*. Use the month and day portion of the *Outpatient Encounter Date* and the *Birthdate* to yield the most accurate age.

# 6. Check Patient Age

- a. If patient age is less than 18 years, patient is not in the Outpatient AMI Population. Patient is not in the AMI Hospital Outpatient Measure Population for OP-2 and OP-3. Patient is not eligible to be sampled for the AMI Hospital Outpatient Measure Set. Set the OP Population Reject Case Flag to Yes. Return to Transmission Data Processing Flow: Clinical in the Data Transmission section.
- b. If patient age is greater than or equal to 18 years, continue processing and proceed to *ICD-10-CM Principal Diagnosis Code*.

#### 7. Check ICD-10-CM Principal Diagnosis Code

- a. If the *ICD-10-CM Principal Diagnosis Code* is not in Appendix A, OP Table 1.1, patient is not in the Outpatient AMI Population. Patient is not in the AMI Hospital Outpatient Measure Population for OP-2 and OP-3. Patient is not eligible to be sampled for the AMI Hospital Outpatient Measure Set. Set the OP Population Reject Case Flag to Yes. Return to Transmission Data Processing Flow: Clinical in the Data Transmission section.
- b. If the *ICD-10-CM Principal Diagnosis Code* is in Appendix A, OP Table 1.1, patient is in the AMI Hospital Outpatient Measure Population for OP-2 and OP-3. Patient is eligible to be sampled for the AMI Hospital Outpatient Measure Set. Set the OP Population Reject Case Flag to No. Return to Transmission Data Processing Flow: Clinical in the Data Transmission section.

# NQF-Endorsed Voluntary Consensus Standards for Hospital Care Measure Information Form

Performance Measure Name: Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival

**Measure ID #:** OP-2

Measure Set: Hospital Outpatient Acute Myocardial Infarction

**Outpatient Setting:** Emergency Department

**Description:** Emergency Department acute myocardial infarction (AMI) patients with ST-segment elevation on the ECG closest to arrival time receiving fibrinolytic therapy during the ED stay and having a time from ED arrival to fibrinolysis of 30 minutes or less.

Rationale: The American Heart Association (AHA) estimates that 790,000 people experience a heart attack, or myocardial infarction, in the United States each year (Benjamin, 2017). Timely treatment (through reperfusion) for patients with ST-segment elevation myocardial infarction (STEMI) is a strong predictor of patient outcomes; fibrinolytic therapy is considered a viable option for patients for whom timely access to primary percutaneous coronary intervention (PCI) on site or via transfer is not feasible (Viergutz, 2016). Recent evidence suggests that fibrinolysis is safe even for those STEMI patients who later receive PCI (Armstrong and Welsh, 2017; Costa, 2016; Hernandez, 2016; Peiyuan, 2016; Puymirat, 2017). Clinical practice guidelines recommend that patients with STEMI receive fibrinolytic therapy be given within 30 minutes of hospital arrival in patients with ST-elevation myocardial infarction (O'Gara, 2013; Chew, 2016). For STEMI patients presenting to the ED, initiating treatment within this recommended time frame has been found to significantly improve short-term survival rates and long-term outcomes, including decreased inhospital mortality and increased years of life saved (Bucholz et al., 2016; Puymirat et al., 2016).

**Type of Measure: Process** 

**Improvement Noted As:** An increase in the rate.

**Numerator Statement:** Emergency Department AMI patients whose time from ED arrival to fibrinolysis is 30 minutes or less.

**Included Populations:** Not applicable

**Excluded Populations: None** 

#### **Data Elements:**

- Arrival Time
- Fibrinolytic Administration Date
- Fibrinolytic Administration Time
- Outpatient Encounter Date

**Denominator Statement:** Emergency Department AMI patients with ST-segment elevation on ECG who received fibrinolytic therapy.

# **Included Populations:**

- An E/M Code for emergency department encounter as defined in Appendix A, OP Table 1.0, and
- Patients discharged/transferred to a short-term general hospital for inpatient care, or to a federal healthcare facility, and

Hospital OQR Specifications Manual

Encounter dates **01-01-20** (**1Q20**) through **12-31-20** (**4Q20**) v13.0a

- An ICD-10-CM Principal Diagnosis Code for AMI as defined in Appendix A, OP Table 1.1, and
- ST-segment elevation on the ECG performed closest to ED arrival, and
- Fibrinolytic Administration.

# **Excluded Populations:**

- Patients less than 18 years of age.
- Patients who did not receive *Fibrinolytic Administration* within 30 minutes **and** had a *Reason for Delay in Fibrinolytic Therapy*.

#### **Data Elements:**

- Birthdate
- Discharge Code
- E/M Code
- Fibrinolytic Administration

- ICD-10-CM Principal Diagnosis Code
- Initial ECG Interpretation
- Reason for Delay in Fibrinolytic Therapy

Risk Adjustment: No

**Data Collection Approach:** Retrospective data sources for required data elements include administrative data and medical record documents. Some hospitals may prefer to gather data concurrently by identifying patients in the population of interest. This approach provides opportunities for improvement at the point of care/service. However, complete documentation includes the principal or other ICD-10-CM diagnosis and procedure codes, which require retrospective data entry.

**Data Accuracy:** Variation may exist in the assignment of ICD-10-CM codes; therefore, coding practices may require evaluation to ensure consistency. There may be additional variation by provider, facility, and documentation protocol for chart-abstracted data elements.

**Measure Analysis Suggestions:** This measure rate will assist in understanding the number of AMI patients that are receiving fibrinolysis within 30 minutes of emergency department arrival and will identify potential opportunities for improvement to increase the rate of patients receiving fibrinolysis in 30 minutes or less.

Sampling: Yes; for additional information see the Population and Sampling Specifications section.

**Data Reported As:** Aggregate rate generated from count data reported as a proportion.


#### **Selected References:**

- Armstrong, P. W. and R. C. Welsh. Recalibrating Reperfusion Waypoints. Circulation, 136(13).
- Benjamin E.J., Blaha M.J., Chiuve S.E., Cushman M., Das S.R., Deo R., et al. Heart Disease and Stroke Statistics—2017 Update: A Report From the American Heart Association. 2017; 135:e1–e458.
- Bucholz E. M., N. M. Butala, S. L. Normand, Y. Wang, and H. M. Krumholz. Association of Guideline-Based Admission Treatments and Life Expectancy After Myocardial Infarction in Elderly Medicare Beneficiaries. Journal of the American College of Cardiology, 2015; 67:20: 2378–2391.
- Chew, D. P., I. A. Scott, L. Cullen J. K. French, T. G. Briffa, P. A. Tideman, S. Woodruffe, A. Kerr, M. Branagan, and P. E. G. Aylward. National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Australian Clinical Guidelines for the Management of Acute Coronary Syndromes. Medical Journal of Australia, 2016; 205:3: 128–133.
- Costa, C., D. Durao, A. Belo, K. Domingues, B. Santos and M. Leal. Coronary angiography after successful thrombolysis Is the recommended time interval of 24h an important issue? International Journal of Cardiology, 2016, 222, 515-520.

- O'Gara P.T., Kusher F.G., Ascheim D.D., Casey D.E., Chung M.K., Lemos J.A., Ettinger S.M., et al. 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: Executive Summary: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation, 2013; 127:1-88. Published online December 17, 2012.
- Puymirat, E., J. Caudron, P. G. Steg, G. Lemesle, Y. Cottin, P. Coste, F. Schiele, A. de Labriolle, V. Bataille, J. Ferrieres, T. Simon and N. Danchin. Prognostic impact of non-compliance with guidelines-recommended times to reperfusion therapy in ST-elevation myocardial infarction. The FAST-MI 2010 registry. Eur Heart J Acute Cardiovasc Care, 2017; 6:1: 26-33.
- Viergutz, T., J. Gruttner, T. Walter, C. Weiss, B. Haaff, G. Pollach, C. Madler, and T. Luiz. Preclinical Fibrinolysis in Patients with ST-segment Elevation Myocardial Infarction in a Rural Region. Anaesthesist, 2016, 65(9): 673–680.

# OP-2: Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival

**Numerator:** Emergency Department AMI patients whose time from ED arrival to fibrinolysis is 30 minutes or less. **Denominator:** Emergency Department AMI patients with ST-segment elevation on ECG who received fibrinolytic therapy.



# Algorithm Narrative for OP-2: Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival

**Numerator:** Emergency Department AMI patients whose time from ED arrival to fibrinolysis is 30 minutes or less.

**Denominator:** Emergency Department AMI patients with ST-segment elevation on ECG who received fibrinolytic therapy.

1. Start. Run all cases that are included in the AMI Hospital Outpatient Population Algorithm and pass the edits defined in the Data Processing Flow through this measure. Proceed to *Initial ECG Interpretation*.

# 2. Check *Initial ECG interpretation*

- a. If *Initial ECG interpretation* is missing, the case will proceed to a Measure Category Assignment of X and will be rejected. Return to Transmission Data Processing Flow: Clinical in the Data Transmission section.
- b. If *Initial ECG Interpretation* equals No, the case will proceed to a Measure Category Assignment of B. Return to Transmission Data Processing Flow: Clinical in the Data Transmission section.
- c. If Initial ECG interpretation equals Yes, the case will proceed to Fibrinolytic Administration.

# 3. Check Fibrinolytic Administration

- a. If *Fibrinolytic Administration* is missing, the case will proceed to a Measure Category Assignment of X and will be rejected. Return to Transmission Data Processing Flow: Clinical in the Data Transmission section.
- b. If *Fibrinolytic Administration* equals No, the case will proceed to a Measure Category Assignment of B. Return to Transmission Data Processing Flow: Clinical in the Data Transmission section.
- c. If Fibrinolytic Administration equals Yes, the case will proceed to Fibrinolytic Administration Date.

# 4. Check Fibrinolytic Administration Date

- a. If *Fibrinolytic Administration Date* is missing, the case will proceed to a Measure Category Assignment of X and will be rejected. Return to Transmission Data Processing Flow: Clinical in the Data Transmission section.
- b. If *Fibrinolytic Administration Date* equals UTD, the case will proceed to a Measure Category Assignment of D. Return to Transmission Data Processing Flow: Clinical in the Data Transmission section.
- c. If *Fibrinolytic Administration Date* equals Non-UTD Value, the case will proceed to *Fibrinolytic Administration Time*.

# 5. Check Fibrinolytic Administration Time

- a. If *Fibrinolytic Administration Time* is missing, the case will proceed to a Measure Category Assignment of X and will be rejected. Return to Transmission Data Processing Flow: Clinical in the Data Transmission section.
- b. If *Fibrinolytic Administration Time* equals UTD, the case will proceed to a Measure Category Assignment of D. Return to Transmission Data Processing Flow: Clinical in the Data Transmission section.
- c. If Fibrinolytic Administration Time Equals Non-UTD Value, the case will proceed to Arrival Time.

#### 6. Check Arrival Time

- a. If *Arrival Time* equals UTD, the case will proceed to a Measure Category Assignment of D. Return to Transmission Data Processing Flow: Clinical in the Data Transmission section.
- b. If Arrival Time equals Non-UTD Value, the case will proceed to Time to Fibrinolysis.

# 7. Calculate the Time to Fibrinolysis

a. Time in minutes is equal to the *Fibrinolytic Administration Date* and *Fibrinolytic Administration Time* (in minutes) minus the *Outpatient Encounter Date* and *Arrival Time* (in minutes).

# 8. Check the Time to Fibrinolysis

- a. If Time to Fibrinolysis is greater than or equal to 0 minutes and less than or equal to 30 minutes, the case will proceed to a Measure Category Assignment of E. Return to Transmission Data Processing Flow: Clinical in the Data Transmission section.
- b. If Time to Fibrinolysis is less than 0 minutes or greater than 360 minutes, the case will proceed to a Measure Category Assignment of B. Return to Transmission Data Processing Flow: Clinical in the Data Transmission section.
- c. If Time to Fibrinolysis is greater than 30 minutes and less than or equal to 360 minutes, the case will proceed to *Reason for Delay in Fibrinolytic Therapy*.

# 9. Check Reason for Delay in Fibrinolytic Therapy

- a. If *Reason for Delay in Fibrinolytic Therapy* is missing, the case will proceed to a Measure Category Assignment of X and the case will be rejected. Return to Transmission Data Processing Flow: Clinical in the Data Transmission section.
- b. If *Reason for Delay in Fibrinolytic Therapy* equals Yes, the case will proceed to a Measure Category Assignment of B. Return to Transmission Data Processing Flow: Clinical in the Data Transmission section.
- c. If *Reason for Delay in Fibrinolytic Therapy* equals No, the case will proceed to a Measure Category Assignment of D. Return to Transmission Data Processing Flow: Clinical in the Data Transmission section.

# NQF-Endorsed Voluntary Consensus Standards for Hospital Care Measure Information Form

**Performance Measure Name:** Median Time to Transfer to Another Facility for Acute Coronary Intervention

Measure ID #: OP-3

Measure Set: Hospital Outpatient Acute Myocardial Infarction

Outpatient Setting: Emergency Department

Set Measure ID #	Performance Measure Name	
OP-3a	Median Time to Transfer to Another Facility for Acute Coronary Intervention-	
OP-3a	Overall Rate	
OP-3b	Median Time to Transfer to Another Facility for Acute Coronary Intervention-	
	Reporting Measure	
OP-3c	Median Time to Transfer to Another Facility for Acute Coronary Intervention-	
OP-30	Quality Improvement Measure	

**Description:** Median time from emergency department arrival to time of transfer to another facility for acute coronary intervention.

Rationale: The American Heart Association (AHA) estimates that 790,000 people experience a heart attack, or myocardial infarction, in the United States each year (Benjamin, 2017). Timely transfer for acute coronary intervention (ACI), such as a percutaneous coronary intervention (PCI), is associated with improved patient outcomes (Bucholz, 2016; Martin, 2016). National clinical practice guidelines support initiating PCI (measured through door-to-balloon time) within 120 minutes or less for ST-segment elevation myocardial infarction (STEMI) patients who need to be transferred from a non-PCI capable hospital to one at which PCI can be performed (O'Gara, 2013).

**Type of Measure:** Process

**Improvement Noted As:** A decrease in the median value.

**Continuous Variable Statement:** Time (in minutes) from emergency department arrival to transfer to another facility for acute coronary intervention.

# **Included Populations:**

- An E/M Code for emergency department encounter as defined in Appendix A, OP Table 1.0, and
- Patients discharged/transferred to a short-term general hospital for inpatient care or to a federal healthcare facility, and
- An ICD-10-CM Principal Diagnosis Code for AMI as defined in Appendix A, OP Table 1.1, and
- ST-segment elevation on the ECG performed closest to ED arrival, and
- Patients with *Transfer for Acute Coronary Intervention*.

#### **Excluded Populations:**

- Patients less than 18 years of age.
- Patients receiving Fibrinolytic Administration.

Hospital OQR Specifications Manual

Encounter dates **01-01-20** (**1Q20**) through **12-31-20** (**4Q20**) v13.0a

# **Data Elements:**

- Arrival Time
- Birthdate
- Discharge Code
- ED Departure Date
- ED Departure Time
- E/M Code
- Fibrinolytic Administration
- ICD-10-CM Principal Diagnosis Code
- Initial ECG Interpretation
- Outpatient Encounter Date
- Reason for Not Administering Fibrinolytic Therapy
- Transfer for Acute Coronary Intervention

# Risk Adjustment: No

**Data Collection Approach:** Retrospective data sources for required data elements include administrative data and medical record documents. Some hospitals may prefer to gather data concurrently by identifying patients in the population of interest. This approach provides opportunities for improvement at the point of care/service. However, complete documentation includes the principal or other ICD-10-CM diagnosis and procedure codes, which require retrospective data entry.

**Data Accuracy:** Variation may exist in the assignment of ICD-10-CM codes; therefore, coding practices may require evaluation to ensure consistency. There may be additional variation by provider, facility, and documentation protocol for chart-abstracted data elements.

Measure Analysis Suggestions: None

**Sampling:** Yes; for additional information see the Population and Sampling Specifications section.


**Data Reported As:** Aggregate measure of central tendency.

#### **Selected References:**

- Benjamin E.J., Blaha M.J., Chiuve S.E., Cushman M., Das S.R., Deo R., et al. Heart Disease and Stroke Statistics—2017 Update: A Report From the American Heart Association. 2017; 135:e1–e458.
- Bucholz E. M., N. M. Butala, S. L. Normand, Y. Wang, and H. M. Krumholz. Association of Guideline-Based Admission Treatments and Life Expectancy After Myocardial Infarction in Elderly Medicare Beneficiaries. Journal of the American College of Cardiology, 2015; 67:20: 2378–2391.
- Martin L., M. Murphy, A. Scanlon, D. Clark, and O. Farouque. "The Impact On Long Term Health Outcomes for STEMI Patients During a Period of Process Change to Reduce Door to Balloon Time." European Journal of Cardiovascular Nursing, vol. 15, no. 3, 2016, pp. e37–44.
- O'Gara PT, Kusher FG, Ascheim DD, Casey DE, Chung MK, Lemos JA, Ettinger SM, et al. 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: Executive Summary: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation, 2013; 127:1-88. Published online December 17, 2012.


# OP-3: Median Time to Transfer to Another Facility for Acute Coronary Intervention

Continuous Variable Statement: Time (in minutes) from emergency department arrival to transfer to another facility for acute coronary intervention



Hospital OQR Specifications Manual

Encounter dates **01-01-20** (**1Q20**) through **12-31-20** (**4Q20**) v13.0a



# Algorithm Narrative for OP-3: Median Time to Transfer to Another Facility for Acute Coronary Intervention

**Continuous Variable Statement:** Time (in minutes) from emergency department arrival to transfer to another facility for acute coronary intervention.

1. Start. Run all cases that are included in the AMI Hospital Outpatient Population Algorithm and pass the edits defined in the Data Processing Flow through this measure. Proceed to *Initial ECG Interpretation*.

# 2. Check Initial ECG Interpretation.

- a. If *Initial ECG Interpretation* is missing, the case will proceed to a Measure Category Assignment of X and will be rejected. Return to Transmission Data Processing Flow: Clinical in the Data Transmission section.
- b. If *Initial ECG Interpretation* equals No, the case will proceed to a Measure Category Assignment of B. Return to Transmission Data Processing Flow: Clinical in the Data Transmission section.
- c. If Initial ECG Interpretation equals Yes, the case will proceed to Fibrinolytic Administration.

# 3. Check Fibrinolytic Administration

- a. If *Fibrinolytic Administration* is missing, the case will proceed to a Measure Category Assignment of X and will be rejected. Return to Transmission Data Processing Flow: Clinical in the Data Transmission section.
- b. If *Fibrinolytic Administration* equals Yes, the case will proceed to a Measure Category Assignment of B. Return to Transmission Data Processing Flow: Clinical in the Data Transmission section.
- c. If Fibrinolytic Administration equals No, the case will proceed to Transfer for Acute Coronary Intervention.

# 4. Check Transfer for Acute Coronary Intervention

- a. If *Transfer for Acute Coronary Intervention* is missing, the case will proceed to a Measure Category Assignment of X and will be rejected. Return to Transmission Data Processing Flow: Clinical in the Data Transmission section.
- b. If *Transfer for Acute Coronary Intervention* equals 2 or 3, the case will proceed to a Measure Category Assignment of B. Return to Transmission Data Processing Flow: Clinical in the Data Transmission section.
- c. If Transfer for Acute Coronary Intervention equals 1, the case will proceed to ED Departure Date.

# 5. Check *ED Departure Date*

- a. If *ED Departure Date* is missing, the case will proceed to a Measure Category Assignment of X and will be rejected. Return to Transmission Data Processing Flow: Clinical in the Data Transmission section.
- b. If *ED Departure Date* equals UTD, the case will proceed to a Measure Category Assignment of Y. Return to Transmission Data Processing Flow: Clinical in the Data Transmission section.
- c. If ED Departure Date equals Non-UTD Value, the case will proceed to ED Departure Time.

# 6. Check ED Departure Time

- a. If *ED Departure Time* is missing, the case will proceed to a Measure Category Assignment of X and will be rejected. Return to Transmission Data Processing Flow: Clinical in the Data Transmission section.
- b. If *ED Departure Time* equals UTD, the case will proceed to a Measure Category Assignment of Y. Return to Transmission Data Processing Flow: Clinical in the Data Transmission section.

c. If ED Departure Time equals Non-UTD Value, the case will proceed to Arrival Time.

#### 7. Check Arrival Time

- a. If *Arrival Time* equals UTD, the case will proceed to a Measure Category Assignment of Y. Return to Transmission Data Processing Flow: Clinical in the Data Transmission section.
- b. If Arrival Time equals Non-UTD Value, the case will proceed to the Measurement Value.

#### 8. Calculate the Measurement Value

a. Time in minutes is equal to the *ED Departure Date* and *ED Departure Time* (in minutes) minus the *Outpatient Encounter Date* and *Arrival Time* (in minutes).

#### 9. Check the Measurement Value

- a. If Measurement Value is less than 0 minutes, the case will proceed to a Measure Category Assignment of X and will be rejected. Return to Transmission Data Processing Flow: Clinical in the Data Transmission section.
- b. If Measurement Value is greater than or equal to 0 minutes, the case will proceed to *Reason for Not Administering Fibrinolytic Therapy*.

# 10. Check Reason for Not Administering Fibrinolytic Therapy

- a. If *Reason for Not Administering Fibrinolytic Therapy* is missing, the case will proceed to a Measure Category Assignment of X and the case will be rejected. Return to Transmission Data Processing Flow: Clinical in the Data Transmission section.
- b. If *Reason for Not Administering Fibrinolytic Therapy* equals 1, 2, or 3, the case will proceed to a Measure Category Assignment of D1, the OP-3a Overall Rate. Initialize the Measure Category Assignment for OP-3b and OP-3c equal to B. Do not change the Measure Category Assignment that was already calculated for the overall rate of OP-3a. Proceed to *Reason for Not Administering Fibrinolytic Therapy*.

# 11. Check Reason for Not Administering Fibrinolytic Therapy

- a. If *Reason for Not Administering Fibrinolytic Therapy* equals 1 or 2, the case will proceed to a Measure Category Assignment of D2, the OP-3c Quality Improvement Rate. Return to Transmission Data Processing Flow: Clinical in the Data Transmission section.
- b. If *Reason for Not Administering Fibrinolytic Therapy* equals 3, the case will proceed to a Measure Category Assignment of D, the OP-3b Reporting Rate. Return to Transmission Data Processing Flow: Clinical in the Data Transmission section.

# Hospital Outpatient Quality Measures ED-Throughput

Set Measure ID #	Measure Short Name
OP-18	Median Time from ED Arrival to ED Departure for Discharged ED Patients
OP-22	Left Without Being Seen*

<sup>\*</sup>Data entry for OP-22 will be achieved through the secure side of QualityNet.org via an online tool available to authorized users. Because the measure uses administrative data and not claims data to determine the measure's denominator population, OP-22 is not included in the ED-Throughput Population.

# **OP ED-Throughput General Data Element List**

General Data Element Name	Collected for:
Arrival Time	All Records
Birthdate	All Records
CMS Certification Number ‡, ‡	All Records
First Name	All Records
Hispanic Ethnicity	All Records
Last Name	All Records
National Provider Identifier ‡, ‡	Optional for All Records
Outpatient Encounter Date	All Records
Patient Identifier	All Records
Payment Source	All Records
Physician 1	Optional for All Records
Physician 2	Optional for All Records
Postal Code	All Records
Race	All Records
Sex	All Records

<sup>†</sup> Transmission Data Element.

# **OP ED-Throughput Specific Data Element List**

OP ED Data Element Name	Collected for:
Arrival Time	OP-18
Discharge Code	OP-18
E/M Code	OP-18
ED Departure Date	OP-18
ED Departure Time	OP-18
ICD-10-CM Principal Diagnosis Code	OP-18
Outpatient Encounter Date	OP-18

<sup>‡</sup> Defined in the Transmission Data Element List within the Hospital Outpatient Measure Data Transmission section of this manual.

# **OP-18 Hospital Outpatient Emergency Department Throughput Population**


# **ED-Throughput**

The population of the OP-18 measure is identified using 1 data element:

• E/M Code

Patients seen in a Hospital Emergency Department (E/M Code in Appendix A OP Table 1.0) are included in the OP-18 Hospital Outpatient Population and are eligible to be sampled if they have an *E/M Code* in Appendix A, OP Table 1.0.

# ED Throughput Hospital Outpatient Population Algorithm OP-18



# Algorithm Narrative for OP-18: ED-Throughput Hospital Outpatient Population

Variable Key: OP Population Reject Case Flag

1. Start ED-Throughput Initial Patient Population logic sub-routine. Process all cases that have successfully reached the point in the Transmission Data Processing Flow: Clinical which calls this Initial Patient Population Algorithm. Do not process cases that have been rejected before this point in the Transmission Data Processing Flow.

### 2. Check E/M Code

- a. If the *E/M Code* is not on OP Table 1.0 (Appendix A), the patient is not in the ED Initial Patient Population and is not eligible to be sampled for the ED-Throughput measure set. Set the Initial Patient Population Reject Case Flag to equal Yes. Return to Transmission Data Processing Flow in the Data Transmission section.
- b. If the *E/M Code* is on OP Table 1.0 (Appendix A), the patient is in the ED Initial Patient Population and is eligible to be sampled for the ED-Throughput measure set. Set Initial Patient Population Reject Case Flag to equal No. Return to Transmission Data Processing Flow in the Data Transmission section.

## NQF-Endorsed Voluntary Consensus Standards for Hospital Care Measure Information Form

Performance Measure Name: Median Time from ED Arrival to ED Departure for Discharged ED Patients

Measure ID #: OP-18

Measure Set: Hospital Outpatient ED-Throughput

Outpatient Setting: Emergency Department

Set Measure ID #	Performance Measure Name
OP-18a	Median Time from ED Arrival to ED Departure for Discharged ED Patients –
OF-10a	Overall Rate
OP-18b	Median Time from ED Arrival to ED Departure for Discharged ED Patients –
OF-180	Reporting Measure
OP-18c	Median Time from ED Arrival to ED Departure for Discharged ED Patients –
OP-18C	Psychiatric/Mental Health Patients
OP-18d	Median Time from ED Arrival to ED Departure for Discharged ED Patients –
Or-180	Transfer Patients

**Description:** Median time from emergency department arrival to time of departure from the emergency room for patients discharged from the emergency department.

Rationale: Empirical evidence demonstrates that emergency department (ED) throughput is an indicator of hospital quality of care and shows that shorter lengths of stay in the ED lead to improved clinical outcomes. Significant ED overcrowding has numerous downstream effects, including prolonged patient waiting times, increased suffering for those who wait, rushed and unpleasant treatment environments, and potentially poor patient outcomes (Gardner, 2018). Quality improvement efforts aimed at reducing ED overcrowding and length of stay have been associated with an increase in ED patient volume, decrease in number of patients who leave without being seen, reduction in costs, and increase in patient satisfaction (Bucci, 2016; Chang, 2017; Zocchi, 2015).

Recent peer-reviewed studies also demonstrate the need for dedicated emergency mental health services, supplying evidence that the clinical needs for these patients substantively differ from the non-psychiatric population (ACEP, 2017; Lester, 2018).

**Type of Measure:** Process

Improvement Noted As: A decrease in the median value.

**Continuous Variable Statement:** Time (in minutes) from ED arrival to ED departure for patients discharged from the emergency department.

### **Included Populations:**

• Any ED patient from the facility's emergency department

### **Excluded Populations:**

• Patients who expired in the emergency department

#### **Data Elements:**

- Arrival Time
- Discharge Code
- E/M Code
- ED Departure Date

- ED Departure Time
- ICD-10-CM Principal Diagnosis Code
- Outpatient Encounter Date

# Risk Adjustment: No

**Data Collection Approach:** Retrospective data sources for required data elements include administrative data and medical record documents. Some hospitals may prefer to gather data concurrently by identifying patients in the population of interest. This approach provides opportunities for improvement at the point of care/service. However, complete documentation includes the principal or other ICD-10-CM diagnosis and procedure codes, which require retrospective data entry.

**Data Accuracy:** There may be variation by provider, facility, and documentation protocol for chart-abstracted data elements.

Measure Analysis Suggestions: None

Sampling: Yes; for additional information see the Population and Sampling Specifications section.


**Data Reported As:** Aggregate measure of central tendency.


### **Selected References:**

- Bucci, S., A. G. de Belvis, S. Marventano, A. C. De Leva, M. Tanzariello, M. L. Specchia, W. Ricciardi and F. Franceschi. Emergency department crowding and hospital bed shortage: Is Lean a smart answer? A systematic review. Eur Rev Med Pharmacol Sci, 2016, 20(20), 4209-4219.
- Chang, A. M., A. Lin, R. Fu, K. J. McConnell and B. Sun. Associations of Emergency Department Length of Stay With Publicly Reported Quality-of-care Measures. Acad Emerg Med, 2017, 24(2), 246-250.
- Gardner, R. M., N. A. Friedman, M. Carlson, T. S. Bradham and T. W. Barrett. Impact of revised triage to improve throughput in an ED with limited traditional fast track population. Am J Emerg Med., 2017, 36(1), 124-127.
- Lester, N. A., L. R. Thompson, K. Herget, J. A. Stephens, J. V. Campo, E. J. Adkins, T. E. Terndrup and S. Moffatt-Bruce. CALM Interventions: Behavioral Health Crisis Assessment, Linkage, and Management Improve Patient Care. Am J Med Qual., 2017, 33(1), 65-71.
- Zocchi, M. S., M. S. McClelland, and J. M. Pines. Increasing Throughput: Results From A 42-Hospital Collaborative To Improve Emergency Department Flow. The Joint Commission Journal on Quality and Patient Safety, 2015, 41(12):532–542.

### OP-18: Median Time from ED Arrival to ED Departure for Discharged ED Patients

Continuous Variable Statement: Time (in minutes) from ED arrival to ED departure for patients discharged from the emergency department.





# Algorithm Narrative for OP-18: Median Time from ED Arrival to ED Departure for Discharged ED Patients

**Continuous Variable Statement:** Time (in minutes) from ED arrival to ED departure for patients discharged from the emergency department.

1. Start processing. Run all cases that are included in the ED-Throughput Hospital Outpatient Population Algorithm and pass the edits defined in the Data Processing Flow through this measure. Proceed to *ICD-10-CM Principal Diagnosis Code*.

# 2. Check Discharge Code

- a. If *Discharge Code* is missing, the case will proceed to a Measure Category Assignment of X and will be rejected. Return to Transmission Data Processing Flow: Clinical in the Data Transmission section.
- b. If *Discharge Code* equals 6, 7, or 8, the case will proceed to a Measure Category Assignment of B. Return to Transmission Data Processing Flow: Clinical in the Data Transmission section.
- c. If Discharge Code equals 1, 2, 3, 4a, 4b, 4c, 4d, or 5, the case will proceed to Arrival Time.

### 3. Check Arrival Time

- a. If *Arrival Time* equals UTD, the case will proceed to a Measure Category Assignment of Y. Return to Transmission Data Processing Flow: Clinical in the Data Transmission section.
- b. If Arrival Time equals Non-UTD Value, the case will proceed to ED Departure Date.

# 4. Check ED Departure Date

- a. If *ED Departure Date* is missing, the case will proceed to a Measure Category Assignment of X and will be rejected. Return to Transmission Data Processing Flow: Clinical in the Data Transmission section.
- b. If *ED Departure Date* equals UTD, the case will proceed to a Measure Category Assignment of Y. Return to Transmission Data Processing Flow: Clinical in the Data Transmission section.
- c. If ED Departure Date equals non-UTD, the case will proceed to ED Departure Time.

### 5. Check *ED Departure Time*

- a. If *ED Departure Time* is missing, the case will proceed to a Measure Category Assignment of X and will be rejected. Return to Transmission Data Processing Flow: Clinical in the Data Transmission section.
- b. If *ED Departure Time* equals UTD, the case will proceed to a Measure Category Assignment of Y. Return to Transmission Data Processing Flow: Clinical in the Data Transmission section.
- c. If ED Departure Time equals non-UTD, the case will proceed to Measurement Value.

### 6. Calculate the Measurement Value

a. Time in minutes is equal to the *ED Departure Date* and *ED Departure Time* (in minutes) minus the *Outpatient Encounter Date* and *Arrival Time* (in minutes).

### 7. Check Measurement Value

- a. If Measurement Value is less than 0 minutes, the case will proceed to a Measure Category Assignment of X and will be rejected. Return to Transmission Data Processing Flow: Clinical in the Data Transmission section.
- b. If Measurement Value is greater than or equal to 0 minutes, the case will proceed to a Measure Category Assignment of D1.

- 8. Initialize the Measure Category Assignment for all cases in D1
- 9. Proceed to ICD-10-CM Principal Diagnosis Code
- 10. Check ICD-10-CM Principal Diagnosis Code
  - a. If *ICD-10-CM Principal Diagnosis Code* is in Appendix A, OP Table 7.01, the case will proceed to a Measure Category Assignment of D2. Proceed to *Discharge Code*.
  - b. If *ICD-10-CM Principal Diagnosis Code* is not in Appendix A, OP Table 7.01, the case will proceed to *Discharge Code*.

### 11. Check Discharge Code

- a. If *Discharge Code* equals 4a or 4d, the case will proceed to a Measure Category Assignment of D3. Proceed to *ICD-10-CM Principal Diagnosis Code*.
- b. If *Discharge Code* equals 1, 2, 3, 4b, 4c, or 5, the case will proceed to *ICD-10-CM Principal Diagnosis Code*.

### 12. Check ICD-10-CM Principal Diagnosis Code

- a. If *ICD-10-CM Principal Diagnosis Code* is in Appendix A, OP Table 7.01, the case will proceed to a Measure Category Assignment of B. Return to Transmission Data Processing Flow: Clinical in the Data Transmission section.
- b. If *ICD-10-CM Principal Diagnosis Code* is not in Appendix A, OP Table 7.01, the case will proceed to *Discharge Code*.

# 13. Check Discharge Code

- a. If *Discharge Code* equals 4a or 4d, the case will proceed to a Measure Category Assignment of B. Return to Transmission Data Processing Flow: Clinical in the Data Transmission section.
- b. If *Discharge Code* equals 1, 2, 3, 4b, 4c, or 5, the case will proceed to a Measure Category Assignment of D. Return to Transmission Data Processing Flow: Clinical in the Data Transmission section.

Performance Measure Name: Left Without Being Seen Measure ID #: OP-22 Measure Set: Hospital Outpatient ED-Throughput Outpatient Setting: Emergency Department **Description:** Percent of patients who leave the Emergency Department (ED) without being evaluated by a physician/advanced practice nurse/physician's assistant (physician/APN/PA). Measure ascertains response to the following question(s): What was the total number of patients who left without being evaluated by a physician/APN/PA? (numerator). What was the total number of patients who presented to the ED? (denominator). **Annual data submission period:** See the timeline posted to QualityNet.org for this measure; select Hospitals-Outpatient and then Data Submission in the drop-down menu. Data entry will be achieved through the secure side of QualityNet.org via an online tool available to authorized users. **Definition for patients who presented to the ED:** • Patients who presented to the ED are those that signed in to be evaluated for emergency services. **Definition for Physician/APN/PA:** Patients who are seen by a resident or intern are to be considered as seen by a physician. An institutionally credentialed provider, acting under the direct supervision of a physician for healthcare services in the emergency department (e.g., an obstetric nurse providing assessment of an obstetric patient) are to be considered as seen by a physician. Advanced Practice Nurse (APN, APRN) titles may vary between state and clinical specialties. Some common titles that represent the advanced practice nurse role are: Nurse Practitioner (NP) Certified Registered Nurse Anesthetist (CRNA) Clinical Nurse Specialist (CNS) Certified Nurse Midwife (CNM)

# **Hospital Outpatient Quality Measure Stroke**

	Measure ID #	Measure Short Name
ſ	(14-74	Head CT or MRI Scan Results for Acute Ischemic Stroke or Hemorrhagic Stroke Patients
'		who Received Head CT or MRI Scan Interpretation Within 45 minutes of ED Arrival

# **OP Stroke General Data Element List**

<b>General Data Element Name</b>	Collected For:
Arrival Time	All Records
Birthdate	All Records
CMS Certification Number ‡, †	All Records
First Name	All Records
Hispanic Ethnicity	All Records
Last Name	All Records
National Provider Identifier ‡, †	Optional for All Records
Outpatient Encounter Date	All Records
Patient Identifier	All Records
Payment Source	All Records
Physician 1	Optional for All Records
Physician 2	Optional for All Records
Postal Code	All Records
Race	All Records
Sex	All Records

<sup>&</sup>lt;sup>‡</sup>Transmission Data Element.

# **OP Stroke Specific Data Element List**

<b>OP Stroke Data Element Name</b>	Collected For:
Arrival Time	OP-23
Discharge Code	OP-23
E/M Code	OP-23
Date Last Known Well	OP-23
ICD-10-CM Principal Diagnosis Code	OP-23
Head CT Scan or MRI Order	OP-23
Head CT Scan or MRI Interpretation Date	OP-23
Head CT Scan or MRI Interpretation Time	OP-23
Last Known Well	OP-23
Time Last Known Well	OP-23

<sup>&</sup>lt;sup>†</sup>Defined in the Transmission Data Element List within the Hospital Outpatient Measure Data Transmission section of this manual.

# **OP-23 Hospital Outpatient Emergency Department Stroke Population**

### Stroke


The population of the OP-23 ED Stroke measure is identified using 4 data elements:

- E/M Code
- Outpatient Encounter Date
- Birthdate
- ICD-10-CM Principal Diagnosis Code

Patients seen in a Hospital Emergency Department (E/M Code in Appendix A, OP Table 1.0) are included in the OP-23 ED Stroke Hospital Outpatient Population and are eligible to be sampled if they have:

- A patient age on Outpatient Encounter Date (Outpatient Encounter Date Birthdate)  $\geq$  18 years, and
- An *ICD-10-CM Principal Diagnosis Code* for Acute Ischemic or Hemorrhagic Stroke as defined in Appendix A, OP Table 8.0

# Stroke Hospital Outpatient Population Algorithm OP-23



Hospital OQR Specifications Manual

Encounter dates 01-01-20 (1Q20) through 12-31-20 (4Q20) v13.0a

# Algorithm Narrative for OP-23: Stroke Hospital Outpatient Population

1. Start Stroke Initial Patient Population logic sub-routine. Process all cases that have successfully reached the point in the Transmission Data Processing Flow: Clinical which calls this Initial Patient Population Algorithm. Do not process cases that have been rejected before this point in the Transmission Data Processing Flow.

### 2. Check E/M Code

- a. If *E/M Code* is not in Appendix A, OP Table 1.0, patient is not in the Outpatient Stroke Population. Patient is not eligible to be sampled for the OP-23 measure. Set the OP Population Reject Case Flag to Yes. Return to Transmission Data Processing Flow: Clinical in the Data Transmission section.
- b. If *E/M Code* is in Appendix A, OP Table 1.0, continue processing and proceed to Measurement Value.
- 3. Calculate Measurement Value. Measurement Value, in years, is equal to the *Outpatient Encounter Date* minus *Birthdate*

### 4. Check Measurement Value

- a. If the Measurement Value is less than 18 years, patient is not in the Outpatient Stroke Population. Patient is not eligible to be sampled for the OP-23 measure. Set the OP Population Reject Case Flag to Yes. Return to Transmission Data Processing Flow: Clinical in the Data Transmission section.
- b. If the Measurement Value is greater than or equal to 18 years, continue processing, and the case will proceed to *ICD-10-CM Principal Diagnosis Code*.

### 5. Check ICD-10-CM Principal Diagnosis Code

- a. If the *ICD-10-CM Principal Diagnosis Code* is on Table 8.0, patient is in the Outpatient Stroke Population. Patient is eligible to be sampled for the OP-23 measure. Set the OP Population Reject Case Flag to No. Return to Transmission Data Processing Flow: Clinical in the Data Transmission section.
- b. If the *ICD-10-CM Principal Diagnosis Code* is not on Table 8.0, patient is not in the Outpatient Stroke Population. Patient is not eligible to be sampled for the OP-23 measure. Set the OP Population Reject Case Flag to Yes. Return to Transmission Data Processing Flow: Clinical in the Data Transmission section.

### NQF-Endorsed Voluntary Consensus Standards for Hospital Care Measure Information Form

**Performance Measure Name:** Head CT or MRI Scan Results for Acute Ischemic Stroke or Hemorrhagic Stroke Patients who Received Head CT or MRI Scan Interpretation Within 45 Minutes of ED Arrival

Measure ID #: OP-23

Measure Set: Hospital Outpatient Stroke

Outpatient Setting: Emergency Department

**Description:** Emergency Department Acute Ischemic Stroke or Hemorrhagic Stroke patients who arrive at the ED within 2 hours of the onset of symptoms who have a head CT or MRI scan performed during the stay and having a time from ED arrival to interpretation of the Head CT or MRI scan within 45 minutes of arrival.

Rationale: The Centers for Disease Control and Prevention (CDC) estimates that nearly 800,000 people experience a stroke in the United States each year; approximately 140,000 deaths annually are related to stroke (Yang et al., 2017). The American Health Association (AHA) and American Stroke Association (ASA) recommend performing emergency imaging of the brain before initiating any specific treatment for acute stroke; for most patients, a non-enhanced brain imaging scan, such as a computed tomography (CT) scan or magnetic resonance imaging (MRI), provides sufficient information to make care decisions (Powers et al., 2018; Jauch et al. 2013). Timely brain imaging is a critical component of ED evaluation for patients with suspected acute stroke because it provides important information about the diagnosis, prognosis, and treatment needs for these patients (Powers et al. 2018). AHA/ASA guidelines recommend that brain imaging be interpreted by a qualified provider within 45 minutes of ED arrival because results from these studies are critical to differentiate ischemic strokes, hemorrhagic strokes, and stroke mimics; imaging findings can be used to identify appropriate candidates for tissue plasminogen activator (tPA), which is the gold standard for treating acute ischemic stroke (Jauch et al. 2013). Because the Food and Drug Administration (FDA) has approved tPA for use within three hours of symptom onset, prompt imaging can accelerate administration of the time-sensitive therapy for eligible patients (Cheng et al. 2015).

Because of the therapeutic window for selecting a stroke treatment, timely completion and interpretation of the CT or MRI scan are imperative; playing a role in evaluating the quality of care a patient receives (Kamal, 2017). Decreasing radiology report turnaround times can improve care team coordination, impact ED length of stay, and reduce the time needed for providers to initiate potentially life-saving interventions for stroke patients (Handel, 2011).

**Type of Measure:** Process

**Improvement Noted As:** An increase in the rate.

**Numerator Statement:** Emergency Department Acute Ischemic Stroke or Hemorrhagic Stroke patients arriving at the ED within 2 hours of the *Time Last Known Well*, with an order for a head CT or MRI scan whose time from ED arrival to interpretation of the Head CT scan is within 45 minutes of arrival.

**Included Populations:** Not Applicable

**Excluded Populations:** None

### **Data Elements:**

- Arrival Time
- Head CT or MRI Scan Interpretation Date
- Head CT or MRI Scan Interpretation Time
- Outpatient Encounter Date

**Denominator Statement:** Emergency Department Acute Ischemic Stroke or Hemorrhagic Stroke patients arriving at the ED within 2 hours of the *Time Last Known Well* with an order for a head CT or MRI scan.

### **Included Populations:**

- Patients with an *ICD-10-CM Principal Diagnosis Code* for acute ischemic stroke, or hemorrhagic stroke as defined in Appendix A, OP Table 8.0; and
- Patients who had a *Head CT or MRI Scan Order*; and
- An E/M Code for emergency department encounter as defined in Appendix A, OP Table 1.0.

### **Excluded Populations:**

- Patients less than 18 years of age.
- Patients who expired.
- Patients who left the emergency department against medical advice, discontinued care, or for whom *Discharge Code* is not documented or unable to be determined (UTD).

#### **Data Elements:**

- Birthdate
- Date Last Known Well
- Discharge Code
- E/M Code

- Head CT or MRI Scan Order
- ICD-10-CM Principal Diagnosis Code
- Last Known Well
- Time Last Known Well

Risk Adjustment: No

**Data Collection Approach:** Retrospective data sources for required data elements include administrative data and medical record documents. Some hospitals may prefer to gather data concurrently by identifying patients in the population of interest. This approach provides opportunities for improvement at the point of care/service. However, complete documentation includes the principal or other ICD-10-CM diagnosis and procedure codes, which require retrospective data entry.

**Data Accuracy:** Variation may exist in the assignment of ICD-10-CM codes; therefore, coding practices may require evaluation to ensure consistency. There may be additional variation by provider, facility, and documentation protocol for chart-abstracted data elements.

Measure Analysis Suggestions: None

Sampling: Yes; for additional information see the Population and Sampling Specifications section.

Data Reported As: Aggregate rate generated from count data reported as a proportion.

# **Suggested References:**

- Cheng NT, Kim AS. Intravenous Thrombolysis for Acute Ischemic Stroke Within 3 Hours Versus Between 3 and 4.5 Hours of Symptom Onset. Demaerschalk BM, ed. The Neurohospitalist, 2015;5(3):101-109.
- Jauch E.C., Saver J.L., Adams H.P. Jr, Bruno A., Connors J.J., Demaerschalk B.M., Khatri P., McMullan PW Jr, Qureshi AI, Rosenfield K, Scott PA, Summers DR, Wang DZ, Wintermark M, Yonas H; on behalf of the American Heart Association Stroke Council, Council on Cardiovascular Nursing, Council on Peripheral Vascular Disease, and Council on Clinical Cardiology. (2013). Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke, 44(3), 870-947

Hospital OQR Specifications Manual


Encounter dates 01-01-20 (1Q20) through 12-31-20 (4Q20) v13.0a

- Handel, D., Epstein, S., Khare, R., Abernethy, D., Klauer, K., Pilgrim, R., Soremekun, O. and O. Sayan. (2011). Interventions to Improve the Timeliness of Emergency Care. Academic Emergency Medicine, 18:1295-302.
- Kamal, N., S. Sheng, Y. Xian, R. Matsouaka, M. D. Hill, D. L. Bhatt, J. L. Saver, M. J. Reeves, G. C. Fonarow, L. H. Schwamm and E. E. Smith. (2017). Delays in Door-to-Needle Times and Their Impact on Treatment Time and Outcomes in Get With The Guidelines-Stroke. Stroke, 48(4), 946-954.
- Powers, W.J., Rabinstein, A.A., Ackerson, T., Adeoye, O. M., et al. (2018). American Heart Association/American Stroke Association.
- Powers, W. J., C. P. Derdeyn, J. Biller, C. S. Coffey, B. L. Hoh, E. C. Jauch, K. C. Johnston, S. C. Johnston, A. A. Khalessi, C. S. Kidwell, J. F. Meschia, B. Ovbiagele, and D. R. Yavagal. (2015). American Heart Association/American Stroke Association Focused Update of the 2013 Guidelines for the Early Management of Patients with Acute Ischemic Stroke Regarding Endovascular Treatment.

# OP-23: Head CT or MRI Scan Results for Acute Ischemic Stroke or Hemorrhagic Stroke Patients who Received Head CT or MRI Scan Interpretation Within 45 Minutes of ED Arrival


**Numerator:** Emergency Department Acute Ischemic Stroke or Hemorrhagic Stroke patients arriving at the ED within 2 hours of the time last known well, with an order for a head CT or MRI scan whose time from ED arrival to interpretation of the Head CT scan is within 45 minutes of arrival.

**Denominator:** Emergency Department Acute Ischemic Stroke or Hemorrhagic Stroke patients arriving at the ED within 2 hours of the time last known well with an order for a head CT or MRI scan.



Hospital OQR Specifications Manual

Encounter dates 01-01-20 (1Q20) through 12-31-20 (4Q20) v13.0a



### **Algorithm Narrative for OP-23:**

# Head CT or MRI Scan Results for Acute Ischemic Stroke or Hemorrhagic Stroke Patients who Received Head CT or MRI Scan Interpretation Within 45 minutes of ED Arrival

**Numerator Statement:** Emergency Department Acute Ischemic Stroke or Hemorrhagic Stroke patients who arrive at the ED within 2 hours of the onset of symptoms who have a head CT or MRI scan performed during the stay and having a time from ED arrival to interpretation of the Head CT or MRI scan within 45 minutes of arrival.

**Denominator Statement:** Emergency Department Acute Ischemic Stroke or Hemorrhagic Stroke patients arriving at the ED within 2 hours of the *Time Last Known Well* with an order for a head CT or MRI scan.

1. Start processing. Run cases that are included in the Stroke Hospital Outpatient Population and pass the edits defined in the Data Processing Flow through this measure.

# 2. Check Discharge Code.

- a. If *Discharge Code* is missing, the case will proceed to a Measure Category Assignment of X and will be rejected. Return to Transmission Data Processing Flow: Clinical in the Data Transmission section.
- b. If *Discharge Code* equals 6, 7, or 8, the case will proceed to a Measure Category Assignment of B and will not be in the Measure Population. Return to Transmission Data Processing Flow: Clinical in the Data Transmission section.
- c. If *Discharge Code* equals 1, 2, 3, 4a, 4b, 4c, 4d, or 5, continue processing and proceed to *Head CT or MRI Scan Order*.

### 3. Check Head CT or MRI Scan Order.

- a. If *Head CT or MRI Scan Order* is missing, the case will proceed to a Measure Category Assignment of X and will be rejected. Return to Transmission Data Processing Flow: Clinical in the Data Transmission section.
- b. If *Head CT or MRI Scan Order* equals No, the case will proceed to a Measure Category Assignment of B and will not be in the Measure Population. Return to Transmission Data Processing Flow: Clinical in the Data Transmission section.
- c. If Head CT or MRI Scan Order equals Yes, continue processing and proceed to Last Known Well.

### 4. Check Last Known Well.

- a. If *Last Known Well* is missing, the case will proceed to a Measure Category Assignment of X and will be rejected. Return to Transmission Data Processing Flow: Clinical in the Data Transmission section.
- b. If *Last Known Well* equals No, the case will proceed to a Measure Category Assignment of B and will not be in the Measure Population. Return to Transmission Data Processing Flow: Clinical in the Data Transmission section.
- c. If Last Known Well equals Yes, continue processing and proceed to Date Last Known Well.

### 5. Check Date Last Known Well.

- a. If *Date Last Known Well* is missing, the case will proceed to a Measure Category Assignment of X and will be rejected. Return to Transmission Data Processing Flow: Clinical in the Data Transmission section.
- b. If *Date Last Known Well* equals UTD, the case will proceed to a Measure Category Assignment of D and will be in the Measure Population. Return to Transmission Data Processing Flow: Clinical in the Data Transmission section.

c. If *Date Last Known Well* equals a Non-UTD Value, continue processing and proceed to *Time Last Known Well*.

# 6. Check Time Last Known Well.

- a. If *Time Last Known Well* is missing, the case will proceed to a Measure Category Assignment of X and will be rejected. Return to Transmission Data Processing Flow: Clinical in the Data Transmission section.
- b. If *Time Last Known Well* equals UTD, the case will proceed to a Measure Category Assignment of D and will be in the Measure Population. Return to Transmission Data Processing Flow: Clinical in the Data Transmission section.
- c. If Time Last Known Well equals a Non-UTD Value, continue processing and proceed to Arrival Time.

### 7. Check Arrival Time.

- a. If *Arrival Time* equals UTD, the case will proceed to a Measure Category Assignment of D and will be in the Measure Population. Return to Transmission Data Processing Flow: Clinical in the Data Transmission section.
- b. If Arrival Time equals a Non-UTD Value, continue processing and proceed to Measurement Value.
- 8. Calculate Measurement Value. Measurement Value, in minutes, is equal to the *Outpatient Encounter Date* and *Arrival Time* minus *Date Last Known Well* and *Time Last Known Well*.

### 9. Check Measurement Value.

- a. If the Measurement Value is greater than 120 minutes, the case will proceed to a Measurement Category Assignment of B and will not be in the Measure Population. Return to Transmission Data Processing Flow: Clinical in the Data Transmission section.
- b. If the Measurement Value is greater than or equal to zero and less than or equal to 120 minutes, continue processing and proceed to *Head CT or MRI Scan Interpretation Date*.
- c. If the Measurement Value is less than zero minutes, the case will proceed to a Measurement Category Assignment of X and will be rejected. Return to Transmission Data Processing Flow: Clinical in the Data Transmission section.

### 10. Check Head CT or MRI Scan Interpretation Date.

- a. If *Head CT or MRI Scan Interpretation Date* is missing, the case will proceed to a Measure Category Assignment of X and will be rejected. Return to Transmission Data Processing Flow: Clinical in the Data Transmission section.
- b. If *Head CT or MRI Scan Interpretation Date* equals UTD, the case will proceed to a Measure Category Assignment of D and will be in the Measure Population. Return to Transmission Data Processing Flow: Clinical in the Data Transmission section.
- c. If *Head CT or MRI Scan Interpretation Date* equals a Non-UTD Value, continue processing and proceed to *Head CT or MRI Scan Interpretation Time*.

# 11. Check Head CT or MRI Scan Interpretation Time.

- a. If *Head CT or MRI Scan Interpretation Time* is missing, the case will proceed to a Measure Category Assignment of X and will be rejected. Return to Transmission Data Processing Flow: Clinical in the Data Transmission section.
- b. If *Head CT Scan Interpretation Time* equals UTD, the case will proceed to a Measure Category Assignment of D and will be in the Measure Population. Return to Transmission Data Processing Flow: Clinical in the Data Transmission section.

- c. If *Head CT Scan Interpretation Time* equals a Non-UTD Value, continue processing and proceed to Measurement Value.
- 12. Calculate Measurement Value. Measurement Value, in minutes, is equal to the *Head CT or MRI Scan Interpretation Date* and *Head CT or MRI Scan Interpretation Time* minus *Outpatient Encounter Date* and *Arrival Time*.

### 13. Check Measurement Value.

- a. If the Measurement Value is greater than 45 minutes, the case will proceed to a Measurement Category Assignment of D and will be in the Measure Population. Return to Transmission Data Processing Flow: Clinical in the Data Transmission section.
- b. If the Measurement Value is greater than or equal to zero and less than or equal to 45 minutes, the case will proceed to a Measure Category Assignment of E and will be in the Measure Population. Return to Transmission Data Processing Flow: Clinical in the Data Transmission section.
- c. If the Measurement Value is less than zero minutes, the case will proceed to a Measure Category Assignment of X and will be rejected. Return to Transmission Data Processing Flow: Clinical in the Data Transmission section.

Performance Measure Name: MRI Lumbar Spine for Low Back Pain

**Measure ID #:** OP-8

Measure Set: Imaging Efficiency Measures

**Description:** This measure calculates the percentage of MRI (Magnetic Resonance Imaging) of the Lumbar Spine studies with a diagnosis of low back pain on the imaging claim and for which the patient did not have prior claims-based evidence of antecedent conservative therapy.

Antecedent conservative therapy may include (see subsequent details for codes):

- 1. Claim(s) for physical therapy in the 60 days preceding the Lumbar Spine MRI.
- 2. Claim(s) for chiropractic evaluation and manipulative treatment in the 60 days preceding the Lumbar Spine MRI.
- 3. Claim(s) for evaluation and management in the period > 28 days and < 60 days preceding the Lumbar Spine MRI.

Detailed specifications for the measures, including measure implementation information, can be found via the following link:

 $\underline{http://www.qualitynet.org/dcs/ContentServer?c=Page\&pagename=QnetPublic\%2FPage\%2FQnetTier2\&cid=1228695266120}$ 

**Performance Measure Name:** Abdomen CT – Use of Contrast Material

Measure ID #: OP-10

Measure Set: Imaging Efficiency Measures

**Description:** This measure calculates the percentage of abdomen studies that are performed with and without contrast out of all abdomen studies performed (those with contrast, those without contrast, and those with both). The measure is calculated based on a one-year window of claims data.

**Technical Note:** To reflect changes made to the CPT coding system, codes for combined abdomen/pelvis studies have been added to those contained within the numerator and denominator, beginning in July 2013, for claims data from 2011 and beyond.

Detailed specifications for the measure, including measure implementation information, can be found via the following link:

 $\underline{http://www.qualitynet.org/dcs/ContentServer?c=Page\&pagename=QnetPublic\%2FPage\%2FQnetTier2\&cid=1228695266120}$ 

**Performance Measure Name:** Cardiac Imaging for Preoperative Risk Assessment for Non-Cardiac Low-Risk Surgery

Measure ID #: OP-13

Measure Set: Imaging Efficiency Measures

**Description:** This measure calculates the percentage of Stress Echocardiography, Single Photon Emission Computed Tomography, Myocardial Perfusion Imaging (SPECT MPI), Cardiac Computed Tomography Angiography (CCTA), or Stress Magnetic Resonance Imaging (MRI) studies performed at a hospital outpatient facility in the 30 days prior to an ambulatory low-risk, non-cardiac surgery performed anywhere.

Detailed specifications for the measures, including measure implementation information, can be found via the following link:

 $\frac{http://qualitynet.org/dcs/ContentServer?c=Page\&pagename=QnetPublic\%2FPage\%2FQnetTier2\&cid=1228\\695266120.$ 

**Performance Measure Name:** Appropriate Follow-up Interval for Normal Colonoscopy in Average Risk Patients

Measure ID #: OP-29

Measure Set: Measures submitted via a web-based tool

**Description:** Percentage of patients aged 50 to 75 years of age receiving a screening colonoscopy without biopsy or polypectomy who had a recommended follow-up interval of at least 10 years for repeat colonoscopy documented in their colonoscopy report.

**Numerator Statement:** Patients who had a recommended follow-up interval of at least 10 years for repeat colonoscopy documented in their colonoscopy report.

**Denominator Statement:** All patients aged 50 to 75 years of age receiving screening colonoscopy without biopsy or polypectomy.

### **Denominator Criteria (Eligible Cases):**

Patients aged  $\geq 50$  and  $\leq 75$  on date of encounter

and

ICD-10-CM Diagnosis code: Z12.11

and

CPT or HCPCS: 44388, 45378, G0121

without

CPT Category I Modifiers: 52, 53, 73, 74

without

ICD-10-CM Diagnosis codes: Z83.71, Z86.010, Z80.0, Z85.038

### **Denominator Exclusions:**

• Documentation of medical reason(s) for not recommending at least a 10-year follow-up interval (e.g. inadequate prep, familial or personal history of colonic polyps, patient had no adenoma and age is ≥66 years old, or life expectancy is <10years, other medical reasons). Medical reason(s) are at the discretion of the physician. Documentation indicating no follow-up colonoscopy is needed or recommended is only acceptable if the patient's age is documented as ≥66 years old, or life expectancy <10 years. Documentation of a medical condition or finding can be used as a medical reason(s) for denominator exclusion purposes only if the documented recommended follow-up interval is less than 10 years.

# Examples:

- Diverticulitis documented in the medical record and a follow-up interval of 5 years in the colonoscopy report.
- Family history of colon cancer and a follow-up interval of 3 years documented in the colonoscopy report.
- Less than adequate prep documented in the medical record with a repeat colonoscopy in 3 years in the colonoscopy report.

**Annual data submission period:** See the timeline posted to QualityNet.org for this measure; select Hospitals-Outpatient and then Data Submission in the drop-down menu. Data entry will be achieved through the secure side of QualityNet.org via an online tool available to authorized users.

**Additional instructions:** Patients will be counted in the numerator if there is reference in the final colonoscopy report that the appropriate follow-up interval for the repeat colonoscopy is at least 10 years from the date of the current colonoscopy (i.e., the colonoscopy performed during the measurement period). A range that includes "10 years" (e.g., 7 to 10 years) is not acceptable.

**Performance Measure Name:** Cataracts – Improvement in Patient's Visual Function within 90 Days Following Cataract Surgery

Measure ID #: OP-31\*

Measure Set: Measures submitted via a web-based tool

**Description:** Percentage of patients aged 18 years and older who had cataract surgery and had improvement in visual function achieved within 90 days following the cataract surgery, based on completing a preoperative and post-operative visual function survey.

**Numerator Statement:** Patients 18 years and older who had improvement in visual function achieved within 90 days following cataract surgery, based on completing **both** a pre-operative and post-operative visual function survey.

**Denominator Statement:** All patients aged 18 years and older who had cataract surgery and completed **both** a pre-operative and post-operative visual function survey.

# **Denominator Criteria (Eligible Cases):**

Patients aged  $\geq$  18 years

and

CPT (with or without modifiers): 66840, 66850, 66852, 66920, 66930, 66940, 66982, 66983, 66984

**Excluded Populations:** Patients who did not complete both a pre-operative and post-operative survey.

**Annual data submission period:** See the timeline posted to QualityNet.org for this measure; select Hospitals-Outpatient and then Data Submission in the drop-down menu. Data entry will be achieved through the secure side of QualityNet.org via an online tool available to authorized users.

**Data Collection Approach:** Include procedures performed from the beginning of the reporting year through 90 days prior to the end of the reporting period. This will allow the post-operative period to occur.

**Definition for Survey:** The data collection instrument is specified as an assessment tool that has been appropriately validated for the population for which it is being used. The surveys can be completed by phone, mail, email, or during physician follow-up. The same data collection instrument used pre-operatively must be used post-operatively.

Examples of tools for visual function assessment include, but are not limited to: National Eye Institute Visual Function Questionnaire (VFQ- <a href="http://www.rand.org/health/surveys\_tools/vfq.html">http://www.rand.org/health/surveys\_tools/vfq.html</a>), the Visual Function (VF)-14, the modified VF-8, the Activities of Daily Vision Scale (ADVS), the Catquest, and the modified Catquest-9. For each of the VF tools (VF-14 or VF-8R), all questions have equal weight, only non-missing questions are included, and the total weight is 100.

Definition of Performance Met: Improvement in visual function achieved within 90 days following cataract surgery (G0913).

Definition of Performance Not Met: Improvement in visual function not achieved within 90 days following cataract surgery (G0915).

Denominator Exception: Patient care survey was not completed by patient (G0914).

\*Finalized in the CY 2015 OPPS/ASC final rule, hospitals have the option to voluntarily collect and submit data for OP-31 for the CY 2017 payment determination and subsequent years. All data submitted voluntarily will be publicly reported as discussed in the CY 2014 OPPS/ASC proposed rule (78 FR 43645) and final rule with comment period (78 FR 75092).

# Centers for Medicare & Medicaid Services (CMS) Facility 7-Day Risk-Standardized Hospital Visit Rate after Outpatient Colonoscopy

### Introduction

This section of the manual includes the Measure Information Form (MIF) for the CMS Facility 7-Day Risk-Standardized Hospital Visit Rate after Outpatient Colonoscopy measure. This is an administrative claims-based measure, so there is no data abstraction responsibility on the part of the facility. The measure includes outpatient colonoscopies performed among Medicare Fee-for-Service (FFS) beneficiaries aged  $\geq 65$  years.

CMS will use the measure results in the Hospital Outpatient Quality Reporting (OQR) Program for payment determination in calendar year 2022. Beginning with payment determination year 2020, CMS will calculate the measure with three years of claims data. For payment determination year 2022, the performance period is January2018 through December 2020.

This measure was developed by a team of clinical and statistical experts from the Yale New Haven Health Services Corporation/Center for Outcomes Research and Evaluation (YNHHSC/CORE), under contract to CMS. The measure is currently endorsed by the National Quality Forum (NQF #2539).

The aim of the MIF is to provide transparency of the measure methodology to the facility and vendor communities. Additional background information about the measure methodology can be found in the Measure Updates and Specifications Report available on the Measure Methodology *QualityNet* page (<a href="http://www.qualitynet.org/dcs/ContentServer?c=Page&pagename=QnetPublic%2FPage%2FQnetTier3&cid=1228775197506">http://www.qualitynet.org/dcs/ContentServer?c=Page&pagename=QnetPublic%2FPage%2FQnetTier3&cid=1228775197506</a>). CMS provides a new report each year to align with the most current calendar year. For example, the 2018 Measure Updates and Specifications Report will align with a performance period ending in calendar year 2018. If the re-evaluation report associated with the performance period of this MIF is not yet available, it is sufficient to use the most recent report. Please submit questions about the measure to the *QualityNet* Question and Answer Tool here: <a href="https://cms-ocsq.custhelp.com/">https://cms-ocsq.custhelp.com/</a>.

CMS calculates a facility-level risk-standardized unplanned hospital visit rate for all eligible facilities. Facilities and their ORYX® Vendors do not have sufficient data to produce facilities' risk-standardized results. CMS uses inpatient and outpatient claims data to determine whether a beneficiary has had an unplanned hospital visit to any acute care hospital within 7 days of the outpatient colonoscopy. In addition, CMS extracts and utilizes physician office, inpatient, and outpatient claims data from the year prior to the colonoscopy, as well as claims data from the colonoscopy, to risk adjust the facility-level outcome rates.

### **Measure Information Form (MIF)**

**Performance Measure Name:** Facility 7-Day Risk-Standardized Hospital Visit Rate after Outpatient Colonoscopy

Measure ID #: OP-32

Measure Set: CMS Outcome Measures (Claims-Based)

**Description:** The Facility 7-Day Risk-Standardized Hospital Visit Rate after Outpatient Colonoscopy Measure, hereafter referred to as the colonoscopy measure, estimates a facility-level rate of risk-standardized, all-cause, unplanned hospital visits within 7 days of an outpatient colonoscopy among Medicare fee-for-service (FFS) patients aged 65 years and older.

**Rationale:** The colonoscopy measure will reduce adverse patient outcomes associated with preparation for colonoscopy, the procedure itself, and follow-up care by capturing and making more visible to providers and patients all unplanned hospital visits following the procedure. The measure score will assess quality and inform quality improvement.

Type of Measure: Outcome

**Improvement Noted As:** A decrease in the facility-level risk-standardized unplanned hospital visit rate. Lower rate indicates better quality.

### **Numerator Statement:**

This outcome measure does not have a traditional numerator and denominator like a core process measure (e.g., percentage of adult patients with diabetes aged 18-75 years receiving one or more hemoglobin A1c tests per year); thus, we are using this field to define the outcome. The calculation of the rate is defined below under the Measure Calculation section below.

The outcome for this measure is all-cause, unplanned hospital visits within 7 days of an outpatient colonoscopy. The measure defines a hospital visit as any emergency department (ED) visit, observation stay, or unplanned inpatient admission.

### **Denominator Statement:**

The target population for this measure includes low-risk colonoscopies performed in the outpatient setting for Medicare FFS patients aged 65 years and older. For implementation in the Outpatient Quality Reporting (OQR) Program, the measure will be calculated among hospital outpatient departments (HOPDs).

# **Included Populations:**

Outpatient colonoscopies for Medicare FFS patients aged 65 years and older. Medicare FFS beneficiaries with an outpatient colonoscopy are included if the patient has been enrolled in Part A and Part B Medicare for the 12 months prior to the date of procedure to ensure a full year of administrative data for risk adjustment.

The measure is focused on low-risk colonoscopies. Cohort codes are located in the data dictionary that accompanies the Measure Updates and Specifications Report, available on the Measure Methodology *QualityNet* page

(http://www.qualitynet.org/dcs/ContentServer?c=Page&pagename=QnetPublic%2FPage%2FQnetTier3&cid=1228775197506). (Note that in prior years, all measure codes are located within the Measure Updates and Specifications Reports.)

The measure does not include colonoscopy Current Procedural Terminology (CPT®) procedure codes that reflect fundamentally higher-risk or different procedures. Qualifying colonoscopies billed with a concurrent high-risk colonoscopy procedure code are not included in the measure; the data dictionary that accompanies the most recent Measure Updates and Specifications Report at the link above contains the complete listing of all high-risk procedure codes.

## **Cohort exclusions (excluded colonoscopies):**

See the Measure Updates and Specifications Report available on the Measure Methodology *QualityNet* page for detailed measure cohort exclusion criteria

(http://www.qualitynet.org/dcs/ContentServer?c=Page&pagename=QnetPublic%2FPage%2FQnetTier3&cid=1228775197506). The accompanying data dictionary file to the report contains current exclusion codes.

# Admissions not counted in the outcome ("Planned admissions"):

Admissions identified as planned by the planned admission algorithm are not counted in the outcome. The "algorithm" is a set of criteria for classifying admissions as planned using Medicare claims. The algorithm identifies admissions that are typically planned and may occur within 7 days of an outpatient colonoscopy. CMS based the planned admission algorithm on three principles:

- 1. A few specific, limited types of care are always considered planned (transplant surgery, maintenance chemotherapy, rehabilitation);
- 2. Otherwise, a planned admission is defined as a non-acute admission for a scheduled procedure; and
- 3. Admissions for acute illness or for complications of care are never planned.

The planned admission algorithm uses a flowchart and four tables of procedures and conditions to operationalize these principles and to classify inpatient admissions as planned. ED visits and observation stays are never considered planned. The flowchart and tables are in the Measure Updates and Specifications Report available on the Measure Methodology *QualityNet* page (<a href="http://www.qualitynet.org/dcs/ContentServer?c=Page&pagename=QnetPublic%2FPage%2FQnetTier3&cid=1228775197506">http://www.qualitynet.org/dcs/ContentServer?c=Page&pagename=QnetPublic%2FPage%2FQnetTier3&cid=1228775197506</a>).

### **Risk Adjustment:**

The measure's approach to risk adjustment is tailored to, and appropriate for, a publicly reported outcome measure as articulated in published scientific guidelines (Krumholz et al., 2006; Normand et al., 2007).

The measure uses a two-level hierarchical logistic regression model to estimate facility-level risk-standardized hospital visit rates. This approach accounts for the clustering of patients within facilities and variation in sample size across facilities.

The risk-adjustment model has 15 patient-level variables (age, concomitant upper GI endoscopy, polypectomy during the procedure, and 12 comorbidity variables). The measure defines comorbidity variables using condition categories (CCs), which are clinically meaningful groupings of the many thousands of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) diagnosis codes. Certain CCs are considered possible complications of care; therefore, the measure does not risk-adjust for them if they occur only at the time of the procedure. Therefore, only comorbidities that convey information about the patient at the time of the procedure or in the 12 months prior, and not complications that arose during the colonoscopy procedure are included in the risk adjustment. The Measure Updates and Specifications Report data dictionary contains complete definitions of risk factors and CCs that are considered possible complications of care and are not risk-adjusted for if they occur only at the time of the procedure.

Table 1: Patient-Level Risk-Adjustment Variables

Patient-level variables	Risk-adjusted variables
Demographics	Age (categorized; 65-69; 70-74; 75-79; 80-84; 85+)
Procedural factors	Concomitant Endoscopy Polypectomy during Procedure
Comorbidities	Congestive Heart Failure Ischemic Heart Disease Stroke/Transient Ischemic Attack (TIA) Chronic Lung Disease Metastatic Cancer Liver Disease Iron Deficiency Anemia Disorders of Fluid, Electrolyte, Acid-Base Pneumonia Psychiatric Disorders Drug and Alcohol Abuse/Dependence
	Arrhythmia Age Categorized x Arrhythmia Interaction

**Note:** The relationship between age and risk of a hospital visit within 7 days was modified by the presence or absence of a cardiac arrhythmia (p-value for interaction < 0.001). Therefore, we included an interaction term (age categorized x arrhythmia) in the final model.

Full details of the development of the risk-adjustment model for this measure are available at: <a href="https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/HospitalQualityInits/Measure-Methodology.html">https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/HospitalQualityInits/Measure-Methodology.html</a>.

Data Collection Approach: Medicare administrative claims and enrollment data.

**Data Accuracy:** The administrative claims data used to calculate the measure are maintained by CMS' Office of Information Services. These data undergo additional quality assurance checks during measure development and maintenance.

Measure Analysis Suggestions: None

Sampling: No

**Data Reported As:** Facility-level 7-day risk-standardized unplanned hospital visit rate following outpatient colonoscopy.

### **Measure Calculation:**

The measure estimates facility-level 7-day risk-standardized unplanned hospital visit rates using hierarchical logistic regression modeling (a form of hierarchical generalized linear modeling [HGLM]). In brief, the approach simultaneously models two levels (patient and facility) to account for the variance in patient outcomes within and between facilities. At the patient level, the model adjusts the log-odds of a hospital visit within 7 days of the procedure for age, procedural factors, and selected clinical covariates. At the facility level, it estimates the facility-specific intercepts as arising from a normal distribution. The facility-specific intercept represents the underlying risk of a hospital visit within 7 days after a colonoscopy at that facility while accounting for patient risk. The facility-specific intercepts also account for the clustering (non-

independence) of patients within the same facility. If there were no differences among facilities, the facility-specific intercepts would be identical across all facilities after adjusting for patient risk.

The statistical modeling approach is described fully in the original technical report: <a href="https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/HospitalQualityInits/Measure-Methodology.html">https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/HospitalQualityInits/Measure-Methodology.html</a>.

### **Selected References:**

- Krumholz HM, Brindis RG, Brush JE, et al. Standards for Statistical Models Used for Public Reporting of Health Outcomes: An American Heart Association Scientific Statement From the Quality of Care and Outcomes Research Interdisciplinary Writing Group: Cosponsored by the Council on Epidemiology and Prevention and the Stroke Council Endorsed by the American College of Cardiology Foundation. Circulation. 2006; 113 (3): 456-462.
- Normand S-LT, Shahian DM. Statistical and Clinical Aspects of Hospital Outcomes Profiling. Stat Sci. 2007; 22 (2): 206-226.

# Centers for Medicare & Medicaid Services (CMS) Admissions and Emergency Department (ED) Visits for Patients Receiving Outpatient Chemotherapy

### Introduction

This section of the manual includes the Measure Information Form (MIF) for the CMS Admissions and Emergency Department (ED) Visits for Patients Receiving Outpatient Chemotherapy measure. This is an administrative claims-based measure, so there is no data abstraction responsibility on the part of the facility. The measure includes Medicare fee-for-service (FFS) patients aged 18 years and older at the start of the performance period with a diagnosis of any cancer (except leukemia), who received at least one outpatient chemotherapy treatment at the reporting hospital during the performance period.

CMS has finalized adoption of the measure into the Hospital Outpatient Quality Reporting (OQR) Program for payment determination beginning in calendar year 2020.

This measure was developed by a team of clinical and statistical experts from the Yale New Haven Health Services Corporation/Center for Outcomes Research and Evaluation (YNHHSC/CORE), under contract to CMS. The measure is currently undergoing initial endorsement review as part of the National Quality Forum's portfolio of cancer care measures.

The aim of the MIF is to provide transparency of the measure methodology to the facility and vendor communities. Additional background information about the measure methodology can be found in the Measure Updates and Specifications Report available on the Measure Methodology *QualityNet* page (<a href="http://www.qualitynet.org/dcs/ContentServer?c=Page&pagename=QnetPublic%2FPage%2FQnetTier3&cid=1228776192121">http://www.qualitynet.org/dcs/ContentServer?c=Page&pagename=QnetPublic%2FPage%2FQnetTier3&cid=1228776192121</a>). CMS provides a new report each year to align with the most current calendar year. For example, the 2018 Measure Updates and Specifications Report will align with a performance period of calendar year 2018. If the re-evaluation report associated with the performance period of this MIF is not yet available, it is sufficient to use the most recent report. Please submit questions about the measure to the *QualityNet* Question and Answer Tool here: <a href="https://cms-ocsq.custhelp.com/">https://cms-ocsq.custhelp.com/</a>.

# **Measure Information Form (MIF)**

**Performance Measure Name:** Admissions and Emergency Department (ED) Visits for Patients Receiving Outpatient Chemotherapy

Measure ID #: OP-35

Measure Set: CMS Outcome Measures (Claims-Based)

**Description:** The Admission and Emergency Department (ED) Visits for Patients Receiving Outpatient Chemotherapy Measure, hereafter referred to as the chemotherapy measure, estimates hospital-level, risk-adjusted rates of inpatient admissions or ED visits for cancer patients ≥18 years of age for at least one of the following diagnoses—anemia, dehydration, diarrhea, emesis, fever, nausea, neutropenia, pain, pneumonia, or sepsis—within 30 days of hospital-based outpatient chemotherapy treatment. Rates of admission and ED visits are calculated and reported separately.

Rationale: Chemotherapy treatment can have severe, predictable side effects, which, if inappropriately managed, can reduce patients' quality of life and increase healthcare utilization and costs. This measure aims to assess the care provided to cancer patients and encourage quality improvement efforts to reduce the number of potentially avoidable inpatient admissions and ED visits among cancer patients receiving chemotherapy in a hospital outpatient setting. Improved management of these potentially preventable clinical conditions that are frequent side effects of chemotherapy treatment—including anemia, dehydration, diarrhea, emesis, fever, nausea, neutropenia, pain, pneumonia, or sepsis—could reduce admissions and ED visits and increase patients' quality of care and quality of life. This measure encourages hospitals to use guidelines from the American Society of Clinical Oncology, National Comprehensive Cancer Network, Oncology Nursing Society, Infectious Diseases Society of America, and other professional societies to integrate and promote use of evidence-based interventions to prevent and treat common side effects and complications of chemotherapy.

Type of Measure: Outcome

**Improvement Noted As:** A decrease in the hospital-level risk-adjusted rates of inpatient admissions or ED visits. Lower rate indicates better quality.

# **Numerator Statement:**

The chemotherapy measure is a risk-adjusted outcome measure and does not have a traditional numerator like a process measure; thus, we use this field to define the measured outcomes of interest as this measure separately reports hospital rates of two outcomes: inpatient admissions and ED visits. The outcomes for this measure are one or more inpatient admissions, and one or more ED visits without an inpatient admission, for one of the following diagnoses—anemia, dehydration, diarrhea, emesis, fever, nausea, neutropenia, pain, pneumonia, or sepsis—within 30 days of receiving hospital-based outpatient chemotherapy treatment for cancer. These 10 conditions are potentially preventable through appropriately managed outpatient care. The qualifying diagnosis on the inpatient admission or ED visit claim must be (1) the principal diagnosis or (2) a secondary diagnosis accompanied by a principal diagnosis of cancer.

Outcomes are identified separately for the inpatient admissions and ED visits categories; a patient can only qualify for an outcome in either category, but not both. Patients who experience both an inpatient admission and an ED visit during the performance period are counted towards the inpatient admission outcome. Among those with no qualifying inpatient admissions, qualifying ED visits will be counted. As a result, the rates can be viewed as an additive to provide a comprehensive performance estimate of quality of care following

Hospital OQR Specifications Manual

Encounter dates **01-01-20** (**1Q20**) through **12-31-20** (**4Q20**) v13.0a

CPT® only copyright 2019 American Medical Association. All rights reserved.

hospital-based outpatient chemotherapy treatment. The rates are calculated separately because the severity and cost of an inpatient admission is different from that of an ED visit, and both adverse events are important signals of quality and represent important healthcare outcomes for patients. The International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and Internal Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) codes that identify these diagnoses are in the data dictionary available on the Measure Methodology *QualityNet* page (<a href="http://www.qualitynet.org/dcs/ContentServer?c=Page&pagename=QnetPublic%2FPage%2FQnetTier3&cid=1228776192121">http://www.qualitynet.org/dcs/ContentServer?c=Page&pagename=QnetPublic%2FPage%2FQnetTier3&cid=1228776192121</a>) on sheets "Numerator-Anemia," "Numerator-Dehydration," "Numerator-Diarrhea," "Numerator-Emesis," "Numerator-Fever," "Numerator-Nausea," "Numerator-Neutropenia," "Numerator-Pain," "Numerator-Pneumonia," and "Numerator-Sepsis." The ICD-9 codes were used during development and testing of the measure; the data dictionary also includes the mapping from these ICD-9 codes to ICD-10 codes.

#### **Denominator Statement:**

The chemotherapy measure cohort includes Medicare fee-for-service (FFS) patients, aged 18 years and older at the start of the performance period, with a diagnosis of any cancer (except leukemia), who received at least one outpatient chemotherapy treatment at the reporting hospital during the performance period. The ICD-9 and ICD-10 codes that identify cancer diagnoses are in the measure data dictionary on sheet "Denominator-Cancer." The measure identifies chemotherapy treatment using ICD-9 and ICD-10 procedure and encounter codes, Current Procedural Terminology (CPT®)/Healthcare Common Procedure Coding System (HCPCS) procedure and medication procedure codes, and Uniform Billing-04 (UB-04) revenue center codes. The ICD-9, ICD-10, CPT®, HCPCS, and revenue center codes that identify chemotherapy treatment are in the measure data dictionary on the following tabs: "Denominator-Chemo Procedure," "Denominator-Chemo Encounter," and "Denominator-Chemo Medicine" (http://www.qualitynet.org/dcs/ContentServer?c=Page&pagename=QnetPublic%2FPage%2FQnetTier3&cid=1228776192121). The ICD-9 diagnosis and procedure codes were used during development and testing of this measure; the data dictionary also includes the mapping from these ICD-9 codes to ICD-10 codes.

#### **Cohort exclusions:**

See the Measure Updated and Specifications Report available on the Measure Methodology *QualityNet* page for detailed measure cohort exclusion criteria:

# **Risk Adjustment:**

Since the measure has two mutually exclusive outcomes—qualifying inpatient admissions and qualifying ED visits—it has two risk-adjustment models, one for each dependent variable (inpatient admissions and ED visits). A two-level hierarchical logistic regression model is used to estimate risk-standardized outcome rates. This approach accounts for differences in patient mix, the clustering of patients within hospitals, and variation in sample size.

The measure adjusts for variables that are clinically relevant and associated with the outcome. It seeks to adjust for differences in patient demographics, clinical comorbidities, and treatment exposure which vary across patient populations and influence the outcome but do not relate to quality. Specifically, the risk-standardized model for inpatient admissions has 21 patient-level variables (age, sex, two exposure variables, nine comorbidity variables, and eight cancer categories). The risk-standardized model for ED visits has 16 patient-level variables (age, sex, two exposure variables, six comorbidity variables, and six cancer categories).

Table 1: Patient-Level Risk-Adjustment Variable

Category	Inpatient Admission Outcome	ED visit outcome
Demographics	Age (years above 18, continuous)	Age (years above 18, continuous)
	Sex	Sex
Exposure	Number of hospital outpatient chemotherapy	Number of hospital outpatient chemotherapy
•	treatments during the performance period	treatments during the performance period
	Whether the patient received concurrent	Whether the patient received concurrent
	radiotherapy and chemotherapy	radiotherapy and chemotherapy
Cancer type	Breast cancer	Breast cancer
	Digestive cancer	Digestive cancer
	Respiratory cancer	Respiratory cancer
	Lymphoma	Other cancer
	Other cancer	Secondary cancer of the lymph nodes
	Prostate cancer	Secondary cancer of solid tumor
	Secondary cancer of the lymph nodes	
	Secondary cancer of solid tumor	
Comorbidities	Respiratory disorder	Respiratory disorder
	Renal disease	Other injuries
	Diabetes	Gastrointestinal disorder
	Other injuries	Psychiatric disorder
	Metabolic disorder	Neurological condition
	Gastrointestinal disorder	Cardiovascular disease
	Psychiatric disorder	
	Neurological condition	
	Cardiovascular disease	

The Condition Categories (CCs) that define each of these comorbidities and the ICD-9 and ICD-10 codes that define the cancer categories are included in the data dictionary (Risk Model: Inpatient Admissions Outcome Model Definitions and Risk Model: Emergency Department Outcome Model Definitions). The comorbidities are based on version 22 of the CMS CC groups. Full Details of the development of the risk-standardization model for this measure are in the Measure Updates and Specifications Report available on the Measure Methodology *QualityNet* page

(http://www.qualitynet.org/dcs/ContentServer?c=Page&pagename=QnetPublic%2FPage%2FQnetTier3&cid=1228776192121).

Data Collection Approach: Medicare administrative claims and enrollment data.

**Data Accuracy:** The administrative claims data used to calculate the measure are maintained by CMS' Office of Information Services. These data undergo additional quality assurance checks during measure development and maintenance.

Measure Analysis Suggestions: None

Sampling: No

**Data Reported As:** Facility-level, risk-standardized rate of inpatient admissions and ED visits for cancer patients within 30 days of hospital-based outpatient chemotherapy treatment.

# **Measure Calculation:**

The measure calculates a hospital-specific risk-adjusted rate for each of the two outcomes. Each rate is calculated as the ratio of a hospital's "predicted" number of outcomes to "expected" number of outcomes multiplied by the national observed outcome rate. It estimates the expected number of outcomes for each hospital using the hospital's patient case mix and the average hospital-specific intercept (that is, the average intercept among all hospitals in the sample). The measure estimates the predicted number of outcomes for each hospital using the same patient case mix, but an estimated hospital-specific intercept. Operationally, the measure obtains the expected number of outcomes for each hospital by summing the expected probabilities of outcomes for all patients treated at the hospital. It calculates the expected probability of outcomes for each patient via the hierarchical model, which applies the estimated regression coefficients to the observed patient characteristics and adds the average of the hospital-specific intercept. It calculates the predicted number of outcomes for each hospital by summing the predicted probabilities for all patients in the hospital. The measure calculates the predicted probability for each patient through the hierarchical model, which applies the estimated regression coefficients to the observed patient characteristics and adds the hospital-specific intercept. If there were no differences among facilities, the facility-specific intercepts would be identical across all facilities after adjusting for patient risk.

If a hospital's ratio of predicted to expected outcomes are less than 1, it indicates that the hospital is performing better than expected given its case mix. If a hospital's ratio of predicted to expected outcomes is greater than 1, it indicates that the hospital is performing worse than expected given its case mix. For ease of interpretation, we transform this ratio to a rate by multiplying by the national observed rate for that outcome. If the "predicted" number of outcomes is higher (or lower) than the "expected" number of outcomes for a given hospital, the risk-adjusted rate will be higher (or lower) than the national observed admission rate.

The statistical modeling approach is fully described in the Measure Updates and Specifications Report available on the Measure Methodology *QualityNet* page

 $(\underline{http://www.qualitynet.org/dcs/ContentServer?c=Page\&pagename=QnetPublic\%2FPage\%2FQnetTier3\&cid=1228776192121}).$ 

Hospital OQR Specifications Manual

Encounter dates 01-01-20 (1Q20) through 12-31-20 (4Q20) v13.0a

CPT® only copyright 2019 American Medical Association. All rights reserved.

# Centers for Medicare & Medicaid Services (CMS) Hospital Visits after Outpatient Surgery Measure

#### Introduction

This section of the manual includes the Measure Information Form (MIF) for the CMS Hospital Visits after Hospital Outpatient Surgery measure. This is an administrative claims-based measure, so there is no data abstraction responsibility on the part of the facility. The measure includes Medicare FFS patients, aged 65 and older, with unplanned hospital visits following same-day surgery at hospital outpatient departments (HOPDs) during the performance period.

CMS has finalized adoption of the measure into the Hospital Outpatient Quality Reporting (OQR) Program for payment determination beginning in calendar year 2020.

This measure was developed by a team of clinical and statistical experts from the Yale New Haven Health Services Corporation/Center for Outcomes Research and Evaluation (YNHHSC/CORE), under contract to CMS. The measure is currently endorsed by the National Quality Forum (NQF #2687).

The aim of the MIF is to be transparent about the measure methodology for the facility and vendor communities. Additional background information about the measure methodology can be found in the Measure Updates and Specifications Report available on the Measure Methodology *QualityNet* page (<a href="http://www.qualitynet.org/dcs/ContentServer?c=Page&pagename=QnetPublic%2FPage%2FQnetTier3&cid=1228776203288">http://www.qualitynet.org/dcs/ContentServer?c=Page&pagename=QnetPublic%2FPage%2FQnetTier3&cid=1228776203288</a>). CMS provides a new report each year. For example, the 2018 Measure Updates and Specification Report will align with a performance period of calendar year 2018. If the re-evaluation report associated with the performance period of this MIF is not yet available, it is sufficient to use the most recent report. Please submit questions about the measure to the *QualityNet* Question and Answer Tool here: <a href="https://cms-ocsq.custhelp.com/">https://cms-ocsq.custhelp.com/</a>.

CMS calculates a facility-level risk-standardized unplanned hospital visit ratio for all eligible facilities. Facilities and their ORYX® Vendors do not have sufficient data to produce facilities' risk-standardized results. CMS inpatient and outpatient claims data are used to determine whether a beneficiary has had an unplanned hospital visit to any acute care hospital within 7 days of the outpatient surgery. In addition, CMS extracts and utilizes physician office, inpatient, and outpatient claims data from the year prior to the surgery as well as claims data from the surgery to risk adjust the facility-level results.

# **Measure Information Form (MIF)**

Performance Measure Name: Hospital Visits after Hospital Outpatient Surgery

Measure ID #: OP-36

Measure Set: CMS Outcome Measures (Claims-Based)

**Description:** Facility-level, post-surgical risk-standardized hospital visit ratio (RSHVR) of the predicted to expected number of all-cause, unplanned hospital visits within 7 days of a same-day surgery at a hospital outpatient department (HOPD) among Medicare fee-for-service (FFS) patients aged 65 years and older.

Rationale: Outpatient same-day surgery is exceedingly common in the United States. Unanticipated hospital visits following same-day surgery reflect quality of care. While most outpatient surgery is safe, there are well-described and potentially preventable adverse events that occur after outpatient surgery, which can result in unanticipated hospital visits. Similarly, direct admissions after surgery that are primarily caused by non-clinical patient considerations, such as lack of transport home upon discharge, or facility logistical issues, such as delayed start of surgery, are common causes of unanticipated yet preventable hospital admissions following same-day surgery. A quality measure of hospital visits following outpatient same-day surgery can improve transparency, inform patients and providers, and foster quality improvement.

Type of Measure: Outcome

**Improvement Noted As:** A decrease in the ratio of predicted-to-expected unplanned hospital visits. Lower score indicates better quality.

#### **Numerator Statement:**

The outcome is all-cause unplanned hospital visits, defined as 1) an inpatient admission directly following surgery or 2) an emergency department [ED] visit, observation stay, or unplanned inpatient admission occurring after discharge from the HOPD and within 7 days of the outpatient surgery.

#### **Denominator Statement:**

Eligible same-day surgeries or cystoscopy procedures with intervention performed at HOPDs for Medicare FFS patients aged 65 years and older with the exception of eye surgeries and same day surgeries performed concurrently with high-risk procedures.

# **Included Populations:**

The target population is Medicare FFS patients aged 65 years and older undergoing same-day surgery (those that do not typically require an overnight stay) at HOPDs. The measure is limited to patients who have been enrolled in Medicare Part A and Part B in the 12 months prior to the date of surgery to ensure adequate data for identifying comorbidities for risk adjustment.

The measure includes surgeries for which a physician claim identifies a qualifying surgery as having been performed in an outpatient setting, and matches to a hospital facility claim to identify the HOPD where the surgery took place. For further information see the Cohort section of the Measure Updates and Specifications report available on the Measure Methodology *QualityNet* page

(<u>http://www.qualitynet.org/dcs/ContentServer?c=Page&pagename=QnetPublic%2FPage%2FQnetTier3&cid=1228776203288</u>). Surgeries for which a facility claim is not filed are not included in the measure cohort.

"Same-day surgeries" are substantive surgeries listed on Medicare's list of covered ambulatory surgery center (ASC) procedures. Medicare developed this list to identify surgeries that can be safely performed as

same-day surgeries and do not typically require an overnight stay. Surgeries on the Medicare's list of covered ASC procedures do not involve or require major or prolonged invasion of body cavities, extensive blood loss, major blood vessels, or care that is either emergent or life-threatening. Although Medicare developed this list of surgeries for ASCs, this measure uses it for two reasons. First, it aligns with the target cohort of surgeries that have a low to moderate risk profile and are safe to be performed as same day surgeries. By only including surgeries on this list, the measure effectively does not include surgeries performed at hospitals that typically require an overnight stay which are more complex, higher risk surgeries. Second, this list of surgeries is annually reviewed and updated by Medicare, and includes a transparent public comment submission and review process for addition and/or removal of procedures codes. The lists are posted at <a href="https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/11">https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/11</a> Addenda Updates.html (refer to Addendum AA of the respective link).

The measure cohort does not include eye surgeries. Although eye surgery is considered a substantive surgery, its risk profile is more representative of "minor" surgery, in that it is characterized by high volume and a low outcome.

The measure includes cystoscopy procedures with intervention because it is a common procedure, often performed for therapeutic intervention by surgical teams, and the outcome rate and causes of hospital visits post-procedure similar to other surgeries in the measure cohort.

Where multiple procedures occur concurrently, the measure only includes surgeries that are performed concurrently with another low to moderate risk procedure. The measure does not include same-day surgeries performed concurrently with a higher risk procedure such as an inpatient-only surgery.

For further details on the included surgeries and measure cohort, see the Measure Updates and Specifications Report available on the Measure Methodology *QualityNet* page (<a href="http://www.qualitynet.org/dcs/ContentServer?c=Page&pagename=QnetPublic%2FPage%2FQnetTier3&cid=1228776203288">http://www.qualitynet.org/dcs/ContentServer?c=Page&pagename=QnetPublic%2FPage%2FQnetTier3&cid=1228776203288</a>).

# **Cohort exclusions:**

See Appendix C: Measure Specification in the latest Measure Updates and Specifications Report available on the Measure Methodology *QualityNet* page for detailed measure cohort exclusion criteria (<a href="http://www.qualitynet.org/dcs/ContentServer?c=Page&pagename=QnetPublic%2FPage%2FQnetTier3&cid=1228776203288">http://www.qualitynet.org/dcs/ContentServer?c=Page&pagename=QnetPublic%2FPage%2FQnetTier3&cid=1228776203288</a>).

# Admissions Not Counted in the Outcome ("Planned Admissions"):

Admissions identified as planned by the planned admission algorithm are not counted in the outcome. The "algorithm" is a set of criteria for classifying admissions as planned using Medicare claims. The algorithm identifies admissions that are typically planned and may occur within 7 days of an outpatient surgery. CMS based the planned admission algorithm on three principles:

- 1. A few specific, limited types of care are always considered planned (transplant surgery, maintenance chemotherapy, rehabilitation);
- 2. Otherwise, a planned admission is defined as a non-acute admission for a scheduled procedure; and
- 3. Admissions for acute illness or for complications of care are never planned.

The planned admission algorithm uses a flowchart and four tables of procedures and conditions to operationalize these principles and to classify inpatient admissions as planned. The measure considers admissions occurring on the day of the surgery (Day 0) and Day 1 post-surgery unplanned. For inpatient

admissions occurring after Day 1 following surgery, the measure only includes unplanned admissions in the measure outcome.

ED visits and observation stays are never considered planned. The flowchart and tables are available in the latest Measure Updates and Specifications Report

# **Risk Adjustment:**

The measure approach to risk adjustment is tailored to, and appropriate for, a publicly reported outcome measure as articulated in published scientific guidelines [1, 2].

The measure uses a two-level hierarchical logistic regression model to estimate RSHVRs. This approach accounts for the clustering of patients within HOPDs and variation in sample size.

The risk-adjustment model has 25 patient-level variables, including age, clinical comorbidities, and indicators of surgical complexity.

The measure defines comorbidity variables using CMS Condition Categories (CCs), which are clinically meaningful groupings of many thousands of ICD-10-CM diagnosis codes. Certain CCs are considered possible complications of care and are not risk-adjusted for if they only occur at the surgery. See the data dictionary available on the Measure Methodology *QualityNet* page

(http://www.qualitynet.org/dcs/ContentServer?c=Page&pagename=QnetPublic%2FPage%2FQnetTier3&cid =1228776203288) for CCs that are considered possible complications of care and are not risk-adjusted for if they only occur at the surgery.

The measure risk adjusts for surgical procedural complexity using two variables. First, it adjusts for surgical procedural complexity using the Work Relative Value Unit (RVU) of the procedure. Work RVUs are assigned to each Current Procedural Terminology (CPT) code and approximate surgical procedural complexity by incorporating elements of physician time and effort. For patients with multiple concurrent CPT procedure codes, the measure risk adjusts for the CPT code with the highest Work RVU value. Second, it classifies each surgery into an anatomical body system group using the Agency for Healthcare Research and Quality (AHRQ) Clinical Classification System (CCS) [3]. The measure uses the body system variable, in addition to the Work RVU of the surgery, to account for organ-specific difference in risk and complications which are not adequately captured by the Work RVU alone. This approach to risk adjustment for surgical procedural complexity is similar to that described in the literature and used for risk adjustment in the American College of Surgeons' National Surgical Quality Improvement Program [4]. The coding list for the body systems is available at: <a href="https://www.hcup-us.ahrq.gov/tools\_software.jsp">https://www.hcup-us.ahrq.gov/tools\_software.jsp</a>.

**Table 1: Patient-Level Risk-Adjustment Variables** 

Patient-level variables	Risk-adjusted variables
Demographics Age (years greater than 65)	
Comorbidities	Cancer Diabetes and DM complications Disorders of fluid/electrolyte/acid-base Intestinal obstruction perforation Inflammatory bowel disease Bone/joint/muscle infections/necrosis

Hematological disorders including coagulation defects and iron deficien			
	Dementia or senility		
	Psychiatric disorders		
	Hemiplegia, paraplegia, paralysis, functional disability		
	Other significant CNS disease		
	Cardiorespiratory arrest, failure and respiratory dependence		
Congestive heart failure			
Ischemic heart disease			
	Hypertension and hypertensive disease		
	Arrhythmias		
	Vascular disease		
	Chronic lung disease		
	UTI and other urinary tract disorders		
	Pelvic inflammatory disease and other specified female genital disorders		
	Chronic ulcers		
	Cellulitis, local skin infection		
	Prior significant fracture		
	Morbid obesity		
Procedural Complexity	Work RVU		
1 Tocedural Complexity	AHRQ surgery body system		

For a detailed description of the development and refinement of the risk-adjustment model, see the Hospital Visits after Hospital Outpatient Surgery: 2016 Measure Updates and Specifications Report <a href="http://www.qualitynet.org/dcs/ContentServer?c=Page&pagename=QnetPublic%2FPage%2FQnetTier3&cid=1228776203288">http://www.qualitynet.org/dcs/ContentServer?c=Page&pagename=QnetPublic%2FPage%2FQnetTier3&cid=1228776203288</a>.

Data Collection Approach: Medicare administrative claims and enrollment data.

**Data Accuracy:** The administrative claims data used to calculate the measure are maintained by CMS' Office of Information Services. These data undergo additional quality assurance checks during measure development and maintenance.

Measure Analysis Suggestions: None

**Sampling:** No

**Data Reported As:** Facility-level 7-day risk-standardized unplanned hospital visit ratio following outpatient surgery.

#### **Measure Calculation:**

To calculate a facility-specific, post-surgical risk-standardized hospital visit ratio (RSHVR) for outpatient surgery patients, the measure uses hierarchical logistic regression to model the log-odds of the outcome as a function of the patient demographic and clinical characteristics, surgical procedure, and a random facility-specific intercept. This strategy accounts for within-facility correlation of the observed outcome, and it accommodates the assumption that underlying differences in quality across HOPDs lead to systematic difference in outcomes. For fairness, the model adjusts for demographic and clinical characteristics and procedural variables that vary across patient populations, are unrelated to quality, and influence the outcome in order to help ensure differences in the measure score do not reflect differences in case mix and surgical procedure mix across HOPDs. If there were no differences among facilities, the facility-specific intercepts would be identical across all facilities after adjusting for patient risk. The statistical approach to calculating

[RSHVR is described in Appendix A of the 2018 Measure Updates and Specification Report and Appendix D of the 2016 Measure Updates and Specifications Report:

http://www.qualitynet.org/dcs/ContentServer?c=Page&pagename=QnetPublic%2FPage%2FQnetTier3&cid=1228776203288).

# **Selected References:**

- 1. Krumholz HM, Brindis RG, Brush JE, et al. Standards for Statistical Models Used for Public Reporting of Health Outcomes: An American Heart Association Scientific Statement From the Quality of Care and Outcomes Research Interdisciplinary Writing Group: Cosponsored by the Council on Epidemiology and Prevention and the Stroke Council Endorsed by the American College of Cardiology Foundation. Circulation. 2006; 113 (3): 456-462.
- 2. Normand S-LT, Shahian DM. Statistical and Clinical Aspects of Hospital Outcomes Profiling. Stat Sci. 2007; 22 (2): 206-226.
- 3. HCUP Clinical Classifications Software for Services and Procedures. Healthcare Cost and Utilization Project (HCUP). 2008. Agency for Healthcare Research and Quality, Rockville, MD http://www.hcup-us.ahrq.gov/toolssoftware/ccs\_svcsproc/ccssvcproc.jsp, 2014.
- 4. Raval MV, Cohen ME, Ingraham AM, et al. Improving American College of Surgeons National Surgical Quality Improvement Program risk adjustment: incorporation of a novel procedure risk score. Journal of the American College of Surgeons. Dec 2010; 211(6): 715-723.

# **Data Dictionary**

# **Introduction:**

This section of the manual describes the data elements required to calculate category assignments and measurements for the Hospital Outpatient measures. It includes information necessary for defining and formatting the data elements, as well as the allowable values for each data element. This information is intended to assist in processing patient-level data elements for Hospital Outpatient measures.

It is of primary importance that all hospitals using Hospital Outpatient measures gather and utilize the data elements as defined in this section. This will ensure that the data are standardized and comparable across hospitals.

Regardless of which measures are selected by a hospital, certain general data elements must be collected and submitted for **every** patient that falls into **any** of the selected outpatient populations. These data elements are considered "general" to each outpatient encounter.

These data elements include:

- Arrival Time
- Birthdate
- CMS Certification Number ‡, †
- Hispanic Ethnicity
- Outpatient Encounter Date
- Patient Identifier
- Payment Source
- Postal Code
- Race
- Sex

‡ Transmission Data Element.

† Defined in the Transmission Data Element List within the Hospital Outpatient Quality Measure Data Transmission section of this manual.

# **Interpretation of Data Dictionary Terms:**

Data elements fall into three broad categories in order to support specific measures. They include:

- General Data Elements Data elements that must be collected by hospitals for each patient record.
  - Data elements required for each hospital outpatient encounter record submitted.
  - Data elements used to identify the hospital on each patient record required for each patient-level record submitted.
  - Patient demographic data required for each hospital outpatient encounter record submitted.
- *Measure-Specific Data Elements* Data elements used by one specific measure or outpatient measure set, such as the ED-Throughput outpatient measure set.
- *Optional Data Elements* Data elements collected to capture information that might be helpful for internal analysis.

<sup>‡</sup> Collected by CMS for patients with a Payment Source of Medicare who have a standard HIC number

# **Data Dictionary Terms**

**Data Element Name:** A short phrase identifying the data element.

**Collected For:** Identifies the measure(s) that utilize this data element or specifies that the data

element is used for data transmission or verification.

**Definition:** A detailed explanation of the data element.

**Suggested Data** 

**Collection Question:** A suggested wording for a data element question in a data abstraction tool.

**Format:** Length = number of characters or digits allowed for the data element

Type = type of information the data element contains (i.e., numeric,

alphanumeric, date, decimal, or time)

Occurs = the number of times the data element occurs in a single encounter

record

Allowable Values: A list of acceptable responses for this data element.

**Notes for Abstraction:** Provided to assist abstractors in the selection of an appropriate value for a data

element.

**Suggested Data Sources:** Source document from which data can be identified such as an administrative

or medical record. Some data elements also list excluded data sources that are

unacceptable sources for collecting information.

Guidelines for Abstraction: Designed to assist abstractors in determining how a data element should be

answered.

# **General Abstraction Guidelines**

The General Abstraction Guidelines are a resource designed to assist abstractors in determining how an abstraction question should be answered. The abstractor should first refer to the specific notes and guidelines under each data element as these instructions should take precedence over the following General Abstraction Guidelines. All of the allowable values for a given data element are outlined, and notes and guidelines are often included in each data element's notes and guidelines which provide the necessary direction for abstracting a data element. Thus, it is important to utilize the information found in the notes and guidelines when entering or selecting the most appropriate answer.

# Medical Record Documentation

The intent of abstraction is to use only documentation that was part of the medical record during the hospitalization (is present upon discharge) and that is present at the time of abstraction. There are instances where an addendum or late entry is added after discharge. This late entry or addendum can be used for abstraction purposes as long as it has been added within 30 days of discharge [Refer to the Medicare Conditions of Participation for Medical Records, 42CFR482.24(c)(4)(viii)], unless otherwise specified in the data element. Documents containing amendments, corrections, or delayed entries must employ the following widely accepted recordkeeping principles (CMS "Medicare Program Integrity Manual" Chapter 3, Section 3.3.2.4):

- Clearly and permanently identify any amendments, corrections, or addenda;
- Clearly indicate the date and author of any amendments, corrections, or addenda; and
- Clearly identify all original content.

It is not the intent to have documentation added at the time of abstraction to ensure the passing of a measure.

Important Note: Data element specific notes and guidelines always take precedence over the General Abstraction Guidelines.

Per the Medicare Conditions of Participation, all documentation in the medical record must be legible and must be timed, dated, and authenticated [42CFR482.24(c) (1)]. However, documentation that is not timed, dated, or authenticated may still be used for abstraction if not required by the specific data element. When abstracting a medical record, if a handwritten document is determined to be not legible, other documentation should be reviewed in an attempt to obtain the answer. If no other source document is able to verify the handwritten documentation, only then is the abstractor to answer unable to determine from the medical record documentation, unless otherwise specified in the data element. Authentication may include written signatures, initials, computer key, or other codes.

Data element information should be retrieved from the current medical record, covering the encounter date being abstracted. Information ascertainable from previous testing or previous history **and** determined to be part of the current medical record may be used in abstraction. Previous testing or history information used in abstraction should be information that was part of the medical record during the encounter when care was being delivered. As electronic data are available at all times during the hospitalization, it is acceptable to use these data for abstraction purposes.

The medical record must be abstracted as documented (i.e., taken at "face value"). When the value documented is obviously in error (not a valid format/range or outside of the parameters for the data element) and no other documentation is found that provides this information, the abstractor should select "UTD."

# Suggested Data Sources

- Suggested Data Sources are listed in alphabetical order, **not** priority order, unless otherwise specified. Suggested Data Sources are designed to provide guidance to the abstractor as to the locations/sources where the information needed to abstract a data element will likely be found. However, the abstractor is not limited to these sources for abstracting the information and is encouraged to review the entire medical record.
- In some instances, a data element may restrict the sources that may be used to gain the information, list a priority in which the sources should be used, or may restrict documentation by only physician/advanced practice nurse/physician assistant. If so, these sources will be identified and labeled as Excluded Data Sources, Only Acceptable Sources, Priority Source, or Physician/APN/PA Documentation Only.
- In the course of abstraction, if conflicting information is found in a source other than the Suggested Data Sources and use of this source is not restricted, consider using this information if it more accurately answers the question, unless otherwise specified.
- If, after due diligence, the abstractor determines that a value is not documented, or the abstractor is not able to determine the answer value, the abstractor must select UTD as the answer.
- Hospitals often label forms and reports with unique names or titles. Suggested Data Sources are listed by commonly used titles; however, information may be abstracted from any source that is equivalent to those listed.

# Inclusions/Exclusions

- Inclusions are acceptable terms that should be abstracted as positive findings (e.g., Yes).
- Inclusion lists are limited to those terms that are believed to be most commonly used in medical record documentation. The list of inclusions should not be considered all-inclusive, unless otherwise specified in the data element.
- Exclusions are unacceptable terms that should be abstracted as negative findings (e.g., No).
- Exclusion lists are limited to those terms an abstractor may most frequently question whether or not to abstract as a positive finding for a particular element. The list of exclusions should not be considered all-inclusive, unless otherwise specified in the data element.
- When both an inclusion and exclusion are documented in a medical record, the inclusion takes precedence over the exclusion and would be abstracted as a positive finding (e.g., answer Yes), unless otherwise specified.

# Physician/Advanced Practice Nurse/Physician Assistant Documentation

- Advanced Practice Nurse (APN, APRN) titles may vary between state and clinical specialties. Some common titles that represent the advanced practice nurse role are:
  - Nurse Practitioner (NP)
  - Certified Registered Nurse Anesthetist (CRNA)
  - Clinical Nurse Specialist (CNS)
  - Certified Nurse Midwife (CNM)
- When a physician/advanced practice nurse/physician assistant (physician/APN/PA) signs a form or report (e.g., ED sheet with triage and nursing information and a physician/APN/PA has signed somewhere on the form), information on that form/report should be considered physician/APN/PA documentation. Rubber-stamped physician/APN/PA signatures are not acceptable on any document within the medical record. Handwritten, electronic signatures, or facsimiles of original written or electronic signatures are acceptable.
- Resident and intern notes should be considered physician documentation. Medical student notes must be co-signed by a physician.

• For purposes of abstraction, telephone or verbal physician/APN/PA orders (TO/VO) in the medical record are considered physician/APN/PA documentation at the time they were written, regardless of whether or not they were authenticated by the physician/APN/PA at the time of abstraction.

# Pharmacist Documentation

Pharmacist titles may vary. Some common titles that represent the pharmacist role are:

- Doctor of Pharmacy (Pharm.D. or D.Ph.)
- Registered Pharmacist (R.Ph.)

#### Medications

- The approved medication tables contained in Appendix C may not be inclusive lists of all available therapeutic agents acceptable for a particular data element. Discrepancies must be reported.
- Whether or not a medication has been administered to a patient is often clear when using medical record sources such as medication administration records, but documentation can be more ambiguous in other sources, namely, physician orders, ED records, and ambulance records. To make a determination using these sources, use the following criteria:
  - For electronic health records (EHRs) only accept documentation that reflects the actual administration of the medication in the context of the chart.
  - If a medication in the physician orders has been initialed and signed off with a time, do **not** presume that the medication was administered. The documentation **must** indicate that the medication was actually given.
  - For an ED or ambulance record, there is no need for documentation indicating that the medication was actually given.
    - Example: If the ED or ambulance record reflects "ASA 325mg po 1300" and no other documentation exists indicating that the medication was actually given (e.g., "given" or "administered"), this is acceptable documentation to abstract.
- Hospitals may allow a patient (or his or her caregiver/support person where appropriate) to self-administer both hospital-issued medications and the patient's own medications brought into the hospital. Hospitals must document the administration of each medication, as reported by the patient (or the patient's caregiver/support person where appropriate) in the patient's medical record [42CFR482.23(c)(6)].

# Nursing Care Plans, Standing Orders, and Protocols

- Per Medicare Conditions of Participation [42CFR482.23(b)(4)], hospitals have the option of having a stand-alone nursing care plan or a single interdisciplinary care plan that addresses nursing and other disciplines.
- Hospitals may use pre-printed and electronic standing orders, order sets, and protocols for patient orders if such orders and protocols are dated, timed, and authenticated promptly in the patient's medical record by the ordering practitioner responsible for the care of the patient [42CFR482.24(c)(3)].

# Diagnostic/Laboratory Tests

Whether or not a diagnostic or laboratory test has been done is usually clear when using medical record sources such as diagnostic test reports, laboratory reports, or progress notes (where a physician might note test findings), but documentation can be more ambiguous in other sources, namely, physician orders and ED records. To make a determination using these sources, use the following criteria:

- If a test in the physician orders has been initialed and signed off with a time, do **not** presume that the test was done. The documentation **must** indicate that the test was actually done (e.g., accompanied by a word such as "done").
- For an ED record, there is no need for explicit documentation indicating that the test was actually done. For example, if an ED record notes "Lipid profile" and this is followed by a signature and/or a time, the abstractor should presume the test was performed.

# Grids

Instructions for reading values recorded on grids: Measure from the midpoint of the symbol, number, or letter. If the value falls between two lines on the grid, abstract the first occurring value.

# Abstraction Recommendations for Multiple Same-Day Encounters

- If two ED visits on the same day are rolled into one claim, abstract the **first** chronological encounter that meets the inclusion criteria for the population.
- If two ED visits on the same encounter date meet the inclusion criteria and are billed as two separate claims, **both** cases may be eligible for abstraction according to sampling requirements. Because the data element *Arrival Time* is used to differentiate between two cases that occur on the same encounter date, if both cases are submitted with UTD for *Arrival Time*, the case submitted last will override the previous case.

# **Alphabetical Data Element List**

Element Name	Page #	Collected For:
Arrival Time	2-76	All Records
Birthdate	2-79	All Records
Date Last Known Well	2-80	OP-23
Discharge Code	2-83	OP-2, OP-3, OP-18, OP-23
E/M Code	2-86	OP-2, OP-3, OP-18, OP-23
ED Departure Date	2-87	OP-3, OP-18
ED Departure Time	2-89	OP-3, OP-18
Fibrinolytic Administration	2-92	OP-2, OP-3
Fibrinolytic Administration Date	2-93	OP-2
Fibrinolytic Administration Time	2-95	OP-2
First Name	2-97	All Records
Head CT or MRI Scan Interpretation	2-98	OP-23
Date		
Head CT or MRI Scan Interpretation	2-100	OP-23
Time		
Head CT or MRI Scan Order	2-102	OP-23
Hispanic Ethnicity	2-103	All Records
ICD-10-CM Principal Diagnosis Code	2-104	OP-2, OP-3, OP-18, OP-23
Initial ECG Interpretation	2-105	OP-2, OP-3
Last Known Well	2-109	OP-23
Last Name	2-111	All Records
Outpatient Encounter Date	2-112	All Records
Patient Identifier	2-113	All Records
Payment Source	2-114	All Records
Physician 1	2-115	Optional for All Records
Physician 2	2-116	Optional for All Records
Postal Code	2-117	All Records
Race	2-118	All Records
Reason for Delay in Fibrinolytic	2-120	OP-2
Therapy		
Reason for Not Administering	2-122	OP-3
Fibrinolytic Therapy		
Sex	2-124	All Records
Time Last Known Well	2-125	OP-23
Transfer for Acute Coronary	2-129	OP-3
Intervention		

Data Element Name: Arrival Time

**Collected For:** All records (used in algorithms for OP-2, OP-3, OP-18, OP-23)

**Definition:** The earliest documented time (military time) the patient arrived at the outpatient or emergency department.

**Suggested Data Collection Question:** What was the **earliest** documented time the patient arrived at the outpatient or emergency department?

# **Format:**

Length: 5 - HH:MM (with or without colon) or UTD

Type: Time

Occurs: 1

# **Allowable Values:**

HH = Hour (00-23)

MM = Minutes (0-59)

UTD = Unable to Determine

Time must be recorded in military time format.

With the exception of midnight and noon:

- If the time is in the a.m., conversion is not required.
- If the time is in the p.m., add 12 to the clock time hour.

Examples:

- Midnight = 0000 Noon = 1200
- 5:31 a.m. = 0531 5:31 p.m. = 1731
- 11:59 a.m. = 1159 11:59 p.m. = 2359

**Note:** 0000 = midnight. If the time is documented as 0000 11-24-20XX, review supporting documentation to determine if the *Outpatient Encounter Date* should remain 11-24-20XX or if it should be converted to 11-25-20XX.

When converting midnight, or 2400, to 0000, do not forget to change the *Outpatient Encounter Date*. *Example:* 

• Midnight or 2400 on 11-24-20XX = 0000 on 11-25-20XX.

#### **Notes for Abstraction:**

- For times that include seconds, remove the seconds and record the time as is. *Example*:
  - 1500:35 would be recorded as 1500
- If the time of the arrival is unable to be determined from medical record documentation, select UTD.
- The medical record must be abstracted as documented (taken at "face value"). When the time documented is obviously in error (not a valid time) **and** no other documentation is found that provides this information, the abstractor should select UTD.

Example:

• Documentation indicates the arrival time was 3300. No other documentation in the list of Only Acceptable Sources provides a valid time. Since the *Arrival Time* is outside of the range in the Allowable Values for Hour, it is not a valid time, and the abstractor should select UTD.

**Note:** Transmission of a case with an invalid time as described above will be rejected from the CMS Clinical Data Warehouse. Use of UTD for *Arrival Time* allows the case to be accepted into the Warehouse.

- Review the Only Acceptable Sources to determine the earliest time the patient arrived at the ED or observation. The intent is to utilize any documentation which reflects processes that occurred after the arrival at the ED or after arrival to observation.
- Documentation outside of the Only Acceptable Sources list should **not** be referenced (e.g., ambulance record, physician office record, H&P).

Examples:

- ED Triage Time 0800. ED rhythm strip 0830. EMS report indicates patient was receiving EMS care from 0805 through 0825. The EMS report is disregarded. Enter 0800 for *Arrival Time*.
- ED noted arrival time of 0945. Lab report shows blood culture collected at 0830. It is not clear that the blood culture was collected in the ED because the lab report does not specify it was collected in the ED (unable to confirm lab report as an Only Acceptable Source). Enter 0945 for *Arrival Time*.
- *Arrival Time* should **not** be abstracted simply as the earliest time in one of the Only Acceptable Sources, without regard to other substantiating documentation. When looking at the Only Acceptable Sources, if the earliest time documented appears to be an obvious error, this time should not be abstracted. *Examples*:
  - ED arrival time notes as 2300 on 10-28-20xx. ED MAR shows an antibiotic administration time of 0100 on 10-28-20xx. Surrounding documentation on the ED MAR makes clear that the 10-28-20xx date is an obvious error- Date was not changed to 10-29-20xx. The antibiotic administration date/time would be converted to 0100 on 10-29-20xx. (Please see the note under the Allowable Values section of this data element). Enter 2300 for *Arrival Time*.

- ED face sheet lists arrival time of 1320. ED Registration Time 1325. ED Triage Time 1330. ED Consent to treat form has 1:17 time but "AM" is circled. ED record documentation suggests the 1:17 AM is an obvious error. Enter 1320 for *Arrival Time*.
- ED ECG timed as 1742. ED Greet Time 2125. ED Triage Time 2130. There is no documentation in the Only Acceptable Sources which suggests the 1742 is an obvious error. Enter 1742 for *Arrival Time*.
- ED RN documents on the nursing triage note, "Blood culture collected at 0730." ED arrival time is documented as 1030. There is no documentation in the Only Acceptable Sources which suggests the 0730 is an obvious error. Enter 0730 for *Arrival Time*.
- The source "Emergency Department record" includes any documentation from the time period that the patient was an ED patient.
- The source "Procedure notes" refers to procedures such as cardiac caths, endoscopies, and surgical procedures. Procedure notes do not include ECG and x-ray reports.
- The Arrival Time may differ from the admission time.

# **Observation Status:**

- If the patient was admitted to observation from an outpatient setting of the hospital, use the time the patient arrived at the ED or on the floor for observation care as the *Arrival Time*.
- If the patient was admitted to observation from the ED of the hospital, use the time the patient arrived at the ED as the *Arrival Time*.

# **Suggested Data Sources:**

# Only Acceptable Sources:

- Emergency Department record, which may include:
  - ED face sheet
  - ED consent/Authorization for treatment forms
  - ED/Outpatient registration/Sign-in forms
  - ED ECG reports
  - ED telemetry/rhythm strips
  - ED laboratory reports
  - ED x-ray reports
- Observation record
- Procedure notes
- Vital signs graphic record

# **Inclusion Guidelines for Abstraction:** None

# **Exclusion Guidelines for Abstraction:**

- Addressographs/stamps
- Pre-printed times on a vital sign graphic record

Data Element Name: Birthdate

Collected For: All records

**Definition:** The month, day, and year the patient was born.

**Note:** Patient Age on *Outpatient Encounter Date* (in years) is calculated by *Outpatient Encounter Date* minus *Birthdate*. The algorithm to calculate age must use the month and day portion of encounter date and birthdate to yield the most accurate age.

**Suggested Data Collection Question:** What is the patient's date of birth?

# **Format:**

Length: 10 – MM-DD-YYYY (includes dashes)

Type: Date

Occurs: 1

# **Allowable Values:**

MM = Month (01-12)

DD = Day (01-31)

YYYY = Year (1880–Current Year)

#### **Notes for Abstraction:**

Because this data element is critical in determining the population for all measures, the abstractor should **not** assume that the claim information for the birthdate is correct. If the abstractor determines through chart review that the date is incorrect, correct and override the downloaded value. If the abstractor is unable to determine the correct birthdate through chart review, default to the date of birth on the claim information.

# **Suggested Data Sources:**

- Outpatient record
- Emergency Department record

**Inclusion Guidelines for Abstraction:** None

**Exclusion Guidelines for Abstraction:** None

Data Element Name: Date Last Known Well

Collected For: OP-23

**Definition:** The date prior to hospital arrival at which the patient was last known to be without the signs and symptoms of the current stroke or at his or her baseline state of health.

**Suggested Data Collection Question:** What was the date associated with the time at which the patient was last known to be well or at his or her baseline state of health?

#### Format:

Length: 10 – MM-DD-YYYY (includes dashes) or UTD

Type: Date

Occurs: 1

#### **Allowable Values:**

MM = Month (01-12)

DD = Day (01-31)

YYYY = Year (20xx)

UTD = Unable to Determine

#### **Notes for Abstraction:**

- Enter the date associated with the *Time Last Known Well*. If the *Date Last Known Well* is unable to be determined from medical record documentation, enter UTD.
- The medical record must be abstracted as documented (taken at "face value"). When the date documented is obviously in error (not a valid date/format) **and** no other documentation is found that provides this information, the abstractor should select UTD.

Example:

Documentation indicates the Date Last Known Well was 03-42-20xx. No other documentation in the medical record provides a valid date. Since the Date Last Known Well is outside of the range listed in the Allowable Values for Day, it is not a valid date, and the abstractor should select UTD.

**Note:** Transmission of case with an invalid date as described above will be rejected from the CMS Clinical Data Warehouse. Use of UTD for *Date Last Known Well* allows the case to be accepted into the Warehouse.

• If the *Date Last Known Well* is documented as a specific date and entered as *Date Last Known Well* on a Code Stroke Form or stroke-specific electronic template, enter that date as *Date Last Known Well*. Documentation of the *Date Last Known Well* on a stroke-specific form or template should be selected regardless of other dates last known well documented elsewhere in the medical record.

# Exceptions:

- Any physician/APN/PA documentation that last known well/onset of signs/symptoms is unknown/uncertain/unclear takes precedence over specific time on a Code Stroke Form.
- References in relation to arrival date are acceptable (e.g., today, tonight, this evening, or this morning). The Date Last Known Well and the arrival date may be the same date or a different date. Examples:
  - "Wife reports patient normal this evening until approximately 9 PM." Hospital arrival is 0030 on 12-10-20xx. Date Last Known Well is 12-09-20xx.
  - "Patient states he felt perfectly fine earlier today. At noon, he began to have trouble seeing." Hospital arrival is 1559 on 12-10-20xx. Date Last Known Well is 12-10-20xx.
- If a reference to date last known well is documented without a specific date, enter that date for Date Last Known Well. If multiple dates are documented, select the earliest date. Examples:
  - "Patient last known well today (day of arrival)." Select arrival date for Date Last Known Well.
  - "Patient normal yesterday" (day before arrival) documented in H&P and consult note documents that patient was last known to be well on Monday (two days prior to arrival). Select Monday's date for *Date Last Known Well*.
- A Code Stroke Form is used by the stroke team or ED staff to document the acute stroke process. See the inclusion list for acceptable terms used for a Code Stroke Form. The list is not all-inclusive.
- Date Last Known Well on a Code Stroke Form may be documented by a nurse or other member of the care team authorized to serve as a scribe.

# **Suggested Data Sources:**

- Ambulance record
- Code Stroke Form/template
- **Emergency Department records**
- History and Physical
- IV flow sheets
- Medication administration record
- Nursing flow sheets
- Progress notes
- Transfer sheet

# **Inclusion Guidelines for Abstraction:**

Signs and Symptoms of Stroke

Sudden numbness or weakness of the face, arm, or leg, especially on one side of the body

- Sudden confusion, trouble speaking or understanding
- Sudden trouble seeing in one or both eyes
- Sudden trouble walking, dizziness, loss of balance or coordination
- Sudden severe headache

# Code Stroke Form

- Stroke Activation Form
- Stroke Alert Form
- Stroke Assessment Form
- Stroke Intervention Form
- Stroke Rapid Response Form
- Thrombolysis Checklist
- tPA Eligibility Form

# **Exclusion Guidelines for Abstraction:**

# Code Stroke Form

- Stroke Education Form
- Core Measure Form

Data Element Name: Discharge Code

Collected For: OP-2, OP-3, OP-18, OP-23

**Definition:** The final place or setting to which the patient was discharged from the outpatient setting.

Suggested Data Collection Question: What was the patient's discharge code from the outpatient setting?

#### Format:

Length: 2

Type: Alphanumeric

Occurs: 1

#### Allowable Values:

- 1 Home
- 2 Hospice Home
- 3 Hospice Health Care Facility
- 4a Acute Care Facility General Inpatient Care
- 4b Acute Care Facility Critical Access Hospital
- 4c Acute Care Facility Cancer Hospital or Children's Hospital
- 4d Acute Care Facility Department of Defense or Veteran's Administration
- 5 Other Health Care Facility
- 6 Expired
- 7 Left Against Medical Advice/AMA
- 8 Not Documented or Unable to Determine (UTD)

# **Notes for Abstraction:**

• If documentation is contradictory, use the latest documentation. If there is documentation that further clarifies the level of care, that documentation should be used to determine the correct value to abstract.

# Example:

• Nursing discharge note documentation reflects that the patient is being discharged to "XYZ" Hospital. The Social Service notes from the day before discharge further clarify that the patient will be transferred to the rehab unit at "XYZ" Hospital; select value 5.

- If the medical record states only that the patient is being discharged to another hospital and does not reflect the level of care that the patient will be receiving, select value 4a.
- When determining whether to select value 7 ("Left Against Medical Advice"):
  - A signed AMA form is not required for this data element, but in the absence of a signed form, the medical record must contain physician or nurse documentation that the patient left against medical advice or AMA.
  - Do not consider AMA documentation and other disposition documentation as "contradictory." If any source states the patient left against medical advice, select value 7, regardless of whether the AMA documentation was written last (e.g., AMA form signed and discharge instruction sheet states "Discharged home with belongings"—Select value 7).
  - Physician order written to discharge to home. Nursing notes reflect that the patient left before discharge instructions could be given; select value 1.

# **Suggested Data Sources:**

- Discharge instruction sheet
- Nursing discharge notes
- Progress notes

- Emergency Department record
- Physician orders
- Transfer record

#### **Excluded Data Sources:**

UB-04

# **Inclusion Guidelines for Abstraction:**

#### For Value 1:

- Assisted Living Facilities
- Court/Law Enforcement includes detention facilities, jails, and prison
- Home includes board and care, foster or residential care, group or personal care homes, and homeless shelters
- Home with Home Health Services
- Outpatient Services including outpatient procedures at another hospital, Outpatient Chemical Dependency Programs, and Partial Hospitalization

#### For Value 3:

- Hospice Care General Inpatient and Respite
- Hospice Care Residential and Skilled Facilities
- Hospice Care Other Health Care Facilities (excludes home)

# For Value 5:

- Extended or Intermediate Care Facility (ECF/ICF)
- Long Term Acute Care Hospital (LTACH)
- Nursing Home or Facility, including Veteran's Administration Nursing Facility
- Psychiatric Hospital or Psychiatric Unit of a Hospital

- Rehabilitation Facility, including Inpatient Rehabilitation Facility/Hospital or Rehabilitation Unit of a Hospital
- Skilled Nursing Facility (SNF), Sub-Acute Care, or Swing Bed
- Transitional Care Unit (TCU)

**Exclusion Guidelines for Abstraction:** None

Data Element Name: E/M Code

Collected For: OP-2, OP-3, OP-18, OP-23

**Definition:** The code used to report evaluation and management services provided in the hospital outpatient department clinic or emergency department.

Suggested Data Collection Question: What was the E/M code documented for this outpatient encounter?

#### Format:

Length: 5

Type: Alphanumeric

Occurs: 1

# **Allowable Values:**

• Select the *E/M Code* from Appendix A, OP Table 1.0.

# **Suggested Data Sources:**

Outpatient record

# **Inclusion Guidelines for Abstraction:**

• Refer to Appendix A, OP Table 1.0, EM Codes.

**Exclusion Guidelines for Abstraction:** None

Data Element Name: ED Departure Date

Collected For: OP-3, OP-18

**Definition:** The month, day, and year at which the patient departed from the emergency department.

Suggested Data Collection Question: What is the date the patient departed from the emergency

department?

#### Format:

Length: 10 – MM-DD-YYYY (includes dashes) or UTD

Type: Date

Occurs: 1

#### **Allowable Values:**

MM = Month (01-12)

DD = Day (01-31)

YYYY = Year (20xx)

UTD = Unable to Determine

# **Notes for Abstraction:**

• The medical record must be abstracted as documented (taken at "face value"). When the date documented is obviously in error (not a valid format/range or outside of the parameters of care **and** no other documentation is found that provides this information), the abstractor should select UTD.

# Examples:

- Documentation indicates the ED departure date was 03-42-20xx. No other documentation in the list of Only Acceptable Sources provides a valid date. Since the *ED Departure Date* is outside of the range listed in the Allowable Values for Day, it is not a valid date, and the abstractor should select UTD.
- Patient expired on 02-12-20xx, and all documentation within the Only Acceptable Sources indicates the *ED Departure Date* was 03-12-20xx. Other documentation in the medical record supports the date of death as being accurate. Since the *ED Departure Date* is after the *Discharge Date* (death), it is not outside of the parameter of care, and the abstractor should select UTD.

**Note:** Transmission of a case with an invalid date as described above will be rejected from the CMS Clinical Data Warehouse. Use of UTD for *ED Departure Date* allows the case to be accepted into the warehouse.

- If the date the patient departed is unable to be determined from medical record documentation, select UTD.
- If the date of departure is not documented but you are able to determine the date from other documentation, this is acceptable (e.g., you are able to identify from documentation the patient arrived and was transferred on the same day).
- If there is documentation the patient left against medical advice and it cannot be determined what date the patient left against medical advice, select UTD.
- For patients who are placed into observation services, use the date of the physician/APN/PA order for observation services as *ED Departure Date*.
- The inclusion and exclusion lists are not to be considered comprehensive lists of inclusions and exclusions.
- If there is a discharge date listed on a disposition sheet, this may be abstracted as *ED Departure Date*.

# **Suggested Data Sources:**

Only Acceptable Sources:

• Emergency Department record

# **Inclusion Guidelines for Abstraction:**

- ED departure date
- ED discharge date
- ED leave date

# **Exclusion Guidelines for Abstraction:**

Disposition date

Data Element Name: ED Departure Time

Collected For: OP-3, OP-18

**Definition:** The time (military time) represented in hours and minutes at which the patient departed from the emergency department.

**Suggested Data Collection Question:** What is the time the patient departed from the emergency department?

#### Format:

Length: 5 - HH-MM (with or without colon) or UTD

Type: Time

Occurs: 1

# **Allowable Values:**

HH = Hour (00-23)

MM = Minutes (0-59)

UTD = Unable to Determine

Time must be recorded in military time format.

With the exception of midnight and noon:

- If the time is in the a.m., conversion is not required.
- If the time is in the p.m., add 12 to the clock time hour.

# Examples:

• Midnight = 
$$0000$$
 Noon =  $1200$ 

**Note:** 0000 = midnight. If the time is documented as  $0000 \ 11-24-20xx$ , review supporting documentation to determine if the *ED Departure Date* should remain 11-24-20xx or if it should be converted to 11-25-20xx.

When converting midnight, or 2400, to 0000, do not forget to change the ED Departure Date.

# Example:

• Midnight or 2400 on 11-24-20xx = 0000 on 11-25-20xx.

#### **Notes for Abstraction:**

- The intention is to capture the latest time at which the patient was receiving care in the emergency department, under the care of emergency department services, or awaiting transport to service/care.
- For times that include seconds, remove the second and record the time as is.

# Example:

- 1500:35 would be recorded as 1500.
- The medical record must be abstracted as documented (taken at "face value"). When the time documented is obviously in error (not a valid format/range) **and** no other documentation is found that provides this information, the abstractor should select UTD.

# Example:

Documentation indicates the ED departure time was 3300. No other documentation in the list of Only Acceptable Sources provides a valid time. Since the ED Departure Time is outside of the range in the Allowable Values for Hour, it is not a valid time, and the abstractor should select UTD.

**Note:** Transmission of a case with an invalid time as described above will be rejected from the CMS Clinical Data Warehouse. Use of UTD for *ED Departure Time* allows the case to be accepted into the warehouse.

- ED Departure Time is the documented time the patient physically left the emergency department.
- Do not use the time the discharge order was written because it may not represent the actual time of departure.
- If there is a discharge time listed on the disposition sheet, this may be used for *ED Departure Time*.
- When more than one emergency department departure/discharge time is documented, abstract the latest time.

#### Examples:

- ED nursing notes contain documentation that the patient was transferred to floor at 1800 and transport documentation states that patient left the ED via stretcher at 1815. There are multiple times documented for departure. Use the later time of 1815 as *ED Departure Time*.
- ED nursing notes contain documentation that the patient departed the ED at 0500. ED record contains documentation of medication administration at 0510 and that the patient departed the ED at 0620. Physician notes contain documentation of an assessment at 0540. As there are multiple departure times documented, enter 0620 for *ED Departure Time*, as it is the latest time documented.
- If the time the patient departed is unable to be determined from medical record documentation, select UTD.

# Example:

- ED nursing notes documented patient departed from the ED at 1225. Nursing notes document medication administration at 1245. Physician progress notes document assessment at 1310. There is substantial documentation to support that the patient was in the ED after documented departure and no additional documented time of ED departure. Enter UTD for ED Departure Time.
- If ED Departure Time is documented prior to arrival, abstract as UTD.
- If patient expired in the ED, use the time of death as the departure time.

• The inclusion and exclusion lists are not to be considered comprehensive lists of inclusions and exclusions.

#### **Observation Status:**

- For patients who are placed into observation services, use the time of the physician/APN/PA order for observation for *ED Departure Time*.
- The intent of this guidance is to abstract the time that the patient is no longer under the care of the ED. When a patient is placed into observation, their clinical workflow may vary from patients who are not placed into observation prior to departure from the ED, so the observation order may be used instead of the actual ED departure time.

# **Suggested Data Sources:**

Only Acceptable Sources:

Emergency Department record

# **Inclusion Guidelines for Abstraction:**

- ED leave time
- ED discharge time
- ED departure time
- ED checkout time
- ED order for observation status
- Gone time
- Transfer time
- The event log, registration sheet, transfer record, etc. (if a discharge time is noted and the document is part of the permanent record)

# **Exclusion Guidelines for Abstraction:**

- Report called time
- Disposition time
- Discharge instructions time
- Coding summary
- Physician's discharge summary
- ED record released from holding time
- Chart closed time
- Off the tracking board time

- Out time
- Transport documented time

Data Element Name: Fibrinolytic Administration

Collected For: OP-2, OP-3

**Definition:** Fibrinolytic therapy is the administration of a pharmacological agent intended to cause lysis of a thrombus (destruction or dissolution of a blood clot).

**Suggested Data Collection Question:** Did the patient receive fibrinolytic therapy at this emergency department?

#### Format:

Length: 1

Type: Alphanumeric

Occurs: 1

# Allowable Values:

Y (Yes) Fibrinolytic therapy was initiated at this emergency department.

N (No) There is no documentation fibrinolytic therapy was initiated at this emergency department, or Unable to Determine from medical record documentation.

# **Notes for Abstraction:**

- In the event the patient was brought to the hospital via ambulance and fibrinolytic therapy was infusing at the time of arrival, select Yes.
- In the event the patient was brought to the emergency department via ambulance and fibrinolytic therapy was infused during transport **but was completed** at the time of the emergency department arrival, select No.
- If the first dose of reteplase (Retavase) is given in the ambulance and the second dose is given in the emergency department, select Yes.

# **Suggested Data Sources:**

Emergency Department record

#### **Inclusion Guidelines for Abstraction:**

• Refer to Appendix C, OP Table 1.3, Fibrinolytic Agents.

**Exclusion Guidelines for Abstraction:** None

Data Element Name: Fibrinolytic Administration Date

Collected For: OP-2

**Definition:** The month, day, and year primary fibrinolytic therapy was administered at this facility. Fibrinolytic therapy is the administration of a pharmacological agent intended to cause lysis of a thrombus (destruction or dissolution of a blood clot).

**Suggested Data Collection Question:** What was the date primary fibrinolytic therapy was initiated during this hospital stay?

# Format:

Length: 10 – MM-DD-YYYY (includes dashes) or UTD

Type: Date

Occurs: 1

# **Allowable Values:**

MM = Month (01-12)

DD = Day (01-31)

YYYY = Year (20xx)

UTD = Unable to Determine

#### **Notes for Abstraction:**

- If the date primary fibrinolytic therapy was initiated is unable to be determined from medical record documentation, enter UTD.
- The medical record must be abstracted as documented (taken at "face value"). When the date documented is obviously in error (not a valid date/format) and no other documentation is found that provides this information, the abstractor should select UTD.

# Example:

Documentation indicates the *Fibrinolytic Administration Date* was 03-42-20xx. No other documentation in the medical record provides a valid date. Since the *Fibrinolytic Administration Date* is outside of the range listed in the Allowable Values for Day, it is not a valid date, and the abstractor should select UTD.

**Note**: Transmission of a case with an invalid date as described above will be rejected from the CMS Clinical Data Warehouse. Use of UTD for *Fibrinolytic Administration Date* allows the case to be accepted into the warehouse.

- If there are two or more different fibrinolytic administration dates (either different fibrinolytic episodes or corresponding with the same episode), enter the earliest date.
- In the event the patient was brought to the hospital via ambulance and fibrinolytic therapy was infusing at the time of hospital arrival, enter the date the patient arrived at this hospital.

# **Suggested Data Sources:**

- Ambulance record
- Discharge summary

- Emergency Department record
- ICU/Nursing flow sheets

- IV flow sheets
- Medication administration record
- **Inclusion Guidelines for Abstraction:** None

# **Exclusion Guidelines for Abstraction:**

• Fibrinolytics given during or after a PCI

- Nursing notes
- Transfer sheet

Data Element Name: Fibrinolytic Administration Time

Collected For: OP-2

**Definition:** The time (military time) that primary fibrinolytic therapy started. Fibrinolytic therapy is the administration of a pharmacological agent intended to cause lysis of a thrombus (destruction or dissolution of a blood clot).

**Suggested Data Collection Question:** What was the time primary fibrinolytic therapy was initiated during this hospital stay?

#### Format:

Length: 5 - HH-MM (with or without colon) or UTD

Type: Time Occurs: 1

#### Allowable Values:

HH = Hour (00–23) MM = Minutes (0–59) UTD = Unable to Determine

Time must be recorded in military time format.

With the exception of midnight and noon:

- If the time is in the a.m., conversion is not required.
- If the time is in the p.m., add 12 to the clock time hour.

### Examples:

Midnight = 0000 Noon = 1200
 5:31 a.m. = 0531 5:31 p.m. = 1731
 11:59 a.m. = 1159 11:59 p.m. = 2359

**Note:** 0000 = midnight. If the time is documented as  $0000 \ 11-24-20xx$ , review documentation to determine if the *Fibrinolytic Administration Date* should remain 11-24-20xx or if it should be converted to 11-25-20xx.

When converting midnight, or 2400, to 0000, do not forget to change the *Fibrinolytic Administration Date*. *Example:* 

• Midnight or 2400 on 11-24-20xx = 0000 on 11-25-20xx.

### **Notes for Abstraction:**

- For times that include seconds, remove the seconds and record the time as is.
  - Example:
    - 1500:35 would be recorded as 1500.
- If the time primary fibrinolytic therapy was initiated is unable to be determined from medical record documentation, enter UTD.
- The medical record must be abstracted as documented (taken at "face value"). When the time documented is obviously in error (not a valid time/format) **and** no other documentation is found that provides this information, the abstractor should select UTD.

Example:

Documentation indicates the Fibrinolytic Administration Time was 3300. No other documentation in the medical record provides a valid time. Since the Fibrinolytic Administration Time is outside of the range listed in the Allowable Values for Hour, it is not a valid time, and the abstractor should select UTD.

**Note:** Transmission of a case with an invalid time as described above will be rejected from the CMS Clinical Data Warehouse. Use of UTD for *Fibrinolytic Administration Time* allows the case to be accepted into the warehouse.

- If there are two or more different fibrinolytic administration times (either different fibrinolytic episodes or corresponding with the same episode), enter the earliest time.
- In the event the patient was brought to the hospital via ambulance and fibrinolytic therapy was infusing at the time of hospital arrival, enter the time the patient arrived at this hospital.

# **Suggested Data Sources:**

- Ambulance record
- Emergency department record
- ICU/nursing flow sheets
- IV flow sheets
- Medication administration record
- Nursing notes
- Transfer sheet

**Inclusion Guidelines for Abstraction:** None

#### **Exclusion Guidelines for Abstraction:**

• Fibrinolytics given during or after a PCI

Data Element Name: First Name

Collected For: All records

**Definition:** The patient's first name.

Suggested Data Collection Question: What is the patient's first name?

Format: Length: 30

Type: Character

Occurs: 1

# **Allowable Values:**

Enter the patient's first name.

Notes for Abstraction: None

# **Suggested Data Sources:**

• Outpatient record

• Emergency Department record

**Inclusion Guidelines for Abstraction:** None

Data Element Name: Head CT or MRI Scan Interpretation Date

Collected For: OP-23

**Definition:** The month, day, and year at which the earliest head CT or MRI scan interpretation was

completed or reported.

**Suggested Data Collection Question:** What is the date the earliest head CT or MRI scan interpretation was completed or reported?

Format:

Length: 10 – MM-DD-YYYY (includes dashes) or UTD

Type: Date Occurs: 1

#### Allowable Values:

MM = Month (01-12) DD = Day (01-31) YYYY = Year (20xx)

UTD = Unable to Determine

### **Notes for Abstraction:**

• The medical record must be abstracted as documented (taken at "face value"). When the date documented is obviously in error (not a valid format/range) or outside of the parameters of care and no other documentation is found that provides this information, the abstractor should select UTD.

# Examples:

- Documentation indicates the Head CT or MRI Scan Interpretation Date was 03-42-20xx. No other documentation in the list of Only Acceptable Sources provides a valid date. Since the Head CT or MRI Scan Interpretation Date is outside of the range listed in the Allowable Values for Day, it is not a valid date, and the abstractor should select UTD.
- Patient expires on 02-12-20xx, and all documentation within the Only Acceptable Sources indicates the *Head CT or MRI Scan Interpretation Date* was 03-12-20xx. Other documentation in the medical record supports the date of death as being accurate. Since the *Head CT or MRI Scan Interpretation Date* is after the date of death, it is outside of the parameter of care, and the abstractor should select UTD.

**Note:** Transmission of a case with an invalid date as described above will be rejected from the CMS Clinical Data Warehouse. Use of UTD for *Head CT or MRI Scan Interpretation Date* allows the case to be accepted into the Warehouse.

- Enter the date associated with *Head CT or MRI Scan Interpretation Time*.
- If the date of the head CT or MRI scan interpretation is unable to be determined from medical record documentation, abstract UTD.
- Abstract the result of the earliest head CT or MRI scan interpretation (closest to arrival).
- If there are multiple result dates documented for the same head CT or MRI scan, use the earliest result date.
- *Head CT or MRI Scan Interpretation Time* should not be abstracted as the time the results of the scan were relayed to the ED physician/APN/PA if an earlier interpretation time is documented.

Example:

• Radiology head CT report at 1100. ED physician notes: "Received head CT report at 1130." *Head CT or MRI Scan Interpretation Time* is 1100.

- Preliminary CT dictated by radiologist at 2205. ED physician documents "Findings discussed directly with radiologist at 2209." *Head CT or MRI Scan Interpretation Time* is 2205.
- Nurse documents "CT scan completed at 1400; physician notified of results at 1445." *Head CT or MRI Scan Interpretation Time* is 1445.

# **Suggested Data Sources:**

• Emergency Department record

**Inclusion Guidelines for Abstraction:** None

Data Element Name: Head CT or MRI Scan Interpretation Time

Collected For: OP-23

**Definition:** The time (military time) represented in hours and minutes at which the earliest head CT or MRI scan interpretation was completed or reported.

**Suggested Data Collection Question:** What is the time the earliest head CT or MRI scan interpretation was completed or reported?

#### Format:

Length: 5 - HH-MM (with or without colon) or UTD

Type: Time Occurs: 1

#### Allowable Values:

HH = Hour (00–23) MM = Minutes (0–59) UTD = Unable to Determine

Time must be recorded in military time format.

With the exception of midnight and noon:

- If the time is in the a.m., conversion is not required.
- If the time is in the p.m., add 12 to the clock time hour.

# Examples:

Midnight = 0000 Noon = 1200
 5:31 a.m. = 0531 5:31 p.m. = 1731
 11:59 a.m. = 1159 11:59 p.m. = 2359

**Note:** 0000 = midnight. If the time is documented as 0000 11-24-20xx, review supporting documentation to determine if the *Head CT or MRI Scan Interpretation Date* should remain 11-24-20xx or if it should be converted to 11-25-20xx.

When converting midnight, or 2400, to 0000, do not forget to change the *Head CT or MRI Scan Interpretation Date*.

Example:

• Midnight or 2400 on 11-24-20xx = 0000 on 11-25-20xx.

#### **Notes for Abstraction:**

- For times that include seconds, remove the seconds and record the time as is.
  - Example:
    - 1500:35 would be recorded as 1500.
- If the *Head CT or MRI Scan Interpretation Time* is unable to be determined from medical record documentation, select UTD.
- The medical record must be abstracted as documented (taken at "face value"). When the time documented is obviously in error (not a valid time) **and** no other documentation is found that provides this information, the abstractor should select UTD.

Example:

 Documentation indicates the head CT or MRI scan interpretation was 3300. No other documentation in the medical record provides a valid time. Since the *Head CT or MRI Scan* *Interpretation Time* is outside of the range listed in the Allowable Values for Hour, it is not a valid time, and the abstractor should select UTD.

**Note:** Transmission of a case with an invalid time as described above will be rejected from the CMS Clinical Data Warehouse. Use of UTD for *Head CT or MRI Scan Interpretation Time* allows the case to be accepted into the warehouse.

- If the time of the head CT or MRI scan interpretation is unable to be determined from medical record documentation, abstract UTD.
- Abstract the result of the earliest head CT or MRI scan interpretation (closest to arrival).
- The dictation time or the time of a preliminary interpretation may be abstracted if it is known to be an accurate representation of when the earliest head CT or MRI scan interpretation time occurred.
- If there are multiple result times documented for the same head CT or MRI scan, use the earliest result time.
- If the head CT or MRI scan interpretation is documented prior to arrival, abstract UTD.
- It is acceptable to use nurse documentation of a head CT or MRI scan interpreted by a physician. The interpretation must be performed by the physician/APN/PA, but it can be documented by a nurse.

## **Suggested Data Sources:**

• Emergency Department record

**Inclusion Guidelines for Abstraction:** None

Data Element Name: Head CT or MRI Scan Order

Collected For: OP-23

**Definition:** Documentation in the medical record that a Computerized Tomography (CT) or Magnetic Resonance Imaging (MRI) scan of the head was ordered during an emergency department visit.

**Suggested Data Collection Question:** Was a head CT or MRI scan ordered by the physician during the emergency department visit?

# Format:

Length: 1

Type: Alphanumeric

Occurs: 1

#### Allowable Values:

Y (Yes) There is documentation a head CT or MRI scan was ordered by the physician/APN/PA during the emergency department visit.

N (No) There is no documentation a head CT or MRI scan was ordered by the physician/APN/PA during the emergency department visit.

## **Notes for Abstraction:**

• If there is documentation a head CT or MRI scan is ordered during the emergency department visit but is cancelled and there are no other head CT or MRI scans ordered during the emergency department visit, abstract No.

# **Suggested Data Sources:**

- Nurses notes
- Physician notes/orders
- Radiology notes

**Inclusion Guidelines for Abstraction:** None

Data Element Name: Hispanic Ethnicity

Collected For: All records

**Definition:** Documentation that the patient is of Hispanic ethnicity or Latino.

Suggested Data Collection Question: Is the patient of Hispanic ethnicity or Latino?

# Format:

Length: 1

Type: Character

Occurs: 1

#### Allowable Values:

Y (Yes) Patient is of Hispanic ethnicity or Latino.

N (No) Patient is not of Hispanic ethnicity or Latino or unable to determine from medical record documentation.

### **Notes for Abstraction:**

• The data element *Race* is required in addition to this data element.

# **Suggested Data Sources:**

- Outpatient record
- Emergency Department record

### **Inclusion Guidelines for Abstraction:**

A person of Cuban, Mexican, Puerto Rican, South or Central American, or other Spanish culture or origin, regardless of race. The term "Spanish origin" can be used in addition to "Hispanic or Latino."

### Examples:

- Black-Hispanic
- Chicano
- H
- Hispanic
- Latin American
- Latino/Latina
- Mexican-American
- Spanish
- White-Hispanic

Data Element Name: ICD-10-CM Principal Diagnosis Code

Collected For: OP-2, OP-3, OP-18, OP-23

**Definition:** The International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) code associated with the diagnosis established after study to be chiefly responsible for the outpatient encounter.

**Suggested Data Collection Question:** What was the ICD-10-CM code selected as the principal diagnosis for this record?

### Format:

Length: 8 (without decimal point or dot)

Type: Alphanumeric

Occurs: 1

### **Allowable Values:**

Any valid diagnosis code as per the CMS ICD-10-CM master code table (Code Descriptions in Tabular Order): <a href="https://www.cms.gov/Medicare/Coding/ICD10/index.html">https://www.cms.gov/Medicare/Coding/ICD10/index.html</a>

Notes for Abstraction: None

## **Suggested Data Sources:**

- Outpatient record
- Emergency Department record
- UB-04

**Inclusion Guidelines for Abstraction:** None

Data Element Name: Initial ECG Interpretation

Collected For: OP-2, OP-3

**Definition:** ST-segment elevation based on the documentation of the electrocardiogram (ECG) performed closest to emergency department arrival. The normal ECG is composed of a P wave (atrial depolarization), Q, R, and S waves (QRS complex, ventricular depolarization), and a T wave (ventricular repolarization). The ST-segment, the segment between the QRS complex and the T wave, may be elevated when myocardial injury (AMI) occurs.

**Suggested Data Collection Question:** Is there documentation of ST-segment elevation on the electrocardiogram (ECG) performed closest to emergency department arrival?

### Format:

Length: 1

Type: Alphanumeric

Occurs: 1

#### **Allowable Values:**

Y (Yes) ST-segment elevation on the interpretation of the 12-lead ECG performed closest to emergency department arrival.

N (No) No ST-elevation on the interpretation of the 12-lead ECG performed closest to emergency department arrival, no interpretation or report available for the ECG performed closest to emergency department arrival, or unable to determine from medical record documentation.

### **Notes for Abstraction:**

# Methodology:

- 1. Identify the ECG performed closest to arrival, either before or after emergency department arrival, but not more than 1 hour prior to arrival. If unable to determine which ECG was performed closest to arrival select No. **Exception:** If the pre-arrival ECG and the first ECG performed after arrival at the hospital are exactly the same amount of time away from hospital arrival (e.g., both ECGs are 10 minutes away from *Arrival Time*), use the first ECG performed after hospital arrival.
- 2. Start with review of the **signed** tracing. Determine if the terms or phrases are Inclusions or Exclusions. Evaluate findings line by line. Do not cross reference between lines except for those Exclusions with "with mention of" phrasing (e.g., LVH and ST-elevation noted on separate lines on the same ECG meets the Exclusion "ST-elevation with any mention of early repolarization, left ventricular hypertrophy (LVH), normal variant, pericarditis, or Printzmetal/Printzmetals variant in one interpretation"). If you have an Exclusion, select No, regardless of other documentation, and there is no need to review further.

- 3. If there is no signed tracing, or in the absence of an Exclusion on the signed tracing, proceed to other interpretations that clearly refer to the ECG done closest to arrival. Only those terms specifically identified or referred to by the physician/APN/PA as ECG findings and where documentation is clear it is from the ECG performed closest to arrival should be considered in abstraction (e.g., "STEMI" listed only as a physician diagnosis or impression would not be used). Do not cross-reference findings between interpretations unless otherwise specified. If you encounter an Exclusion in any of the other interpretations, select No, regardless of other documentation, and there is no need to review further.
- 4. At the end of your review, if you have no Exclusions, and either the signed ECG tracing or interpretations of this ECG tracing include at least one Inclusion, select Yes. Otherwise, select No.
- ECG interpretation is defined as:
  - 12-lead tracing with name/initials of the physician/advanced practice nurse/physician assistant (physician/APN/PA) who reviewed the ECG signed or typed on the report, or
  - Physician/APN/PA documentation of ECG findings in another source (e.g., ED record).
- Do not measure ST-segments from the tracing itself.
- Consider a tracing 12-lead if it has the appropriate markings (the presence of at least 12-leads: I, II, III, AVR, AVL, AVF, V1–V6).
- If ECG documentation outside of a tracing is not specified as 12-lead, assume it is 12-lead unless documentation indicates otherwise.
- Disregard any description of an MI or ST-segment that is not on either the Inclusion list or the Exclusion list
- If documentation is contradictory within the same interpretation or between different interpretations, select No.

## Examples:

- "ST-elevation" and "No ST-elevation"
- "Acute anterior MI" and "no acute MI"
  - O Documentation such as "STEMI" and "no ST-elevation" should not be considered contradictory for the purposes of this data element.
- Notations which describe ST-elevation as old, chronic, age unknown, recent, or previously seen, or which state ST-elevation and "no new changes," "unchanged," "no acute changes," or "no significant changes" when compared to a prior ECG should be disregarded. Other documentation of ST-elevation within the same interpretation or a different interpretation may still count as an Inclusion or Exclusion.

### Exception:

- When the ST-elevation on the ECG done closest to arrival is described as previously seen on an ECG done by EMS or physician office prior to arrival, this ST-elevation may count as an Inclusion. Documentation must be explicit within the ECG interpretation itself (e.g., "Initial ECG shows ST-elevation 1mm V1-V2. Improved from ECG done in the field"). Abstractors should **not** make inferences based on documentation outside of the interpretation (context, sequence of events, etc.).
- Notations which describe ST-elevation as a range where it cannot be determined if elevation is less than 1 mm/.10mV (e.g., "0.5-1 mm ST-elevation," "ST greater than 0.06 mV V2-V6") should be disregarded. Other documentation of ST-elevation within the same interpretation or a different interpretation may still count as an Inclusion or Exclusion.

- If any of the inclusion terms are described using the qualifier "possible," "probable," "potential," or "likely" disregard that finding (neither Inclusion nor Exclusion). This is not an all-inclusive list of qualifiers.
- Do not consider "subendocardial" an MI "location" (e.g., "acute subendocardial MI" should be disregarded).

## **Suggested Data Sources:**

Physician/APN/PA Documentation Only

- ECG reports
- Emergency Department record

### **Inclusion Guidelines for Abstraction:**

ST-segment elevation

- Myocardial infarction (MI), with any mention of location or combinations of locations (e.g., anterior, apical, basal, inferior, lateral, posterior, or combination), if described as acute/evolving (e.g., "posterior AMI").
- Q wave MI, if described as acute/evolving
- ST ↑
- ST consistent with injury or acute/evolving MI
- ST abnormality consistent with injury or acute/evolving MI
- ST changes consistent with injury or acute/evolving MI
- ST-elevation (STE)
- ST-elevation myocardial infarction (STEMI)
- ST-segment noted as greater than or equal to .10mV
- ST-segment noted as greater than or equal to 1 mm
- STEMI or equivalent
- Transmural MI, if described as acute/evolving

## **Exclusion Guidelines for Abstraction:**

ST-segment elevation

- Documentation of the absence of STEMI (In reference to the ECG performed closest to arrival) e.g., "No STEMI," "not consistent with STEMI," "not diagnostic of STEMI."
- Non Q wave MI (NQWMI)
- Non ST-elevation MI (NSTEMI)
- ST-elevation (ST \u2221) clearly described as confined to **one** lead.
- All ST-elevation (ST \, STE) in one interpretation described in one or more of the following ways:
  - Minimal
  - Non-diagnostic
  - Non-specific
  - ST-elevation or ST-segment noted as less than .10 mV in elevation
  - ST-elevation or ST-segment noted as less than 1mm in elevation
  - ST-elevation (or ST-segment noted as greater than or equal to .10mV/1mm) described using one of the negative modifiers or qualifiers listed under the Exclusion Guidelines for Abstraction
- ST-elevation (ST ↑) with any mention of the following in one interpretation:
  - Early repolarization
  - Left ventricular hypertrophy (LVH)
  - Normal variant

- Printzmetal/Printzmetal's variant
- ST, ST abnormality, or ST changes consistent with injury or acute/evolving MI **or** any of the "myocardial infarction" (MI) inclusion terms described using one of the negative modifiers or qualifiers listed under the Exclusion Guidelines for Abstraction.
- ST-segment elevation, or any of the other ST-segment elevation inclusion terms, with any mention of pacemaker/pacing (unless atrial only or nonfunctioning pacemaker) in one interpretation.

### **Qualifiers and Modifiers**

The following qualifiers and modifiers should be abstracted as negative findings, unless otherwise specified. Consider this list all-inclusive:

### **Qualifiers**

- And/or (+/-; e.g., "ST abnormalities consistent with ischemia and/or injury"), except when comparing only Inclusions (e.g., "ST segment elevation and/or STEMI").
- Cannot exclude
- Cannot rule out
- Consider
- Could/may/might be
- Could/may/might have
- Could/may/might have been
- Could/may/might have had
- Could/may/might indicate
- Or, except when comparing only Inclusions
- Questionable (?)
- Risk of
- Ruled out (r'd/o, r/o'd)
- Suggestive of
- Suspect
- Suspicious
- Vs., except when comparing only Inclusions

### **Modifiers:**

- Borderline
- Insignificant/not significant/no significance
- Minor
- Scant
- Slight
- Sub-clinical
- Subtle
- Trace
- Trivial

Data Element Name: Last Known Well

Collected For: OP-23

**Definition:** The date and time prior to hospital arrival at which it was witnessed or reported that the patient was last known to be without the signs and symptoms of the current stroke or at his or her baseline state of health.

**Suggested Data Collection Question:** Is there documentation that the date and time of *Last Known Well* was witnessed or reported?

### **Format:**

Length:

Type: Alphanumeric

Occurs: 1

#### **Allowable Values:**

Y (Yes) There is documentation that the date and time of Last Known Well was witnessed or reported.

N (No) There is no documentation that the date and time of *Last Known Well* was witnessed or reported, **or** Unable to Determine from medical record documentation.

#### **Notes for Abstraction:**

- Select Yes if **both** a date *Last Known Well* and a *Time Last Known Well* are documented.
- Select No if there is **any** physician/APN/PA documentation that the *Time Last Known Well* is "unknown." Documentation must explicitly state that the *Time Last Known Well* is unknown/uncertain.
- Documentation must explicitly state that the *Time Last Known Well* is unknown/uncertain/unclear. Documentation that time of symptom onset is unknown/uncertain/unclear is also acceptable when *Time Last Known Well* is not documented. If *Last Known Well* is not explicitly documented as unknown, do not make inferences (e.g., do not assume that patient awoke with stroke so *Last Known Well* unknown unless explicitly documented).
  - If one physician documents a *Time Last Known Well* and another documents time of symptom onset unknown, select Yes.
  - If one physician documents a *Time Last Known Well* and nurse/EMS documents *Last Known Well* unknown, select Yes.
  - If one physician documents *Time Last Known Well* unknown, and another documents a *Time Last Known Well*, select No.

### Exception:

- If the physician documents *Last Known Well* as unknown and the same physician crosses out unknown, or mentions in a later note that *Last Known Well* is now known with a time documented, select Yes.
- If the *Time Last Known Well* is clearly greater than 2 hours prior to hospital arrival **and** no specific time is documented, select No.

### Example:

- "Patient OK last night." Select No because no other documentation of a specific time/time range/time reference was present in the medical record and the time is required for the *Time Last Known Well*.
- If there is no documentation that *Last Known Well* or stroke signs/symptoms occurred prior to hospital arrival but there is documentation that *Last Known Well* first occurred after *Arrival Time* (e.g., in-house stroke), select No.

## **Suggested Data Sources:**

- Ambulance record
- Code Stroke Form/template
- Emergency department record
- History and Physical
- Nursing flow sheets
- Progress notes
- Transfer sheet

### **Inclusion Guidelines for Abstraction:**

Signs and Symptoms of Stroke

- Sudden numbness or weakness of the face, arm, or leg, especially on one side of the body
- Sudden confusion, trouble speaking or understanding
- Sudden trouble seeing in one or both eyes
- Sudden trouble walking, dizziness, loss of balance or coordination
- Sudden severe headache
- Syncope
- Seizure

### **Exclusion Guidelines for Abstraction:**

None

Data Element Name: Last Name

Collected For: All records

**Definition:** The patient's last name.

Suggested Data Collection Question: What is the patient's last name?

Format: Length: 60

Type: Character

Occurs: 1

### **Allowable Values:**

Enter the patient's last name.

Notes for Abstraction: None

# **Suggested Data Sources:**

• Outpatient record

• Emergency Department record

**Inclusion Guidelines for Abstraction:** None

Data Element Name: Outpatient Encounter Date

Collected For: All records

**Definition:** The documented month, day, and year the patient arrived in the hospital outpatient setting.

**Suggested Data Collection Question:** What was the date the patient arrived in the hospital outpatient setting?

## Format:

Length: 10 – MM-DD-YYYY (includes dashes)

Type: Date Occurs: 1

#### **Allowable Values:**

MM = Month (01-12) DD = Day (01-31) YYYY = Year (20xx)

### **Notes for Abstraction:**

- The intent of this data element is to determine the date the patient arrived in the hospital outpatient setting.
- UTD is **not** an allowable value.
- Consider the outpatient encounter date as the earliest documented date the patient arrived in the applicable hospital outpatient setting.

# **Suggested Data Sources:**

- Outpatient record
- Emergency Department record

**Inclusion Guidelines for Abstraction:** None

## **Exclusion Guidelines for Abstraction:**

• Preoperative tests or screening

Data Element Name: Patient Identifier

Collected For: All records

**Definition:** The number used by the hospital to identify this patient's hospital outpatient encounter. The number provided will be used to identify the patient in communications with the hospital outpatient setting, e.g., Medical Record Number, Account Number, Unique Identifiable Number as determined by the facility, etc.

A Patient Identifier is required.

Suggested Data Collection Question: What was the number used to identify this outpatient encounter?

#### **Format:**

Length: 40

Type: Character

Occurs: 1

## Allowable Values:

Up to 40 letters and/or numbers

**Notes for Abstraction:** None

# **Suggested Data Sources:**

- Outpatient record
- Emergency Department record

**Inclusion Guidelines for Abstraction:** None

Data Element Name: Payment Source

Collected For: All records

**Definition:** The source of payment for this outpatient encounter.

Suggested Data Collection Question: What is the patient's source of payment for this outpatient encounter?

#### Format:

Length: 1

Type: Alphanumeric

Occurs: 1

#### **Allowable Values:**

- 1 Source of payment is Medicare.
- 2 Source of payment is Non-Medicare.

## **Notes for Abstraction:**

- If Medicare is listed as the primary, secondary, tertiary, or even lower down on the list of payers, select 1.
- If the patient is an Undocumented Alien or illegal immigrant, select 1. *Undocumented Alien:* Section 1011 of the Medicare Modernization Act of 2003 allows for reimbursement for services rendered to patients who are: Undocumented or illegal aliens (immigrants), aliens who have been paroled into a United States port of entry, and Mexican citizens permitted to enter the United States on a laser visa.

## **Suggested Data Sources:**

- Face sheet
- UB-04

### **Inclusion Guidelines for Abstraction:**

*Medicare includes, but is not limited to:* 

- Black Lung
- End Stage Renal Disease (ESRD)
- Medicare Fee-for-Service (includes DRG or PPS)
- Medicare HMO/Medicare Advantage
- Medicare Secondary Payer
- Railroad Retirement Board (RRB)

Data Element Name: Physician 1

Collected For: All records (optional element)

**Definition:** The first physician identifier.

Suggested Data Collection Question: What is the first physician identifier?

# Format:

Length: 50

Type: Alphanumeric

Occurs: 1

## **Allowable Values:**

Enter the first physician identifier, as directed. Up to 50 letters, numbers, and/or special characters can be entered.

Note: Only the following special characters will be allowed:

$$\sim ! @ # $ % ^* () _+ { } | : ? ` -= [ ] \ ; ` ., / and space$$

### **Notes for Abstraction:**

This data element may be used to capture physician information that might be helpful in internal analysis. This information is for internal analysis only and will not be shared with any external parties in any data output.

Suggested Data Sources: None

**Inclusion Guidelines for Abstraction:** None

Data Element Name: Physician 2

Collected For: All records (optional element)

**Definition:** A second physician identifier.

**Suggested Data Collection Question:** What is the second physician identifier?

### Format:

Length: 50

Type: Alphanumeric

Occurs: 1

## **Allowable Values:**

Enter the second physician identifiers, as directed. Up to 50 letters, numbers, and/or special characters can be entered.

Note: Only the following special characters will be allowed:

$$\sim ! @ # $ % ^* () _+ { } | : ? `-=[] \setminus ; . , / and space$$

### **Notes for Abstraction:**

This data element may be used to capture physician information that might be helpful in internal analysis. This information is for internal analysis only and will not be shared with any external parties in any data output.

Suggested Data Sources: None

**Inclusion Guidelines for Abstraction:** None

Data Element Name: Postal Code

Collected For: All records

**Definition:** The postal code of the patient's residence. For United States ZIP codes, the hyphen is implied. If the patient is determined to not have a permanent residence, then the patient is considered homeless.

Suggested Data Collection Question: What is the postal code of the patient's residence?

### Format:

Length: 9

Type: Character

Occurs: 1

#### **Allowable Values:**

Any valid five or nine-digit postal code, or "homeless" if the patient is determined not to have a permanent residence. If the patient is not a resident of the United States, use "non-US."

#### **Notes for Abstraction:**

• If the postal code of the patient is unable to be determined from medical record documentation, enter the provider's postal code.

# **Suggested Data Sources:**

- Outpatient record
- Emergency Department record
- UB-04

**Inclusion Guidelines for Abstraction:** None

Data Element Name: Race

Collected For: All records

**Definition:** Documentation of the patient's race.

**Suggested Data Collection Question:** What is the patient's race?

Format:

Length: 1

Type: Character

Occurs: 1

#### **Allowable Values:**

- 1 White: Patient's race is White or the patient has origins in Europe, the Middle East, or North Africa.
- 2 Black or African American: Patient's race is Black or African American.
- 3 American Indian or Alaska Native: Patient's race is American Indian/Alaska Native.
- 4 **Asian:** Patient's race is Asian.
- 5 Native Hawaiian or Pacific Islander: Patient's race is Native Hawaiian/Pacific Islander.
- 7 **UTD:** Unable to determine the patient's race or not stated (e.g., not documented, conflicting documentation, or patient unwilling to provide).

### **Notes for Abstraction:**

- The data element *Hispanic Ethnicity* is required in addition to this data element.
- If documentation indicates the patient has more than one race (e.g., Black-White, Indian-White), select the first listed race.
- Although the terms "Hispanic" and "Latino" are actually descriptions of the patient's ethnicity, it is not uncommon to find them referenced as race. If the patient's race is documented only as Hispanic/Latino, select "White." If the race is documented as mixed Hispanic/Latino with another race, use whatever race is given (e.g., Black Hispanic select "Black"). Other terms for Hispanic/Latino include Chicano, Cuban, H (for Hispanic), Latin American, Latina, Mexican, Mexican-American, Puerto Rican, South or Central American, and Spanish.

### **Suggested Data Sources:**

- Outpatient record
- Emergency Department record

## **Inclusion Guidelines for Abstraction:**

Black or African American

A person having origins in any of the black racial groups of Africa. Terms such as "Haitian" or "Negro" can be used in addition to "Black" or "African American."

American Indian or Alaska Native

A person having origins in any of the original peoples of North and South America (including Central America) and who maintains tribal affiliation or community attachment (e.g., any recognized tribal entity in North and South America [including Central America], Native American).

Asian

A person having origins in any of the original peoples of the Far East, Southeast Asia, or the Indian subcontinent including, for example, Cambodia, China, India, Japan, Korea, Malaysia, Pakistan, the Philippine Islands, Thailand, and Vietnam.

White

A person having origins in any of the original peoples of Europe, the Middle East, or North Africa (e.g., Caucasian, Iranian, White).

Native Hawaiian or Pacific Islander

A person having origins in any of the other original peoples of Hawaii, Guam, Samoa, or other Pacific Islands.

Data Element Name: Reason for Delay in Fibrinolytic Therapy

Collected For: OP-2

**Definition:** Documentation of a reason for a delay in initiating fibrinolytic therapy after hospital arrival by a physician/advanced practice nurse/physician assistant (physician/APN/PA). System reasons for delay are **not** acceptable.

**Suggested Data Collection Question:** Is there a reason documented by a physician/APN/PA for a delay in initiating fibrinolytic therapy after hospital arrival?

#### Format:

Length: 1

Type: Alphanumeric

Occurs: 1

#### Allowable Values:

Y (Yes) Reason documented by a physician/APN/PA for a delay in initiating fibrinolytic therapy after hospital arrival.

N (No) No reason documented by a physician/APN/PA for a delay in initiating fibrinolytic therapy after hospital arrival, or unable to determine from medical record documentation.

### **Notes for Abstraction:**

• System reasons for delay are not acceptable, regardless of any linkage to the delay in fibrinolysis/reperfusion.

# Examples:

- Equipment-related (e.g., IV pump malfunction)
- Staff-related (e.g., waiting for fibrinolytic agent from pharmacy)
- Consultation with other clinician that is not clearly linked to a patient-centered (non-system) reason for delay
- Documentation must be made clear somewhere in the medical record that (1) a "hold," "delay," "deferral," or "wait" in initiating fibrinolysis/reperfusion actually occurred, **and** (2) that the underlying reason for that delay was non-system in nature. Abstractors should **not** make inferences from documentation of a sequence of events alone or otherwise attempt to interpret from documentation. Clinical judgment should not be used in abstraction.

Examples of acceptable documentation:

- "Hold on fibrinolytics. Will do CT scan to r/o bleed."
- "Patient waiting for family and clergy to arrive wishes to consult with them before fibrinolysis."
- "Fibrinolysis delayed due to need to control blood pressure before administering fibrinolysis."
- "Hold fibrinolytics. Need to consult with neurology regarding bleeding risk."
- "Fibrinolytic therapy initially deferred due to shock."

## **Exceptions:**

• Physician/APN/PA documentation that a cardiopulmonary arrest, mechanical circulatory assist device placement, or intubation occurred within 30 minutes after hospital arrival **or** initial patient/family refusal of fibrinolysis/reperfusion (documented by a physician/APN/PA) are acceptable reasons for delay that do **not** require documentation that a "hold," "delay," "deferral," or "wait" in initiating fibrinolysis actually occurred. In order for cardiopulmonary arrest, mechanical circulatory assist device placement, or intubation within 30 minutes after hospital arrival to be considered an automatic acceptable reason for

delay, physician/APN/PA documentation that it occurred within 30 minutes after hospital arrival must be **clear**.

- If unable to determine that a documented reason is system in nature, select No.
- Reasons for delay in fibrinolytic therapy should be collected regardless of how soon after arrival it was ultimately initiated or how minimal the delay.

# **Suggested Data Sources:**

Physician/APN/PA Documentation Only:

- Code sheet (if signed by physician/APN/PA)
- Consultation notes
- Discharge summary
- Emergency Department record

- · History and Physical
- Physician orders
- Progress notes

### **Excluded Data Sources:**

• Any documentation dated/timed after discharge, except discharge summary and operative/procedure/diagnostic test reports from procedure done during hospital stay.

### **Inclusion Guidelines for Abstraction:**

Mechanical circulatory assist devices

- Aortic balloon pump
- Biventricular assist device (BiVAD)
- Intra-aortic balloon (IAB)
- Intra-aortic balloon counterpulsation (IABC)
- Intra-aortic balloon pump (IABP)
- Cardiopulmonary arrest
- Cardiac arrest
- Cardiopulmonary resuscitation (CPR)
- Defibrillation
- Intubation
- Endotracheal intubation (ETI)
- Mechanical ventilation

- Intra-aortic counterpulsation (IAC)
- Intra-aortic counterpulsation balloon pump (IACBP)
- Left ventricular assistive device (LVAD)
- Percutaneous ventricular assist device (PVAD)
- Ventricular assist device (VAD)
- Respiratory arrest
- Ventricular fibrillation (V-fib)
- Nasotracheal intubation (NTI)
- Orotracheal intubation

Data Element Name: Reason for Not Administering Fibrinolytic Therapy

Collected For: OP-3

**Definition:** Contraindications/reasons for not administering fibrinolytic therapy include: patient refusal, cardiogenic shock, contraindications, or other reasons documented by a physician/APN/PA or pharmacist for not giving fibrinolytics.

#### Format:

Length: 1

Type: Alphanumeric

Occurs: 1

## **Suggested Data Collection Question:**

Select one of the following potential contraindications or reasons for not administering fibrinolytic therapy:

#### Allowable Values:

- 1 **Documented contraindication/reason:** There is a contraindication or other reason documented by a physician/APN/PA or pharmacist for not prescribing fibrinolytic therapy, including patient refusal.
- 2 **Cardiogenic Shock:** There is physician/APN/PA documentation the patient has a diagnosis of cardiogenic shock.
- 3 **No documented contraindication/reason or Unable to Determine (UTD):** There is no documentation of contraindication/reason for not prescribing fibrinolytic therapy or unable to determine from medical record documentation.

#### **Notes for Abstraction:**

- When conflicting information is documented in a medical record, a positive finding (fibrinolytic allergy) should take precedence over a negative finding (no known allergy).
- If a contraindication/reason listed under the Inclusion Guidelines for Abstraction is clearly documented in the content of the Emergency Department record, then this is sufficient to abstract value 1 for this data element. There does not need to be explicit documentation of a rationale by a provider linking the documented contraindication/reason and the decision to not administer fibrinolytic therapy if the contraindication/reason is listed under the Inclusion Guidelines for Abstraction.
- If a contraindication/reason for not administering fibrinolytic therapy that is not listed under the Inclusion Guidelines for Abstraction is clearly documented in the content of the Emergency Department record, and there is clear documentation by a physician/APN/PA or pharmacist linking this contraindication/reason to the decision to not administer fibrinolytic therapy, then this is also sufficient to abstract value 1 for this data element.
- In situations where there is documentation that would support more than one of the allowable values, 1-3, select the lowest value. Example: Patient has a documented contraindication from the inclusion list and a diagnosis of cardiogenic shock; select value 1.

### **Suggested Data Sources:**

• Emergency Department record

#### **Inclusion Guidelines for Abstraction:**

### **Contraindications**

• Any prior intracranial hemorrhage

- Known structural cerebral vascular lesion (e.g., AVM)
- Known malignant intracranial neoplasm (primary or metastatic)
- Ischemia stroke within 3 months **except** acute ischemic stroke within 3 hours
- Suspected aortic dissection
- Active bleeding or bleeding diathesis (excluding menses)
- Significant closed head trauma or facial trauma within 3 months
- Severe uncontrolled hypertension on presentation (SBP > 180 mmHg or DBP > 110 mmHg)
- History of prior ischemic stroke > 3 months, dementia, or known intracranial pathology not covered in contraindications
- Traumatic or prolonged (> 10 minutes) CPR or major surgery (< 3 weeks)
- Recent (within 2 to 4 weeks) internal bleeding
- Noncompressible vascular punctures
- For streptokinase/anistreplase: prior expose (>5 days ago) or prior allergic reaction to these agents
- Pregnancy
- Active peptic ulcer

Current use of any of the following anticoagulants prior to arrival:

- Apixaban
- Coumadin
- Dabigatran
- Eliquis
- Jantoven
- Pradaxa
- Rivaroxaban
- Warfarin
- Warfarin Sodium
- Xarelto

#### Risk

• Cardiogenic shock

Data Element Name: Sex

Collected For: All records

**Definition:** The patient's documented sex on arrival at the hospital.

Suggested Data Collection Question: What was the patient's sex on arrival?

Format:

Length: 1

Type: Character

Occurs: 1

#### **Allowable Values:**

M = Male F = Female U = Unknown

## **Notes for Abstraction:**

- Collect the documented patient's sex at admission or the first documentation after arrival.
- Consider the sex to be unable to be determined and select "Unknown" if:
  - The patient refuses to provide their sex.
  - Documentation is contradictory.
  - Documentation indicates the patient is transexual.
  - Documentation indicates the patient is a hermaphrodite.

# **Suggested Data Sources:**

- Consultation notes
- Emergency Department record
- Face sheet
- History and Physical
- Nursing admission notes
- Progress notes
- UB-04

**Inclusion Guidelines for Abstraction:** None

Data Element Name: Time Last Known Well

Collected For: OP-23

**Definition:** The time prior to hospital arrival at which the patient was last known to be without the signs and symptoms of the current stroke or at his or her baseline state of health.

**Suggested Data Collection Question:** At what time was the patient last known to be well or at his or her prior baseline state of health?

#### Format:

Length: 5 – HH-MM (with or without colon) or UTD

Type: Time Occurs: 1

#### Allowable Values:

HH = Hour (00–23) MM = Minutes (00–59) UTD = Unable to Determine

Time must be recorded in military time format.

With the exception of midnight and noon:

- If the time is in the a.m., conversion is not required.
- If the time is in the p.m., add 12 to the clock time hour.

# Examples:

Midnight = 0000 Noon = 1200
 5:31 a.m. = 0531 5:31 p.m. = 1731
 11:59 a.m. = 1159 11:59 p.m. = 2359

**Note:** 0000 = midnight. If the time is documented as 0000 11-24-20XX, review supporting documentation to determine if the *Date Last Known Well* should remain 11-24-20xx or if it should be converted to 11-25-20xx.

When converting midnight, or 2400, to 0000, do not forget to change the Date Last Known Well.

Example:

• Midnight or 2400 on 11-24-20XX = 0000 on 11-25-20XX.

### **Notes for Abstraction:**

• For times that include seconds, remove the seconds and record the time as is.

Example:

- 1500:35 would be recorded as 1500
- If the *Time Last Known Well* is unable to be determined from medical record documentation, select UTD.

# **Exception:**

• If the only *Time Last Known Well* is documented as a time immediately before hospital arrival without a specific time range in minutes, e.g., "symptoms started just prior to ED arrival," and no other documentation mentioning *Time Last Known Well* is available in the medical record, use the *Arrival Time* for *Time Last Known Well*.

• The medical record must be abstracted as documented (taken at "face value"). When the time documented is obviously in error (not a valid time) and no other documentation is found that provides this information, the abstractor should select UTD.

### Example:

Documentation indicates the *Time Last Known Well* was 3300. No other documentation in the
medical record provides a valid time. Since the *Time Last Known Well* is outside of the range
listed in the Allowable Values for Hour, it is not a valid time, and the abstractor should select
UTD.

**Note:** Transmission of a case with an invalid time as described above will be rejected from the CMS Clinical Data Warehouse. Use of UTD for *Time Last Known Well* allows the case to be accepted into the Warehouse.

• If the *Time Last Known Well* is documented as a specific time and entered as *Time Last Known Well* on a Code Stroke Form or stroke-specific electronic template, enter that time as the *Time Last Known Well*. Documentation of the *Time Last Known Well* on a stroke-specific form or template should be selected regardless of other times last known well documented elsewhere in the medical record.

# Exceptions:

- **Any** physician/APN/PA documentation that *Last Known Well*/onset of signs/symptoms is unknown/uncertain/unclear takes precedence over specific time on a Code Stroke Form.
- Crossing out of a specific time on a Code Stroke Form and a specific time documented on the same or different Code Stroke Form, use the specific time that is not crossed out.
- A specific time on a Code Stroke Form and another time reference documented, e.g., 8 hours, on the same or different Code Stroke Forms, use the specific time.
- Multiple specific times on the same or different Code Stroke Forms, use abstraction guidelines for multiple times *Last Known Well*.
- If unable to determine if a form is a Code Stroke Form, continue to review the medical record for *Time Last Known Well* documentation in other sources.
- If the *Time Last Known Well* is documented as being a specific number of hours prior to arrival (e.g., felt left side go numb 2 hours ago) rather than a specific time, subtract that number from the time of ED arrival and enter that time as the *Time Last Known Well*.
- If the *Time Last Known Well* is noted to be a range of time prior to ED arrival (e.g., felt left side go numb 2 hours to 3 hours ago), assume the maximum time from the range (e.g., 3 hours), and subtract that number of hours from the time of arrival to compute the *Time Last Known Well*.
- If both the *Time Last Known Well* and symptom onset are documented, select the *Time Last Known Well*. *Examples:* 
  - H&P states, "Patient watching TV with family and complained of blurred vision in both eyes at 8:30 PM." ED MD notes, "Patient normal at 8:30 PM." *Time Last Known Well* is 2030.
  - "Patient was doing well at 4:30 PM noticed difficulty speaking around 6:00 pm." *Time Last Known Well* is 1630.
  - "Patient normal at 2200 before going to bed. Awoke at 0200 with headache and took two aspirin before returning to sleep. OK at 0700 and went to work. Felt confused, unable to speak without slurring at 0800." *Time Last Known Well* is 0700.
- If the only time documented is time of symptom onset without mention of when the patient was last known well, use the time of symptom onset for the *Time Last Known Well*.

### Example:

• "Sudden onset headache one hour before ED arrival," documented by ED MD. *Arrival Time* 1924. No other documentation referencing time last known well available in the medical record. *Time Last Known Well* is 1824.

• If there are multiple times of last known well documented in the absence of the *Time Last Known Well* explicitly documented on a Code Stroke Form, use physician documentation first before other sources, e.g., nursing, EMS.

# Example:

- "Patient last seen normal this morning at 1000" per H&P. ED nurse documented 0950 as time last well. *Time Last Known Well* is 1000.
- If multiple times last known well are documented by different physicians or the same provider, use the earliest time documented.
- If there is documentation of one or more episodes of stroke symptoms and documentation of symptom resolution between episodes, use the time of the most recent (last) episode prior to arrival, regardless if all symptoms resolved prior to arrival.

## Examples:

- "Patient reported right hand paresthesia two days ago that resolved spontaneously after a few minutes. New onset of symptoms today around 0700 involving right arm and right leg." *Time Last Known Well* is 0700.
- "Wife states that he was having trouble with slurred speech and confusion yesterday. Symptom free this morning. Return of symptoms with facial droop noted around noon." *Time Last Known Well* is 1200.
- "Wife noticed slurred speech at 8:30 last night. Without symptoms early this morning. Wife noticed slurred speech again at 9:00 during breakfast conversation." *Time Last Known Well* is 0900.
- "Wife noticed slurred speech at 8:30 last night. Symptom-free this morning. Came to ED to get checked out." *Time Last Known Well* is 2030.
- A Code Stroke Form is used by the stroke team or ED staff to document the acute stroke process. See the inclusion list for acceptable terms used for a Code Stroke Form. The list is not all-inclusive.
- *Time Last Known Well* on a Code Stroke Form may be documented by a nurse or other member of the care team authorized to serve as a scribe.
- If the time is noted to be "less than" a period of time prior to ED arrival, assume the maximum range. Example: *Time Last Known Well* less than one hour ago. Subtract one hour from the time of arrival to compute *Time Last Known Well*.

# **Suggested Data Sources:**

- Ambulance record
- Code Stroke Form/template
- Emergency Department record
- History and physical
- IV flow sheets
- Medication administration record
- Nursing flow sheets
- Progress notes
- Transfer sheet

### **Inclusion Guidelines for Abstraction:**

Signs and Symptoms of Stroke

- Sudden numbness or weakness of the face, arm, or leg, especially on one side of the body
- Sudden confusion, trouble speaking or understanding
- Sudden trouble seeing in one or both eyes
- Sudden trouble walking, dizziness, loss of balance or coordination

• Sudden severe headache

## Code Stroke Form

- Stroke Activation Form
- Stroke Alert Form
- Stroke Assessment Form
- Stroke Intervention Form
- Stroke Rapid Response Form
- Thrombolysis Checklist
- tPA Eligibility Form

# **Exclusion Guidelines for Abstraction:**

Code Stroke Form

- Stroke Education Form
- Core Measure Form

Data Element Name: Transfer for Acute Coronary Intervention

Collected For: OP-3

**Definition:** Documentation the patient was transferred from this facility's emergency department to another facility for acute coronary intervention.

**Suggested Data Collection Question:** Was there documentation the patient was transferred from this facility's emergency department to another facility for acute coronary intervention?

#### Format:

Length: 1

Type: Alphanumeric

Occurs: 1

#### Allowable Values:

- 1 There was documentation the patient was transferred from this facility's emergency department to another facility specifically for acute coronary intervention.
- 2 There was documentation the patient was admitted to observation status prior to transfer.
- 3 There was documentation the patient was transferred from this facility's emergency department to another facility for reasons other than acute coronary intervention, or the specific reason for transfer was unable to be determined from medical record documentation.

#### **Notes for Abstraction:**

- To select value 1, documentation must include a specifically defined reason for transfer such as "Percutaneous Coronary Intervention," "Angioplasty," or "for cardiac cath," or "for cath lab."
- The Inclusion Guidelines for Abstraction is not an all-inclusive list. If the acute coronary intervention is not listed in the Inclusion Guidelines for Abstraction, but it is a defined reason for transfer, this is sufficient to abstract a 1.
- To select value 2, there must be documentation of a physician/APN/PA order to admit to observation status
- If a patient receives acute coronary intervention prior to transfer, then abstract value 3.
- The reason for transfer must be a defined ACI. As such, if implicit reasons for transfer, such as "Patient has STEMI" or "Transferred for cardiology consult to discuss possible cath lab" are listed, then select value 3.

## **Suggested Data Sources:**

• Emergency Department record

## **Inclusion Guidelines for Abstraction:**

- Acute angiogram
- Acute cardiac intervention
- Acute coronary intervention
- Angioplasty
- Cath lab
- Cardiac catheterization

- Interventional cardiology
- Percutaneous Coronary Intervention
- Primary Percutaneous Coronary Intervention
- Primary PCI
- PCI

# Missing and Invalid Data

#### Introduction

Missing data are data elements required for calculating a hospital outpatient measure that have no values present for one or more encounters. Invalid data are data element values required for calculating a hospital outpatient measure that fall outside of the range of allowable values defined for that data element.

Reducing the levels of missing and invalid data is important as it minimizes the potential for measure rate bias. Because records with missing or invalid data cannot be included in the calculation of the observed measure rate, a measure's observed rate may not accurately reflect the patient population. The excluded records may have differed significantly from the records with no missing data (i.e., the records remaining may not be representative of the actual population).

## Data Collection and the Unable to be Determined (UTD) Allowable Value

Abstractors provide an answer to every data element that is applicable per the combined skip logic for all measures in a hospital outpatient measure set for the record to be deemed complete and to not be rejected. While there is an expectation that all data elements are collected, it is recognized that, in certain situations, information may not be available (dates, times, codes, etc.). If, after due diligence, the abstractor determines that a value is not documented or is not able to determine the answer value, the abstractor must select UTD as the answer. Note that some data elements do not allow a UTD value for data transmission. The UTD allowable value is used as follows:

- Birthdate, CPT® Code, E/M Code, ICD-10-CM Principal and Other Diagnosis Codes and Outpatient Encounter Date do not have a UTD allowable value for data transmission. Encounter records containing UTD for any of these data elements are rejected when submitted.
- Date, time, and numeric data elements, other than *Birthdate* and *Outpatient Encounter Date*, have a UTD allowable value option.
  - Rate-based algorithms evaluate records to a Measure Category Assignment = D (failed) when a date, time, or numeric data element containing an allowable value of UTD is evaluated.
  - Continuous variable algorithms evaluate records to a Measure Category Assignment = Y
     (UTD value exists) when a date, time, or numeric data element containing an allowable value of UTD is evaluated.
  - The method by which data collection software collects UTD information is determined by each software vendor, except the software cannot automatically default to a UTD answer. The decision to enter a UTD for each data element must be made by the abstractor, not the software.
- Yes/No data elements: The allowable value No incorporates UTD into the definition. Refer to the measure algorithms in which each Yes/No data element is used to determine how the record is treated.
- Data elements containing two or more categorical values: The UTD value is either classified as a separate allowable value or included in the same category as "None of the above/Not documented." Refer to the measure algorithms in which each categorical data element is used to determine how the record is treated.

## Missing and Invalid Data

For rejected data to be accepted, errors must be corrected and the data resubmitted before the transmission deadline.

- The majority of general data elements that are missing data\* cause the encounter record to be rejected. Refer to the Data Dictionary Introduction in this manual for the complete list of general data elements.
- In addition, if both the *ICD-10-CM Principal Diagnosis Code* and the CPT® Code data elements are missing data\*, the entire record will be rejected.
- Not all patients have *ICD-10-CM Other Diagnosis Codes*. Records will be accepted for missing data for this data element.
- Measure-specific data elements that are missing data\* cause the record to be rejected if any measure algorithm results in a Measure Category Assignment = X (missing data). If no measure evaluates to a category assignment of X, the record will be accepted.
- General and measure-specific data elements that contain invalid data cause the record to be rejected.

**Note:** \*A missing value occurs when the abstractor does not select an answer for a data element (leaves it blank) or the software incorrectly transmits a "null" instead of the correct value for a data element. A UTD allowable value is not considered missing data.

## **Abstraction Software Skip Logic and Missing Data**

Skip logic allows hospitals and vendors to minimize abstraction burden by using vendor software edit logic to bypass abstraction of data elements not utilized in the measure algorithm. However, these bypassed elements will negatively impact data quality and the hospital's CMS chart audit validation results when elements are incorrectly abstracted and subsequent data elements are bypassed and left blank.

The use of skip logic by hospitals and vendors is optional and not required. Hospitals should be aware of the potential impact of skip logic on data quality, abstraction burden, and CMS chart audit validation scores. Vendors and hospitals utilizing skip logic should closely monitor the accuracy rate of abstracted data elements, particularly data elements placed higher in the algorithm flow.

## Missing, Invalid, UTD Data Summary:

- Missing Data No data element value is present (blank or "null").
- Invalid Data The data element value falls outside of the range of defined allowable values.
- UTD The allowable value of UTD is present for the data element.

## **Population and Sampling Specifications**

#### Introduction

## Population

Defining the population is the first step to estimate a hospital's performance. A population is generally defined as a collection of patients sharing a common set of universally measured characteristics, such as an ICD-10-CM Principal Diagnosis or CPT® Code. The outpatient population and diagnosis/CPT® codes meet this description for the hospital outpatient quality measures. For the purpose of measuring hospital outpatient quality measures, the term "outpatient population" is defined below:

• An outpatient population refers to all patients (Medicare and non-Medicare) who share a common set of specified, administratively derived data elements. This may include ICD-10-CM diagnosis codes, CPT<sup>®</sup> codes, or other population characteristics such as age. For example, the population for the Acute Myocardial Infarction (AMI) outpatient OP- 2 and OP-3 measures include all patients with an *E/M Code* on Appendix A, OP Table 1.0, an *ICD-10-CM Principal Diagnosis Code* as defined in Appendix A, OP Table 1.1, and a Patient Age (*Outpatient Encounter Date – Birthdate*) ≥ 18 years.

Population sampling algorithms have been developed for the selected seven measures. Each algorithm defines the initial population on the basis of a limited number of criteria such as age, CPT® codes (including Evaluation/Management [E/M] codes), and ICD-10-CM codes. These basic data elements could be easily obtained from electronic files (e.g., from the billing department) and usually allow a computer-based sampling process to be employed.

**Note:** Data entry for OP-22 will be achieved through the secure side of QualityNet.org via an online tool available to authorized users. Because the measure uses administrative data and not claims data to determine the measure's denominator population, OP-22 is not included in the ED-Throughput Population Algorithm.

The measure sets and measure populations are presented in Table 1 below.

Measure Set:AMIPopulation:Acute Myocardial Infarction (AMI)Measure(s):OP-2, OP-3Measure Set:ED-ThroughputPopulation:ThroughputMeasure(s):OP-18

Stroke Stroke

**OP-23** 

OP-29, OP-31

**Table 1: Hospital Outpatient Measure Sets and Measure Populations** 

Note: Data entry for OP-29, and OP-31 will be achieved through the secure side of QualityNet.org via an
online tool available to authorized users. These measures use chart-abstracted data to enter a numeric value
as a numerator and denominator via the web-based tool

Endoscopy/Cataract/EBRT

Measures Submitted via a Web-Based Tool

**Measure Set:** 

**Measure Set:** 

Population:

Measure(s):

Population: Measure(s):

For the definition of the outpatient population for each sampling population, refer to the appropriate outpatient population discussion in the Measure Information section of this manual.

## Sampling

Sampling is a process of selecting a representative part of a population in order to estimate the hospital's performance without collecting data for its entire population. Using a statistically valid sample, a hospital can measure its performance in an effective and efficient manner. Sampling is a particularly useful technique for performance measures that require primary data collection from a source such as the medical record. Sampling should not be used unless the hospital has a large number of cases in the outpatient population because a fairly large number of sample cases are needed to achieve a representative sample of the population. For the purpose of sampling hospital outpatient quality measures, the terms "sample," "effective sample," and "case" are defined below:

- The "sample" is the fraction of the population that is selected for further study.
- "Effective sample" refers to the part of the sample that makes it into the denominator of an outpatient measure set. This is defined as the sample for an outpatient measure set minus all the exclusions and contraindications for the outpatient measure set in the sample.
- A "case" refers to a single record (or an encounter) within the population. For example, during the first quarter a hospital may have 100 patients who had a principal diagnosis associated with the OP- 2 and 3 measures. The hospital's outpatient population would include 100 cases or 100 outpatient records for these measures during the first quarter.

To obtain statistically valid sample data, the sample size should be carefully determined, and the sample cases should be randomly selected in such a way that the individual cases in the population have an equal chance of being selected. Only when the sample data truly represent the whole population can the sample-based performance outpatient measure set data be meaningful and useful. Each hospital is ultimately responsible for adhering to the sampling requirements outlined in this manual.

As a general rule/policy of CMS, providers are encouraged to submit as many cases as possible up to the entire population of cases if reasonably feasible. For example, if the raw data can be easily extracted from an existing electronic database or the abstraction burden is manageable, providers should consider submitting the entire population of cases that meet the initial selection criteria. Otherwise, a statistically valid sample can be selected.

**Note:** Hospitals are **not** required to sample their data if they elect to include all eligible cases. For example, a hospital has 100 cases for the quarter and must select a sample of 80 cases. The hospital may choose to use all 100 cases given the minimal benefit sampling would offer.


#### **Order of Data Flow**

Each outpatient measure set has a unique definition of outpatient population. However, the same data flow or process steps can be used to identify the data that are transmitted to the CMS Clinical Data Warehouse. These process steps are:

- First, identify the outpatient population for the outpatient measure set. An outpatient population is defined for each outpatient measure set, and the count is collected in the *Outpatient Population Size* data element. This data pull utilizes administrative data such as ICD-10-CM diagnosis codes, CPT® codes, outpatient encounter date, and birthdate.
  - All ICD-10-CM diagnosis codes and CPT® codes included in the appropriate outpatient population definition must be applied. This identification process must be completed prior to application of the data integrity filter, outpatient measure set exclusions, and sampling methodology.
  - For specific outpatient measure set definitions, refer to the appropriate outpatient population discussion in the Measure Information section of this manual.

- Second, if the hospital is sampling, use the outpatient population identified above and pull the sample of medical records for each outpatient measure set using the requirements identified in the Quarterly Sampling Requirements section.
- Third, collect or abstract from the identified medical records the general and outpatient measure setspecific data elements that are needed for the sampling population. The count of the number of cases used in this step is collected in the *Outpatient Sample Size* data elements (Note: If the hospital is not sampling, the *Outpatient Sample Size* will equal the *Outpatient Population Size*).
  - If the hospital is not sampling, use all medical records identified in the outpatient population.
  - If the hospital is sampling, use the medical records from the cases in the identified sample.

## Order of Data Flow/Process Steps



#### Sample Size Requirements

Each hospital is ultimately responsible for meeting or exceeding the sample size requirements outlined below. Hospital samples must be monitored to ensure that sampling procedures consistently produce statistically valid and useful data. As a general rule and based on prior experience with CMS hospital inpatient measures, sample size requirements for this project are based on commonly accepted sampling criteria for surveys:

- A five percent margin of error is recommended. The margin of error is the extent of error the investigator is willing to tolerate. Lower margins of error (e.g., three percent) would require substantially larger sample sizes and generate more reliable results from the samples, but the burden of abstraction may not be acceptable for most providers. Inversely, higher margins of error would require relatively smaller sample sizes but less reliable results from those samples.
- For OP-18, in order to reduce the burden of abstraction for smaller hospitals, a 10 percent margin of error was employed to limit the number of cases for the sample size requirements.
- The size of the population, also referred to as the universe population, is the volume of eligible patients from which the sample will be drawn. This number is obviously expected to vary widely among providers. Different sample size estimates are provided for various populations. See Tables 2, 3, and 4 for sample size requirements.
- Given that the number of cases in the sample could further be reduced during the analysis phase due to missing data in the medical records and additional outpatient measure set-specific exclusion criteria, hospitals are strongly advised to overestimate their sample sizes by 10 to 20 percent, or as much as possible.
- A hospital may choose to use a larger sample size than is required.
- Hospitals whose outpatient population size is less than the minimum number of cases for the sampling population must include all eligible cases in their data.
- As a quality check to ensure that sampling methodology was applied correctly, the provider must run a basic comparative analysis of common demographic variables including age distribution, gender ratio, race/ethnicity distribution, and the proportion of Medicare patients between the sampled set and the population of eligible patients. The relative frequencies or distribution of these common variables should be very close between the two data sets. Any significant discrepancy should trigger a review and a restart of the sampling process.
- As indicated earlier, the adequacy of the sample size will be monitored as the project progresses and revised, as needed. Providers that choose to sample are responsible for the sampling process. However, for each sampled case, providers are required to clearly indicate the sample size (n) to which the case belongs, the population size (N) from which the sample was drawn, and the proportion of Medicare and non-Medicare patients in the sample.

## Sampling Requirements

A hospital may choose to use a larger sample size than is required. Hospitals whose population size is less than the minimum number of cases per quarter for the measure set cannot sample. Refer to **Table 2** to determine the minimum number of cases that need to be sampled for each population per quarter per hospital for all measure sets except OP-18, OP-29, and , OP-31. Refer to **Table 3** to determine the minimum number of cases that need to be sampled for each population per quarter per hospital for OP-18. Refer to **Table 4** to determine the annual sample size requirements for OP-29 and OP-31.

It is important to point out that if a hospital elects to use the monthly sampling guidelines, the hospital is still required to meet the minimum sampling requirements. Given the potential for substantial variation in monthly sampling population sizes, the monthly sample sizes should be based on the known or anticipated population size. When necessary, appropriate oversampling should be employed to ensure that the hospital meets the minimum sample size requirements.

Table 2: Sample Size Requirements per Quarter per Hospital for OP-2, OP-3, and OP-23

Population Per Quarter	≤80
Quarterly Sample Size	Use all cases
Monthly Sample Size	Use all cases
Population Per Quarter	81-100
Quarterly Sample Size	80
Monthly Sample Size	27
Population Per Quarter	101-125
Quarterly Sample Size	95
Monthly Sample Size	32
Population Per Quarter	126-150
Quarterly Sample Size	109
Monthly Sample Size	37
<b>Population Per Quarter</b>	151-175
Quarterly Sample Size	121
Monthly Sample Size	41
Population Per Quarter	176-200
Quarterly Sample Size	132
Monthly Sample Size	44
Population Per Quarter	201-225
Quarterly Sample Size	143
Monthly Sample Size	48
Population Per Quarter	226-250
Quarterly Sample Size	152
Monthly Sample Size	51
Population Per Quarter	251-275
Quarterly Sample Size	161
Monthly Sample Size	54
Population Per Quarter	276-300
Quarterly Sample Size	169
Monthly Sample Size	57
Population Per Quarter	301-325
Quarterly Sample Size	177
Monthly Sample Size	59
Population Per Quarter	326-350
Quarterly Sample Size	184
Monthly Sample Size	62
Population Per Quarter	351-375
Quarterly Sample Size	191
Monthly Sample Size	64
Population Per Quarter	376-400
Quarterly Sample Size	197
Monthly Sample Size	66

Population Per Quarter	401-425
Quarterly Sample Size	203
Monthly Sample Size	68
Population Per Quarter	426-450
Quarterly Sample Size	208
Monthly Sample Size	70
Population Per Quarter	451-500
Quarterly Sample Size	218
Monthly Sample Size	73
Population Per Quarter	501-600
Quarterly Sample Size	235
Monthly Sample Size	79
Population Per Quarter	601-700
Quarterly Sample Size	249
Monthly Sample Size	83
Population Per Quarter	701-800
Quarterly Sample Size	260
Monthly Sample Size	87
Population Per Quarter	801-900
Quarterly Sample Size	270
Monthly Sample Size	90
Population Per Quarter	901-1,000
Quarterly Sample Size	278
Monthly Sample Size	93
Population Per Quarter	1,001-2,000
Quarterly Sample Size	323
Monthly Sample Size	108
Population Per Quarter	2,001-3,000
Quarterly Sample Size	341
Monthly Sample Size	114
Population Per Quarter	3,001-4,000
Quarterly Sample Size	351
Monthly Sample Size	117
Population Per Quarter	4,001-5,000
Quarterly Sample Size	357
Monthly Sample Size	119
Population Per Quarter	5,001-10,000
Quarterly Sample Size	370
Monthly Sample Size	124
Population Per Quarter	≥ 10,001
Quarterly Sample Size	377
Monthly Sample Size	126

**Table 3: Sample Size Requirements per Quarter per Hospital** for OP-18

Population Per Quarter	0-900
Quarterly Sample Size	63
Monthly Sample Size	21
Population Per Quarter	≥ 901
Population Per Quarter Quarterly Sample Size	≥ <b>901</b> 96

Table 4: \*Sample Size Requirements per Year per Hospital for OP-29 and OP-31

Population Per Year	0-900
Yearly Sample Size	63
Quarterly Sample Size	16
Monthly Sample Size	6
Population Per Year	≥ 901
Yearly Sample Size	96
Quarterly Sample Size	24
Monthly Sample Size	8

<sup>\*</sup>If a hospital has 20 or fewer cases, it is not required to submit any data, but it may voluntarily submit these data.

## Sampling Approaches

#### **OP-29** and **OP-31**

Hospitals have the option to sample from their population or submit their entire population. Hospitals that choose to sample for these measures should use a simple sample approach, selecting the population from cases that meet requirements to be included in the denominator. Once the population has been determined, the sample size will be determined based on Table 4 and will either be 63 or 96 cases for the year. This will constitute an acceptable sample methodology and will meet the annual reporting size requirements. If hospitals choose to select data monthly or quarterly, one option they can use is to select the first month of each quarter/year until they meet the annual reporting requirements.

## **Sample Size Examples**

#### OP-2 and OP-3

• A hospital's outpatient population for OP-2 and OP-3 is 10 patients during the quarter. According to Table 2, the required quarterly sample size would be 100 percent of the OP-2 and OP-3 patient population or 10 cases for the quarter.

## **OP-18**

• A hospital's outpatient population size for OP-18 is 700 during the third quarter. According to Table 3, the required quarterly sample size would be 63 cases per quarter. The same hospital has an outpatient population size for OP-18 of 2,000 during the fourth quarter. The hospital had an increase in population size of 1,300 between quarters three and four; the required quarterly sample size would be 96 because the quarterly sample size has been capped at 96 for population sizes of equal to or greater than 901.

#### **OP-29** and **OP-31**

- A hospital's outpatient population size for OP-29 or OP-31 is 430 during the year. If a hospital elects to sample monthly based on Table 4, the monthly sample size would be a minimum of six patients per month. The hospital is ultimately responsible for meeting the yearly sample size requirement, which is a minimum of 63 patients for the year.
- A hospital's outpatient population size for OP-29 or OP-31 is 950 during the year. According to Table 4, the required yearly sample size would be 96 cases.
- A hospital's outpatient center performs 950 cataract operations during the year; 800 patients complete a pre- and post-operative visual function survey. Select 96 patients out of the 800 patients that have completed both surveys to determine the denominator and meet the required annual sample size.

## **Sampling Approaches**

As previously stated in this section, hospitals have the option to sample from their population or submit their entire population. Hospitals that choose to sample must ensure that the sampled data represents their

outpatient population by using either the simple random sampling or systematic random sampling method and that the sampling techniques are applied consistently within a quarter. For example, quarterly samples for a sampling population must use consistent sampling techniques across the quarterly submission period.

- Simple random sampling Selecting a sample size (n) from the population of size (N) in such a way that every case has the same chance of being selected.
- Systematic random sampling Selecting every  $k^{th}$  record from a population size (N) in such a way that a sample size of n is obtained, where k = N/n rounded to the lower digit. The first sample record (i.e., the starting point) must be randomly selected before taking every  $k^{th}$  record. This is a two-step process:
  - 1. Randomly select the starting point by choosing a number between one and k using a table on random number or a computer-generated random number, then
  - 2. Select every  $k^{th}$  record thereafter until the selection of the sample size is completed.

Each hospital is ultimately responsible that the sampling techniques applied for their hospital adhere to the sampling requirements outlined in this manual. Performance measurement systems are responsible for ensuring that the sampling techniques are applied consistently across their client hospitals.

## **Transmission of Outpatient Population and Sample Data Elements**

Refer to the QualityNet website or the Hospital Outpatient Quality Measure Data Transmission section of this manual for the most current CMS Hospital OQR Program submission requirements for transmission of outpatient population and sample count data elements to the CMS Clinical Data Warehouse. Transmission of outpatient population and sample count data elements are used to assist in evaluating completeness of submission in accordance with CMS sampling requirements.

All ICD-10-CM diagnosis codes and CPT® codes included in the appropriate outpatient population definition must be applied. This identification process must be completed prior to the application of a data integrity filter, outpatient measure set exclusions, and sampling methodology. For specific definitions, refer to the appropriate outpatient population in this manual.

The outpatient population and sample data elements are:

- Outpatient Population Size Medicare Only
- Outpatient Population Size Non-Medicare Only
- Outpatient Sampling Frequency
- Outpatient Sample Size Medicare Only
- Outpatient Sample Size Non-Medicare Only

Outpatient Sampling Frequency indicates whether the hospital sampled its original population, whether the entire population was used for the specific time period, or the hospital had five or fewer encounters for the encounter quarter and did not submit patient-level data.

## **Outpatient Population and Sample Size Examples**

## Example 1 – Hospital does not sample

A hospital uses the OP-3 CPT® Codes (as listed in Appendix A, Table 1.1) and patient age to identify 125 cases in the OP-3 outpatient population during the second quarter. The hospital does not sample the OP-3 outpatient measure set, so data for all 125 cases are collected and used to calculate the hospital's rate for the outpatient measure set. Forty of the 125 cases in the OP-3 outpatient population are Medicare patients.

The breakdown of data by month and Medicare/Non-Medicare is:

	April	May	June	Total
Outpatient Population – Medicare patients	10	15	15	40
Outpatient Population – Non-Medicare patients	20	30	35	85

Hospital OQR Specifications Manual

Encounter dates 01-01-20 (1Q20) through 12-31-20 (4Q20) v13.0a

<b>Total Outpatient Population Size</b>	30	45	50	125
Outpatient Sample Size – Medicare patients	10	15	15	40
Outpatient Sample Size – Non-Medicare patients	20	30	35	85
Total Sample Size	30	45	50	125

The following is transmitted for each month in the quarter:

	April	May	June
Outpatient Population Size – Medicare only	10	15	15
Outpatient Population Size – Non-Medicare only	20	30	35
Outpatient Sampling Frequency (2 = not sampling)	2	2	2
Outpatient Sample Size – Medicare only	10	15	15
Outpatient Sample Size – Non-Medicare only	20	30	35

## Example 2 – Hospital samples

A hospital uses the OP-2 CPT® Codes (as listed in Appendix A, OP Table 1.1) and patient age to identify 125 cases in the OP-3 outpatient population during the second quarter. From these 125 cases, the hospital randomly selects a sample of 95 cases. Data for these 95 cases are collected and are then used to calculate the hospital's rate for each OP-3 outpatient measure. Forty of the 125 cases in the OP-3 outpatient population are Medicare patients, and 25 of these cases were included in the sample.

The breakdown of data by month and Medicare/Non-Medicare is:

	April	May	June	Total
Outpatient Population – Medicare patients	10	15	15	40
Outpatient Population – Non-Medicare patients	20	30	35	85
<b>Total Outpatient Population Size</b>	30	45	50	125
Outpatient Sample Size – Medicare patients	5	10	10	25
Outpatient Sample Size – Non-Medicare patients	15	25	30	70
Total Sample Size	20	35	40	95

The following is transmitted for each month in the quarter:

	April	May	June
Outpatient Population Size – Medicare only	10	15	15
Outpatient Population – Non-Medicare only	20	30	35
Outpatient Sampling Frequency (1 = sampled data)	1	1	1
Outpatient Sample Size – Medicare only	5	10	10
Outpatient Same Size – Non-Medicare only	15	25	30

## **Hospital Outpatient Quality Measure Data Transmission**

#### Introduction

This section of the manual is provided to highlight the unique data transmission specifications for Hospital Outpatient measure data for the Centers for Medicare & Medicaid Services (CMS) and the CMS Clinical Data Warehouse.

This section is divided into three parts: Guidelines for Submission of Data, Transmission Data Element List, and Transmission Data Processing Flow.

The Guidelines for Submission of Data section provides the user with the data standards required for submission to the CMS Clinical Data Warehouse. It includes an overview of the data required for submission to the CMS Clinical Data Warehouse, as well as the Hospital Outpatient Clinical Data XML file layout and the *Hospital Outpatient Population Data XML File Layout*.

The Transmission Data Element List describes the data elements that are either used to identify the hospital and Hospital Outpatient measure set associated to the transmitted data or is calculated by the vendor using the hospital's patient-level data and measure results. These data elements are not used in the Population Algorithms or Measure Algorithms.

The Transmission Data Processing Flow contains information regarding the order in which the CMS Clinical Data Warehouse evaluates the Hospital Outpatient measures.

#### **IMPORTANT SUBMISSION ALERT!!**

At this time, for submission of the Hospital Outpatient measures to CMS under the Hospital Outpatient Quality Reporting (OQR) Program, files must meet the specifications in this CMS manual only. Otherwise, the files will be rejected as not meeting CMS quality data submission requirements for receiving the full payment update.

Providers who are planning to also submit the Hospital Outpatient measures to The Joint Commission must refer to the transmission section separately issued by The Joint Commission. This is important because, at this time, CMS can only accept files which meet the CMS transmission manual specifications, and such files cannot contain the additional Joint Commission transmission data elements (e.g., vendor tracking ID, measure category assignment, measure value).

#### **Guidelines for Submission of Data**

Data collected for CMS are transmitted to the CMS Clinical Data Warehouse. All data submitted are required to meet transmission requirements. The file layout requirements are included in the sections that follow.

#### Submission Threshold

In order to reduce the burden on hospitals that treat a low number of patients but otherwise meet the submission requirements for a particular quality measure, hospitals that have five or fewer cases in a quarter (both Medicare and non-Medicare) for any measure set (i.e., Stroke) will **not** be required to submit patient-level data for the entire measure set for that quarter.

## **Submission of Hospital Outpatient Clinical Data**

Hospital Outpatient Clinical Data are submitted to the CMS Clinical Data Warehouse on a quarterly submission schedule. All clinical data submitted to the CMS Clinical Data Warehouse must adhere to the *Hospital Outpatient Clinical Data XML File Layout* specifications provided later in the transmission section. Each case must have a separate XML file. For example, if you have 12 records that you have abstracted, you

Hospital OQR Specifications Manual

Encounter dates **01-01-20** (**1Q20**) through **12-31-20** (**4Q20**) v13.0a

must have 12 separate XML files. If you have abstracted more than one Hospital Outpatient measure set for a patient encounter, then a separate XML file must be created for each Hospital Outpatient measure set. Each Hospital Outpatient measure can only be abstracted once for the same medical record.

## **Submission of Hospital Outpatient Population Data**

CMS collects population size and declaration of sampling by Hospital Outpatient measure set on a quarterly basis. For hospitals submitting the Hospital Outpatient Population Data, information may be submitted via an XML file to the CMS Clinical Data Warehouse. All population data submitted to the CMS Clinical Data Warehouse must adhere to the *Hospital Outpatient Population Data XML File Layout* specifications provided later in the transmission section. Each file may contain data for only one provider.

Additional guidelines related to the submission of Hospital Outpatient Clinical Data and Hospital Outpatient Population Data are outlined below.

#### Overview

The guidelines below are for the submission of Hospital Outpatient Clinical Data and Hospital Outpatient Population Data to CMS.

#### **Data Submission Verification**

Prior to processing measure outcomes, all data will be verified according to the rules in the Data Transmission section and the edits documents. Cases submitted to the CMS Clinical Data Warehouse that do not meet the requirements outlined in these documents will be rejected.

## Requirements for XML Tags and Associated Data

Do not put spaces between XML tags and associated data. Cases with inappropriate spaces will be rejected from the CMS Clinical Data Warehouse.

## **Export File Character Limitations**

Cases exported for submission to the CMS Clinical Data Warehouse may not have greater than 50 characters in the file name.

#### **Missing Data Policy**

All cases submitted to the CMS Clinical Data Warehouse must have all data required to calculate the measures. Files submitted, which are missing data required to calculate measures (any case that would result in a Measure Category X assignment), will be rejected from the Warehouse. These cases should be reviewed by the provider, corrected, and resubmitted prior to the submission deadline with an allowable value indicated for any data element that was missing. Please refer to the Missing and Invalid Data Section for additional information.

## Required Patient Identifiers Based on Payment Source

1. All cases submitted to the CMS Clinical Data Warehouse are required to include the Patient Identifier. Please refer to the Data Dictionary for the definition of this data element.

## Unique Record Key (What fields make a record unique?)

CMS Certification Number, Patient Identifier, Arrival Time, Outpatient Encounter Date, and Outpatient Measure Set.

#### **Principal and Other Diagnosis Codes**

Effective March 1, 2007, the National Uniform Billing Committee implemented a Present on Admission (POA) indicator for Principal and other Diagnosis codes. These POA indicators do not apply to outpatient billing and should not be present on outpatient claims. Therefore, data submitted to the CMS Clinical Data

Hospital OQR Specifications Manual

Encounter dates **01-01-20** (**1Q20**) through **12-31-20** (**4Q20**) v13.0a

Warehouse must have any POA Indicator removed prior to submission. Failure to remove the indicator will result in cases being rejected from the CMS Clinical Data Warehouse.

## **Hospital Outpatient Clinical Data XML File Layout**

The XML file layout is divided into the following sections. Please refer to the Hospital Outpatient Clinical Data XML file layout example for details on how the file elements are nested.

**submission** – Parent element. This is a **required** element.

The following attributes identify the initiative and file content of this element:

- 1. **type** Describes the setting for which the data are being submitted (OUTPATIENT).
- 2. **data** Describes the type of data being submitted (CLINICAL).
- 3. **version** The version of the file layout (1.0).
- 4. **action-code** Describes the intended action of the file being submitted (ADD or DELETE). **Note:** In order to replace or delete an existing case utilizing the action–code ADD or DELETE, the following data element values must match:
  - CMS Certification Number (provider-id),
  - Patient Identifier (patient-id),
  - Arrival Time (arrival-time),
  - Encounter Date (encounter-date), and
  - *Measure Set (encounter measure-set).*

**file-audit-data** – Sub-element of "submission" used to identify file characteristics. This sub-element is **not required** for the parent element "submission" and has no attributes.

The following identifies the file content on the "file-audit-data" sub-element. This file content is **not a required** sub-element of "file-audit-data" and has attributes.

- 1. **create-date** Sub-element of "*file-audit-data*" identifying the month, day, and year the file was created.
- 2. **create-time** Sub-element of "*file-audit-data*" identifying the hour and minutes representing the time the file was created.
- 3. **create-by** Sub-element of "file-audit-data" identifying the entity creating the file.
- 4. **version** Sub-element of "file-audit-data" identifying the version of the file being submitted.
- 5. **create-by-tool** Sub-element of "*file-audit-data*" identifying the tool used to create the file.

**abstraction-audit-data** – Sub-element of "*submission*" identifying characteristics of the abstraction. This sub-element is not required for the parent element "*submission*" and has no attributes.

The following identifies the file content of the "abstraction-audit-data" sub-element. This file content is **not a required** sub-element of "abstraction-audit-data" and has no attributes.

- 1. **abstraction-date** Sub-element of "abstraction-audit-data" identifying the month, day, and year the abstraction was created.
- 2. **abstractor-id** Sub-element of "abstraction-audit-data" identifying the abstractor.
- 3. **total-abstraction-time** Sub-element of "*abstraction-audit-data*" identifying the total time in seconds required to abstract the information,
- 4. **comment** Sub-element of "abstraction-audit-data" containing abstractor comments.

**provider** – **Required** sub-element of "*submission*" identifying provider, patient, and encounter information. This sub-element and the file content listed below have no attributes.

- 1. **provider-id Required** sub-element of "*provider*" identifying the provider's CMS Certification Number (CCN).
- 2. **npi** Sub-element of "*provider*" identifying the provider's National Provider Identifier (NPI). This is not a required sub-element of "*provider*."

**patient** – **Required** sub-element of "*provider*" identifying patient demographics. This sub-element has no attributes.

- 1. **first-name** Sub-element of "*patient*" providing the patient's first name. This is not a required sub-element of "*patient*" and has no attributes.
- 2. **last-name** Sub-element of "patient" providing the patient's last name. This is not a required sub-element of "patient" and has no attributes.
- 3. **birthdate** Sub-element of "*patient*" providing the patient's birthdate. This is a **required** sub-element of "*patient*" and has no attributes.
- 4. **sex** Sub-element of "*patient*" identifying the patient's gender. This is a **required** sub-element of "*patient*" and has no attributes.
- 5. **race** Sub-element of "patient" identifying the patient's race. This is a **required** sub-element of "patient" and has no attributes.
- 6. **ethnic** Sub-element of "*patient*" identifying the patient's Hispanic ethnicity. This is a **required** sub-element of "*patient*" and has no attributes.
- 7. **postal-code** Sub-element of "*patient*" providing the patient's ZIP code. This is a **required** sub-element of "*patient*" and has no attributes.

**encounter** – **Required** sub-element of "*patient*" identifying the measure set and the patient's abstracted data. The following attributes identify the initiative and file content of this element:

- 1. **measure set** Identifies the measure set for which the data were abstracted. The attribute of "encounter" identifies the measure set.
- 2. **encounter-date Required** sub-element of "encounter" identifying the month, day, and year the patient encounter occurred. This sub-element has no attributes.
- 3. **arrival-time Required** sub-element of "*encounter*" providing the patient's arrival time. This sub-element has no attributes.
- 4. **patient-id Required** sub-element of "*encounter*" identifying the patient associated with the abstracted data. This sub-element has no attributes.

**detail** – **Required** sub-element of "*encounter*" identifying the provider-abstracted information. The following attributes of "*detail*" identify the abstracted information.

- 1. **question-cd** Question being asked of the abstractor.
- 2. **answer-cd** Answer identification code provided by the abstractor.
- 3. **row-number** Sequential number identifying each response to a multiple answer question.

**answer-value** – Sub-element of "*detail*" providing the answer value text attributable to the answer-cd. This is **not a required** sub-element of "detail" and has no attributes.

## **Example of nested Hospital Outpatient Clinical XML file elements:**

- submission (plus attributes type, data, version, and action-code)
  - file-audit-data
    - create-date
    - create-time
    - create-by

- version
- create-by-tool
- abstraction-audit-data
  - abstraction-date
  - abstractor-id
  - total abstraction-time
  - comment
- provider
  - provider-id
  - npi
  - patient
    - first-name
    - last-name
    - birthdate
    - sex
    - race
    - ethnic
    - postal-code
    - encounter (plus attribute measure-set)
      - encounter-date
      - arrival-time
      - patient-id
      - detail (plus attributes answer-code, question-cd, row-number)
        - answer-value

To obtain further information about these questions and their possible attribute values, refer to the applicable data element names (as identified in the first column, Question of the Clinical Data Elements worksheet) in Section 2, Data.

## **Hospital Outpatient Population Data XML File Layout**

The XML file layout is divided into the following sections. Please refer to the *Hospital Outpatient Population Data XML file layout* example for details on how the file elements are nested.

**submission** – Parent element. This element is required.

The following attributes identify the initiative and file content of this element.

- 1. **type** Describes the setting for which the data are being submitted (OUTPATIENT).
- 2. data Describes the type of data being submitted (POPULATION).
- 3. **version** The version of the file layout (1.0).
- 4. **action-code** Describes the intended action of the file being submitted (ADD).

**Note:** In order to replace an existing case utilizing the action-code ADD, the following data element values must match.

- CMS Certification Number (provider-id),
- Time period start date (time-period start-date),
- Time period end date (time-period end-date), and
- *Measure Set* (encounter measure-set).

**file-audit-data** – Sub-element of "submission" used to identify file characteristics of the file. This sub-element and the file content listed below **are not required** and have no attributes.

The following identify the file content of the "file-audit-data" sub-element:

- 1. **create-date** Sub-element of "*file-audit-data*" identifying the month, day, and year the file was created.
- 2. **create-time** Sub-element of "*file-audit-data*" identifying the hours and minutes representing the time the file was created.
- 3. **create-by** Sub-element of "*file-audit-data*" identifying the entity creating the file.
- 4. **version** Sub-element of "file-audit-data" identifying the version of the file being submitted.
- 5. **create-by-tool** Sub-element of "*file-audit-data*" identifying the tool used to create the file.

**provider** – **Required** sub-element of "*submission*" identifying encounter period and population data. There are no attributes for this element.

- 1. **provider-id** Sub-element of "*provider*" identifying the provider.
- 2. **npi** Sub-element of "*provider*" identifying the provider's National Provider Identifier (NPI). This is not a required sub-element of "provider."

**time-period** – **Required** sub-element of "provider" with attributes of delimiting the encounter period.

- 1. **start-date** The starting month, day, and year for the encounters associated with the submitted data.
- 2. **end-date** The ending month, day, and year for the encounters associated with the submitted data. **Note:** Dates in these fields should reflect the encounter time period related to the data being submitted. Time period start and end dates must reflect full month increments and not be greater than one month. Files submitted to the CMS Clinical Data Warehouse are required to contain three onemonth time-periods comprising the calendar quarter for which data are being submitted.

## Example

If the Hospital Outpatient Population Data file is being submitted for the second quarter of 2020, the file must contain the following time periods and appropriate associated data (including all data elements as the Population Details section that follows):

April 2020

May 2020

June 2020

Files submitted with time periods that do not meet the above requirements will be rejected from the CMS Clinical Data Warehouse.

**encounter** – **Required** sub-element of "*time-period*" identifying the measure set and the population. The following attributes identify the file content of this element:

- 1. **measure set** Identifies the outpatient measure set for which the case was abstracted.
- 2. **population size Required** sub-element of "*encounter*" identifying population components. There are no attributes for this element.
  - a. **Medicare Required** sub-element of "*population-size*" identifying the numbers of Medicare submissions. There are no attributes for this element.
  - b. **non-Medicare Required** sub-element of "*population-size*" identifying the number of non-Medicare submissions. There are no attributes for this element.
- 3. **patient-id Required** sub-element of "*encounter*" identifying the patient associated with the abstracted data. This sub-element has no attributes.
- 4. **sampling frequency Required** sub-element of "*encounter*" identifying if the provider is sampling. This sub-element has no attributes.
- 5. **sample-size Required** sub-element of "*encounter*" identifying sampled population sizes. This sub-element has no attributes.

- a. **Medicare Required** sub-element of "*sample-size*" identifying the number of Medicare submissions in the sample. There are no attributes for this element.
- b. **non-Medicare Required** sub-element of "*sample-size*" identifying the number of non-Medicare submissions in the sample. There are no attributes for this element.

## **Example of nested Hospital Outpatient Population XML file elements:**

The XML file elements are nested as follows:

- submission (plus attributes type, data, version, and action-code)
  - file-audit-data
    - create-date
    - create-time
    - create-by
    - version
    - create-by-tool
  - provider
    - provider-id
    - npi
    - time period (plus attributes start-date and end-date)
      - encounter (plus attribute measure-set)
        - population-size
          - Medicare
          - non-Medicare
        - sampling-frequency
        - sample-size
          - Medicare
          - non-Medicare

Please refer to the Transmission Data Element List for further definition of the data elements. Please refer to *Hospital Outpatient Population Data XML File Layout* for further information on details of the XML file format. All data elements are based on encounters that occurred during the associated time period.

#### Measures Submitted Via a Web-Based Tool

**Annual Data Submission Period:** See the timeline posted to QualityNet.org for these measures; select Hospital Outpatient and then Data Submission in the drop-down menu.

#### **Submission Instruction:**

Data entry will be achieved through the secure side of QualityNet.org via an online tool available to authorized users. After logging into the secure portal:

- Select Hospital Quality Reporting from the Quality Programs drop-down menu to open the "Quality Reporting System My Tasks" page.
- Select the Manage Measures option for view/edit of Structural/Web-Based Measures
- Select Hospital Outpatient Web-Based Measures
- Select the appropriate payment year from the drop-down menu
- Select measure for submitting data, saving each measure as the data is entered.

<ul> <li>Repeat the process for each required measure until data entry for all required measures are complete (select the measure, submit measure data, and save the data). Facilities that do not have data for a required measure should report zeros in both the Numerator and Denominator.</li> </ul>				
<ul> <li>All measure data must be submitted by the deadline</li> </ul>				
OQR Specifications Manual				

#### **Transmission Data Element List**

These data elements are used either to identify the hospital and Hospital Outpatient measure set associated to the transmitted data or are calculated by the vendor using the hospital's patient-level data measure results. These data elements are not used in the Outpatient Population Algorithms or Measure Algorithms.

Element Name	Page #	Collected For:
CMS Certification Number	5-151	All Records
National Provider Number (NPI)	5-152	Optional for All Records
Outpatient Measure Set	5-153	Used in transmission of the Hospital Outpatient Population Data XML file and the Hospital Outpatient Clinical Data XML file
Outpatient Population Size – Medicare Only	5-154	Used in transmission of the Hospital Outpatient Population Data XML file
Outpatient Population Size – Non-Medicare Only	5-155	Used in transmission of the Hospital Outpatient Population Data XML file
Outpatient Sample Size – Medicare Only	5-156	Used in transmission of the Hospital Outpatient Population Data XML file
Outpatient Sample Size – Non-Medicare Only	5-157	Used in transmission of the Hospital Outpatient Population Data XML file
Outpatient Sampling Frequency	5-158	Used in transmission of the Hospital Outpatient Population Data XML file

#### **IMPORTANT SUBMISSION ALERT!!**

At this time, for submission of the Hospital Outpatient measures to CMS under the Hospital Outpatient Quality Reporting (OQR) Program, files must meet the specifications in this CMS manual only. Otherwise, the files will be rejected as not meeting CMS quality data submission requirements for receiving the full payment update.

Providers who are planning to also submit the Hospital Outpatient measures to The Joint Commission must refer to the transmission section separately issued by The Joint Commission. This is important because, at this time, CMS can only accept files which meet the CMS transmission manual specifications, and such files cannot contain the additional Joint Commission transmission data elements (e.g., vendor tracking ID, measure category assignment, measurement value).

Data Element Name: CMS Certification Number

Collected For: All records

**Definition:** Hospital's six-digit acute care CMS Certification Number (CCN).

Suggested Data Collection Question: What is the hospital's six-digit acute care CMS Certification

Number?

Format: Length: 6

Type: Character

Occurs: 1

#### **Allowable Values:**

Any valid six-digit CMS Certification Number.

The first two digits are the numeric state code. The third digit of zero represents an acute facility. The third digit of "1" and fourth digit of "3" represents a Critical Access Hospital (CAH).

Notes for Abstraction: None

Suggested Data Sources: None

**Inclusion Guidelines for Abstraction:** None

Data Element Name: National Provider Identifier (NPI)

Collected For: Optional for all records

**Definition:** All Health Insurance Portability and Accountability Act of 1996 (HIPAA) covered healthcare providers must obtain an NPI. The NPI may be provided in addition to the Medicare provider number.

**Suggested Data Collection Question:** What is the NPI for this provider?

Format:

Length: 10

Type: Character

Occurs: 1

Allowable Values: Any valid 10-digit NPI number.

The 10th digit is a numeric check digit based off the first 9 digits.

Notes for Abstraction: None

Suggested Data Sources: UB-04, Field Location: 56

**Inclusion Guidelines for Abstraction:** None

Data Element Name: Outpatient Measure Set

**Collected For:** Used in transmission of the Hospital Outpatient Population Data XML file and the Hospital Outpatient Clinical XML file.

**Definition:** Indicates which Hospital Outpatient measure set is being transmitted for the hospital.

Suggested Data Collection Question: Not Applicable.

Format:

Length: 22

Type: Character

Occurs: 1

**Allowable Values:** Refer to the Hospital Outpatient Clinical Data XML file and the Hospital Outpatient Population Data XML file layouts located just after the Transmission Data Processing Flow portion of this section.

Notes for Abstraction: None

Suggested Data Sources: Not Applicable

**Inclusion Guidelines for Abstraction:** None

Data Element Name: Outpatient Population Size - Medicare Only

**Collected For:** Used in transmission of the Hospital Outpatient Population Data XML file.

**Note:** Refer to the Hospital Outpatient Population Data XML file layout located just after the Transmission Data Processing Flow portion of this section.

**Definition:** Indicates the number of encounter records identified for a hospital with Medicare listed as a payment source prior to the application of data integrity filters, measure exclusions, and/or sampling methodology for the specified time period.

The data element is based on the hospital's initial identification of Medicare encounter records for a Hospital Outpatient measure set. *Outpatient Population Size – Medicare Only* includes all patients that are billed under Medicare or Title 18. Medicare can be listed as a primary, secondary, tertiary, or lower on the list of payment sources for the patient. In addition, patients who are participating as a member of a Medicare HMO/Medicare Advantage are included in the Medicare counts, e.g., Medicare Blue, Humana Gold, Secure Horizons, AARP, Coventry Advantra, etc. This initial data pull utilizes administrative data such as ICD-10-CM diagnosis codes, CPT® codes, outpatient encounter date, and birthdate.

For specific Hospital Outpatient measure set definitions, refer to the appropriate outpatient population discussion in the Measure Information section of this manual.

Note: If the hospital's data have been sampled, this field contains the population from which the sample was originally drawn, **not** the sample size.

Suggested Data Collection Question: Not Applicable.

#### Format:

Length: 6

Type: Numeric

Occurs: One Outpatient Population Size – Medicare Only per Hospital Outpatient measure set

Allowable Values: 0 through 999,999

**Notes for Abstraction:** *Outpatient Population Size – Medicare Only* must contain the actual number of patients in the population.

Suggested Data Sources: Not Applicable

**Inclusion Guidelines for Abstraction:** None

Data Element Name: Outpatient Population Size - Non-Medicare Only

**Collected For:** Used in transmission of the Hospital Outpatient Population Data XML file.

**Note:** Refer to the Hospital Outpatient Population Data XML file layout located just after the Transmission Data Processing Flow portion of this section.

**Definition:** Indicates the number of encounter records identified for a hospital with Medicare <u>not</u> listed as a payment source prior to the application of data integrity filters, measure exclusions, and/or sampling methodology for the specified time period.

The data element is based on the hospital's initial identification of non-Medicare encounter records for a Hospital Outpatient measure set. This initial data pull utilizes administrative data such as ICD-10-CM diagnosis codes, CPT® codes, outpatient encounter date, and birthdate.

For specific Hospital Outpatient measure set definitions, refer to the appropriate outpatient population discussion in the Measure Information section of this manual.

**Note:** If the hospital's data have been sampled, this field contains the population from which the sample was originally drawn, **not** the sample size.

Suggested Data Collection Question: Not Applicable.

#### Format:

Length: 6

Type: Numeric

Occurs: One *Outpatient Population Size – Non-Medicare Only* per Hospital Outpatient measure set

Allowable Values: 0 through 999,999

**Notes for Abstraction:** *Outpatient Population Size – Non-Medicare Only* must contain the actual number of patients in the population.

Suggested Data Sources: Not Applicable

**Inclusion Guidelines for Abstraction:** None

Data Element Name: Outpatient Sample Size – Medicare Only

**Collected For:** Used in transmission of the Hospital Outpatient Population Data XML file.

**Note:** For more information, refer to the Population and Sampling Specifications section and the Hospital Outpatient Population Data XML file layout located just after the Transmission Data Processing Flow portion of this section.

**Definition:** Indicates the number of encounter records identified for a hospital with Medicare listed as a payment source for a hospital to perform data abstraction on. This count is after the appropriate sampling methodology, if any, has been applied for the specific time period.

#### **Notes:**

- If the hospital is sampling the Hospital Outpatient measure set, then the *Outpatient Sample Size Medicare Only* will be less than the *Outpatient Population Size Medicare Only* for the Hospital Outpatient measure set.
- If the hospital is not sampling the Hospital Outpatient measure set, then the *Outpatient Sample Size Medicare Only* will equal the *Outpatient Population Size Medicare Only* for the Hospital Outpatient measure set.

Suggested Data Collection Question: Not Applicable.

#### Format:

Length: 6

Type: Numeric

Occurs: One Outpatient Sample Size – Medicare Only per Hospital Outpatient measure set

Allowable Values: 0 through 999,999

**Notes for Abstraction:** When *Outpatient Sampling Frequency* = "N/A" because the hospital decided to not submit patient-level data, *Outpatient Sample Size* – *Medicare Only* equals zero.

Suggested Data Sources: Not Applicable

**Inclusion Guidelines for Abstraction:** None

Data Element Name: Outpatient Sample Size – Non-Medicare Only

**Collected For:** Used in transmission of the Hospital Outpatient Population Data XML file.

**Note:** For more information, refer to the Population and Sampling Specifications section and the Hospital Outpatient Population Data XML file layout located just after the Transmission Data Processing Flow portion of this section.

**Definition:** Indicates the number of encounter records identified for a hospital with Medicare **not** listed as a payment source for a hospital to perform data abstraction on. This count is after the appropriate sampling methodology, if any, has been applied for the specific time period.

#### **Notes:**

- If the hospital is sampling the Hospital Outpatient measure set, then the *Outpatient Sample Size Non-Medicare Only* will be less than the *Outpatient Population Size Non-Medicare Only* for the Hospital Outpatient measure set.
- If the hospital is not sampling the Hospital Outpatient measure set, then the *Outpatient Sample Size Non-Medicare Only* will equal the *Outpatient Population Size Non-Medicare Only* for the Hospital Outpatient measure set.

Suggested Data Collection Question: Not Applicable.

#### Format:

Length: 6

Type: Numeric

Occurs: One Outpatient Sample Size – Non-Medicare Only per Hospital Outpatient measure set

Allowable Values: 0 through 999,999

**Notes for Abstraction:** When *Outpatient Sample Frequency* = "N/A" because the hospital decided not to submit patient-level data, *Outpatient Sample Size* – *Non-Medicare Only* equals zero.

Suggested Data Sources: Not Applicable

**Inclusion Guidelines for Abstraction:** None

Data Element Name: Outpatient Sampling Frequency

**Collected For:** Used in transmission of the Hospital Outpatient Population Data XML file.

**Note:** Refer to the Population and Sampling Specifications section and the Hospital Outpatient Population Data XML file layout located just after the Transmission Data Processing Flow portion of this section.

**Definition:** Indicates if the data being transmitted for a hospital have been sampled or represent an entire population for the specified time period.

Suggested Data Collection Question: Not Applicable.

#### Format:

Length: 1

Type: Character

Occurs: One Outpatient Sampling Frequency per Hospital Outpatient measure set

#### **Allowable Values:**

- 1. Yes, the hospital is sampling.
- 2. No, the hospital is not sampling.
- 3. N/A, submission of patient-level data is not required.

**Notes for Abstraction:** Hospitals that have five or fewer cases (both Medicare and non-Medicare) for any measures included in a measure topic (i.e., ED and Stroke) in a quarter will not be required to submit patient-level data for the entire measure topic for that quarter. For example, hospitals with five or fewer cases (both Medicare and non-Medicare) for the ED measure topic in a quarter will not be required to submit patient-level data for that quarter.

Suggested Data Sources: Not Applicable

**Inclusion Guidelines for Abstraction:** None

## **Transmission Data Processing Flow**

#### Introduction

This section contains information regarding the order in which the CMS Clinical Data Warehouse evaluates the Hospital Outpatient measures.

The data processing flow ensures that only valid data are used in the measure algorithms. Each case that is rejected by the process will be listed on a report along with a brief description of the problem. The CMS Clinical Data Warehouse has reports available to assist the submitter to determine how the data were processed. For the CMS Clinical Data Warehouse, please refer to QualityNet.org for more information about the data upload process and these reports.

## **Data Processing Flow**

## All data transmitted pass through the following process:

- 1. If appropriate, files are verified to be proper ZIP and XML files.
  - If the files are invalid, reject the files(s) and stop processing.
  - If the files are valid, continue processing.

## Starting with this step, processing is per case (individual XML file):

- 2. Data are evaluated to ensure the quarter associated to the *Outpatient Encounter Date* is open for data transmission.
  - If the encounter date is missing or not valid per the calendar year, issue the appropriate critical error message, reject the individual XML file, and stop processing.
  - If the encounter date is valid per the calendar year, continue processing.
  - If the Data Collection quarter is closed, issue the appropriate critical error message, reject the individual XML file, and stop processing.
  - If the Data Collection quarter is open, continue processing.
- 3. Data are evaluated to ensure the *Outpatient Measure Set* is expected from the submitter for the time frame (*Outpatient Encounter Date*) in question. In addition, the CMS Clinical Data Warehouse verifies the data are expected for *CMS Certification Number*.
  - If the data are not expected, missing, or invalid, issue the appropriate critical error message, reject the individual XML file, and stop processing.
  - If the data are expected, continue processing.
- 4. Check the action-code.
  - If the action-code = ADD, continue with step #5.
  - If the action-code = DELETE, check submission data type.
  - If the submission data type = POPULATION, issue appropriate critical message and reject file(s).
  - If the submission data type = CLINICAL, continue with step # 13.

## The following steps are performed if the record's action-code = ADD:

- 5. The general data elements, as defined in the Data Dictionary section, are evaluated to ensure they exist and contain valid allowable values. These data elements are generally required for all Hospital Outpatient measures (with the exception of NPI).
  - If any general data element is missing or invalid, issue the appropriate critical error message(s), reject the individual XML file, and stop processing.
  - If all general data elements exist and contain valid allowable values, continue processing.
- 6. The Outpatient Population Algorithm associated to the *Outpatient Measure Set* is evaluated to ensure that the data are in the population of the set. Refer to the appropriate *Outpatient Measure Set* Data Element List for the algorithm.
  - If the Outpatient Population Algorithm returns an **Outpatient Population Reject Case Flag** = Yes (case is not in the outpatient population), reject the XML file and stop processing.
  - If the Outpatient Population Algorithm returns an **Outpatient Population Reject Case Flag** = No (case is not in the outpatient population), reject the XML file and stop processing.
- 7. The *Outpatient Measure Set* specific data elements are evaluated to ensure they contain valid allowable values. This step does not evaluate for missing data because that process is performed by the measure algorithms.
  - If any *Outpatient Measure Set* specific data elements are invalid, issue the appropriate critical error message(s), set the Edit Reject Case Flag = Yes, and continue processing with step #8.
  - If all *Outpatient Measure Set* specific data elements contain valid allowable values, continue processing.
- 8. If appropriate for the *Outpatient Measure Set*, grid data elements are evaluated to ensure each row does not contain missing data. This step does not ensure that the entire grid is empty because that process is performed by the measure algorithms.
  - If any row of the grid is missing data, issue the appropriate critical error message(s), set the Edit Reject Case Flag = Yes, and continue processing with step #9.
  - If all data elements exist in each row, continue processing.
- 9. Each XML file is evaluated for unexpected data. While a case may be in the population of more than one outpatient measure set, each XML file is associated to only one set.
- If any data exist that are not expected for the *Outpatient Measure Set*, issue the appropriate critical error message(s), set the Edit Reject Case Flag = Yes, and continue processing with step #10.


If no unexpected data for the Outpatient Measure Set exist, continue processing.

- 10. Evaluate the Edit Reject Case Flag.
- If the Edit Reject Case Flag = Yes, issue the appropriate critical error message(s), reject the individual XML file, and stop processing.
- If the Edit Reject Case Flag = No, continue with step #11.
- 11. Execute each measure algorithm associated to the measures the hospital has selected for the *Outpatient Measure Set*. Refer to the appropriate Measure Information Forms for the *Outpatient Measure Set* for the measure algorithms.
  - If any measure evaluates with a Measure Category Assignment = X, reject the XML file and stop processing.
  - If all measures evaluate with Measure Category Assignment = B, D, E, and/or Y, continue processing.
- 12. The case is accepted into the CMS Clinical Data Warehouse.


## The following steps are performed if the record's action-code = DELETE:

- 13. The remaining data elements that are part of the Unique Record Key are evaluated to ensure they exist and contain valid allowable values. These data elements are required for all *Outpatient Measure Sets*.
  - If any Unique Record Key data element is missing or invalid, reject the XML file and stop processing.
  - If all Unique Record Key data elements exist and contain valid allowable values, continue processing.
- 14. The database is checked to see if a record with the same Unique Record Key already exists.
  - If the case does not already exist in the database, then the transmitted DELETE record is rejected.
  - If the record already exists in the database, it is deleted.


## **Data Processing Flow**



Hospital OQR Specifications Manual Encounter dates **01-01-20** (**1Q20**) through **12-31-20** (**4Q20**) v13.0a



Hospital OQR Specifications Manual Encounter dates **01-01-20** (**1Q20**) through **12-31-20** (**4Q20**) v13.0a



# **Alphabetical Tools and Resources List**

Element Name	Page #
ED Arrival Time -Guidelines	6 - 166
ED Departure Time -Guidelines	6 - 168
Reason for Delay in Fibrinolytic Therapy -	6 - 170
guidelines	
OP-29: Appropriate Follow-up Interval for	6 - 171
Normal Colonoscopy in Average Risk Patients-	
Template	
OP-29: Appropriate Follow-up Interval for	6 - 172
Normal Colonoscopy in Average Risk Patients-	
Algorithm	
OP-29: Appropriate Follow-up Interval for	6 - 173
Normal Colonoscopy in Average Risk Patients-	
Denominator Codes	
OP-29: Appropriate Follow-up Interval for	6 - 174
Normal Colonoscopy in Average Risk Patients-	
Fact Sheet	
OP-31: Cataracts—Improvement in Patient's	6 - 175
Visual Function within 90 Days Following	
Cataract Surgery- Data Collection Guidelines	

## **Hospital OQR Arrival Time: Guidelines**

To be applied when abstracting all measures included in the Hospital OQR Program (OP-2, OP-3, OP-18, and OP-23):

Remember, the definition of Arrival Time is "the earliest documented time (military time) the patient arrived at the outpatient or emergency department."

- If the time of the arrival is unable to be determined from medical record documentation, select "UTD."
- Review the only acceptable sources to determine the earliest time the patient arrived at the ED or observation. Documentation outside of the only acceptable sources list should **not** be referenced (such as ambulance record, physician office record, or H&P).
- "Emergency department record" includes any documentation from the time period that the patient was an ED patient, e.g., ED face sheet, ED consent/authorization for treatment forms, ED/outpatient registration/sign-in forms, triage record, ED physician orders, ECG reports, telemetry rhythm strips, laboratory reports, x-ray reports, etc.
- If the time on the face/registration sheet is not labeled "arrival," "registration," or "admit" time, or is labeled simply "time," then the time can be considered a nondescript time and should **not** be used as *Arrival Time*.
- *Arrival Time* can be the time the patient first sees triage, registration, or the volunteer who puts her/his name on a page with a time. It does **not** have to be a professional who documents the arrival time.
- **Do not** use a time stamp unless it is clear that it is used specifically for patient arrival time.
- **Do not** use pre-printed times on a vital sign graphic record.
- **Do not** use a stamp or label that has a consistent time on every page.

Note the following frequently asked questions:

**QUESTION:** If the patient enters the ED, is signed in by a volunteer at 1950, and then sits in the waiting room until called by triage at 2012, what is the correct *Arrival Time*?

**ANSWER:** The earliest documented time the patient arrived in the ED - 1950.

**QUESTION:** The patient arrives by ambulance and has an ECG, IV, and O2 that are all recorded as 1300. A Nurses Note is documented as 12:55. A note in the ambulance run sheet indicates that the patient arrived at 1240. What is the correct *Arrival Time*?

**ANSWER:** The earliest documented time the patient arrived in the ED -1255. You cannot use the ambulance run sheet as a time of arrival; you may only use the run sheet (if you must) to substantiate that the patient was not in the ED at 1240.

**QUESTION:** The record indicates a non-labeled/non-descript time of 1840 on the registration sheet, the time is not labeled "Admit" or "Registered," there is a time of 1850 on the triage note, an ECG time of 1845, and a lab collection time of 0000. What is the *Arrival Time*?

**Answer:** The earliest documented time the patient arrived in the ED -1845. Unless there is other documentation to substantiate that the patient was present at 0000, ignore that time and use the next earliest time -1845. The 1840 time is not valid to use since it was not labeled "arrival," registration," or "admit."

#### **Hospital OQR ED Departure Time: Guidelines**

When abstracting *ED Departure Time* for OP-3 (Median Time to Transfer to Another Facility for Acute Coronary Intervention) and OP-18 (Median Time from ED Arrival to ED Departure for Discharged ED Patients):

Remember, the intent of abstraction "...is to capture the latest time at which the patient was receiving care in the emergency department, under the care of emergency department services, or awaiting transport to service/care."

Source: General Abstraction Guidelines, Medical Record Documentation

- **Do use** the later departure time if two departure/discharge times are noted.
- **Do use** the time of the observation order written by the physician/APN/PA for patients who are placed into observation.

#### Do not use:

- Coding Summary
- Physician's Discharge Summary
- ED record released from holding time
- Chart closed time
- Off the tracking board time
- Report called time
- Disposition time
- Discharge instruction time
- **Do <u>not</u> use** any time that cannot be substantiated in the medical record. For example, if there is a departure time of 2015 and a note from the physician or nurse written at 2200 with no other information available that the patient was still in the facility, the departure time would be 2015.
- **Do not use** Medication or Vital Signs if they are later than the *ED Departure Time*.
- **Do not use** the time the discharge order was written because it may not represent the actual time of departure.

#### Do use:

- Discharge time (if it is listed on the disposition sheet)
- Release time
- Out time
- Gone time
- Checkout time
- Transport documented time
- The Event Log, Registration sheet, Transfer record, etc. (if a discharge time is noted and the document is part of the permanent medical record)
- Transfer time
- Order for observation status time
- Any other synonym that can easily be understood to mean "Departure" or "Discharge"

Note the following frequently asked questions:

**Question:** Patient was admitted to 'Observation' from the ED. The nurse documents that the patient physically left the ED at 1440. The order for 'Observation' was written at 1700. What time should be abstracted for *ED Departure Time*?

**Answer:** If the order for 'Observation' is written after the patient departed the ED select the time the patient physically left the ED. In this example, abstract 1440 as the *ED Departure Time*.

**Question:** *ED Discharge Time* is documented on the face sheet at 1400. A nursing note is documented, "EMS at bedside" at 1422 and medication administration noted at 1428. What would be the appropriate *ED Departure Time*?

**Answer:** Because there is substantial documentation to support that the patient was in the ED after the documented *Discharge Time* and there is no additional documented time of ED departure, it cannot be determined when the patient physically left the ED. Enter 'UTD' for *ED Departure Time*. Medication administration times are not acceptable for establishing the *ED Departure Time*.

**Question:** A nurse's note indicates when the patient was discharged from the ED. No other care is documented beyond that time. There is also an electronic time entered after the documented *ED Departure Time* that states "patient removed from the system." Which documentation should be used for abstracting the *ED Departure Time*?

Answer: The intent is to capture the latest time the patient was receiving care in the emergency department. In this example, there is a documented discharge time. The documented discharge time from the nurse's note would be used to abstract *ED Departure Time*. An electronic time or stamp cannot be abstracted for *ED Departure Time* as it does not provide substantial documentation that the patient has physically departed the ED. Similarly, documentation that the patient was removed from system is insufficient for abstracting *ED Departure Time* because it does not provide substantial documentation that the patient physically departed the ED.

#### Hospital OQR Reason for Delay in Fibrinolytic Therapy: Guidelines

When abstracting for OP-2 (Fibrinolytic Therapy Received within 30 Minutes of ED Arrival):

Remember, the definition of Reason for Delay in Fibrinolytic Therapy is "a reason for a delay in initiating fibrinolytic therapy after hospital arrival by a physician/advanced practice nurse/physician assistant (physician/APN/PA). System reasons for delay are not acceptable."

- Documentation must be made clear somewhere in the medical record that:
  - A "hold," "delay," "deferral," or "wait" in initiating fibrinolysis/reperfusion actually occurred, and
  - The underlying reason for the delay was non-system in nature.
- Abstractors should **not** make inferences from documentation of a sequence of events alone or otherwise attempt to interpret from documentation. Clinical judgments should not be used in abstraction.
- System reasons for delay are not acceptable, regardless of any linkage to the delay in fibrinolysis/reperfusion. Examples of non-acceptable system reasons are:
  - Equipment-related.
  - Staff-related.
  - Consultation with other clinician that is not clearly linked to patient-centered (non-system) reason for delay.
- Examples of **acceptable** documentation in the medical record:
  - "Hold on fibrinolytics. Will do CT scan to r/o bleed."
  - "Patient waiting for family and clergy to arrive wishes to consult with them prior to fibrinolysis."
  - "Fibrinolysis delayed due to need to control blood pressure before administering fibrinolysis."
  - "Hold fibrinolytics. Need to consult neurology regarding bleeding risk."
  - "Fibrinolytic therapy initially deferred due to shock."
- Examples of automatic, acceptable reasons that do **not** require documentation of a delay in fibrinolytic administration:
  - Cardiopulmonary arrest, mechanical circulatory assist device placement, or intubation occurring within 30 minutes after hospital arrival (clearly documented by a physician/APN/PA), or
  - Initial patient/family refusal of fibrinolysis/reperfusion (documented by a physician/APN/PA).

Reasons for delay in fibrinolytic therapy should be collected regardless of how soon after arrival fibrinolysis was ultimately initiated or how minimal the delay.

#### **Template for Collecting OP-29 Data**


Answer the questions in the tables below to determine whether colonoscopy patients fall into the OP-29 measure, keeping in mind that OP-29 looks forward to recommendations for future care.

	OP-29: Appropriate Follow-up Interval for Normal Colonoscopy in Average Risk Patients			
M	Measure Criteria		Denominator/Numerator Determination	
1.	Patient had a screening colonoscopy, without biopsy or polypectomy, <b>and</b> is $\geq 50$ to $\leq 75$ years of age on date of encounter	$\begin{array}{c} \text{Yes} \longrightarrow \\ \text{No} \longrightarrow \end{array}$	Include in <i>denominator</i> population, continue to 1(a) Exclude from <i>denominator</i> population	
	a) Documentation of medical reason(s) for not recommending at least a 10-year follow-up interval (e.g., above average risk patient or inadequate prep or if age is documented as a medical reason)	Yes> No>	Exclude from <i>denominator</i> population Continue to Question 2	
2.	Recommended follow-up interval of at least 10 years for repeat colonoscopy is documented in colonoscopy report	$\begin{array}{c} \text{Yes} \longrightarrow \\ \text{No} \longrightarrow \end{array}$	Include in <i>numerator</i> population Exclude from <i>numerator</i> population	

#### OP-29: Appropriate Follow-Up Interval for Normal Colonoscopy in Average Risk Patients

<u>Numerator Statement</u>: Patients who had a recommended follow-up interval of at least 10 years for repeat colonoscopy documented in their colonoscopy report

**Denominator Statement**: All patients  $\geq 50$  to  $\leq 75$  years of age receiving screening colonoscopy without biopsy or polypectomy



#### Measure OP-29: Appropriate Follow-Up Interval for Normal Colonoscopy in Average Risk Patients

#### **Denominator Codes**

The following codes are derived from the Measure Information Form (MIF) for OP-29 that can be found in the Specifications Manual posted on *QualityNet* at <u>www.qualitynet.org</u>.

#### Denominator criteria always include both:

- Patients aged  $\geq 50$  and  $\geq 75$ on date of encounter
- **Z12.11**: Colonoscopy screen with anesthesia

#### and one of the following:

- 44388: Colonoscopy through stoma; diagnostic
- 45378: Diagnostic colonoscopy/screening colonoscopy for non-Medicare patients
- **G0121**: Screening colonoscopy for other Medicare patients

#### without any of the following modifiers:

- **52**: **Reduced Services**—Under certain circumstances a service or procedure is partially reduced or eliminated at the physician's discretion
- **53**: **Discontinued Procedure**—Under certain circumstances, the physician may elect to terminate a surgical or diagnostic procedure
- 73: Discontinued Out-Patient Hospital/Ambulatory Surgery Center (ASC) Procedure Prior to the Administration of Anesthesia—Due to extenuating circumstances or those that threaten the well-being of the patient
- 74: Discontinued Out-Patient Hospital/Ambulatory Surgery Center (ASC) Procedure After Administration of Anesthesia—Due to extenuating circumstances or those that threaten the well-being of the patient
- **Z83.71**: Family history of colonic polyps
- **Z86.010**: Personal history of colonic polyps
- **Z80.0**: Family history of malignant neoplasm of gastrointestinal tract
- **Z85.038**: Personal history of malignant neoplasm of large intestine

6-173

#### Measure OP-29: Appropriate Follow-Up Interval for Normal Colonoscopy in Average Risk Patients Fact Sheet

**Measure Description:** Percentage of patients aged 50 to 75 years of age receiving a screening

colonoscopy without biopsy or polypectomy who had a recommended follow-up interval of at least 10 years for repeat colonoscopy documented in

their colonoscopy report.

**Denominator Statement:** All patients aged 50 to 75 years of age receiving screening colonoscopy

without biopsy or polypectomy.

**Numerator Statement:** Patients who had a recommended follow-up interval of at least 10 years for

repeat colonoscopy documented in their colonoscopy report.

For the purposes of determining this measure, **do**:

• Use the final colonoscopy report only to abstract the recommended follow-up interval. If your facility utilizes another report that is equivalent to or contains the final colonoscopy report, utilize this report for abstraction.

- Use any medical reason, such as a diagnosis, symptom, or condition that is documented in the medical record, to exclude a case from the denominator population **only** when the recommended follow-up interval is less than 10 years. Please note that you must have **both** an interval of less than 10 years and the medical reason documented in order to use this as an exclusion from the denominator. Some examples are:
  - Above average risk patient.
  - Inadequate prep.
  - Family history of colon cancer.
  - Diverticulitis documented in the medical record.

• Exclude a case if there is documentation indicating no follow-up colonoscopy is needed or recommended **and** patient's age is ≥66 years old, or life expectancy <10 years.

For the purposes of determining this measure, **do not**:

- Use records with CPT/HCPCS modifiers 52, 53, 73, or 74.
- Use time frames, such as "5–10 years," "many," "prn," or "when symptomatic," since they are not acceptable terms for the recommended follow-up interval of at least 10 years.

<sup>\*</sup>Please remember that there is no comprehensive list of medical reasons.

#### OP-31: Cataracts—Improvement in Patient's Visual Function within 90 Days Following Cataract Surgery: Data Collection Guidelines

#### **Sampling**

When collecting data for OP-31, a facility may choose to sample data monthly, quarterly, or annually. Follow the sampling guidelines in the Specifications Manual (<u>Population and Sampling Specifications</u>).

#### Reporting

At this time, OP-31 remains a **voluntary** measure. Hospitals that choose not to report the measure will not be subject to a reduction in payment update. However, any data submitted for the measure **will be publicly reported**.

#### **Measure Requirements**

#### **Survey Tool**

OP-31 requires that patients complete both a pre- and post-operative survey using the *same* visual function tool. Patients who do not complete a pre-op survey and post-op survey are excluded from the measure. Surveys may be completed in person, by mail, by phone, or another method of the hospital's choosing. The data collection survey is specified as an assessment tool that has been appropriately validated for the population for which it is being used. The survey tool measures **visual function**, not visual acuity. **A visual assessment tool may not be utilized.** Examples of tools for visual function assessment are found in the Measure Information Form (MIF) in the Specifications Manual under the Definition for Survey (OP-31: Cataracts - Improvement in Patient's Visual Function within 90 days Following Cataract Surgery).

#### **Data Collection Log**

You are not required to use the Data Collection Log provided by the OQR Support Contractor (<u>Data Collection Tool</u>). But, if you choose to use it, you may modify it for your facility. You may require fewer columns or fewer rows to accommodate the number of physicians from whom you need to gather data. Or, you may add columns to track other helpful data, such as the total number of surgeries performed at your facility per provider. Consider using the tool as a master log and delete rows to use as a spreadsheet for sending\* to individual providers for their input. Designate a sheet for data collection for each month, quarter, or year, and indicate the sample frequency on the log.

\*Since no specific patient-level data is collected, there are no Health Insurance Portability and Accountability Act (HIPAA) issues involved with emailing the spreadsheet.

#### **Table of Contents**

OP Table	Code Category	Page Number
OP Table 1.0	E/M Codes for Emergency Department Encounters	A – 1
OP Table 1.1	Acute Myocardial Infarction (AMI) Diagnosis Codes	A – 1
OP Table 7.01	Mental Disorders	A-2
OP Table 8.0	Ischemic and Hemorrhagic Stroke	A – 37

#### **OP Table 1.0: E/M Codes for Emergency Department Encounters**

Code	Shortened Description
99281	Emergency department visit, new or established patient
99282	Emergency department visit, new or established patient
99283	Emergency department visit, new or established patient
99284	Emergency department visit, new or established patient
99285	Emergency department visit, new or established patient
99291	Critical care, evaluation and management

#### **OP Table 1.1: Acute Myocardial Infarction (AMI) Diagnosis Codes**

Code	Shortened Description
I2101	ST elevation (STEMI) myocardial infarction involving left main coronary artery
I2102	ST elevation (STEMI) myocardial infarction involving left anterior descending coronary artery
I2109	ST elevation (STEMI) myocardial infarction involving other coronary artery of anterior wall
I2111	ST elevation (STEMI) myocardial infarction involving right coronary artery
I2119	ST elevation (STEMI) myocardial infarction involving other coronary artery of inferior wall
I2121	ST elevation (STEMI) myocardial infarction involving left circumflex coronary artery
I2129	ST elevation (STEMI) myocardial infarction involving other sites
I213	ST elevation (STEMI) myocardial infarction of unspecified site
I214	Non-ST elevation (NSTEMI) myocardial infarction
I219	Acute myocardial infarction, unspecified
I21A1	Myocardial infarction type 2
I21A9	Other myocardial infaraction type
I220	Subsequent ST elevation (STEMI) myocardial infarction of anterior wall
I221	Subsequent ST elevation (STEMI) myocardial infarction of inferior wall
I222	Subsequent non-ST elevation (NSTEMI) myocardial infarction
I228	Subsequent ST elevation (STEMI) myocardial infarction of other sites
I229	Subsequent ST elevation (STEMI) myocardial infarction of unspecified site
I97190	Other postprocedural cardiac functional disturbances following cardiac surgery
I97191	Other postprocedural cardiac functional disturbances following other surgery
197790	Other intraoperative cardiac functional disturbances during cardiac surgery
I97791	Other intraoperative cardiac functional disturbances during other surgery

#### **OP Table 7.01: Mental Disorders**

F0150		OP Table 7.01: Mental Disorders
F0390	Code	Shortened Description
F0390		
F034 Amestic disorder due to known physiological condition F05 Delirium due to known physiological condition F060 Psychotic disorder with hallucinations due to known physiological condition F061 Catatonic disorder with hallucinations due to known physiological condition F062 Psychotic disorder with delusions due to known physiological condition F0630 Mood disorder due to known physiological condition, unspecified F0631 Mood disorder due to known physiological condition, unspecified F0632 Mood disorder due to known physiological condition with depressive features F0633 Mood disorder due to known physiological condition with major depressive-like episode F0633 Mood disorder due to known physiological condition with major depressive-like episode F0634 Mood disorder due to known physiological condition with mixed features F0644 Anxiety disorder due to known physiological condition F068 Other specified mental disorders due to known physiological condition F079 Personality change due to known physiological condition F079 Postconcussional syndrome F0789 Other personality and behavioral disorders due to known physiological condition F079 Unspecified personality and behavioral disorders due to known physiological condition F079 Unspecified mental disorder due to known physiological condition F079 Unspecified mental disorder due to known physiological condition F079 Unspecified wental disorder due to known physiological condition F079 Unspecified mental disorder due to known physiological condition F070 Alcohol abuse with intoxication, uncomplicated F1011 Alcohol abuse with alcohol-induced psychotic disorder with delusions F10120 Alcohol abuse with alcohol-induced psychotic disorder F1014 Alcohol abuse with alcohol-induced psychotic disorder with ballucinations F10150 Alcohol abuse with alcohol-induced psychotic disorder with delusions F10161 Alcohol abuse with alcohol-induced disorder F10170 Alcohol abuse with alcohol-induced disorder F10180 Alcohol dependence with intoxication, uncomplicated F1021 Alcohol dependence wi	F0151	Vascular dementia with behavioral disturbance
F04 Amnestic disorder due to known physiological condition F05 Delirium due to known physiological condition F060 Psychotic disorder with hallucinations due to known physiological condition F061 Catatonic disorder due to known physiological condition F062 Psychotic disorder due to known physiological condition F0630 Mood disorder due to known physiological condition with depressive features F0631 Mood disorder due to known physiological condition with depressive features F0632 Mood disorder due to known physiological condition with major depressive-like episode F0633 Mood disorder due to known physiological condition with major depressive-like episode F0634 Mood disorder due to known physiological condition with mixer features F0634 Mood disorder due to known physiological condition with mixer features F064 Anxiety disorder due to known physiological condition F068 Other specified mental disorders due to known physiological condition F079 Personality change due to known physiological condition F0781 Postconcussional syndrome F0789 Other personality and behavioral disorders due to known physiological condition F079 Unspecified personality and behavioral disorders due to known physiological condition F070 Unspecified mental disorder due to known physiological condition F070 Unspecified mental disorder due to known physiological condition F070 Unspecified mental disorder due to known physiological condition F070 Unspecified personality and behavioral disorder due to known physiological condition F1010 Alcohol abuse, uncomplicated F1011 Alcohol abuse, with intoxication, uncomplicated F1012 Alcohol abuse with intoxication delirium F1012 Alcohol abuse with intoxication delirium F1013 Alcohol abuse with alcohol-induced psychotic disorder with delusions F1015 Alcohol abuse with alcohol-induced mixer disorder with delusions F1018 Alcohol abuse with alcohol-induced disorder F1018 Alcohol abuse with alcohol-induced disorder F1018 Alcohol abuse with alcohol-induced disorder F1019 Alcohol dependence with intoxication, uncom	F0390	Unspecified dementia without behavioral disturbance
F050   Defirium due to known physiological condition	F0391	Unspecified dementia with behavioral disturbance
Pose	F04	
F061   Catatonic disorder due to known physiological condition	F05	Delirium due to known physiological condition
Poscal	F060	Psychotic disorder with hallucinations due to known physiological condition
F0630   Mood disorder due to known physiological condition, unspecified	F061	Catatonic disorder due to known physiological condition
F0631 Mood disorder due to known physiological condition with depressive features F0632 Mood disorder due to known physiological condition with major depressive-like episode F0633 Mood disorder due to known physiological condition with maine features F0634 Mood disorder due to known physiological condition with mixed features F064 Anxiery disorder due to known physiological condition F068 Other specified mental disorders due to known physiological condition F070 Personality change due to known physiological condition F0781 Postconcussional syndrome F0789 Other personality and behavioral disorders due to known physiological condition F079 Unspecified personality and behavioral disorder due to known physiological condition F070 Unspecified personality and behavioral disorder due to known physiological condition F070 Unspecified mental disorder due to known physiological condition F070 Unspecified mental disorder due to known physiological condition F070 Unspecified mental disorder due to known physiological condition F070 Unspecified mental disorder due to known physiological condition F070 Alcohol abuse, uncomplicated F1011 Alcohol abuse, in remission F10120 Alcohol abuse with intoxication uncomplicated F10121 Alcohol abuse with intoxication delirium F10129 Alcohol abuse with alcohol-induced mood disorder F10150 Alcohol abuse with alcohol-induced psychotic disorder with delusions F10151 Alcohol abuse with alcohol-induced psychotic disorder with hallucinations F10150 Alcohol abuse with alcohol-induced psychotic disorder, unspecified F10180 Alcohol abuse with alcohol-induced psychotic disorder F10181 Alcohol abuse with alcohol-induced sychotic disorder F10182 Alcohol abuse with alcohol-induced disorder F10183 Alcohol abuse with alcohol-induced disorder F1019 Alcohol dependence, uncomplicated F1021 Alcohol dependence with intoxication, uncomplicated F1022 Alcohol dependence with intoxication, unspecified F10231 Alcohol dependence with intoxication, unspecified F10231 Alcohol dependence with withdrawal uncomplicated	F062	Psychotic disorder with delusions due to known physiological condition
F0632   Mood disorder due to known physiological condition with major depressive-like episode   F0633   Mood disorder due to known physiological condition with manic features   F064   Mood disorder due to known physiological condition with mixed features   F064   Anxiety disorder due to known physiological condition   F068   Other specified mental disorders due to known physiological condition   F079   Personality change due to known physiological condition   F0781   Postconcussional syndrome   F0789   Other personality and behavioral disorders due to known physiological condition   F079   Unspecified personality and behavioral disorder due to known physiological condition   F079   Unspecified mental disorder due to known physiological condition   F079   Unspecified mental disorder due to known physiological condition   F079   Unspecified mental disorder due to known physiological condition   F079   Unspecified mental disorder due to known physiological condition   F079   Unspecified mental disorder due to known physiological condition   F070   Alcohol abuse, uncomplicated   F0012   Alcohol abuse, uncomplicated   F0012   Alcohol abuse with intoxication, uncomplicated   F0012   Alcohol abuse with intoxication, unspecified   F1012   Alcohol abuse with intoxication, unspecified   F1014   Alcohol abuse with alcohol-induced mood disorder   F1015   Alcohol abuse with alcohol-induced psychotic disorder with delusions   F1015   Alcohol abuse with alcohol-induced psychotic disorder with hallucinations   F1015   Alcohol abuse with alcohol-induced psychotic disorder unspecified   F1018   Alcohol abuse with alcohol-induced psychotic disorder   Unspecified   F1018   Alcohol abuse with alcohol-induced sexual dysfunction   F1018   Alcohol abuse with alcohol-induced sexual dysfunction   F1018   Alcohol abuse with alcohol-induced sexual dysfunction   F1018   Alcohol abuse with unspecified   F1019   Alcohol abuse with unspecified   F1019   Alcohol dependence with unspecified   F1019   Alcohol dependence with unspecified   F101	F0630	Mood disorder due to known physiological condition, unspecified
F0633   Mood disorder due to known physiological condition with manic features   F0634   Mood disorder due to known physiological condition with mixed features   F064   Anxiety disorder due to known physiological condition   F068   Other specified mental disorders due to known physiological condition   F070   Personality change due to known physiological condition   F0781   Postconcussional syndrome   F0782   Other personality and behavioral disorders due to known physiological condition   F079   Unspecified personality and behavioral disorder due to known physiological condition   F079   Unspecified mental disorder due to known physiological condition   F070   Unspecified mental disorder due to known physiological condition   F070   Unspecified mental disorder due to known physiological condition   F070   Unspecified mental disorder due to known physiological condition   F070   Unspecified mental disorder due to known physiological condition   F070   Unspecified mental disorder due to known physiological condition   F070   Alcohol abuse, uncomplicated   F1011   Alcohol abuse, uncomplicated   F1012   Alcohol abuse with intoxication, uncomplicated   F1012   Alcohol abuse with intoxication, unspecified   F1014   Alcohol abuse with alcohol-induced mood disorder   F1015   Alcohol abuse with alcohol-induced psychotic disorder with delusions   F1015   Alcohol abuse with alcohol-induced psychotic disorder with hallucinations   F1015   Alcohol abuse with alcohol-induced seep disorder   F1018   Alcohol abuse with alcohol-induced anxiety disorder   F1018   Alcohol abuse with alcohol-induced seep disorder   F1018   Alcohol abuse with alcohol-induced disorder   F1019   Alcohol abuse with other alcohol-induced disorder   F1010   Alcohol dependence, uncomplicated   F1021   Alcohol abuse with intoxication, uncomplicated   F1022   Alcohol dependence with intoxication, unspecified   F1023   Alcohol dependence with withdrawal with perceptual disturbance   F1023   Alcohol dependence with withdrawal with perceptual disturbance	F0631	Mood disorder due to known physiological condition with depressive features
F0634   Mood disorder due to known physiological condition	F0632	Mood disorder due to known physiological condition with major depressive-like episode
F064 Anxiety disorder due to known physiological condition F068 Other specified mental disorders due to known physiological condition F078 Personality change due to known physiological condition F0781 Postconcussional syndrome F0789 Other personality and behavioral disorders due to known physiological condition F079 Unspecified personality and behavioral disorder due to known physiological condition F079 Unspecified mental disorder due to known physiological condition F070 Unspecified mental disorder due to known physiological condition F070 Alcohol abuse, uncomplicated F1011 Alcohol abuse, in remission F10120 Alcohol abuse with intoxication, uncomplicated F10111 Alcohol abuse with intoxication, uncomplicated F10112 Alcohol abuse with intoxication, unspecified F1014 Alcohol abuse with alcohol-induced mood disorder F10150 Alcohol abuse with alcohol-induced mood disorder F10151 Alcohol abuse with alcohol-induced psychotic disorder with hallucinations F10151 Alcohol abuse with alcohol-induced psychotic disorder, unspecified F10180 Alcohol abuse with alcohol-induced psychotic disorder, unspecified F10181 Alcohol abuse with alcohol-induced systemation F10182 Alcohol abuse with alcohol-induced sexual dysfunction F10182 Alcohol abuse with alcohol-induced sexual dysfunction F10183 Alcohol abuse with alcohol-induced sexual dysfunction F1019 Alcohol abuse with horizontal disorder F1019 Alcohol abuse with intoxication, uncomplicated F1021 Alcohol dependence, uncomplicated F1021 Alcohol dependence, in remission F10220 Alcohol dependence with intoxication, unspecified F10230 Alcohol dependence with intoxication, unspecified F10230 Alcohol dependence with withdrawal uncomplicated F10231 Alcohol dependence with withdrawal unspecified F10232 Alcohol dependence with withdrawal unspecified F10233 Alcohol dependence with withdrawal unspecified F1024 Alcohol dependence with withdrawal unspecified F1025 Alcohol dependence with withdrawal unspecified F1026 Alcohol dependence with withdrawal with perceptual disturbance F10275 Alcohol	F0633	Mood disorder due to known physiological condition with manic features
F068 Other specified mental disorders due to known physiological condition F070 Personality change due to known physiological condition F0781 Postconcussional syndrome F0789 Other personality and behavioral disorders due to known physiological condition F079 Unspecified personality and behavioral disorder due to known physiological condition F070 Unspecified mental disorder due to known physiological condition F0710 Alcohol abuse, uncomplicated F1011 Alcohol abuse, in remission F10120 Alcohol abuse, in remission F10121 Alcohol abuse with intoxication, uncomplicated F10121 Alcohol abuse with intoxication delirium F10129 Alcohol abuse with intoxication delirium F10129 Alcohol abuse with alcohol-induced mood disorder F10150 Alcohol abuse with alcohol-induced psychotic disorder with delusions F10151 Alcohol abuse with alcohol-induced psychotic disorder with hallucinations F10159 Alcohol abuse with alcohol-induced psychotic disorder, unspecified F10180 Alcohol abuse with alcohol-induced psychotic disorder, unspecified F10181 Alcohol abuse with alcohol-induced sexual dysfunction F10182 Alcohol abuse with alcohol-induced sexual dysfunction F10183 Alcohol abuse with alcohol-induced sleep disorder F1019 Alcohol abuse with other alcohol-induced disorder F1010 Alcohol abuse with intoxication delirium F1021 Alcohol dependence, in remission F10220 Alcohol dependence with intoxication, uncomplicated F10221 Alcohol dependence with intoxication, unspecified F10229 Alcohol dependence with intoxication, unspecified F10230 Alcohol dependence with withdrawal, uncomplicated F10231 Alcohol dependence with withdrawal, uncomplicated F10232 Alcohol dependence with withdrawal, unspecified F10233 Alcohol dependence with withdrawal delirium F10232 Alcohol dependence with withdrawal unspecified F1024 Alcohol dependence with withdrawal, unspecified F1025 Alcohol dependence with withdrawal with perceptual disturbance F10250 Alcohol dependence with alcohol-induced mood disorder F10251 Alcohol dependence with alcohol-induced mood disorder with	F0634	Mood disorder due to known physiological condition with mixed features
F070 Personality change due to known physiological condition F0781 Postconcussional syndrome F0789 Other personality and behavioral disorders due to known physiological condition F079 Unspecified personality and behavioral disorder due to known physiological condition F09 Unspecified mental disorder due to known physiological condition F1010 Alcohol abuse, uncomplicated F1011 Alcohol abuse, in remission F10120 Alcohol abuse with intoxication, uncomplicated F10121 Alcohol abuse with intoxication delirium F10129 Alcohol abuse with intoxication, unspecified F1014 Alcohol abuse with alcohol-induced mood disorder F10150 Alcohol abuse with alcohol-induced psychotic disorder with delusions F10151 Alcohol abuse with alcohol-induced psychotic disorder with hallucinations F10159 Alcohol abuse with alcohol-induced psychotic disorder; unspecified F10180 Alcohol abuse with alcohol-induced anxiety disorder F10181 Alcohol abuse with alcohol-induced anxiety disorder F10182 Alcohol abuse with alcohol-induced sexual dysfunction F10188 Alcohol abuse with alcohol-induced sleep disorder F1019 Alcohol abuse with unspecified alcohol-induced disorder F1019 Alcohol abuse with unspecified alcohol-induced disorder F1020 Alcohol dependence, uncomplicated F1021 Alcohol dependence, in remission F10220 Alcohol dependence with intoxication, unspecified F10221 Alcohol dependence with intoxication, unspecified F10230 Alcohol dependence with withdrawal, unspecified F10231 Alcohol dependence with withdrawal delirium F10232 Alcohol dependence with withdrawal unspecified F10233 Alcohol dependence with withdrawal, unspecified F10233 Alcohol dependence with withdrawal, unspecified F10234 Alcohol dependence with withdrawal, unspecified F1024 Alcohol dependence with withdrawal unspecified F1025 Alcohol dependence with withdrawal unspecified F1026 Alcohol dependence with withdrawal unspecified F10275 Alcohol dependence with alcohol-induced psychotic disorder with hallucinations F10251 Alcohol dependence with alcohol-induced psychotic disorder with hallu	F064	Anxiety disorder due to known physiological condition
F0781 Postconcussional syndrome F0789 Other personality and behavioral disorders due to known physiological condition F079 Unspecified personality and behavioral disorder due to known physiological condition F080 Unspecified mental disorder due to known physiological condition F1010 Alcohol abuse, uncomplicated F1011 Alcohol abuse, in remission F10120 Alcohol abuse with intoxication, uncomplicated F10121 Alcohol abuse with intoxication delirium F10129 Alcohol abuse with intoxication delirium F1014 Alcohol abuse with alcohol-induced mood disorder F10150 Alcohol abuse with alcohol-induced psychotic disorder with delusions F10151 Alcohol abuse with alcohol-induced psychotic disorder with hallucinations F10159 Alcohol abuse with alcohol-induced psychotic disorder, unspecified F10180 Alcohol abuse with alcohol-induced psychotic disorder, unspecified F10181 Alcohol abuse with alcohol-induced sexual dysfunction F10182 Alcohol abuse with alcohol-induced sexual dysfunction F10183 Alcohol abuse with alcohol-induced sleep disorder F10184 Alcohol abuse with other alcohol-induced disorder F1019 Alcohol abuse with other alcohol-induced disorder F1019 Alcohol abuse with unspecified alcohol-induced disorder F1019 Alcohol abuse with intoxication delirium F1020 Alcohol dependence, uncomplicated F1021 Alcohol dependence with intoxication, uncomplicated F10221 Alcohol dependence with intoxication, unspecified F10220 Alcohol dependence with intoxication, unspecified F10230 Alcohol dependence with withdrawal, uncomplicated F10230 Alcohol dependence with withdrawal, uncomplicated F10231 Alcohol dependence with withdrawal, uncomplicated F10232 Alcohol dependence with withdrawal, unspecified F10233 Alcohol dependence with withdrawal, unspecified F1024 Alcohol dependence with alcohol-induced psychotic disorder with delusions F10251 Alcohol dependence with alcohol-induced psychotic disorder with delusions F10251 Alcohol dependence with alcohol-induced psychotic disorder with hallucinations	F068	Other specified mental disorders due to known physiological condition
F0789 Other personality and behavioral disorders due to known physiological condition F079 Unspecified personality and behavioral disorder due to known physiological condition F09 Unspecified mental disorder due to known physiological condition F1010 Alcohol abuse, uncomplicated F1011 Alcohol abuse, in remission F10120 Alcohol abuse with intoxication, uncomplicated F10121 Alcohol abuse with intoxication delirium F10129 Alcohol abuse with intoxication delirium F10150 Alcohol abuse with alcohol-induced mood disorder F10151 Alcohol abuse with alcohol-induced psychotic disorder with delusions F10151 Alcohol abuse with alcohol-induced psychotic disorder with hallucinations F10159 Alcohol abuse with alcohol-induced psychotic disorder, unspecified F10180 Alcohol abuse with alcohol-induced anxiety disorder F10181 Alcohol abuse with alcohol-induced sexual dysfunction F10182 Alcohol abuse with alcohol-induced sexual dysfunction F10183 Alcohol abuse with alcohol-induced disorder F10184 Alcohol abuse with alcohol-induced disorder F1019 Alcohol abuse with other alcohol-induced disorder F1019 Alcohol dependence, uncomplicated F1020 Alcohol dependence, in remission F1021 Alcohol dependence with intoxication, uncomplicated F10221 Alcohol dependence with intoxication, uncomplicated F10221 Alcohol dependence with intoxication, unspecified F10230 Alcohol dependence with withdrawal, uncomplicated F10231 Alcohol dependence with withdrawal, uncomplicated F10232 Alcohol dependence with withdrawal, unspecified F10233 Alcohol dependence with withdrawal, unspecified F10234 Alcohol dependence with withdrawal, unspecified F10235 Alcohol dependence with alcohol-induced mood disorder F10255 Alcohol dependence with alcohol-induced mood disorder F10251 Alcohol dependence with alcohol-induced mood disorder F10251 Alcohol dependence with alcohol-induced psychotic disorder with hallucinations	F070	Personality change due to known physiological condition
F079 Unspecified personality and behavioral disorder due to known physiological condition F09 Unspecified mental disorder due to known physiological condition F1010 Alcohol abuse, uncomplicated F1011 Alcohol abuse, in remission F10120 Alcohol abuse with intoxication, uncomplicated F10121 Alcohol abuse with intoxication, unspecified F10129 Alcohol abuse with intoxication, unspecified F10140 Alcohol abuse with alcohol-induced mood disorder F10150 Alcohol abuse with alcohol-induced psychotic disorder with delusions F10151 Alcohol abuse with alcohol-induced psychotic disorder with hallucinations F10159 Alcohol abuse with alcohol-induced psychotic disorder, unspecified F10180 Alcohol abuse with alcohol-induced anxiety disorder F10181 Alcohol abuse with alcohol-induced sexual dysfunction F10182 Alcohol abuse with alcohol-induced sexual dysfunction F10183 Alcohol abuse with alcohol-induced disorder F10184 Alcohol abuse with alcohol-induced disorder F1019 Alcohol abuse with unspecified alcohol-induced disorder F1020 Alcohol abuse with unspecified alcohol-induced disorder F1021 Alcohol dependence, in remission F10220 Alcohol dependence with intoxication, uncomplicated F10221 Alcohol dependence with intoxication, unspecified F10221 Alcohol dependence with intoxication, unspecified F10231 Alcohol dependence with withdrawal, uncomplicated F10232 Alcohol dependence with withdrawal delirium F10232 Alcohol dependence with withdrawal with perceptual disturbance F10233 Alcohol dependence with withdrawal with perceptual disturbance F1024 Alcohol dependence with withdrawal with perceptual disturbance F10250 Alcohol dependence with alcohol-induced psychotic disorder with delusions F10251 Alcohol dependence with alcohol-induced psychotic disorder with hallucinations	F0781	Postconcussional syndrome
F09 Unspecified mental disorder due to known physiological condition F1010 Alcohol abuse, uncomplicated F1011 Alcohol abuse, in remission F10120 Alcohol abuse with intoxication, uncomplicated F10121 Alcohol abuse with intoxication delirium F10129 Alcohol abuse with intoxication delirium F1014 Alcohol abuse with alcohol-induced mood disorder F10150 Alcohol abuse with alcohol-induced psychotic disorder with delusions F10151 Alcohol abuse with alcohol-induced psychotic disorder with hallucinations F10159 Alcohol abuse with alcohol-induced psychotic disorder, unspecified F10180 Alcohol abuse with alcohol-induced psychotic disorder, unspecified F10181 Alcohol abuse with alcohol-induced anxiety disorder F10182 Alcohol abuse with alcohol-induced sexual dysfunction F10183 Alcohol abuse with alcohol-induced sexual dysfunction F10184 Alcohol abuse with unspecified alcohol-induced disorder F10195 Alcohol abuse with unspecified alcohol-induced disorder F10196 Alcohol dependence, uncomplicated F1020 Alcohol dependence, uncomplicated F1021 Alcohol dependence, uncomplicated F10221 Alcohol dependence with intoxication, uncomplicated F10221 Alcohol dependence with intoxication delirium F10229 Alcohol dependence with intoxication unspecified F10230 Alcohol dependence with withdrawal, uncomplicated F10231 Alcohol dependence with withdrawal, uncomplicated F10232 Alcohol dependence with withdrawal delirium F10232 Alcohol dependence with withdrawal with perceptual disturbance F10239 Alcohol dependence with withdrawal, unspecified F1024 Alcohol dependence with withdrawal, unspecified F10250 Alcohol dependence with alcohol-induced psychotic disorder with hallucinations F10251 Alcohol dependence with alcohol-induced psychotic disorder with hallucinations	F0789	Other personality and behavioral disorders due to known physiological condition
F1010 Alcohol abuse, uncomplicated F1011 Alcohol abuse, in remission F10120 Alcohol abuse with intoxication, uncomplicated F10121 Alcohol abuse with intoxication, unspecified F10129 Alcohol abuse with intoxication, unspecified F1014 Alcohol abuse with alcohol-induced mood disorder F10150 Alcohol abuse with alcohol-induced psychotic disorder with delusions F10151 Alcohol abuse with alcohol-induced psychotic disorder with hallucinations F10159 Alcohol abuse with alcohol-induced psychotic disorder, unspecified F10180 Alcohol abuse with alcohol-induced psychotic disorder, unspecified F10181 Alcohol abuse with alcohol-induced sexual dysfunction F10182 Alcohol abuse with alcohol-induced sexual dysfunction F10188 Alcohol abuse with other alcohol-induced disorder F1019 Alcohol abuse with unspecified alcohol-induced disorder F1010 Alcohol dependence, uncomplicated F1020 Alcohol dependence, in remission F1021 Alcohol dependence with intoxication, uncomplicated F1022 Alcohol dependence with intoxication delirium F10229 Alcohol dependence with intoxication delirium F10230 Alcohol dependence with withdrawal, uncomplicated F10231 Alcohol dependence with withdrawal, uncomplicated F10232 Alcohol dependence with withdrawal delirium F10232 Alcohol dependence with withdrawal delirium F10233 Alcohol dependence with withdrawal delirium F10234 Alcohol dependence with withdrawal, uncomplicated F10235 Alcohol dependence with withdrawal with perceptual disturbance F10236 Alcohol dependence with withdrawal, unspecified F1024 Alcohol dependence with withdrawal, unspecified F10250 Alcohol dependence with withdrawal, unspecified F10250 Alcohol dependence with alcohol-induced mood disorder F10251 Alcohol dependence with alcohol-induced psychotic disorder with hallucinations	F079	Unspecified personality and behavioral disorder due to known physiological condition
F1011 Alcohol abuse, in remission F10120 Alcohol abuse with intoxication, uncomplicated F10121 Alcohol abuse with intoxication delirium F10129 Alcohol abuse with intoxication, unspecified F1014 Alcohol abuse with alcohol-induced mood disorder F10150 Alcohol abuse with alcohol-induced psychotic disorder with delusions F10151 Alcohol abuse with alcohol-induced psychotic disorder with hallucinations F10159 Alcohol abuse with alcohol-induced psychotic disorder, unspecified F10180 Alcohol abuse with alcohol-induced anxiety disorder F10181 Alcohol abuse with alcohol-induced sexual dysfunction F10182 Alcohol abuse with alcohol-induced sexual dysfunction F10188 Alcohol abuse with other alcohol-induced disorder F1019 Alcohol abuse with unspecified alcohol-induced disorder F1010 Alcohol dependence, uncomplicated F1021 Alcohol dependence, in remission F10220 Alcohol dependence with intoxication, uncomplicated F1021 Alcohol dependence with intoxication delirium F10220 Alcohol dependence with intoxication delirium F10230 Alcohol dependence with withdrawal, uncomplicated F10231 Alcohol dependence with withdrawal delirium F10232 Alcohol dependence with withdrawal delirium F10233 Alcohol dependence with withdrawal with perceptual disturbance F10239 Alcohol dependence with withdrawal with perceptual disturbance F10230 Alcohol dependence with withdrawal with perceptual disturbance F10230 Alcohol dependence with withdrawal with perceptual disturbance F10231 Alcohol dependence with withdrawal with perceptual disturbance F10232 Alcohol dependence with withdrawal with perceptual disturbance F10233 Alcohol dependence with withdrawal with perceptual disturbance F10234 Alcohol dependence with withdrawal with perceptual disturbance F10235 Alcohol dependence with withdrawal with perceptual disturbance F10245 Alcohol dependence with alcohol-induced psychotic disorder with hallucinations	F09	Unspecified mental disorder due to known physiological condition
F10120 Alcohol abuse with intoxication, uncomplicated F10121 Alcohol abuse with intoxication delirium F10129 Alcohol abuse with intoxication, unspecified F1014 Alcohol abuse with alcohol-induced mood disorder F10150 Alcohol abuse with alcohol-induced psychotic disorder with delusions F10151 Alcohol abuse with alcohol-induced psychotic disorder with hallucinations F10159 Alcohol abuse with alcohol-induced psychotic disorder, unspecified F10180 Alcohol abuse with alcohol-induced anxiety disorder F10181 Alcohol abuse with alcohol-induced sexual dysfunction F10182 Alcohol abuse with alcohol-induced sleep disorder F10188 Alcohol abuse with other alcohol-induced disorder F1019 Alcohol abuse with unspecified alcohol-induced disorder F1020 Alcohol dependence, uncomplicated F1021 Alcohol dependence, in remission F10221 Alcohol dependence with intoxication, uncomplicated F10221 Alcohol dependence with intoxication delirium F10229 Alcohol dependence with withdrawal, uncomplicated F10230 Alcohol dependence with withdrawal delirium F10231 Alcohol dependence with withdrawal delirium F10232 Alcohol dependence with withdrawal delirium F10233 Alcohol dependence with withdrawal delirium F10234 Alcohol dependence with withdrawal with perceptual disturbance F10235 Alcohol dependence with withdrawal with perceptual disturbance F1024 Alcohol dependence with withdrawal with perceptual disturbance F10250 Alcohol dependence with alcohol-induced mood disorder F10250 Alcohol dependence with alcohol-induced mood disorder with delusions F10251 Alcohol dependence with alcohol-induced psychotic disorder with hallucinations	F1010	Alcohol abuse, uncomplicated
F10121 Alcohol abuse with intoxication delirium F10129 Alcohol abuse with intoxication, unspecified F1014 Alcohol abuse with alcohol-induced mood disorder F10150 Alcohol abuse with alcohol-induced psychotic disorder with delusions F10151 Alcohol abuse with alcohol-induced psychotic disorder with hallucinations F10159 Alcohol abuse with alcohol-induced psychotic disorder, unspecified F10180 Alcohol abuse with alcohol-induced psychotic disorder F10181 Alcohol abuse with alcohol-induced anxiety disorder F10182 Alcohol abuse with alcohol-induced sexual dysfunction F10183 Alcohol abuse with other alcohol-induced disorder F1019 Alcohol abuse with unspecified alcohol-induced disorder F1020 Alcohol dependence, uncomplicated F1021 Alcohol dependence, in remission F10220 Alcohol dependence with intoxication, uncomplicated F10221 Alcohol dependence with intoxication delirium F10229 Alcohol dependence with intoxication delirium F10230 Alcohol dependence with withdrawal, uncomplicated F10231 Alcohol dependence with withdrawal delirium F10232 Alcohol dependence with withdrawal delirium F10233 Alcohol dependence with withdrawal with perceptual disturbance F10239 Alcohol dependence with withdrawal with perceptual disturbance F10239 Alcohol dependence with withdrawal, unspecified F1024 Alcohol dependence with withdrawal, unspecified F10250 Alcohol dependence with alcohol-induced mood disorder F10250 Alcohol dependence with alcohol-induced psychotic disorder with delusions F10251 Alcohol dependence with alcohol-induced psychotic disorder with hallucinations	F1011	Alcohol abuse, in remission
F10129 Alcohol abuse with intoxication, unspecified F1014 Alcohol abuse with alcohol-induced mood disorder F10150 Alcohol abuse with alcohol-induced psychotic disorder with delusions F10151 Alcohol abuse with alcohol-induced psychotic disorder with hallucinations F10159 Alcohol abuse with alcohol-induced psychotic disorder, unspecified F10180 Alcohol abuse with alcohol-induced anxiety disorder F10181 Alcohol abuse with alcohol-induced sexual dysfunction F10182 Alcohol abuse with alcohol-induced sleep disorder F10188 Alcohol abuse with other alcohol-induced disorder F1019 Alcohol abuse with unspecified alcohol-induced disorder F1020 Alcohol dependence, uncomplicated F1021 Alcohol dependence with intoxication, uncomplicated F10221 Alcohol dependence with intoxication delirium F10229 Alcohol dependence with intoxication, unspecified F10230 Alcohol dependence with withdrawal, uncomplicated F10231 Alcohol dependence with withdrawal, uncomplicated F10232 Alcohol dependence with withdrawal with perceptual disturbance F10232 Alcohol dependence with withdrawal with perceptual disturbance F10239 Alcohol dependence with withdrawal, unspecified F1024 Alcohol dependence with withdrawal, unspecified F10250 Alcohol dependence with alcohol-induced mood disorder F10251 Alcohol dependence with alcohol-induced psychotic disorder with allucinations	F10120	Alcohol abuse with intoxication, uncomplicated
F1014 Alcohol abuse with alcohol-induced mood disorder F10150 Alcohol abuse with alcohol-induced psychotic disorder with delusions F10151 Alcohol abuse with alcohol-induced psychotic disorder with hallucinations F10159 Alcohol abuse with alcohol-induced psychotic disorder, unspecified F10180 Alcohol abuse with alcohol-induced anxiety disorder F10181 Alcohol abuse with alcohol-induced sexual dysfunction F10182 Alcohol abuse with alcohol-induced sleep disorder F10188 Alcohol abuse with other alcohol-induced disorder F1019 Alcohol dependence, uncomplicated F1020 Alcohol dependence, in remission F1021 Alcohol dependence with intoxication, uncomplicated F10220 Alcohol dependence with intoxication delirium F10229 Alcohol dependence with intoxication, unspecified F10230 Alcohol dependence with withdrawal, uncomplicated F10231 Alcohol dependence with withdrawal delirium F10232 Alcohol dependence with withdrawal with perceptual disturbance F10239 Alcohol dependence with withdrawal with perceptual disturbance F1024 Alcohol dependence with withdrawal, unspecified F10250 Alcohol dependence with alcohol-induced mood disorder F10250 Alcohol dependence with alcohol-induced mood disorder with delusions F10251 Alcohol dependence with alcohol-induced psychotic disorder with hallucinations	F10121	Alcohol abuse with intoxication delirium
F10150 Alcohol abuse with alcohol-induced psychotic disorder with delusions F10151 Alcohol abuse with alcohol-induced psychotic disorder with hallucinations F10159 Alcohol abuse with alcohol-induced psychotic disorder, unspecified F10180 Alcohol abuse with alcohol-induced anxiety disorder F10181 Alcohol abuse with alcohol-induced sexual dysfunction F10182 Alcohol abuse with alcohol-induced sleep disorder F10188 Alcohol abuse with other alcohol-induced disorder F1019 Alcohol abuse with unspecified alcohol-induced disorder F1020 Alcohol dependence, uncomplicated F1021 Alcohol dependence, in remission F10220 Alcohol dependence with intoxication, uncomplicated F10221 Alcohol dependence with intoxication, unspecified F10229 Alcohol dependence with intoxication, unspecified F10230 Alcohol dependence with withdrawal, uncomplicated F10231 Alcohol dependence with withdrawal delirium F10232 Alcohol dependence with withdrawal with perceptual disturbance F10239 Alcohol dependence with withdrawal, unspecified F1024 Alcohol dependence with alcohol-induced mood disorder F10250 Alcohol dependence with alcohol-induced psychotic disorder with delusions F10251 Alcohol dependence with alcohol-induced psychotic disorder with hallucinations	F10129	Alcohol abuse with intoxication, unspecified
F10151 Alcohol abuse with alcohol-induced psychotic disorder with hallucinations F10159 Alcohol abuse with alcohol-induced psychotic disorder, unspecified F10180 Alcohol abuse with alcohol-induced anxiety disorder F10181 Alcohol abuse with alcohol-induced sexual dysfunction F10182 Alcohol abuse with alcohol-induced sleep disorder F10188 Alcohol abuse with other alcohol-induced disorder F1019 Alcohol abuse with unspecified alcohol-induced disorder F1020 Alcohol dependence, uncomplicated F1021 Alcohol dependence, in remission F10220 Alcohol dependence with intoxication, uncomplicated F10221 Alcohol dependence with intoxication delirium F10229 Alcohol dependence with intoxication, unspecified F10230 Alcohol dependence with withdrawal, uncomplicated F10231 Alcohol dependence with withdrawal delirium F10232 Alcohol dependence with withdrawal with perceptual disturbance F10239 Alcohol dependence with withdrawal with perceptual disturbance F1024 Alcohol dependence with alcohol-induced mood disorder F10250 Alcohol dependence with alcohol-induced psychotic disorder with delusions F10251 Alcohol dependence with alcohol-induced psychotic disorder with hallucinations	F1014	Alcohol abuse with alcohol-induced mood disorder
F10159 Alcohol abuse with alcohol-induced psychotic disorder, unspecified F10180 Alcohol abuse with alcohol-induced anxiety disorder F10181 Alcohol abuse with alcohol-induced sexual dysfunction F10182 Alcohol abuse with alcohol-induced sleep disorder F10188 Alcohol abuse with other alcohol-induced disorder F1019 Alcohol abuse with unspecified alcohol-induced disorder F1020 Alcohol dependence, uncomplicated F1021 Alcohol dependence, in remission F10220 Alcohol dependence with intoxication, uncomplicated F10221 Alcohol dependence with intoxication delirium F10229 Alcohol dependence with intoxication, unspecified F10230 Alcohol dependence with withdrawal, uncomplicated F10231 Alcohol dependence with withdrawal delirium F10232 Alcohol dependence with withdrawal with perceptual disturbance F10239 Alcohol dependence with withdrawal, unspecified F1024 Alcohol dependence with alcohol-induced mood disorder F10250 Alcohol dependence with alcohol-induced psychotic disorder with delusions F10251 Alcohol dependence with alcohol-induced psychotic disorder with hallucinations	F10150	Alcohol abuse with alcohol-induced psychotic disorder with delusions
F10180 Alcohol abuse with alcohol-induced anxiety disorder F10181 Alcohol abuse with alcohol-induced sexual dysfunction F10182 Alcohol abuse with alcohol-induced sleep disorder F10188 Alcohol abuse with other alcohol-induced disorder F1019 Alcohol abuse with unspecified alcohol-induced disorder F1020 Alcohol dependence, uncomplicated F1021 Alcohol dependence, in remission F10220 Alcohol dependence with intoxication, uncomplicated F10221 Alcohol dependence with intoxication delirium F10229 Alcohol dependence with intoxication, unspecified F10230 Alcohol dependence with withdrawal, uncomplicated F10231 Alcohol dependence with withdrawal delirium F10232 Alcohol dependence with withdrawal with perceptual disturbance F10239 Alcohol dependence with withdrawal, unspecified F1024 Alcohol dependence with alcohol-induced mood disorder F10250 Alcohol dependence with alcohol-induced psychotic disorder with hallucinations F10251 Alcohol dependence with alcohol-induced psychotic disorder with hallucinations	F10151	Alcohol abuse with alcohol-induced psychotic disorder with hallucinations
F10181 Alcohol abuse with alcohol-induced sexual dysfunction F10182 Alcohol abuse with alcohol-induced sleep disorder F10188 Alcohol abuse with other alcohol-induced disorder F1019 Alcohol abuse with unspecified alcohol-induced disorder F1020 Alcohol dependence, uncomplicated F1021 Alcohol dependence, in remission F10220 Alcohol dependence with intoxication, uncomplicated F10221 Alcohol dependence with intoxication delirium F10229 Alcohol dependence with intoxication, unspecified F10230 Alcohol dependence with withdrawal, uncomplicated F10231 Alcohol dependence with withdrawal delirium F10232 Alcohol dependence with withdrawal with perceptual disturbance F10239 Alcohol dependence with withdrawal, unspecified F1024 Alcohol dependence with alcohol-induced mood disorder F10250 Alcohol dependence with alcohol-induced psychotic disorder with hallucinations F10251 Alcohol dependence with alcohol-induced psychotic disorder with hallucinations	F10159	Alcohol abuse with alcohol-induced psychotic disorder, unspecified
F10182 Alcohol abuse with alcohol-induced sleep disorder F10188 Alcohol abuse with other alcohol-induced disorder F1019 Alcohol abuse with unspecified alcohol-induced disorder F1020 Alcohol dependence, uncomplicated F1021 Alcohol dependence, in remission F10220 Alcohol dependence with intoxication, uncomplicated F10221 Alcohol dependence with intoxication delirium F10229 Alcohol dependence with intoxication, unspecified F10230 Alcohol dependence with withdrawal, uncomplicated F10231 Alcohol dependence with withdrawal delirium F10232 Alcohol dependence with withdrawal with perceptual disturbance F10239 Alcohol dependence with withdrawal, unspecified F1024 Alcohol dependence with alcohol-induced mood disorder F10250 Alcohol dependence with alcohol-induced psychotic disorder with delusions F10251 Alcohol dependence with alcohol-induced psychotic disorder with hallucinations	F10180	Alcohol abuse with alcohol-induced anxiety disorder
F1018 Alcohol abuse with other alcohol-induced disorder F1019 Alcohol abuse with unspecified alcohol-induced disorder F1020 Alcohol dependence, uncomplicated F1021 Alcohol dependence with intoxication, uncomplicated F10220 Alcohol dependence with intoxication, uncomplicated F10221 Alcohol dependence with intoxication delirium F10229 Alcohol dependence with intoxication, unspecified F10230 Alcohol dependence with withdrawal, uncomplicated F10231 Alcohol dependence with withdrawal delirium F10232 Alcohol dependence with withdrawal with perceptual disturbance F10239 Alcohol dependence with withdrawal, unspecified F1024 Alcohol dependence with alcohol-induced mood disorder F10250 Alcohol dependence with alcohol-induced psychotic disorder with delusions F10251 Alcohol dependence with alcohol-induced psychotic disorder with hallucinations		Alcohol abuse with alcohol-induced sexual dysfunction
F1020 Alcohol abuse with unspecified alcohol-induced disorder  F1021 Alcohol dependence, uncomplicated  F1021 Alcohol dependence with intoxication, uncomplicated  F10220 Alcohol dependence with intoxication, uncomplicated  F10221 Alcohol dependence with intoxication delirium  F10229 Alcohol dependence with intoxication, unspecified  F10230 Alcohol dependence with withdrawal, uncomplicated  F10231 Alcohol dependence with withdrawal delirium  F10232 Alcohol dependence with withdrawal with perceptual disturbance  F10239 Alcohol dependence with withdrawal, unspecified  F1024 Alcohol dependence with alcohol-induced mood disorder  F10250 Alcohol dependence with alcohol-induced psychotic disorder with delusions  F10251 Alcohol dependence with alcohol-induced psychotic disorder with hallucinations	F10182	
F1021 Alcohol dependence, uncomplicated F1021 Alcohol dependence with intoxication, uncomplicated F10220 Alcohol dependence with intoxication, uncomplicated F10221 Alcohol dependence with intoxication delirium F10229 Alcohol dependence with intoxication, unspecified F10230 Alcohol dependence with withdrawal, uncomplicated F10231 Alcohol dependence with withdrawal delirium F10232 Alcohol dependence with withdrawal with perceptual disturbance F10239 Alcohol dependence with withdrawal, unspecified F1024 Alcohol dependence with alcohol-induced mood disorder F10250 Alcohol dependence with alcohol-induced psychotic disorder with delusions F10251 Alcohol dependence with alcohol-induced psychotic disorder with hallucinations	F10188	Alcohol abuse with other alcohol-induced disorder
F1021 Alcohol dependence, in remission F10220 Alcohol dependence with intoxication, uncomplicated F10221 Alcohol dependence with intoxication delirium F10229 Alcohol dependence with intoxication, unspecified F10230 Alcohol dependence with withdrawal, uncomplicated F10231 Alcohol dependence with withdrawal delirium F10232 Alcohol dependence with withdrawal with perceptual disturbance F10239 Alcohol dependence with withdrawal, unspecified F1024 Alcohol dependence with alcohol-induced mood disorder F10250 Alcohol dependence with alcohol-induced psychotic disorder with delusions F10251 Alcohol dependence with alcohol-induced psychotic disorder with hallucinations	F1019	Alcohol abuse with unspecified alcohol-induced disorder
F10220 Alcohol dependence with intoxication, uncomplicated F10221 Alcohol dependence with intoxication delirium F10229 Alcohol dependence with intoxication, unspecified F10230 Alcohol dependence with withdrawal, uncomplicated F10231 Alcohol dependence with withdrawal delirium F10232 Alcohol dependence with withdrawal with perceptual disturbance F10239 Alcohol dependence with withdrawal, unspecified F1024 Alcohol dependence with alcohol-induced mood disorder F10250 Alcohol dependence with alcohol-induced psychotic disorder with delusions F10251 Alcohol dependence with alcohol-induced psychotic disorder with hallucinations	F1020	Alcohol dependence, uncomplicated
F10221 Alcohol dependence with intoxication delirium F10229 Alcohol dependence with intoxication, unspecified F10230 Alcohol dependence with withdrawal, uncomplicated F10231 Alcohol dependence with withdrawal delirium F10232 Alcohol dependence with withdrawal with perceptual disturbance F10239 Alcohol dependence with withdrawal, unspecified F1024 Alcohol dependence with alcohol-induced mood disorder F10250 Alcohol dependence with alcohol-induced psychotic disorder with delusions F10251 Alcohol dependence with alcohol-induced psychotic disorder with hallucinations	F1021	Alcohol dependence, in remission
F10229 Alcohol dependence with intoxication, unspecified F10230 Alcohol dependence with withdrawal, uncomplicated F10231 Alcohol dependence with withdrawal delirium F10232 Alcohol dependence with withdrawal with perceptual disturbance F10239 Alcohol dependence with withdrawal, unspecified F1024 Alcohol dependence with alcohol-induced mood disorder F10250 Alcohol dependence with alcohol-induced psychotic disorder with delusions F10251 Alcohol dependence with alcohol-induced psychotic disorder with hallucinations	F10220	
F10230 Alcohol dependence with withdrawal, uncomplicated F10231 Alcohol dependence with withdrawal delirium F10232 Alcohol dependence with withdrawal with perceptual disturbance F10239 Alcohol dependence with withdrawal, unspecified F1024 Alcohol dependence with alcohol-induced mood disorder F10250 Alcohol dependence with alcohol-induced psychotic disorder with delusions F10251 Alcohol dependence with alcohol-induced psychotic disorder with hallucinations		Alcohol dependence with intoxication delirium
F10231 Alcohol dependence with withdrawal delirium F10232 Alcohol dependence with withdrawal with perceptual disturbance F10239 Alcohol dependence with withdrawal, unspecified F1024 Alcohol dependence with alcohol-induced mood disorder F10250 Alcohol dependence with alcohol-induced psychotic disorder with delusions F10251 Alcohol dependence with alcohol-induced psychotic disorder with hallucinations	F10229	Alcohol dependence with intoxication, unspecified
F10232 Alcohol dependence with withdrawal with perceptual disturbance F10239 Alcohol dependence with withdrawal, unspecified F1024 Alcohol dependence with alcohol-induced mood disorder F10250 Alcohol dependence with alcohol-induced psychotic disorder with delusions F10251 Alcohol dependence with alcohol-induced psychotic disorder with hallucinations	F10230	Alcohol dependence with withdrawal, uncomplicated
F10239 Alcohol dependence with withdrawal, unspecified F1024 Alcohol dependence with alcohol-induced mood disorder F10250 Alcohol dependence with alcohol-induced psychotic disorder with delusions F10251 Alcohol dependence with alcohol-induced psychotic disorder with hallucinations	F10231	Alcohol dependence with withdrawal delirium
F1024 Alcohol dependence with alcohol-induced mood disorder F10250 Alcohol dependence with alcohol-induced psychotic disorder with delusions F10251 Alcohol dependence with alcohol-induced psychotic disorder with hallucinations	F10232	Alcohol dependence with withdrawal with perceptual disturbance
F10250 Alcohol dependence with alcohol-induced psychotic disorder with delusions F10251 Alcohol dependence with alcohol-induced psychotic disorder with hallucinations	F10239	Alcohol dependence with withdrawal, unspecified
F10251 Alcohol dependence with alcohol-induced psychotic disorder with hallucinations	F1024	Alcohol dependence with alcohol-induced mood disorder
	F10250	Alcohol dependence with alcohol-induced psychotic disorder with delusions
	F10251	
	F10259	Alcohol dependence with alcohol-induced psychotic disorder, unspecified
F1026 Alcohol dependence with alcohol-induced persisting amnestic disorder		Alcohol dependence with alcohol-induced persisting amnestic disorder
F1027 Alcohol dependence with alcohol-induced persisting dementia	F1027	Alcohol dependence with alcohol-induced persisting dementia
F10280 Alcohol dependence with alcohol-induced anxiety disorder		Alcohol dependence with alcohol-induced anxiety disorder
F10281 Alcohol dependence with alcohol-induced sexual dysfunction	F10281	Alcohol dependence with alcohol-induced sexual dysfunction
F10282 Alcohol dependence with alcohol-induced sleep disorder	F10282	Alcohol dependence with alcohol-induced sleep disorder
F10288 Alcohol dependence with other alcohol-induced disorder	F10288	Alcohol dependence with other alcohol-induced disorder

Code	Shortened Description
F1029	Alcohol dependence with unspecified alcohol-induced disorder
F10920	Alcohol use, unspecified with intoxication, uncomplicated
F10921	Alcohol use, unspecified with intoxication delirium
F10929	Alcohol use, unspecified with intoxication, unspecified
F1094	Alcohol use, unspecified with alcohol-induced mood disorder
F10950	Alcohol use, unspecified with alcohol-induced psychotic disorder with delusions
F10951	Alcohol use, unspecified with alcohol-induced psychotic disorder with hallucinations
F10959	Alcohol use, unspecified with alcohol-induced psychotic disorder, unspecified
F1096	Alcohol use, unspecified with alcohol-induced persisting amnestic disorder
F1097	Alcohol use, unspecified with alcohol-induced persisting dementia
F10980	Alcohol use, unspecified with alcohol-induced anxiety disorder
F10981	Alcohol use, unspecified with alcohol-induced sexual dysfunction
F10982	Alcohol use, unspecified with alcohol-induced sleep disorder
F10988	Alcohol use, unspecified with other alcohol-induced disorder
F1099	Alcohol use, unspecified with unspecified alcohol-induced disorder
F1110	Opioid abuse, uncomplicated
F1111	Opioid abuse, in remission
F11120	Opioid abuse with intoxication, uncomplicated
F11121	Opioid abuse with intoxication delirium
F11122	Opioid abuse with intoxication with perceptual disturbance
F11129	Opioid abuse with intoxication, unspecified
F1114	Opioid abuse with opioid-induced mood disorder
F11150	Opioid abuse with opioid-induced psychotic disorder with delusions
F11151	Opioid abuse with opioid-induced psychotic disorder with hallucinations
F11159	Opioid abuse with opioid-induced psychotic disorder, unspecified
F11181	Opioid abuse with opioid-induced sexual dysfunction
F11182	Opioid abuse with opioid-induced sleep disorder
F11188	Opioid abuse with other opioid-induced disorder
F1119	Opioid abuse with unspecified opioid-induced disorder
F1120	Opioid dependence, uncomplicated
F1121	Opioid dependence, in remission
F11220	Opioid dependence with intoxication, uncomplicated
F11221	Opioid dependence with intoxication delirium
F11222	Opioid dependence with intoxication with perceptual disturbance
F11229	Opioid dependence with intoxication, unspecified
F1123	Opioid dependence with withdrawal
F1124	Opioid dependence with opioid-induced mood disorder
F11250	Opioid dependence with opioid-induced psychotic disorder with delusions
F11251	Opioid dependence with opioid-induced psychotic disorder with hallucinations
F11259	Opioid dependence with opioid-induced psychotic disorder, unspecified
F11281	Opioid dependence with opioid-induced sexual dysfunction
F11282	Opioid dependence with opioid-induced sleep disorder
F11288	Opioid dependence with other opioid-induced disorder
F1129	Opioid dependence with unspecified opioid-induced disorder
F1190	Opioid use, unspecified, uncomplicated
F11920	Opioid use, unspecified with intoxication, uncomplicated
F11921	Opioid use, unspecified with intoxication delirium
F11922	Opioid use, unspecified with intoxication with perceptual disturbance
F11929	Opioid use, unspecified with intoxication, unspecified
F1193	Opioid use, unspecified with withdrawal
F1194	Opioid use, unspecified with opioid-induced mood disorder
F11950	Opioid use, unspecified with opioid-induced psychotic disorder with delusions
F11951	Opioid use, unspecified with opioid-induced psychotic disorder with hallucinations
F11959	Opioid use, unspecified with opioid-induced psychotic disorder, unspecified
F11981	Opioid use, unspecified with opioid-induced sexual dysfunction

Code	Shortened Description	
F11982	Opioid use, unspecified with opioid-induced sleep disorder	
F11988	Opioid use, unspecified with other opioid-induced disorder	
F1199	Opioid use, unspecified with unspecified opioid-induced disorder	
F1210	Cannabis abuse, uncomplicated	
F1211	Cannabis abuse, in remission	
F12120	Cannabis abuse with intoxication, uncomplicated	
F12121	Cannabis abuse with intoxication delirium	
F12122	Cannabis abuse with intoxication with perceptual disturbance	
F12129	Cannabis abuse with intoxication, unspecified	
F12150	Cannabis abuse with psychotic disorder with delusions	
F12151	Cannabis abuse with psychotic disorder with hallucinations	
F12159	Cannabis abuse with psychotic disorder, unspecified	
F12180	Cannabis abuse with cannabis-induced anxiety disorder	
F12188	Cannabis abuse with other cannabis-induced disorder	
F1219	Cannabis abuse with unspecified cannabis-induced disorder	
F1220	Cannabis dependence, uncomplicated	
F1221	Cannabis dependence, in remission	
F12220	Cannabis dependence with intoxication, uncomplicated	
F12221	Cannabis dependence with intoxication delirium	
F12222	Cannabis dependence with intoxication with perceptual disturbance	
F12229	Cannabis dependence with intoxication, unspecified	
F1223	Cannabis dependence with withdrawal	
F12250	Cannabis dependence with windrawar  Cannabis dependence with psychotic disorder with delusions	
F12251	Cannabis dependence with psychotic disorder with hallucinations  Cannabis dependence with psychotic disorder with hallucinations	
F12251	Cannabis dependence with psychotic disorder, unspecified	
F12239	Cannabis dependence with psychotic disorder, dispectified  Cannabis dependence with cannabis-induced anxiety disorder	
F12288	Cannabis dependence with cannabis-induced disorder  Cannabis dependence with other cannabis-induced disorder	
F12288	Cannabis dependence with other cannabis-induced disorder  Cannabis dependence with unspecified cannabis-induced disorder	
F1229 F1290	Cannabis use, unspecified, uncomplicated	
F1290	Cannabis use, unspecified with intoxication, uncomplicated	
F12920 F12921	Cannabis use, unspecified with intoxication, uncomplicated  Cannabis use, unspecified with intoxication delirium	
F12921 F12922	Cannabis use, unspecified with intoxication definition  Cannabis use, unspecified with intoxication with perceptual disturbance	
F12922 F12929		
F12929 F1293	Cannabis use, unspecified with intoxication, unspecified  Cannabis use, unspecified with withdrawal	
F12950	Cannabis use, unspecified with psychotic disorder with delusions	
F12951	Cannabis use, unspecified with psychotic disorder with hallucinations	
F12959 F12980	Cannabis use, unspecified with psychotic disorder, unspecified	
	Cannabis use, unspecified with anxiety disorder	
F12988	Cannabis use, unspecified with other cannabis-induced disorder	
F1299	Cannabis use, unspecified with unspecified cannabis-induced disorder	
F1310	Sedative, hypnotic or anxiolytic abuse, uncomplicated	
F1311	Sedative, hypnotic or anxiolytic abuse, in remission	
F13120	Sedative, hypnotic or anxiolytic abuse with intoxication, uncomplicated	
F13121	Sedative, hypnotic or anxiolytic abuse with intoxication delirium	
F13129	Sedative, hypnotic or anxiolytic abuse with intoxication, unspecified	
F1314	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced mood disorder	
F13150	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced psychotic disorder with delusions	
F13151	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced psychotic disorder with hallucinations	
	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced psychotic disorder,	
F13159	unspecified	
F13180	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced anxiety disorder	
F13181	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced sexual dysfunction	
F13182	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced sleep disorder	
113104	poculative, hypnotic of anxiotytic abuse with scalarive, hypnotic of anxiotytic-induced sleep disorder	

Code	Shortened Description
F13188	Sedative, hypnotic or anxiolytic abuse with other sedative, hypnotic or anxiolytic-induced disorder
F1319	Sedative, hypnotic or anxiolytic abuse with unspecified sedative, hypnotic or anxiolytic-induced disorder
F1320	Sedative, hypnotic or anxiolytic dependence, uncomplicated
F1321	Sedative, hypnotic or anxiolytic dependence, in remission
F13220	Sedative, hypnotic or anxiolytic dependence with intoxication, uncomplicated
F13221	Sedative, hypnotic or anxiolytic dependence with intoxication delirium
F13229	Sedative, hypnotic or anxiolytic dependence with intoxication, unspecified
F13230	Sedative, hypnotic or anxiolytic dependence with withdrawal, uncomplicated
F13231	Sedative, hypnotic or anxiolytic dependence with withdrawal delirium
F13232	Sedative, hypnotic or anxiolytic dependence with withdrawal with perceptual disturbance
F13239	Sedative, hypnotic or anxiolytic dependence with withdrawal, unspecified
F1324	Sedative, hypnotic or anxiolytic dependence with windawar, unspecified  Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced mood disorder
1 1327	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced psychotic disorder
F13250	with delusions
	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced psychotic disorder
F13251	with hallucinations
	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced psychotic disorder,
F13259	
	unspecified
F1326	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced persisting amnestic
	disorder
F1327	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced persisting dementia
F13280	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced anxiety disorder
F13281	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced sexual dysfunction
F13282	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced sleep disorder
F13288	Sedative, hypnotic or anxiolytic dependence with other sedative, hypnotic or anxiolytic-induced disorder
F1329	Sedative, hypnotic or anxiolytic dependence with unspecified sedative, hypnotic or anxiolytic-induced disorder
F1390	Sedative, hypnotic, or anxiolytic use, unspecified, uncomplicated
F13920	Sedative, hypnotic or anxiolytic use, unspecified with intoxication, uncomplicated
F13921	Sedative, hypnotic or anxiolytic use, unspecified with intoxication delirium
F13929	Sedative, hypnotic or anxiolytic use, unspecified with intoxication, unspecified
F13930	Sedative, hypnotic or anxiolytic use, unspecified with withdrawal, uncomplicated
F13931	Sedative, hypnotic or anxiolytic use, unspecified with withdrawal delirium
F13932	Sedative, hypnotic or anxiolytic use, unspecified with withdrawal with perceptual disturbances
F13939	Sedative, hypnotic or anxiolytic use, unspecified with withdrawal, unspecified
	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced mood disorder
F1394	bedative, hyphotic of anxiotytic use, anspectified with sedative, hyphotic of anxiotytic-induced mood disorder
	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced psychotic
F13950	
	disorder with delusions
F13951	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced psychotic
	disorder with hallucinations
F13959	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced psychotic
	disorder, unspecified
F1396	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced persisting
	amnestic disorder
F1397	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced persisting
1 1 3 7 1	dementia
E13000	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced anxiety disorder
F13980	
E12001	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced sexual
F13981	dysfunction

Code	Shortened Description
F13982	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced sleep disorder
F13988	Sedative, hypnotic or anxiolytic use, unspecified with other sedative, hypnotic or anxiolytic-induced disorder
E1200	Sedative, hypnotic or anxiolytic use, unspecified with unspecified sedative, hypnotic or anxiolytic-induced
F1399	disorder
F1410	Cocaine abuse, uncomplicated
F1411	Cocaine abuse, in remission
F14120	Cocaine abuse with intoxication, uncomplicated
F14121	Cocaine abuse with intoxication with delirium
F14122	Cocaine abuse with intoxication with perceptual disturbance
F14129	Cocaine abuse with intoxication, unspecified
F1414	Cocaine abuse with cocaine-induced mood disorder
F14150	Cocaine abuse with cocaine-induced psychotic disorder with delusions
F14151	Cocaine abuse with cocaine-induced psychotic disorder with hallucinations
F14159	Cocaine abuse with cocaine-induced psychotic disorder, unspecified
F14180	Cocaine abuse with cocaine-induced anxiety disorder
F14181	Cocaine abuse with cocaine-induced sexual dysfunction
F14182	Cocaine abuse with cocaine-induced sleep disorder
F14188	Cocaine abuse with other cocaine-induced disorder
F1419	Cocaine abuse with unspecified cocaine-induced disorder
F1420	Cocaine dependence, uncomplicated
F1421	Cocaine dependence, in remission
F14220	Cocaine dependence with intoxication, uncomplicated
F14221	Cocaine dependence with intoxication delirium
F14222	Cocaine dependence with intoxication with perceptual disturbance
F14229	Cocaine dependence with intoxication, unspecified
F1423	Cocaine dependence with withdrawal
F1424	Cocaine dependence with cocaine-induced mood disorder
F14250	Cocaine dependence with cocaine-induced psychotic disorder with delusions
F14251	Cocaine dependence with cocaine-induced psychotic disorder with hallucinations
F14259	Cocaine dependence with cocaine-induced psychotic disorder, unspecified
F14280	Cocaine dependence with cocaine-induced anxiety disorder
F14281	Cocaine dependence with cocaine-induced sexual dysfunction
F14282	Cocaine dependence with cocaine-induced sleep disorder
F14288	Cocaine dependence with other cocaine-induced disorder
F1429	Cocaine dependence with unspecified cocaine-induced disorder
F1490	Cocaine use, unspecified, uncomplicated
F14920	Cocaine use, unspecified with intoxication, uncomplicated
F14921	Cocaine use, unspecified with intoxication delirium
F14922	Cocaine use, unspecified with intoxication with perceptual disturbance
F14929	Cocaine use, unspecified with intoxication, unspecified
F1494	Cocaine use, unspecified with cocaine-induced mood disorder
F14950	Cocaine use, unspecified with cocaine-induced psychotic disorder with delusions
F14951	Cocaine use, unspecified with cocaine-induced psychotic disorder with hallucinations
F14959	Cocaine use, unspecified with cocaine-induced psychotic disorder, unspecified
F14980	Cocaine use, unspecified with cocaine-induced anxiety disorder
F14981	Cocaine use, unspecified with cocaine-induced sexual dysfunction
F14982	Cocaine use, unspecified with cocaine-induced sleep disorder
L14000	Cocaine use, unspecified with other cocaine-induced disorder
F14988	Cooring use unangeified with unangeified acceing induced disorder
F1499	Cocaine use, unspecified with unspecified cocaine-induced disorder  Other stimulant abuse, unsamplicated
F1499 F1510	Other stimulant abuse, uncomplicated
F14988 F1499 F1510 F1511 F15120	

Code	Shortened Description
F15122	Other stimulant abuse with intoxication with perceptual disturbance
F15129	Other stimulant abuse with intoxication, unspecified
F1514	Other stimulant abuse with stimulant-induced mood disorder
F15150	Other stimulant abuse with stimulant-induced psychotic disorder with delusions
F15151	Other stimulant abuse with stimulant-induced psychotic disorder with hallucinations
F15159	Other stimulant abuse with stimulant-induced psychotic disorder, unspecified
F15180	Other stimulant abuse with stimulant-induced anxiety disorder
F15181	Other stimulant abuse with stimulant-induced sexual dysfunction
F15182	Other stimulant abuse with stimulant-induced sleep disorder
F15188	Other stimulant abuse with other stimulant-induced disorder
F1519	Other stimulant abuse with unspecified stimulant-induced disorder
F1520	Other stimulant dependence, uncomplicated
F1521	Other stimulant dependence, in remission
F15220	Other stimulant dependence with intoxication, uncomplicated
F15221	Other stimulant dependence with intoxication delirium
F15222	Other stimulant dependence with intoxication with perceptual disturbance
F15229	Other stimulant dependence with intoxication, unspecified
F1523	Other stimulant dependence with withdrawal
F1524	Other stimulant dependence with stimulant-induced mood disorder
F15250	Other stimulant dependence with stimulant-induced psychotic disorder with delusions
F15251	Other stimulant dependence with stimulant-induced psychotic disorder with hallucinations
F15259	Other stimulant dependence with stimulant-induced psychotic disorder, unspecified
F15280	Other stimulant dependence with stimulant-induced anxiety disorder
F15281	Other stimulant dependence with stimulant-induced sexual dysfunction
F15282	Other stimulant dependence with stimulant-induced sleep disorder
F15288	Other stimulant dependence with other stimulant-induced disorder
F1529	Other stimulant dependence with unspecified stimulant-induced disorder
F1590	Other stimulant use, unspecified, uncomplicated
F15920	Other stimulant use, unspecified with intoxication, uncomplicated
F15921	Other stimulant use, unspecified with intoxication delirium
F15922	Other stimulant use, unspecified with intoxication with perceptual disturbance
F15929	Other stimulant use, unspecified with intoxication, unspecified
F1593	Other stimulant use, unspecified with withdrawal
F1594	Other stimulant use, unspecified with stimulant-induced mood disorder
F15950	Other stimulant use, unspecified with stimulant-induced psychotic disorder with delusions
F15951	Other stimulant use, unspecified with stimulant-induced psychotic disorder with hallucinations
F15959	Other stimulant use, unspecified with stimulant-induced psychotic disorder, unspecified
F15980	Other stimulant use, unspecified with stimulant-induced anxiety disorder
F15981	Other stimulant use, unspecified with stimulant-induced sexual dysfunction
F15982	Other stimulant use, unspecified with stimulant-induced sleep disorder
F15988	Other stimulant use, unspecified with other stimulant-induced disorder
F1599	Other stimulant use, unspecified with unspecified stimulant-induced disorder
F1610	Hallucinogen abuse, uncomplicated
F1611	Hallucinogen abuse, in remission
F16120	Hallucinogen abuse with intoxication, uncomplicated
F16121	Hallucinogen abuse with intoxication with delirium
F16122	Hallucinogen abuse with intoxication with perceptual disturbance
F16129	Hallucinogen abuse with intoxication, unspecified
F1614	Hallucinogen abuse with hallucinogen-induced mood disorder
F16150	Hallucinogen abuse with hallucinogen-induced psychotic disorder with delusions
F16151	Hallucinogen abuse with hallucinogen-induced psychotic disorder with hallucinations
F16159	Hallucinogen abuse with hallucinogen-induced psychotic disorder, unspecified
F16180	Hallucinogen abuse with hallucinogen-induced anxiety disorder
F16183	Hallucinogen abuse with hallucinogen persisting perception disorder (flashbacks)
F16188	Hallucinogen abuse with other hallucinogen-induced disorder

Code	Chautanad Dagawatian
F1619	Shortened Description
	Hallucinogen abuse with unspecified hallucinogen-induced disorder
F1620	Hallucinogen dependence, uncomplicated
F1621	Hallucinogen dependence, in remission
F16220	Hallucinogen dependence with intoxication, uncomplicated
F16221	Hallucinogen dependence with intoxication with delirium
F16229	Hallucinogen dependence with intoxication, unspecified
F1624	Hallucinogen dependence with hallucinogen-induced mood disorder
F16250	Hallucinogen dependence with hallucinogen-induced psychotic disorder with delusions
F16251	Hallucinogen dependence with hallucinogen-induced psychotic disorder with hallucinations
F16259	Hallucinogen dependence with hallucinogen-induced psychotic disorder, unspecified
F16280	Hallucinogen dependence with hallucinogen-induced anxiety disorder
F16283	Hallucinogen dependence with hallucinogen persisting perception disorder (flashbacks)
F16288	Hallucinogen dependence with other hallucinogen-induced disorder
F1629	Hallucinogen dependence with unspecified hallucinogen-induced disorder
F1690	Hallucinogen use, unspecified, uncomplicated
F16920	Hallucinogen use, unspecified with intoxication, uncomplicated
F16921	Hallucinogen use, unspecified with intoxication with delirium
F16929	Hallucinogen use, unspecified with intoxication, unspecified
F1694	Hallucinogen use, unspecified with hallucinogen-induced mood disorder
F16950	Hallucinogen use, unspecified with hallucinogen-induced psychotic disorder with delusions
F16951	Hallucinogen use, unspecified with hallucinogen-induced psychotic disorder with hallucinations
F16959	Hallucinogen use, unspecified with hallucinogen-induced psychotic disorder, unspecified
F16980	Hallucinogen use, unspecified with hallucinogen-induced anxiety disorder
F16983	Hallucinogen use, unspecified with hallucinogen persisting perception disorder (flashbacks)
F16988	Hallucinogen use, unspecified with other hallucinogen-induced disorder
F1699	Hallucinogen use, unspecified with unspecified hallucinogen-induced disorder
F1810	Inhalant abuse, uncomplicated
F1811	Inhalant abuse, in remission
F18120	Inhalant abuse with intoxication, uncomplicated
F18121	Inhalant abuse with intoxication delirium
F18129	Inhalant abuse with intoxication, unspecified
F1814	Inhalant abuse with inhalant-induced mood disorder
F18150	Inhalant abuse with inhalant-induced psychotic disorder with delusions
F18151	Inhalant abuse with inhalant-induced psychotic disorder with hallucinations
F18159	Inhalant abuse with inhalant-induced psychotic disorder, unspecified
F1817	Inhalant abuse with inhalant-induced dementia
F18180	Inhalant abuse with inhalant-induced anxiety disorder
F18188	Inhalant abuse with other inhalant-induced disorder
F1819	Inhalant abuse with unspecified inhalant-induced disorder
F1820	Inhalant dependence, uncomplicated
F1821	Inhalant dependence, in remission
F18220	Inhalant dependence with intoxication, uncomplicated
F18221	Inhalant dependence with intoxication delirium
F18229	Inhalant dependence with intoxication, unspecified
F1824	Inhalant dependence with inhalant-induced mood disorder
F18250	Inhalant dependence with inhalant-induced psychotic disorder with delusions
F18251	Inhalant dependence with inhalant-induced psychotic disorder with hallucinations
F18259	Inhalant dependence with inhalant-induced psychotic disorder, unspecified
F1827	Inhalant dependence with inhalant-induced dementia
F18280	Inhalant dependence with inhalant-induced anxiety disorder
F18288	Inhalant dependence with other inhalant-induced disorder
F1829	Inhalant dependence with unspecified inhalant-induced disorder
F1890	Inhalant use, unspecified, uncomplicated
F18920	Inhalant use, unspecified with intoxication, uncomplicated
F18921	Inhalant use, unspecified with intoxication with delirium
•	•

Code	Shortened Description
F18929	Inhalant use, unspecified with intoxication, unspecified
F1894	Inhalant use, unspecified with inhalant-induced mood disorder
F18950	Inhalant use, unspecified with inhalant-induced psychotic disorder with delusions
F18951	Inhalant use, unspecified with inhalant-induced psychotic disorder with hallucinations
F18959	Inhalant use, unspecified with inhalant-induced psychotic disorder, unspecified
F1897	Inhalant use, unspecified with inhalant-induced persisting dementia
F18980	Inhalant use, unspecified with inhalant-induced anxiety disorder
F18988	Inhalant use, unspecified with other inhalant-induced disorder
F1899	Inhalant use, unspecified with unspecified inhalant-induced disorder
F1910	Other psychoactive substance abuse, uncomplicated
F1911	Other psychoactive substance abuse, in remission
F19120	Other psychoactive substance abuse with intoxication, uncomplicated
F19121	Other psychoactive substance abuse with intoxication delirium
F19122	Other psychoactive substance abuse with intoxication with perceptual disturbances
F19129	Other psychoactive substance abuse with intoxication, unspecified
F1914	Other psychoactive substance abuse with psychoactive substance-induced mood disorder
F19150	Other psychoactive substance abuse with psychoactive substance-induced psychotic disorder with delusions
F19151	Other psychoactive substance abuse with psychoactive substance-induced psychotic disorder with hallucinations
F19159	Other psychoactive substance abuse with psychoactive substance-induced psychotic disorder, unspecified
F1916	Other psychoactive substance abuse with psychoactive substance-induced persisting amnestic disorder
F1917	Other psychoactive substance abuse with psychoactive substance-induced persisting dementia
F19180	Other psychoactive substance abuse with psychoactive substance-induced anxiety disorder
F19181	Other psychoactive substance abuse with psychoactive substance-induced sexual dysfunction
F19182	Other psychoactive substance abuse with psychoactive substance-induced sleep disorder
F19188	Other psychoactive substance abuse with other psychoactive substance-induced disorder
F1919	Other psychoactive substance abuse with unspecified psychoactive substance-induced disorder
F1920	Other psychoactive substance dependence, uncomplicated
F1921	Other psychoactive substance dependence, in remission
F19220	Other psychoactive substance dependence with intoxication, uncomplicated
F19221	Other psychoactive substance dependence with intoxication delirium
F19222	Other psychoactive substance dependence with intoxication with perceptual disturbance
F19229	Other psychoactive substance dependence with intoxication, unspecified
F19230	Other psychoactive substance dependence with withdrawal, uncomplicated
F19231	Other psychoactive substance dependence with withdrawal delirium
F19232	Other psychoactive substance dependence with withdrawal with perceptual disturbance
F19239	Other psychoactive substance dependence with withdrawal, unspecified
F1924	Other psychoactive substance dependence with psychoactive substance-induced mood disorder
F19250	Other psychoactive substance dependence with psychoactive substance-induced psychotic disorder with delusions
F19251	Other psychoactive substance dependence with psychoactive substance-induced psychotic disorder with hallucinations
F19259	Other psychoactive substance dependence with psychoactive substance-induced psychotic disorder, unspecified
F1926	Other psychoactive substance dependence with psychoactive substance-induced persisting amnestic disorder
F1927	Other psychoactive substance dependence with psychoactive substance-induced persisting dementia
F19280	Other psychoactive substance dependence with psychoactive substance-induced anxiety disorder
F19281	Other psychoactive substance dependence with psychoactive substance-induced anxiety disorder  Other psychoactive substance dependence with psychoactive substance-induced sexual dysfunction
F19282	Other psychoactive substance dependence with psychoactive substance-induced sleep disorder
F19288	Other psychoactive substance dependence with psychoactive substance-induced disorder  Other psychoactive substance dependence with other psychoactive substance-induced disorder
F1929	Other psychoactive substance dependence with other psychoactive substance-induced disorder
F1990	Other psychoactive substance use, unspecified, uncomplicated
F19920	Other psychoactive substance use, unspecified with intoxication, uncomplicated

Code	Shortened Description
F19921	Other psychoactive substance use, unspecified with intoxication with delirium
F19922	Other psychoactive substance use, unspecified with intoxication with perceptual disturbance
F19929	Other psychoactive substance use, unspecified with intoxication, unspecified
F19930	Other psychoactive substance use, unspecified with withdrawal, uncomplicated
F19931	Other psychoactive substance use, unspecified with withdrawal delirium
F19932	Other psychoactive substance use, unspecified with withdrawal with perceptual disturbance
F19939	Other psychoactive substance use, unspecified with withdrawal, unspecified
F1994	Other psychoactive substance use, unspecified with psychoactive substance-induced mood disorder
F19950	Other psychoactive substance use, unspecified with psychoactive substance-induced psychotic disorder with delusions
F19951	Other psychoactive substance use, unspecified with psychoactive substance-induced psychotic disorder with hallucinations
F19959	Other psychoactive substance use, unspecified with psychoactive substance-induced psychotic disorder, unspecified
F1996	Other psychoactive substance use, unspecified with psychoactive substance-induced persisting amnestic disorder
F1997	Other psychoactive substance use, unspecified with psychoactive substance-induced persisting dementia
F19980	Other psychoactive substance use, unspecified with psychoactive substance-induced anxiety disorder
F19981	Other psychoactive substance use, unspecified with psychoactive substance-induced sexual dysfunction
F19982	Other psychoactive substance use, unspecified with psychoactive substance-induced sleep disorder
F19988	Other psychoactive substance use, unspecified with other psychoactive substance-induced disorder
F1999	Other psychoactive substance use, unspecified with unspecified psychoactive substance-induced disorder
F200	Paranoid schizophrenia
F201	Disorganized schizophrenia
F202	Catatonic schizophrenia
F203	Undifferentiated schizophrenia
F205	Residual schizophrenia
F2081	Schizophreniform disorder
F2089	Other schizophrenia
F209	Schizophrenia, unspecified
F21	Schizotypal disorder
F22	Delusional disorders
F23	Brief psychotic disorder
F24	Shared psychotic disorder
F250	Schizoaffective disorder, bipolar type
F251	Schizoaffective disorder, depressive type
F258	Other schizoaffective disorders
F259	Schizoaffective disorder, unspecified
F28	Other psychotic disorder not due to a substance or known physiological condition
F29	Unspecified psychosis not due to a substance or known physiological condition
F3010	Manic episode without psychotic symptoms, unspecified
F3011	Manic episode without psychotic symptoms, mild
F3012	Manic episode without psychotic symptoms, moderate
F3013	Manic episode, severe, without psychotic symptoms
F302	Manic episode, severe with psychotic symptoms
F303	Manic episode in partial remission
F304	Manic episode in full remission
F308	Other manic episodes
F309	Manic episode, unspecified
F310	Bipolar disorder, current episode hypomanic
F3110	Bipolar disorder, current episode manic without psychotic features, unspecified
F3111	Bipolar disorder, current episode manic without psychotic features, mild
F3112	Bipolar disorder, current episode manic without psychotic features, moderate
F3113	Bipolar disorder, current episode manic without psychotic features, severe
F312	Bipolar disorder, current episode manic severe with psychotic features

Code	Shortened Description
F3130	Bipolar disorder, current episode depressed, mild or moderate severity, unspecified
F3131	Bipolar disorder, current episode depressed, mild
F3132	Bipolar disorder, current episode depressed, moderate
F314	Bipolar disorder, current episode depressed, severe, without psychotic features
F315	Bipolar disorder, current episode depressed, severe, with psychotic features
F3160	Bipolar disorder, current episode mixed, unspecified
F3161	Bipolar disorder, current episode mixed, mild
F3162	Bipolar disorder, current episode mixed, moderate
F3163	Bipolar disorder, current episode mixed, severe, without psychotic features
F3164	Bipolar disorder, current episode mixed, severe, with psychotic features
F3170	Bipolar disorder, currently in remission, most recent episode unspecified
F3171	Bipolar disorder, in partial remission, most recent episode hypomanic
F3172	Bipolar disorder, in full remission, most recent episode hypomanic
F3173	Bipolar disorder, in partial remission, most recent episode manic
F3174	Bipolar disorder, in full remission, most recent episode manic
F3175	Bipolar disorder, in partial remission, most recent episode depressed
F3176	Bipolar disorder, in full remission, most recent episode depressed
F3177	Bipolar disorder, in partial remission, most recent episode mixed
F3178	Bipolar disorder, in full remission, most recent episode mixed
F3181	Bipolar II disorder
F3189	Other bipolar disorder
F319	Bipolar disorder, unspecified
F320	Major depressive disorder, single episode, mild
F321	Major depressive disorder, single episode, moderate
F322	Major depressive disorder, single episode, severe without psychotic features
F323	Major depressive disorder, single episode, severe with psychotic features
F324	Major depressive disorder, single episode, in partial remission
F325	Major depressive disorder, single episode, in full remission
F3281	Premenstrual dysphoric disorder
F3289	Other specified depressive episodes
F329	Major depressive disorder, single episode, unspecified
F330	Major depressive disorder, recurrent, mild
F331	Major depressive disorder, recurrent, moderate
F332	Major depressive disorder, recurrent severe without psychotic features
F333	Major depressive disorder, recurrent, severe with psychotic symptoms
F3340	Major depressive disorder, recurrent, in remission, unspecified
F3341	Major depressive disorder, recurrent, in partial remission
F3342	Major depressive disorder, recurrent, in full remission
F338	Other recurrent depressive disorders
F339	Major depressive disorder, recurrent, unspecified
F340	Cyclothymic disorder
F341	Dysthymic disorder
F3481	Disruptive mood dysregulation disorder
F3489	Other specified persistent mood disorders
F349	Persistent mood (affective) disorder, unspecified
F39	Unspecified mood (affective) disorder
F4000	Agoraphobia, unspecified
F4001	Agoraphobia with panic disorder
F4002	Agoraphobia without panic disorder
F4010	Social phobia, unspecified
F4011	Social phobia, generalized
F40210	Arachnophobia
F40218	Other animal type phobia
F40220	Fear of thunderstorms
F40228	Other natural environment type phobia

Code	Shortened Description
F40230	Fear of blood
F40231	Fear of injections and transfusions
F40232	Fear of other medical care
F40233	Fear of injury
F40240	Claustrophobia
F40241	Acrophobia
F40242	Fear of bridges
F40243	Fear of flying
F40248	Other situational type phobia
F40290	Androphobia
F40291	Gynephobia
F40298	Other specified phobia
F408	Other phobic anxiety disorders
F409	Phobic anxiety disorder, unspecified
F410	Panic disorder (episodic paroxysmal anxiety)
F411	Generalized anxiety disorder
F413	Other mixed anxiety disorders
F418	Other specified anxiety disorders
F419	Anxiety disorder, unspecified
F422	Mixed obsessional thoughts and acts
F423	Hoarding disorder
F424	Excoriation (skin-picking) disorder
F428	Other obsessive-compulsive disorder
F429	Obsessive-compulsive disorder, unspecified
F430	Acute stress reaction
F4310	Post-traumatic stress disorder, unspecified
F4311	Post-traumatic stress disorder, acute
F4312	Post-traumatic stress disorder, chronic
F4320	Adjustment disorder, unspecified
F4321	Adjustment disorder with depressed mood
F4322	Adjustment disorder with anxiety
F4323	Adjustment disorder with mixed anxiety and depressed mood
F4324	Adjustment disorder with disturbance of conduct
F4325	Adjustment disorder with mixed disturbance of emotions and conduct
F4329	Adjustment disorder with other symptoms
F438	Other reactions to severe stress
F439	Reaction to severe stress, unspecified
F440	Dissociative amnesia
F441	Dissociative fugue
F442	Dissociative stupor
F444	Conversion disorder with motor symptom or deficit
F445	Conversion disorder with seizures or convulsions
F446	Conversion disorder with sensory symptom or deficit
F447	Conversion disorder with mixed symptom presentation
F4481	Dissociative identity disorder
F4489	Other dissociative and conversion disorders
F449	Dissociative and conversion disorder, unspecified
F450	Somatization disorder
F451	Undifferentiated somatoform disorder
F4520	Hypochondriacal disorder, unspecified
F4521	Hypochondriasis
F4522	Body dysmorphic disorder
F4529	Other hypochondriacal disorders
F4541	Pain disorder exclusively related to psychological factors
F4542	Pain disorder with related psychological factors

Code	Shortened Description
F458	Other somatoform disorders
F459	Somatoform disorder, unspecified
F481	Depersonalization-derealization syndrome
F482	Pseudobulbar affect
F488	Other specified nonpsychotic mental disorders
F489	Nonpsychotic mental disorder, unspecified
F5000	Anorexia nervosa, unspecified
F5001	Anorexia nervosa, restricting type
F5002	Anorexia nervosa, binge eating/purging type
F502	Bulimia nervosa
F5081	Binge eating disorder
F5082	Avoidant/restrictive food intake disorder
F5089	Other specified eating disorder
F509	Eating disorder, unspecified
F5101	Primary insomnia
F5102	Adjustment insomnia
F5103	Paradoxical insomnia
F5104	Psychophysiologic insomnia
F5105	Insomnia due to other mental disorder
F5109	Other insomnia not due to a substance or known physiological condition
F5111	Primary hypersomnia
F5112	Insufficient sleep syndrome
F5113	Hypersomnia due to other mental disorder
F5119	Other hypersomnia not due to a substance or known physiological condition
F513	Sleepwalking (somnambulism)
F514	Sleep terrors (night terrors)
F515	Nightmare disorder
F518	Other sleep disorders not due to a substance or known physiological condition
F519	Sleep disorder not due to a substance or known physiological condition, unspecified
F520	Hypoactive sexual desire disorder
F521	Sexual aversion disorder
F5221	Male erectile disorder
F5222	Female sexual arousal disorder
F5231	Female orgasmic disorder
F5232	Male orgasmic disorder
F524	Premature ejaculation
F525	Vaginismus not due to a substance or known physiological condition
F526	Dyspareunia not due to a substance or known physiological condition
F528	Other sexual dysfunction not due to a substance or known physiological condition
F529	Unspecified sexual dysfunction not due to a substance or known physiological condition
F530	Postpartum depression
F531	Puerperal psychosis
F550	Abuse of antacids
F551	Abuse of herbal or folk remedies
F552	Abuse of laxatives
F553	Abuse of steroids or hormones
F554	Abuse of vitamins
F558	Abuse of other non-psychoactive substances
F59	Unspecified behavioral syndromes associated with physiological disturbances and physical factors
F600	Paranoid personality disorder
F601	Schizoid personality disorder
F602	Antisocial personality disorder
F603	Borderline personality disorder
F604	Histrionic personality disorder
F605	Obsessive-compulsive personality disorder

Code	Shortened Description
F606	Avoidant personality disorder
F607	Dependent personality disorder  Dependent personality disorder
F6081	Narcissistic personality disorder
F6089	Other specific personality disorders
F609	Personality disorder, unspecified
F630	Pathological gambling
F631	Pyromania
	Kleptomania
F632	Trichotillomania
F633	
F6381	Intermittent explosive disorder
F6389	Other impulse disorders
F639	Impulse disorder, unspecified
F640	Transsexualism
F641	Dual role transvestism
F642	Gender identity disorder of childhood
F648	Other gender identity disorders
F649	Gender identity disorder, unspecified
F650	Fetishism
F651	Transvestic fetishism
F652	Exhibitionism
F653	Voyeurism
F654	Pedophilia
F6550	Sadomasochism, unspecified
F6551	Sexual masochism
F6552	Sexual sadism
F6581	Frotteurism
F6589	Other paraphilias
F659	Paraphilia, unspecified
F66	Other sexual disorders
F68A	Factitious disorder imposed on another
F6810	Factitious disorder imposed on self, unspecified
F6811	Factitious disorder imposed on self, with predominantly psychological signs and symptoms
F6812	Factitious disorder imposed on self, with predominantly physical signs and symptoms
F6813	Factitious disorder imposed on self, with combined psychological and physical signs and symptoms
F688	Other specified disorders of adult personality and behavior
F69	Unspecified disorder of adult personality and behavior
F70	Mild intellectual disabilities
F71	Moderate intellectual disabilities
F72	Severe intellectual disabilities
F73	Profound intellectual disabilities
F78	Other intellectual disabilities
F79	Unspecified intellectual disabilities
F800	Phonological disorder
F801	Expressive language disorder
F802	Mixed receptive-expressive language disorder
F804	Speech and language development delay due to hearing loss
F8081	Childhood onset fluency disorder
F8082	Social pragmatic communication disorder
F8089	Other developmental disorders of speech and language
F809	Developmental disorder of speech and language, unspecified
F810	Specific reading disorder
	Mathematics disorder
F812	
F8181	Disorder of written expression
F8189	Other developmental disorders of scholastic skills
F819	Developmental disorder of scholastic skills, unspecified

Code	Shortened Description
F82	Specific developmental disorder of motor function
F840	Autistic disorder
F842	Rett's syndrome
F843	Other childhood disintegrative disorder
F845	Asperger's syndrome
F848	Other pervasive developmental disorders
F849	Pervasive developmental disorder, unspecified
F88	Other disorders of psychological development
F89	Unspecified disorder of psychological development
F900	Attention-deficit hyperactivity disorder, predominantly inattentive type
F901	Attention-deficit hyperactivity disorder, predominantly hyperactive type
F902	Attention-deficit hyperactivity disorder, combined type
F908	Attention-deficit hyperactivity disorder, other type
F909	Attention-deficit hyperactivity disorder, unspecified type
F910	Conduct disorder confined to family context
F911	Conduct disorder, childhood-onset type
F912	Conduct disorder, adolescent-onset type
F913	Oppositional defiant disorder
F918	Other conduct disorders
F919	Conduct disorder, unspecified
F930	Separation anxiety disorder of childhood
F938	Other childhood emotional disorders
F939	Childhood emotional disorder, unspecified
F940	Selective mutism
F941	Reactive attachment disorder of childhood
F942	Disinhibited attachment disorder of childhood
F948	Other childhood disorders of social functioning
F949	Childhood disorder of social functioning, unspecified
F950	Transient tic disorder
F951	Chronic motor or vocal tic disorder
F952	Tourette's disorder
F958	Other tic disorders
F959	Tic disorder, unspecified
F980	Enuresis not due to a substance or known physiological condition
F981	Encopresis not due to a substance or known physiological condition
F9821	Rumination disorder of infancy
F9829	Other feeding disorders of infancy and early childhood
F983	Pica of infancy and childhood
F984	Stereotyped movement disorders
F985	Adult onset fluency disorder
F988	Other specified behavioral and emotional disorders with onset usually occurring in childhood and adolescence
F989	Unspecified behavioral and emotional disorders with onset usually occurring in childhood and adolescence
F99	Mental disorder, not otherwise specified
G2561	Drug induced tics
R401	Stupor
R404	Transient alteration of awareness
R410	Disorientation, unspecified
R411	Anterograde amnesia
R412	Retrograde amnesia
R413	Other amnesia
R4182	Altered mental status, unspecified
R4189	Other symptoms and signs involving cognitive functions and awareness
R440	Auditory hallucinations
R441	Visual hallucinations
R442	Other hallucinations

R448 Other symptoms and signs involving general sensations and perceptions R450 Nervousness R451 Restlessness and agitation R452 Unhappiness R453 Demoralization and apathy R454 Iritability and anger R455 Violent behavior R457 State of emotional shock and stress, unspecified R4581 Low self-esteem R4581 Low self-esteem R4582 Wories R4583 Excessive crying of child, adolescent or adult R4584 Island self-stress R4583 Excessive crying of child, adolescent or adult R45851 Suicidal ideations R45853 Emotional lability R45851 Suicidal ideations R45853 Emotional lability R4585 Island self-personal appearance R4686 Diversory self-personal appearance R469 Other symptoms and signs involving emotional state R460 Undue concern and preoccupation with stressful events R460 Undue concern and preoccupation with stressful events R460 Undue concern and preoccupation with stressful events R4681 Obsessive-compulsive behavior R4690 Other symptoms and signs involving appearance and behavior R4690 Other symptoms and signs involving appearance and behavior R4690 Other symptoms and signs involving appearance and behavior R4691 Obsessive-compulsive behavior R4692 Obsessive-compulsive behavior R4693 Obsessive-compulsive behavior R4694 Obsessive-compulsive behavior R4695 Obsessive-compulsive behavior R4696 Obsessive-compulsive behavior R4697 Obsessive openations and signs involving appearance and behavior R4698 Obsessive-compulsive behavior R4698 Obsessive-compulsive behavior R4699 Obsessive-compulsive behavior R4690 Obsessive-compulsive behavior R4691 Obsessive openations and signs involving appearance and behavior R4690 Obsessive-compulsive behavior R4690	Code	Shortened Description
R450 Nervousness R451 Restlessness and agitation R452 Unhappiness R453 Demoralization and apathy R454 Irriability and anger R455 Hostility R456 Violent behavior R457 State of emotional shock and stress, unspecified R458 Low self-esteem R458 Low self-esteem R4581 Low self-esteem R4582 Worries R4583 Low self-esteem R4584 Anhedonia R4585 Anhedonia R4585 Homicidal ideations R4585 Emotional lability R4585 Emotional lability R4586 Emotional lability R4587 Suicidal ideations R4588 Emotional lability R4589 Ober symptoms and signs involving emotional state R4680 Emotional lability R4681 Signary and signs involving emotional state R4681 Low self-esteem R4682 Verreis R4683 Low self-esteem R4684 Coveractivity R4686 Emotional lability R4687 Verbesity and circumstantial detail disbecuring reason for contact R4680 Undue concern and procecupation with stressful events R4681 Obsessive-compulsive behavior R4689 Obsessive-compulsive scale and self-harm, initial encounter R4689 Dissoning by penicillins, intentional self-harm, subsequent encounter R4689 Poisoning by penicillins, intentional self-harm, subsequent encounter R4680 Poisoning by colonal proportions and other beta-lactam antibiotics, intentional self-harm, sequela R4680 Poisoning by terracyclines, intentional self-harm, subsequent encounter R4680 Poisoning by terracyclines		*
R451 Restlessness and agitation R452 Unhappiness R453 Demoralization and apathy R454 Iriability and anger R455 Hostility R456 Violent behavior R457 State of emotional shock and stress, unspecified R4581 Low self-esteem R4582 Worries R4583 Excessive crying of child, adolescent or adult R4584 Anhedonia R4585 Iliomicidal ideations R4585 Iliomicidal ideations R4585 Iliomicidal ideations R4585 Unionicidal ideations R4585 Iliomicidal ideations R4585 Iliomicidal ideations R4585 Iliomicidal ideations R4586 Iliomicidal ideations R4587 Impulsiveness R4588 Other symptoms and signs involving emotional state R468 Iliomicidal ideations R4686 Coveractivity R4681 Suspiciousness and marked evasiveness R460 Undue concern and procecupation with stressful events R461 Verbosity and circumstantial detail obscuring reason for contact R4680 Obsessive-compulsive behavior R4681 Obsessive-compulsive behavior R4680 Obsessive-compulsive behavior R4681 Obsessive-compulsive behavior R4682 Obsessive-compulsive behavior R4683 Obsessive-compulsive behavior R4684 Obsessive-compulsive behavior R4684 Obsessive-compulsive behavior R4685 Obsessive-compulsive behavior R4686 Obsessive-compulsive behavior R4687 Verbosity and circumstantial off-larm, initial encounter R4688 Obsessive-compulsive behavior R4689 Obsessive-compulsive deviation of the state and the state of the state of		
R451 Restlessness and agitation R452 Unhappiness R453 Demoralization and apathy R454 Iritability and anger R455 Hostility R456 Violent behavior R457 State of emotional shock and stress, unspecified R4581 Low self-esteen R4582 Worries R4583 Low self-esteen R4584 Anhedonia R4585 Stacessive crying of child, adolescent or adult R4585 Anhedonia R4585 Stacessive crying of child, adolescent or adult R4586 Anhedonia R4587 Anhedonia R4586 Emotional lability R4586 Emotional lability R4587 Impulsiveness R4580 Other symptoms and signs involving emotional state R4581 Size Stacessive crying of child, adolescent or adult R4586 Emotional lability R4587 Impulsiveness R4580 Other symptoms and signs involving emotional state R4681 Dizarre personal appearance R460 Undue concern and preoecupation with stressful events R461 Undue concern and preoecupation with stressful events R462 Strange and inexplicable behavior R463 Overactivity R4681 Obessive-compulsive behavior R4681 Obessive-compulsive behavior R4681 Obessive-compulsive behavior R4682 Other symptoms and signs involving appearance and behavior R4683 Other symptoms and signs involving appearance and behavior R469 Other symptoms and signs involving appearance and behavior R469 Obessive-compulsive behavior R460 O		
R452 Unhappiness R453 Demoralization and apathy R454 Irritability and anger R455 Hostility R456 Violent behavior R457 State of emotional shock and stress, unspecified R4581 Low self-esteem R4582 Worries R4583 Excessive crying of child, adolescent or adult R4584 Anhedonia R4585 Homicidal ideations R4585 State of emotional shock and stress, unspecified R4585 Excessive crying of child, adolescent or adult R4586 Homicidal ideations R4587 Inspulsiveness R4588 Emotional lability R4588 Impulsiveness R4588 Unbrief of the stress of the s		
R453 Demoralization and apathy R454 Irritability and anger R455 Hostility R456 Violent behavior R457 State of emotional shock and stress, unspecified R4581 Low self-esteem R4582 Worries R4583 Low self-esteem R4583 Excessive crying of child, adolescent or adult R4584 Anhedonia R4585 Bit of emotional shock and stress, unspecified R4585 Excessive crying of child, adolescent or adult R4586 Emotional lability R4585 Bit of emotional lability R4586 Emotional lability R4587 Impulsiveness R4588 Dither symptoms and signs involving emotional state R468 Bit of emotional lability R4680 Overactivity R461 Bit of emotional generations R462 Strange and inexplicable behavior R463 Overactivity R464 Undue concern and preoccupation with stressful events R467 Verbosity and circumstantial detail obscuring reason for contact R4681 Obsessive-compulsive behavior R4680 Obsessive-compulsive behavior R4681 Obsessive-compulsive behavior R4682 Other symptoms and signs involving appearance and behavior R4683 Obsessive-compulsive behavior R4684 Obsessive-compulsive behavior R4685 Obsessive-compulsive behavior R4686 Obsessive-compulsive behavior R4687 Obsessive-compulsive behavior R4688 Obsessive-compulsive behavior R4689 Other symptoms and signs involving appearance and behavior R4689 Obsessive-compulsive behavior R4680 Obsessive-compulsive behavior R4681 Obsessive-compulsive behavior R4682 Obsoincing by penicillins, intentional self-harm, subsequent encounter R4690 Obsoining by penicillins, intentional self-harm, subsequent encounter R4600 Obsoining by penicillins, intentional self-harm, subsequent encounter R4600 Obsoining by cephalosporins and other beta-lactam antibiotics, intentional self-harm, subsequent encounter R4600 Obsoining by emplaced proup, intentional self-harm, initial encounter R4600 Obsoining by emplaced proup intentional self-harm, initial encounter R4600 Obsoining by macrolides, intentional self-harm, initial encounter R4600 Obso		
R454   Irritability and anger R455   Hostility R457   State of emotional shock and stress, unspecified R4581   Low self-esteem R4582   Worries R4583   Excessive crying of child, adolescent or adult R4581   Anhedonia R4583   Anhedonia R4583   Suicidal ideations R4585   Homicidal ideations R4585   Minerial ideations R4585   Minerial ideations R4586   Homicidal ideations R4587   Impulsiveness R4588   Coversiveness R4589   Other symptoms and signs involving emotional state R461   Bizarre personal appearance R462   Strange and inexplicable behavior R463   Overactivity R465   Suspiciousness and marked evasiveness R466   Undue concern and procecupation with stressful events R467   Verbosity and circumstantial datali obscuring reason for contact R4680   Obsessive-compulsive behavior R4681   Obsessive-compulsive behavior R4689   Other symptoms and signs involving appearance and behavior R4681   Obsessive-compulsive behavior R4689   Other symptoms and signs involving appearance and behavior R469   Other symptoms and signs involving appearance and behavior R469   Other symptoms and signs involving appearance and behavior R469   Other symptoms and signs involving appearance and behavior R469   Other symptoms and signs involving appearance and behavior R469   Other symptoms and signs involving appearance and behavior R469   Other symptoms and signs involving appearance and behavior R469   Other symptoms and signs involving appearance and behavior R469   Other symptoms and signs involving appearance and behavior R469   Other symptoms and signs involving appearance and behavior R469   Other symptoms and signs involving appearance and behavior R469   Other symptoms and signs involving appearance and behavior R469   Other symptoms and signs involving appearance and behavior R469   Other symptoms and signs involving appearance and behavior R469   Other symptoms and signs involving appearance and behavior R469   Other symptoms and signs involving appearance and behavior R469   Other symptoms and signs involving appearance and beh		**
R455 Violent behavior R4561 Violent behavior R457 State of emotional shock and stress, unspecified R4581 Low self-esteem R4583 Excessive crying of child, adolescent or adult R4583 Excessive crying of child, adolescent or adult R4584 Anhedonia R4585 Homicidal ideations R4585 Excessive sping of child, adolescent or adult R4586 Emotional lability R4587 Impulsiveness R4588 Discidal ideations R4588 Emotional lability R4587 Impulsiveness R4589 Other symptoms and signs involving emotional state R461 Bizarre personal appearance R462 Strange and inexplicable behavior R463 Overactivity R465 Suspiciousness and marked evasiveness R466 Undue concern and preoccupation with stressful events R467 Verbosity and circumstantial detail obscuring reason for contact R4681 Obsessive-compulsive behavior R4680 Other symptoms and signs involving appearance and behavior R4681 Obsessive-compulsive behavior R4680 Other symptoms and signs involving appearance and behavior R4681 Sucicide attempt, initial encounter R469 Other symptoms and signs involving appearance and behavior R469 Other symptoms and signs involving appearance and behavior R469 Poisoning by penicillins, intentional self-harm, initial encounter R460X2A Poisoning by penicillins, intentional self-harm, subsequent encounter R460X2B Poisoning by penicillins, intentional self-harm, sequela R460X2B Poisoning by cephalosporins and other beta-lactam antibiotics, intentional self-harm, subsequent encounter R461X2B Poisoning by chloramphenicol group, intentional self-harm, initial encounter R461X2B Poisoning by chloramphenicol group, intentional self-harm, subsequent encounter R461X2B Poisoning by thoramphenicol group, intentional self-harm, subsequent encounter R461X2B Poisoning by thoramphenicol group, intentional self-harm, subsequent encounter R461X2B Poisoning by chloramphenicol group, intentional self-harm, subsequent encounter R461X2B Poisoning by macrolides, intentional self-harm, subsequent encounter R461X2B Poisoning by macrolides, intentional self-harm, subsequent encounter		1 1
R456   Violent behavior R457   State of emotional shock and stress, unspecified R4581   Low self-siteem R4582   Worries R4582   Worries R4583   Excessive crying of child, adolescent or adult R4584   Anhedonia R45850   Homicidal ideations R45850   Suicidal ideations R4586   Emotional lability R4587   Impulsiveness R4588   Other symptoms and signs involving emotional state R461   Bizarre personal appearance R462   Strange and inexplicable behavior R463   Overactivity   R464   Overactivity   R465   Suspiciousness and marked evasiveness R460   Undue concern and preoccupation with stressful events R461   Obsessive-compulsive behavior R462   Verbosity and circumstantial detail obscuring reason for contact R463   Obsessive-compulsive behavior R4640   Obsessive-compulsive behavior R4651   Obsessive-compulsive behavior R4661   Obsessive-compulsive behavior R4662   Obsessive-compulsive behavior R4689   Other symptoms and signs involving appearance and behavior R4691   Obsessive-compulsive behavior R4690   Other symptoms and signs involving appearance and behavior R4691   Obsessive-compulsive behavior R4692   Obsessive-compulsive behavior R4693   Obsessive-compulsive behavior R4694   Obsessive-compulsive behavior R4699   Obsessive-compulsive behavior R4690   Obsessive-compulsive behavior R4691   Obsessive-compulsive behavior R4691   Obsessive-compulsive behavior R4691   Obsessive-compulsive behavior R4691   Obsessive-compulsive behavior R4690   Obsessive-compulsive behavior R4691   Obsessive-compulsive behavior R4690   Obsessive-compulsi		, c
R457   State of emotional shock and stress, unspecified R4581   Low self-esteem R4582   Worries R4583   Excessive crying of child, adolescent or adult R4584   Anhedonia R45854   Homicidal ideations R4585   Suicidal ideations R4585   Suicidal ideations R4586   Emotional lability R4586   Emotional lability R4587   Impulsiveness R4588   Impulsiveness R4589   Other symptoms and signs involving emotional state R461   Bizarre personal appearance R462   Strange and inexplicable behavior R463   Overactivity R465   Suspiciousness and marked evasiveness R466   Undue concern and preoccupation with stressful events R467   Verbosity and circumstantial detail obscuring reason for contact R468   Obsessive-compulsive behavior R4689   Other symptoms and signs involving appearance and behavior R4689   Other symptoms and signs involving appearance and behavior R4689   Other symptoms and signs involving appearance and behavior R4689   Suicide attempt, initial encounter R4680   Suicide attempt, initial encounter R469   Poisoning by penicillins, intentional self-harm, subsequent encounter R460   Poisoning by pepicillins, intentional self-harm, subsequent encounter R460   Poisoning by pepicillins, intentional self-harm, subsequent encounter R460   Poisoning by cephalosporins and other beta-lactam antibiotics, intentional self-harm, initial encounter R461   Poisoning by cephalosporins and other beta-lactam antibiotics, intentional self-harm, sequela R461   Poisoning by cephalosporins and other beta-lactam antibiotics, intentional self-harm, sequela R461   Poisoning by macrolides, intentional self-harm, subsequent encounter R461   Poisoning by macrolides, intentional self-harm, subsequent encounter R461   Poisoning by macrolides, intentional self-harm, initial encounter R461   Poisoning by macrolides, intentional self-harm, subsequent encounter R461   Poisoning by macrolides, intentional self-harm, subsequent encounter R461   Poisoning by macrolides, intentional self-harm, subsequent encounter R461   Poisoning by macrolides, intentiona		·
R4581 Low self-esteem R4582 Wories R4583 Excessive crying of child, adolescent or adult R4583 (Anhedonia Anhedonia Anhedonia R45850) Homicidal ideations R45851 Suicidal ideations R45851 Suicidal ideations R4586 Emotional lability R4587 Impulsiveness R4589 Other symptoms and signs involving emotional state R461 Bizarre personal appearance R462 Strange and inexplicable behavior R463 Overactivity R463 Overactivity R465 Suspiciousness and marked evasiveness R466 Undue concern and preoccupation with stressful events R467 Verbosity and circumstantial detail obscuring reason for contact R4681 Obsessive-compulsive behavior R4681 Obsessive-compulsive behavior R4682 Other symptoms and signs involving appearance and behavior R4683 Other symptoms and signs involving appearance and behavior R4689 Other symptoms and signs involving appearance and behavior R4689 Other symptoms and signs involving appearance and behavior R4689 Other symptoms and signs involving appearance and behavior R469 Other symptoms and signs involving appearance and behavior R469 Other symptoms and signs involving appearance and behavior R469 Other symptoms and signs involving appearance and behavior R469 Other symptoms and signs involving appearance and behavior R469 Other symptoms and signs involving appearance and behavior R4610 Obsessive-compulsive behavior R4610 Obsessive periodilins, intentional self-harm, subsequent encounter R4611 Obsing by penicillins, intentional self-harm, subsequent encounter R4611 Obsing by penicillins, intentional self-harm, sequela R4612 Poisoning by cephalosporins and other beta-lactam antibiotics, intentional self-harm, sequela R4612 Poisoning by cephalosporins and other beta-lactam antibiotics, intentional self-harm, sequela R4612 Poisoning by penicolides, intentional self-harm, subsequent encounter R4612 Poisoning by macrolides, intentional self-harm, subsequent encounter R4612 Poisoning by macrolides, intentional self-harm, initial encounter R4612 Poisoning by macrolides, intentional self-harm, subsequent encounter R4		
R4582 Worries R4583 Excessive crying of child, adolescent or adult R4584 Anhedonia R45850 Homicidal ideations R45851 Suicidal ideations R45851 Suicidal ideations R45851 Suicidal ideations R4587 Impulsiveness R4589 Other symptoms and signs involving emotional state R4680 Emotional lability R4587 Impulsiveness R4589 Other symptoms and signs involving emotional state R461 Bizarre personal appearance R462 Strange and inexplicable behavior R463 Overactivity R465 Suspiciousness and marked evasiveness R466 Unduc concern and preoccupation with stressful events R467 Verbosity and circumstantial detail obscuring reason for contact R4681 Obsessive-compulsive behavior R4689 Other symptoms and signs involving appearance and behavior R4689 Other symptoms and signs involving appearance and behavior R4689 Suicide attempt, initial encounter R4691 Suicide attempt, sequela R360X2A Poisoning by penicillins, intentional self-harm, initial encounter R460X2D Poisoning by penicillins, intentional self-harm, subsequent encounter R361X2D Poisoning by penicillins, intentional self-harm, sequela R361X2A Poisoning by cephalosporins and other beta-lactam antibiotics, intentional self-harm, subsequent encounter R361X2D Poisoning by cephalosporins and other beta-lactam antibiotics, intentional self-harm, sequela R362X2A Poisoning by chloramphenicol group, intentional self-harm, subsequent encounter R363X2A Poisoning by macrolides, intentional self-harm, initial encounter R363X2D Poisoning by macrolides, intentional self-harm, subsequent encounter R363X2D Poisoning by macrolides, intentional self-harm, initial encounter R363X2A Poisoning by macrolides, intentional self-harm, initial encounter R363X2A Poisoning by macrolides, intentional self-harm, initial encounter R363X2A Poisoning by macrolides, intentional self-harm, subsequent encounter R365X2A Poisoning by rifampicins, intentional self-harm, initial encounter R365X2A Poisoning by rifampicins, intentional self-harm, intial encounter R365X2A Poisoning by rifampicins, intentional self-harm,		
R4583         Excessive crying of child, adolescent or adult           R4584         Anhedonia           R45851         Homicidal ideations           R45851         Suicidal ideations           R45851         Impulsiveness           R4587         Impulsiveness           R4587         Impulsiveness           R4589         Other symptoms and signs involving emotional state           R461         Bizarre personal appearance           R462         Strange and inexplicable behavior           R463         Overactivity           R464         Undue concern and preoccupation with stressful events           R467         Verbosity and circumstantial detail obscuring reason for contact           R4681         Obsessive-compulsive behavior           R4682         Other symptoms and signs involving appearance and behavior           T1491XA         Suicide attempt, initial encounter           T1491XD         Suicide attempt, subsequent encounter           T1491XD         Suicide attempt, sequela           T360X2A         Poisoning by penicillins, intentional self-harm, initial encounter           T360X2A         Poisoning by penicillins, intentional self-harm, sequela           T361X2A         Poisoning by cphalosporins and other beta-lactam antibiotics, intentional self-harm, subsequent encounter     <		
R4584         Anhedonia           R45850         Homiculal ideations           R45851         Suicidal ideations           R4586         Emotional lability           R4587         Impulsiveness           R4589         Other symptoms and signs involving emotional state           R461         Bizarre personal appearance           R462         Strange and inexplicable behavior           R463         Overactivity           R465         Suspiciousness and marked evasiveness           R466         Undue concern and procecupation with stressful events           Verbosity and circumstantial detail obscuring reason for contact           R467         Verbosity and circumstantial detail obscuring reason for contact           R4681         Obsessive-compulsive behavior           R4682         Other symptoms and signs involving appearance and behavior           T1491XD         Suicide attempt, subsequent encounter           T1491XS         Suicide attempt, subsequent encounter           T360X2A         Poisoning by penicillins, intentional self-harm, subsequent encounter           T360X2D         Poisoning by penicillins, intentional self-harm, subsequent encounter           T361X2A         Poisoning by cephalosporins and other beta-lactam antibiotics, intentional self-harm, sequela           T361X2A         Poison		
R45850 Homicidal ideations R45851 Sucidal ideations R45861 Emotional lability R4587 Impulsiveness R4589 Other symptoms and signs involving emotional state R461 Bizarre personal appearance R462 Strange and inexplicable behavior R463 Overactivity R465 Suspiciousness and marked evasiveness R466 Undue concern and preoccupation with stressful events R467 Verbosity and circumstantial detail obscuring reason for contact R4681 Obsessive-compulsive behavior R4689 Other symptoms and signs involving appearance and behavior R4689 Other symptoms and signs involving appearance and behavior R4689 Other symptoms and signs involving appearance and behavior R4689 Suicide attempt, initial encounter R4689 Suicide attempt, subsequent encounter R4689 Suicide attempt, subsequent encounter R4689 Suicide attempt, sequela R36022A Poisoning by penicillins, intentional self-harm, initial encounter R36022D Poisoning by penicillins, intentional self-harm, subsequent encounter R36022D Poisoning by penicillins, intentional self-harm, subsequent encounter R3612AD Poisoning by eephalosporins and other beta-lactam antibiotics, intentional self-harm, subsequent encounter R3612AD Poisoning by eephalosporins and other beta-lactam antibiotics, intentional self-harm, subsequent encounter R3622AD Poisoning by echphalosporins and other beta-lactam antibiotics, intentional self-harm, subsequent encounter R3622AD Poisoning by cephalosporins and other beta-lactam antibiotics, intentional self-harm, sequela R3632AD Poisoning by chloramphenicol group, intentional self-harm, initial encounter R3622AD Poisoning by phoreamphenicol group, intentional self-harm, subsequent encounter R3632AD Poisoning by macrolides, intentional self-harm, subsequent encounter R3632AD Poisoning by macrolides, intentional self-harm, initial encounter R3632AD Poisoning by macrolides, intentional self-harm, subsequent encounter R3642AD Poisoning by aminoglycosides, intentional self-harm, subsequent encounter R3642AD Poisoning by aminoglycosides, intentional self-harm, subsequent enco		
R45851 Suicidal ideations R4586 Emotional lability R4587 Impulsiveness R4589 Other symptoms and signs involving emotional state R461 Bizarre personal appearance R462 Strange and inexplicable behavior R463 Overactivity R465 Suspiciousness and marked evasiveness R466 Undue concern and preoccupation with stressful events R467 Verbosity and circumstantial detail obscuring reason for contact R4681 Obsessive-compulsive behavior R4689 Other symptoms and signs involving appearance and behavior T1491XD Suicide attempt, initial encounter T1491XD Suicide attempt, subsequent encounter T1491XD Suicide attempt, subsequent encounter T1491XD Poisoning by penicillins, intentional self-harm, initial encounter T360X2D Poisoning by penicillins, intentional self-harm, subsequent encounter T360X2D Poisoning by penicillins, intentional self-harm, sequela T361X2A Poisoning by ephalosporins and other beta-lactam antibiotics, intentional self-harm, subsequent encounter T361X2D Poisoning by ephalosporins and other beta-lactam antibiotics, intentional self-harm, sequela T362X2A Poisoning by cephalosporins and other beta-lactam antibiotics, intentional self-harm, sequela T362X2A Poisoning by chloramphenicol group, intentional self-harm, initial encounter T362X2A Poisoning by chloramphenicol group, intentional self-harm, sequela T362X2D Poisoning by chloramphenicol group, intentional self-harm, sequela T363X2A Poisoning by macrolides, intentional self-harm, subsequent encounter T363X2D Poisoning by macrolides, intentional self-harm, subsequent encounter T363X2D Poisoning by macrolides, intentional self-harm, subsequent encounter T364X2B Poisoning by macrolides, intentional self-harm, sequela T365X2A Poisoning by tetracyclines, intentional self-harm, sequela T365X2A Poisoning by aminoglycosides, intentional self-harm, sequela T365X2D Poisoning by aminoglycosides, intentional self-harm, subsequent encounter T365X2D Poisoning by aminoglycosides, intentional self-harm, subsequent encounter T365X2A Poisoning by rifampicins, intentional self-harm		
R4586 Emotional lability R4587 Impulsiveness R4589 Other symptoms and signs involving emotional state R461 Bizarre personal appearance R462 Strange and inexplicable behavior R463 Overactivity R465 Suspiciousness and marked evasiveness R466 Undue concern and procecupation with stressful events R467 Verbosity and circumstantial detail obscuring reason for contact R4681 Obsessive-compulsive behavior R4689 Other symptoms and signs involving appearance and behavior R4689 Other symptoms and signs involving appearance and behavior R4689 Other symptoms and signs involving appearance and behavior R4681 Suicide attempt, initial encounter R4681 Suicide attempt, subsequent encounter R4682 Obsessive-compulsive behavior R4683 Obsessive-compulsive behavior R4684 Obsessive-compulsive behavior R4685 Other symptoms and signs involving appearance and behavior R4686 Undue tempt, subsequent encounter R4681 Suicide attempt, subsequent encounter R4682 Suicide attempt, subsequent encounter R4682 Poisoning by penicillins, intentional self-harm, initial encounter R4683 Poisoning by penicillins, intentional self-harm, sequela R4684 Poisoning by eephalosporins and other beta-lactam antibiotics, intentional self-harm, subsequent encounter R4684 Poisoning by eephalosporins and other beta-lactam antibiotics, intentional self-harm, sequela R4684 Poisoning by cephalosporins and other beta-lactam antibiotics, intentional self-harm, sequela R4684 Poisoning by cephalosporins and other beta-lactam antibiotics, intentional self-harm, sequela R4684 Poisoning by cephalosporins and other beta-lactam antibiotics, intentional self-harm, sequela R4684 Poisoning by cephalosporins and other beta-lactam antibiotics, intentional self-harm, sequela R4684 Poisoning by cephalosporins and other beta-lactam antibiotics, intentional self-harm, sequela R4684 Poisoning by macrolides, intentional self-harm, subsequent encounter R4684 Poisoning by macrolides, intentional self-harm, subsequent encounter R4684 Poisoning by macrolides, intentional self-harm, subsequent e		
R4587 Impulsiveness R4589 Other symptoms and signs involving emotional state R461 Bizarre personal appearance R462 Strange and inexplicable behavior R463 Overactivity R465 Suspiciousness and marked evasiveness R466 Undue concern and preoccupation with stressful events R467 Verbosity and circumstantial detail obscuring reason for contact R4681 Obsessive-compulsive behavior R4681 Obsessive-compulsive behavior R4681 Obsessive-compulsive behavior R4681 Suicide attempt, sinitial encounter R4682 Other symptoms and signs involving appearance and behavior R4683 Suicide attempt, sequela R4684 Suicide attempt, sequela R4685 Suicide attempt, sequela R4686 Suicide attempt, sequela R4686 Poisoning by penicillins, intentional self-harm, initial encounter R4687 Poisoning by penicillins, intentional self-harm, subsequent encounter R4688 Poisoning by penicillins, intentional self-harm, sequela R4689 Poisoning by cephalosporins and other beta-lactam antibiotics, intentional self-harm, subsequent encounter R461828 Poisoning by chloramphenicol group, intentional self-harm, initial encounter R461828 Poisoning by chloramphenicol group, intentional self-harm, subsequent encounter R461828 Poisoning by macrolides, intentional self-harm, subsequent encounter R461828 Poisoning by tetracyclines, intentional self-harm, subsequent encounter R461828 Poisoning by tetracyclines, intentional self-harm, sequela R461828 Poisoning by aminoglycosides, intentional self-harm, subsequent encounter R461828 Poisoning by aminoglycosides, intentional self-harm, subsequent encounter R461828 Poisoning by aminoglycosides, intentional self-harm, subsequent encounter R461828 Poisoning by rifampicins, intentional self-harm, subsequent encounter R461828 Poisoning by rifampicins, intentional self-harm, subsequent encounter R461828 Poisoning by rifampicins, intentional self-harm, subsequent encounte		
R4589 Other symptoms and signs involving emotional state R461 Bizarre personal appearance R462 Strange and inexplicable behavior R463 Overactivity R465 Suspiciousness and marked evasiveness R466 Undue concern and preoccupation with stressful events R467 Verbosity and circumstantial detail obscuring reason for contact R4681 Obsessive-compulsive behavior R4689 Other symptoms and signs involving appearance and behavior T1491XA Suicide attempt, initial encounter T1491XS Suicide attempt, subsequent encounter T1491XS Suicide attempt, sequela T360X2A Poisoning by penicillins, intentional self-harm, initial encounter T360X2D Poisoning by penicillins, intentional self-harm, sequela T361X2A Poisoning by penicillins, intentional self-harm antibiotics, intentional self-harm, initial encounter T361X2D Poisoning by cephalosporins and other beta-lactam antibiotics, intentional self-harm, subsequent encounter T361X2D Poisoning by cephalosporins and other beta-lactam antibiotics, intentional self-harm, subsequent encounter T362X2A Poisoning by chloramphenicol group, intentional self-harm, subsequent encounter T362X2D Poisoning by chloramphenicol group, intentional self-harm, subsequent encounter T362X2D Poisoning by macrolides, intentional self-harm, subsequent encounter T363X2C Poisoning by macrolides, intentional self-harm, subsequent encounter T363X2D Poisoning by macrolides, intentional self-harm, initial encounter T363X2D Poisoning by tetracyclines, intentional self-harm, initial encounter T364X2A Poisoning by tetracyclines, intentional self-harm, subsequent encounter T364X2B Poisoning by amarolides, intentional self-harm, initial encounter T364X2B Poisoning by tetracyclines, intentional self-harm, subsequent encounter T365X2B Poisoning by aminoglycosides, intentional self-harm, subsequent encounter T365X2B Poisoning by aminoglycosides, intentional self-harm, subsequent encounter T365X2B Poisoning by aminoglycosides, intentional self-harm, subsequent encounter T365X2B Poisoning by rifampicins, intentional self-harm, subseq		· · · · · · · · · · · · · · · · · · ·
R461         Bizarre personal appearance           R462         Strange and inexplicable behavior           R463         Overactivity           R465         Suspiciousness and marked evasiveness           R466         Undue concern and proccupation with stressful events           R467         Verbosity and circumstantial detail obscuring reason for contact           R4689         Other symptoms and signs involving appearance and behavior           R1491XA         Suicide attempt, initial encounter           T1491XS         Suicide attempt, sequela           T360X2A         Poisoning by penicillins, intentional self-harm, initial encounter           T360X2D         Poisoning by penicillins, intentional self-harm, sequela           T361X2A         Poisoning by penicillins, intentional self-harm, sequela           T361X2A         Poisoning by cephalosporins and other beta-lactam antibiotics, intentional self-harm, subsequent encounter           T361X2D         Poisoning by cephalosporins and other beta-lactam antibiotics, intentional self-harm, sequela           T362X2D         Poisoning by cephalosporins and other beta-lactam antibiotics, intentional self-harm, sequela           T362X2D         Poisoning by chloramphenicol group, intentional self-harm, initial encounter           T362X2D         Poisoning by chloramphenicol group, intentional self-harm, sequela           T363X2A         Poisoning b		
R462 Strange and inexplicable behavior R463 Overactivity R465 Suspiciousness and marked evasiveness R466 Undue concern and preoccupation with stressful events R467 Verbosity and circumstantial detail obscuring reason for contact R4681 Obsessive-compulsive behavior R4689 Other symptoms and signs involving appearance and behavior T1491XB Suicide attempt, initial encounter T1491XB Suicide attempt, subsequent encounter T1491XB Suicide attempt, sequela T360X2A Poisoning by penicillins, intentional self-harm, initial encounter T360X2D Poisoning by penicillins, intentional self-harm, sequela P360X2S Poisoning by penicillins, intentional self-harm, sequela P361X2A Poisoning by ecphalosporins and other beta-lactam antibiotics, intentional self-harm, subsequent encounter T361X2D Poisoning by ecphalosporins and other beta-lactam antibiotics, intentional self-harm, sequela P361X2A Poisoning by ecphalosporins and other beta-lactam antibiotics, intentional self-harm, sequela P362X2A Poisoning by cephalosporins and other beta-lactam antibiotics, intentional self-harm, sequela P362X2D Poisoning by chloramphenicol group, intentional self-harm, initial encounter P363X2A Poisoning by chloramphenicol group, intentional self-harm, subsequent encounter P363X2B Poisoning by macrolides, intentional self-harm, subsequent encounter P363X2B Poisoning by macrolides, intentional self-harm, sequela P363X2D Poisoning by tetracyclines, intentional self-harm, sequela P363X2A Poisoning by tetracyclines, intentional self-harm, subsequent encounter P364X2B Poisoning by tetracyclines, intentional self-harm, subsequent encounter P365X2A Poisoning by aminoglycosides, intentional self-harm, subsequent encounter P365X2A Poisoning by aminoglycosides, intentional self-harm, subsequent encounter P365X2B Poisoning by aminoglycosides, intentional self-harm, subsequent encounter P365X2B Poisoning by rifampicins, intentional self-harm, subsequent encounter P365X2B Poisoning by rifampicins, intentional self-harm, subsequent encounter P366X2D Poisoning by rifa		
R463 Overactivity R465 Suspiciousness and marked evasiveness R466 Undue concern and preoccupation with stressful events R467 Verbosity and circumstantial detail obscuring reason for contact R4681 Obsessive-compulsive behavior R4689 Other symptoms and signs involving appearance and behavior T1491XA Suicide attempt, initial encounter T1491XB Suicide attempt, sequela T360X2A Poisoning by penicillins, intentional self-harm, initial encounter T360X2A Poisoning by penicillins, intentional self-harm, subsequent encounter T360X2D Poisoning by penicillins, intentional self-harm, subsequent encounter T361X2D Poisoning by cephalosporins and other beta-lactam antibiotics, intentional self-harm, subsequent encounter T361X2D Poisoning by cephalosporins and other beta-lactam antibiotics, intentional self-harm, subsequent encounter T362X2A Poisoning by cephalosporins and other beta-lactam antibiotics, intentional self-harm, subsequent encounter T362X2A Poisoning by chloramphenicol group, intentional self-harm, initial encounter T362X2B Poisoning by chloramphenicol group, intentional self-harm, subsequent encounter T363X2A Poisoning by macrolides, intentional self-harm, initial encounter T363X2A Poisoning by macrolides, intentional self-harm, sequela T363X2A Poisoning by macrolides, intentional self-harm, subsequent encounter T364X2B Poisoning by tetracyclines, intentional self-harm, subsequent encounter T364X2B Poisoning by tetracyclines, intentional self-harm, subsequent encounter T365X2B Poisoning by tetracyclines, intentional self-harm, subsequent encounter T365X2B Poisoning by tetracyclines, intentional self-harm, subsequent encounter T365X2B Poisoning by triampicines, intentional self-harm, subsequent encounter T365X2B Poisoning by rifampicines, intentional self-harm, subsequent encounter T365X2B Poisoning by rifampicines, intentional self-harm, subsequent encounter T365X2B Poisoning by rifampicins, intentional self-harm, subsequent encounter T365X2B Poisoning by rifampicins, intentional self-harm, sequela T365X2B Poisoni		1 11
R465         Suspiciousness and marked evasiveness           R466         Undue concern and preoccupation with stressful events           R467         Verbosity and circumstantial detail obscuring reason for contact           R4681         Obsessive-compulsive behavior           R4689         Other symptoms and signs involving appearance and behavior           T1491XA         Suicide attempt, initial encounter           T1491XD         Suicide attempt, subsequent encounter           T360X2A         Poisoning by penicillins, intentional self-harm, initial encounter           T360X2D         Poisoning by penicillins, intentional self-harm, subsequent encounter           T360X2D         Poisoning by penicillins, intentional self-harm, subsequent encounter           T361X2D         Poisoning by penicillins, intentional self-harm, subsequent           T361X2D         Poisoning by penicillins, intentional self-harm, sequela           T361X2D         Poisoning by cephalosporins and other beta-lactam antibiotics, intentional self-harm, subsequent encounter           T361X2D         Poisoning by cephalosporins and other beta-lactam antibiotics, intentional self-harm, sequela           T362X2D         Poisoning by chloramphenicol group, intentional self-harm, initial encounter           T362X2D         Poisoning by chloramphenicol group, intentional self-harm, sequela           T363X2A         Poisoning by macrolides, intentional self-harm,		Ü î
R466 Undue concern and preoccupation with stressful events R467 Verbosity and circumstantial detail obscuring reason for contact R4681 Obsessive-compulsive behavior R4681 Obsessive-compulsive behavior T1491XA Suicide attempt, initial encounter T1491XB Suicide attempt, subsequent encounter Suicide attempt, subsequent encounter T1491XB Suicide attempt, sequela T360X2A Poisoning by penicillins, intentional self-harm, initial encounter T360X2D Poisoning by penicillins, intentional self-harm, subsequent encounter T360X2D Poisoning by penicillins, intentional self-harm, sequela T361X2A Poisoning by cephalosporins and other beta-lactam antibiotics, intentional self-harm, initial encounter T361X2D Poisoning by cephalosporins and other beta-lactam antibiotics, intentional self-harm, subsequent encounter T361X2A Poisoning by cephalosporins and other beta-lactam antibiotics, intentional self-harm, sequela T362X2A Poisoning by chloramphenicol group, intentional self-harm, initial encounter T362X2D Poisoning by chloramphenicol group, intentional self-harm, subsequent encounter T362X2S Poisoning by macrolides, intentional self-harm, subsequent encounter T363X2A Poisoning by macrolides, intentional self-harm, subsequent encounter T363X2D Poisoning by macrolides, intentional self-harm, subsequent encounter T364X2A Poisoning by macrolides, intentional self-harm, subsequent encounter T364X2A Poisoning by tetracyclines, intentional self-harm, subsequent encounter T364X2B Poisoning by tetracyclines, intentional self-harm, initial encounter T365X2B Poisoning by tetracyclines, intentional self-harm, subsequent encounter T365X2B Poisoning by aminoglycosides, intentional self-harm, subsequent encounter T365X2B Poisoning by rifampicins, intentional self-harm, initial encounter T365X2B Poisoning by rifampicins, intentional self-harm, initial encounter T365X2B Poisoning by rifampicins, intentional self-harm, subsequent encounter T365X2B Poisoning by rifampicins, intentional self-harm, subsequent encounter T366X2B Poisoning by rifampicins		
R467         Verbosity and circumstantial detail obscuring reason for contact           R4681         Obsessive-compulsive behavior           R4689         Other symptoms and signs involving appearance and behavior           T1491XA         Suicide attempt, initial encounter           T1491XD         Suicide attempt, subsequent encounter           T360X2A         Poisoning by penicillins, intentional self-harm, initial encounter           T360X2D         Poisoning by penicillins, intentional self-harm, subsequent encounter           T360X2A         Poisoning by penicillins, intentional self-harm, subsequent encounter           T360X2B         Poisoning by penicillins, intentional self-harm, subsequent encounter           T361X2A         Poisoning by penicillins, intentional self-harm, sequela           T361X2D         Poisoning by cephalosporins and other beta-lactam antibiotics, intentional self-harm, subsequent encounter           T361X2B         Poisoning by cephalosporins and other beta-lactam antibiotics, intentional self-harm, sequela           T362X2D         Poisoning by chloramphenicol group, intentional self-harm, initial encounter           T362X2D         Poisoning by chloramphenicol group, intentional self-harm, sequela           T363X2D         Poisoning by macrolides, intentional self-harm, subsequent encounter           T363X2D         Poisoning by macrolides, intentional self-harm, subsequent encounter           T364X2A <td></td> <td>1</td>		1
R4681         Obsessive-compulsive behavior           R4689         Other symptoms and signs involving appearance and behavior           T1491XD         Suicide attempt, initial encounter           T1491XS         Suicide attempt, subsequent encounter           T360X2A         Poisoning by penicillins, intentional self-harm, initial encounter           T360X2D         Poisoning by penicillins, intentional self-harm, subsequent encounter           T360X2D         Poisoning by penicillins, intentional self-harm, subsequent encounter           T361X2A         Poisoning by penicillins, intentional self-harm, sequela           T361X2D         Poisoning by eephalosporins and other beta-lactam antibiotics, intentional self-harm, subsequent encounter           T361X2D         Poisoning by cephalosporins and other beta-lactam antibiotics, intentional self-harm, sequela           T362X2A         Poisoning by chloramphenicol group, intentional self-harm, initial encounter           T362X2A         Poisoning by chloramphenicol group, intentional self-harm, sequela           T363X2D         Poisoning by macrolides, intentional self-harm, initial encounter           T363X2D         Poisoning by macrolides, intentional self-harm, sequela           T364X2A         Poisoning by macrolides, intentional self-harm, subsequent encounter           T364X2A         Poisoning by tetracyclines, intentional self-harm, subsequent encounter           T365X2A		
R4689         Other symptoms and signs involving appearance and behavior           T1491XA         Suicide attempt, initial encounter           T1491XB         Suicide attempt, subsequent encounter           T360X2A         Poisoning by penicillins, intentional self-harm, initial encounter           T360X2D         Poisoning by penicillins, intentional self-harm, subsequent encounter           T360X2D         Poisoning by penicillins, intentional self-harm, sequela           T361X2A         Poisoning by cephalosporins and other beta-lactam antibiotics, intentional self-harm, initial encounter           T361X2D         Poisoning by cephalosporins and other beta-lactam antibiotics, intentional self-harm, subsequent encounter           T361X2D         Poisoning by cephalosporins and other beta-lactam antibiotics, intentional self-harm, sequela           T361X2D         Poisoning by chloramphenicol group, intentional self-harm, initial encounter           T362X2D         Poisoning by chloramphenicol group, intentional self-harm, sequela           T363X2A         Poisoning by macrolides, intentional self-harm, subsequent encounter           T363X2D         Poisoning by macrolides, intentional self-harm, subsequent encounter           T364X2A         Poisoning by macrolides, intentional self-harm, subsequent encounter           T364X2B         Poisoning by tetracyclines, intentional self-harm, initial encounter           T365X2A         Poisoning by atminoglycosides, int		·
T1491XA         Suicide attempt, subsequent encounter           T1491XB         Suicide attempt, subsequent encounter           T360X2A         Poisoning by penicillins, intentional self-harm, initial encounter           T360X2B         Poisoning by penicillins, intentional self-harm, subsequent encounter           T360X2B         Poisoning by penicillins, intentional self-harm, subsequent encounter           T361X2A         Poisoning by cephalosporins and other beta-lactam antibiotics, intentional self-harm, initial encounter           T361X2D         Poisoning by cephalosporins and other beta-lactam antibiotics, intentional self-harm, subsequent encounter           T361X2B         Poisoning by cephalosporins and other beta-lactam antibiotics, intentional self-harm, subsequent encounter           T361X2B         Poisoning by cephalosporins and other beta-lactam antibiotics, intentional self-harm, sequela           T362X2A         Poisoning by cephalosporins and other beta-lactam antibiotics, intentional self-harm, sequela           T362X2A         Poisoning by chloramphenicol group, intentional self-harm, subsequent encounter           T362X2A         Poisoning by chloramphenicol group, intentional self-harm, sequela           T363X2A         Poisoning by macrolides, intentional self-harm, subsequent encounter           T363X2B         Poisoning by macrolides, intentional self-harm, subsequent encounter           T364X2A         Poisoning by tetracyclines, intentional self-harm, sequela </td <td></td> <td></td>		
T1491XD         Suicide attempt, sequela           T360X2A         Poisoning by penicillins, intentional self-harm, initial encounter           T360X2D         Poisoning by penicillins, intentional self-harm, subsequent encounter           T360X2S         Poisoning by penicillins, intentional self-harm, subsequent encounter           T361X2A         Poisoning by cephalosporins and other beta-lactam antibiotics, intentional self-harm, initial encounter           T361X2D         Poisoning by cephalosporins and other beta-lactam antibiotics, intentional self-harm, subsequent encounter           T361X2S         Poisoning by cephalosporins and other beta-lactam antibiotics, intentional self-harm, sequela           T362X2A         Poisoning by chloramphenicol group, intentional self-harm, initial encounter           T362X2D         Poisoning by chloramphenicol group, intentional self-harm, sequela           T363X2A         Poisoning by macrolides, intentional self-harm, initial encounter           T363X2A         Poisoning by macrolides, intentional self-harm, subsequent encounter           T363X2D         Poisoning by macrolides, intentional self-harm, sequela           T363X2D         Poisoning by tetracyclines, intentional self-harm, subsequent encounter           T364X2A         Poisoning by tetracyclines, intentional self-harm, subsequent encounter           T365X2A         Poisoning by aminoglycosides, intentional self-harm, sequela           T365X2B         Poison		
T1491XS         Suicide attempt, sequela           T360X2A         Poisoning by penicillins, intentional self-harm, subsequent encounter           T360X2B         Poisoning by penicillins, intentional self-harm, subsequent encounter           T360X2S         Poisoning by penicillins, intentional self-harm, subsequent encounter           T361X2A         Poisoning by cephalosporins and other beta-lactam antibiotics, intentional self-harm, subsequent encounter           T361X2D         Poisoning by cephalosporins and other beta-lactam antibiotics, intentional self-harm, subsequent encounter           T361X2A         Poisoning by chloramphenicol group, intentional self-harm, initial encounter           T362X2A         Poisoning by chloramphenicol group, intentional self-harm, subsequent encounter           T362X2B         Poisoning by chloramphenicol group, intentional self-harm, sequela           T363X2A         Poisoning by macrolides, intentional self-harm, initial encounter           T363X2D         Poisoning by macrolides, intentional self-harm, subsequent encounter           T363X2D         Poisoning by macrolides, intentional self-harm, sequela           T364X2A         Poisoning by tetracyclines, intentional self-harm, subsequent encounter           T364X2B         Poisoning by tetracyclines, intentional self-harm, sequela           T365X2A         Poisoning by aminoglycosides, intentional self-harm, sequela           T365X2B         Poisoning by marrolides, in		
T360X2APoisoning by penicillins, intentional self-harm, initial encounterT360X2DPoisoning by penicillins, intentional self-harm, subsequent encounterT360X2SPoisoning by penicillins, intentional self-harm, sequelaT361X2APoisoning by cephalosporins and other beta-lactam antibiotics, intentional self-harm, subsequent encounterT361X2DPoisoning by cephalosporins and other beta-lactam antibiotics, intentional self-harm, subsequent encounterT361X2SPoisoning by cephalosporins and other beta-lactam antibiotics, intentional self-harm, subsequent encounterT362X2APoisoning by chloramphenicol group, intentional self-harm, initial encounterT362X2DPoisoning by chloramphenicol group, intentional self-harm, subsequent encounterT363X2APoisoning by macrolides, intentional self-harm, initial encounterT363X2DPoisoning by macrolides, intentional self-harm, subsequent encounterT363X2SPoisoning by macrolides, intentional self-harm, sequelaT364X2APoisoning by tetracyclines, intentional self-harm, subsequent encounterT364X2BPoisoning by tetracyclines, intentional self-harm, subsequent encounterT365X2APoisoning by aminoglycosides, intentional self-harm, subsequent encounterT365X2BPoisoning by aminoglycosides, intentional self-harm, subsequent encounterT365X2BPoisoning by aminoglycosides, intentional self-harm, subsequent encounterT365X2BPoisoning by minoglycosides, intentional self-harm, sequelaT366X2BPoisoning by rifampicins, intentional self-harm, subsequent encounterT366X2BPoisoning by rifampicins, intentional self-harm, subsequent e		* *
T360X2DPoisoning by penicillins, intentional self-harm, subsequent encounterT360X2SPoisoning by penicillins, intentional self-harm, sequelaT361X2APoisoning by cephalosporins and other beta-lactam antibiotics, intentional self-harm, initial encounterT361X2DPoisoning by cephalosporins and other beta-lactam antibiotics, intentional self-harm, subsequent encounterT361X2SPoisoning by cephalosporins and other beta-lactam antibiotics, intentional self-harm, subsequent encounterT362X2APoisoning by chloramphenicol group, intentional self-harm, initial encounterT362X2DPoisoning by chloramphenicol group, intentional self-harm, subsequent encounterT363X2APoisoning by macrolides, intentional self-harm, initial encounterT363X2DPoisoning by macrolides, intentional self-harm, subsequent encounterT363X2BPoisoning by macrolides, intentional self-harm, sequelaT364X2APoisoning by tetracyclines, intentional self-harm, initial encounterT364X2BPoisoning by tetracyclines, intentional self-harm, subsequent encounterT364X2BPoisoning by tetracyclines, intentional self-harm, sequelaT365X2APoisoning by aminoglycosides, intentional self-harm, initial encounterT365X2BPoisoning by aminoglycosides, intentional self-harm, subsequent encounterT365X2BPoisoning by aminoglycosides, intentional self-harm, subsequent encounterT365X2BPoisoning by rifampicins, intentional self-harm, initial encounterT366X2BPoisoning by rifampicins, intentional self-harm, subsequent encounterT366X2BPoisoning by rifampicins, intentional self-harm, sequela<		
T360X2S Poisoning by penicillins, intentional self-harm, sequela T361X2A Poisoning by cephalosporins and other beta-lactam antibiotics, intentional self-harm, initial encounter T361X2D Poisoning by cephalosporins and other beta-lactam antibiotics, intentional self-harm, subsequent encounter T361X2S Poisoning by cephalosporins and other beta-lactam antibiotics, intentional self-harm, subsequent encounter T362X2A Poisoning by chloramphenicol group, intentional self-harm, initial encounter T362X2B Poisoning by chloramphenicol group, intentional self-harm, subsequent encounter T362X2B Poisoning by macrolides, intentional self-harm, initial encounter T363X2A Poisoning by macrolides, intentional self-harm, subsequent encounter T363X2B Poisoning by macrolides, intentional self-harm, sequela T364X2A Poisoning by tetracyclines, intentional self-harm, initial encounter T364X2B Poisoning by tetracyclines, intentional self-harm, subsequent encounter T364X2B Poisoning by tetracyclines, intentional self-harm, sequela T365X2A Poisoning by aminoglycosides, intentional self-harm, initial encounter T365X2B Poisoning by aminoglycosides, intentional self-harm, subsequent encounter T365X2B Poisoning by aminoglycosides, intentional self-harm, subsequent encounter T365X2B Poisoning by rifampicins, intentional self-harm, sequela T365X2A Poisoning by rifampicins, intentional self-harm, subsequent encounter		
T361X2A Poisoning by cephalosporins and other beta-lactam antibiotics, intentional self-harm, initial encounter T361X2D Poisoning by cephalosporins and other beta-lactam antibiotics, intentional self-harm, subsequent encounter T361X2S Poisoning by cephalosporins and other beta-lactam antibiotics, intentional self-harm, sequela T362X2A Poisoning by chloramphenicol group, intentional self-harm, initial encounter T362X2D Poisoning by chloramphenicol group, intentional self-harm, subsequent encounter T363X2A Poisoning by macrolides, intentional self-harm, initial encounter T363X2D Poisoning by macrolides, intentional self-harm, subsequent encounter T363X2S Poisoning by macrolides, intentional self-harm, sequela T364X2A Poisoning by tetracyclines, intentional self-harm, initial encounter T364X2D Poisoning by tetracyclines, intentional self-harm, subsequent encounter T364X2B Poisoning by tetracyclines, intentional self-harm, sequela T365X2A Poisoning by aminoglycosides, intentional self-harm, initial encounter T365X2B Poisoning by aminoglycosides, intentional self-harm, subsequent encounter T365X2B Poisoning by rifampicins, intentional self-harm, sequela T366X2A Poisoning by rifampicins, intentional self-harm, initial encounter T366X2B Poisoning by rifampicins, intentional self-harm, subsequent encounter		
T361X2DPoisoning by cephalosporins and other beta-lactam antibiotics, intentional self-harm, subsequent encounterT361X2SPoisoning by cephalosporins and other beta-lactam antibiotics, intentional self-harm, sequelaT362X2APoisoning by chloramphenicol group, intentional self-harm, initial encounterT362X2DPoisoning by chloramphenicol group, intentional self-harm, subsequent encounterT363X2APoisoning by macrolides, intentional self-harm, initial encounterT363X2DPoisoning by macrolides, intentional self-harm, subsequent encounterT363X2SPoisoning by macrolides, intentional self-harm, sequelaT364X2APoisoning by tetracyclines, intentional self-harm, initial encounterT364X2DPoisoning by tetracyclines, intentional self-harm, subsequent encounterT364X2SPoisoning by tetracyclines, intentional self-harm, sequelaT365X2APoisoning by aminoglycosides, intentional self-harm, initial encounterT365X2DPoisoning by aminoglycosides, intentional self-harm, subsequent encounterT365X2SPoisoning by rifampicins, intentional self-harm, sequelaT366X2APoisoning by rifampicins, intentional self-harm, subsequent encounterT366X2BPoisoning by antifungal antibiotics, systemically used, intentional self-harm, initial encounter		
T361X2S Poisoning by cephalosporins and other beta-lactam antibiotics, intentional self-harm, sequela T362X2A Poisoning by chloramphenicol group, intentional self-harm, initial encounter T362X2D Poisoning by chloramphenicol group, intentional self-harm, subsequent encounter T362X2S Poisoning by macrolides, intentional self-harm, initial encounter T363X2A Poisoning by macrolides, intentional self-harm, subsequent encounter T363X2D Poisoning by macrolides, intentional self-harm, subsequent encounter T363X2S Poisoning by macrolides, intentional self-harm, sequela T364X2A Poisoning by tetracyclines, intentional self-harm, initial encounter T364X2D Poisoning by tetracyclines, intentional self-harm, subsequent encounter T364X2B Poisoning by tetracyclines, intentional self-harm, sequela T365X2A Poisoning by aminoglycosides, intentional self-harm, initial encounter T365X2D Poisoning by aminoglycosides, intentional self-harm, subsequent encounter T365X2B Poisoning by rifampicins, intentional self-harm, sequela T365X2A Poisoning by rifampicins, intentional self-harm, initial encounter T366X2A Poisoning by rifampicins, intentional self-harm, subsequent encounter T366X2B Poisoning by rifampicins, intentional self-harm, subsequent encounter		
T362X2A Poisoning by chloramphenicol group, intentional self-harm, initial encounter T362X2D Poisoning by chloramphenicol group, intentional self-harm, subsequent encounter T362X2S Poisoning by chloramphenicol group, intentional self-harm, sequela T363X2A Poisoning by macrolides, intentional self-harm, initial encounter T363X2D Poisoning by macrolides, intentional self-harm, subsequent encounter T363X2S Poisoning by macrolides, intentional self-harm, sequela T364X2A Poisoning by tetracyclines, intentional self-harm, initial encounter T364X2D Poisoning by tetracyclines, intentional self-harm, subsequent encounter T364X2S Poisoning by tetracyclines, intentional self-harm, sequela T365X2A Poisoning by aminoglycosides, intentional self-harm, initial encounter T365X2D Poisoning by aminoglycosides, intentional self-harm, subsequent encounter T365X2A Poisoning by rifampicins, intentional self-harm, initial encounter T366X2A Poisoning by rifampicins, intentional self-harm, initial encounter T366X2D Poisoning by rifampicins, intentional self-harm, subsequent encounter T366X2B Poisoning by rifampicins, intentional self-harm, subsequent encounter T366X2B Poisoning by rifampicins, intentional self-harm, subsequent encounter T366X2B Poisoning by rifampicins, intentional self-harm, subsequent encounter		
T362X2D Poisoning by chloramphenicol group, intentional self-harm, subsequent encounter T362X2S Poisoning by macrolides, intentional self-harm, initial encounter T363X2A Poisoning by macrolides, intentional self-harm, subsequent encounter T363X2D Poisoning by macrolides, intentional self-harm, subsequent encounter T363X2S Poisoning by macrolides, intentional self-harm, sequela T364X2A Poisoning by tetracyclines, intentional self-harm, initial encounter T364X2D Poisoning by tetracyclines, intentional self-harm, subsequent encounter T364X2S Poisoning by tetracyclines, intentional self-harm, sequela T365X2A Poisoning by aminoglycosides, intentional self-harm, initial encounter T365X2D Poisoning by aminoglycosides, intentional self-harm, subsequent encounter T365X2S Poisoning by rifampicins, intentional self-harm, sequela T366X2A Poisoning by rifampicins, intentional self-harm, initial encounter T366X2D Poisoning by rifampicins, intentional self-harm, subsequent encounter T366X2D Poisoning by rifampicins, intentional self-harm, subsequent encounter T366X2S Poisoning by rifampicins, intentional self-harm, sequela T367X2A Poisoning by antifungal antibiotics, systemically used, intentional self-harm, initial encounter		
T362X2S Poisoning by chloramphenicol group, intentional self-harm, sequela T363X2A Poisoning by macrolides, intentional self-harm, initial encounter T363X2D Poisoning by macrolides, intentional self-harm, subsequent encounter T363X2S Poisoning by macrolides, intentional self-harm, sequela T364X2A Poisoning by tetracyclines, intentional self-harm, initial encounter T364X2D Poisoning by tetracyclines, intentional self-harm, subsequent encounter T364X2S Poisoning by tetracyclines, intentional self-harm, sequela T365X2A Poisoning by aminoglycosides, intentional self-harm, initial encounter T365X2D Poisoning by aminoglycosides, intentional self-harm, subsequent encounter T365X2S Poisoning by rifampicins, intentional self-harm, initial encounter T366X2A Poisoning by rifampicins, intentional self-harm, initial encounter T366X2D Poisoning by rifampicins, intentional self-harm, subsequent encounter T366X2B Poisoning by rifampicins, intentional self-harm, sequela T367X2A Poisoning by antifungal antibiotics, systemically used, intentional self-harm, initial encounter	T362X2D	
T363X2A Poisoning by macrolides, intentional self-harm, initial encounter T363X2D Poisoning by macrolides, intentional self-harm, subsequent encounter T363X2S Poisoning by macrolides, intentional self-harm, sequela T364X2A Poisoning by tetracyclines, intentional self-harm, initial encounter T364X2D Poisoning by tetracyclines, intentional self-harm, subsequent encounter T364X2S Poisoning by tetracyclines, intentional self-harm, sequela T365X2A Poisoning by aminoglycosides, intentional self-harm, initial encounter T365X2D Poisoning by aminoglycosides, intentional self-harm, subsequent encounter T365X2S Poisoning by rifampicins, intentional self-harm, sequela T366X2A Poisoning by rifampicins, intentional self-harm, initial encounter T366X2D Poisoning by rifampicins, intentional self-harm, subsequent encounter T366X2B Poisoning by rifampicins, intentional self-harm, sequela T367X2A Poisoning by antifungal antibiotics, systemically used, intentional self-harm, initial encounter		
T363X2D Poisoning by macrolides, intentional self-harm, subsequent encounter T363X2S Poisoning by macrolides, intentional self-harm, sequela T364X2A Poisoning by tetracyclines, intentional self-harm, initial encounter T364X2D Poisoning by tetracyclines, intentional self-harm, subsequent encounter T364X2S Poisoning by tetracyclines, intentional self-harm, sequela T365X2A Poisoning by aminoglycosides, intentional self-harm, initial encounter T365X2D Poisoning by aminoglycosides, intentional self-harm, subsequent encounter T365X2S Poisoning by aminoglycosides, intentional self-harm, sequela T366X2A Poisoning by rifampicins, intentional self-harm, initial encounter T366X2D Poisoning by rifampicins, intentional self-harm, subsequent encounter T366X2S Poisoning by rifampicins, intentional self-harm, sequela T367X2A Poisoning by antifungal antibiotics, systemically used, intentional self-harm, initial encounter		
T364X2A Poisoning by macrolides, intentional self-harm, sequela T364X2D Poisoning by tetracyclines, intentional self-harm, initial encounter T364X2D Poisoning by tetracyclines, intentional self-harm, subsequent encounter T364X2S Poisoning by tetracyclines, intentional self-harm, sequela T365X2A Poisoning by aminoglycosides, intentional self-harm, initial encounter T365X2D Poisoning by aminoglycosides, intentional self-harm, subsequent encounter T365X2S Poisoning by aminoglycosides, intentional self-harm, sequela T366X2A Poisoning by rifampicins, intentional self-harm, initial encounter T366X2D Poisoning by rifampicins, intentional self-harm, subsequent encounter T366X2S Poisoning by rifampicins, intentional self-harm, sequela T367X2A Poisoning by antifungal antibiotics, systemically used, intentional self-harm, initial encounter		
T364X2A Poisoning by tetracyclines, intentional self-harm, initial encounter T364X2D Poisoning by tetracyclines, intentional self-harm, subsequent encounter T364X2S Poisoning by tetracyclines, intentional self-harm, sequela T365X2A Poisoning by aminoglycosides, intentional self-harm, initial encounter T365X2D Poisoning by aminoglycosides, intentional self-harm, subsequent encounter T365X2S Poisoning by aminoglycosides, intentional self-harm, sequela T366X2A Poisoning by rifampicins, intentional self-harm, initial encounter T366X2D Poisoning by rifampicins, intentional self-harm, subsequent encounter T366X2S Poisoning by rifampicins, intentional self-harm, sequela T367X2A Poisoning by antifungal antibiotics, systemically used, intentional self-harm, initial encounter		
T364X2D Poisoning by tetracyclines, intentional self-harm, subsequent encounter T365X2A Poisoning by aminoglycosides, intentional self-harm, initial encounter T365X2D Poisoning by aminoglycosides, intentional self-harm, subsequent encounter T365X2S Poisoning by aminoglycosides, intentional self-harm, subsequent encounter T365X2A Poisoning by rifampicins, intentional self-harm, initial encounter T366X2A Poisoning by rifampicins, intentional self-harm, subsequent encounter T366X2D Poisoning by rifampicins, intentional self-harm, subsequent encounter T366X2S Poisoning by rifampicins, intentional self-harm, sequela T367X2A Poisoning by antifungal antibiotics, systemically used, intentional self-harm, initial encounter		
T364X2S Poisoning by tetracyclines, intentional self-harm, sequela T365X2A Poisoning by aminoglycosides, intentional self-harm, initial encounter T365X2D Poisoning by aminoglycosides, intentional self-harm, subsequent encounter T365X2S Poisoning by aminoglycosides, intentional self-harm, sequela T366X2A Poisoning by rifampicins, intentional self-harm, initial encounter T366X2D Poisoning by rifampicins, intentional self-harm, subsequent encounter T366X2S Poisoning by rifampicins, intentional self-harm, sequela T367X2A Poisoning by antifungal antibiotics, systemically used, intentional self-harm, initial encounter		
T365X2A Poisoning by aminoglycosides, intentional self-harm, initial encounter T365X2D Poisoning by aminoglycosides, intentional self-harm, subsequent encounter T365X2S Poisoning by aminoglycosides, intentional self-harm, sequela T366X2A Poisoning by rifampicins, intentional self-harm, initial encounter T366X2D Poisoning by rifampicins, intentional self-harm, subsequent encounter T366X2S Poisoning by rifampicins, intentional self-harm, sequela T367X2A Poisoning by antifungal antibiotics, systemically used, intentional self-harm, initial encounter		
T365X2DPoisoning by aminoglycosides, intentional self-harm, subsequent encounterT365X2SPoisoning by aminoglycosides, intentional self-harm, sequelaT366X2APoisoning by rifampicins, intentional self-harm, initial encounterT366X2DPoisoning by rifampicins, intentional self-harm, subsequent encounterT366X2SPoisoning by rifampicins, intentional self-harm, sequelaT367X2APoisoning by antifungal antibiotics, systemically used, intentional self-harm, initial encounter		
T365X2S Poisoning by aminoglycosides, intentional self-harm, sequela T366X2A Poisoning by rifampicins, intentional self-harm, initial encounter T366X2D Poisoning by rifampicins, intentional self-harm, subsequent encounter T366X2S Poisoning by rifampicins, intentional self-harm, sequela T367X2A Poisoning by antifungal antibiotics, systemically used, intentional self-harm, initial encounter		
T366X2APoisoning by rifampicins, intentional self-harm, initial encounterT366X2DPoisoning by rifampicins, intentional self-harm, subsequent encounterT366X2SPoisoning by rifampicins, intentional self-harm, sequelaT367X2APoisoning by antifungal antibiotics, systemically used, intentional self-harm, initial encounter		
T366X2D Poisoning by rifampicins, intentional self-harm, subsequent encounter T366X2S Poisoning by rifampicins, intentional self-harm, sequela T367X2A Poisoning by antifungal antibiotics, systemically used, intentional self-harm, initial encounter	T366X2A	
T366X2S Poisoning by rifampicins, intentional self-harm, sequela T367X2A Poisoning by antifungal antibiotics, systemically used, intentional self-harm, initial encounter		7 7 1
T367X2A Poisoning by antifungal antibiotics, systemically used, intentional self-harm, initial encounter		
		Poisoning by antifungal antibiotics, systemically used, intentional self-harm, initial encounter
[136/X2D] Poisoning by antifungal antibiotics, systemically used, intentional self-harm, subsequent encounter	T367X2D	Poisoning by antifungal antibiotics, systemically used, intentional self-harm, subsequent encounter
T367X2S Poisoning by antifungal antibiotics, systemically used, intentional self-harm, sequela	T367X2S	Poisoning by antifungal antibiotics, systemically used, intentional self-harm, sequela
T368X2A Poisoning by other systemic antibiotics, intentional self-harm, initial encounter	T368X2A	Poisoning by other systemic antibiotics, intentional self-harm, initial encounter

Code	Shortened Description
T368X2D	Poisoning by other systemic antibiotics, intentional self-harm, subsequent encounter
T368X2S	Poisoning by other systemic antibiotics, intentional self-harm, sequela
T3692XA	Poisoning by unspecified systemic antibiotic, intentional self-harm, initial encounter
T3692XD	Poisoning by unspecified systemic antibiotic, intentional self-harm, subsequent encounter
T3692XS	Poisoning by unspecified systemic antibiotic, intentional self-harm, sequela
T370X2A	Poisoning by sulfonamides, intentional self-harm, initial encounter
T370X2D	Poisoning by sulfonamides, intentional self-harm, subsequent encounter
T370X2S	Poisoning by sulfonamides, intentional self-harm, sequela
T371X2A	Poisoning by antimycobacterial drugs, intentional self-harm, initial encounter
T371X2D	Poisoning by antimycobacterial drugs, intentional self-harm, subsequent encounter
T371X2S	Poisoning by antimycobacterial drugs, intentional self-harm, sequela
T372X2A	Poisoning by antimalarials and drugs acting on other blood protozoa, intentional self-harm, initial encounter
T372X2D	Poisoning by antimalarials and drugs acting on other blood protozoa, intentional self-harm, subsequent encounter
T372X2S	Poisoning by antimalarials and drugs acting on other blood protozoa, intentional self-harm, sequela
T373X2A	Poisoning by other antiprotozoal drugs, intentional self-harm, initial encounter
T373X2D	Poisoning by other antiprotozoal drugs, intentional self-harm, subsequent encounter
T373X2S	Poisoning by other antiprotozoal drugs, intentional self-harm, sequela
T374X2A	Poisoning by anthelminthics, intentional self-harm, initial encounter
T374X2D	Poisoning by anthelminthics, intentional self-harm, subsequent encounter
T374X2S	Poisoning by anthelminthics, intentional self-harm, sequela
T375X2A	Poisoning by antiviral drugs, intentional self-harm, initial encounter
T375X2D	Poisoning by antiviral drugs, intentional self-harm, subsequent encounter
T375X2S	Poisoning by antiviral drugs, intentional self-harm, sequela
T378X2A	Poisoning by other specified systemic anti-infectives and antiparasitics, intentional self-harm, initial encounter
137071271	Poisoning by other specified systemic anti-infectives and antiparasities, intentional self-harm, subsequent
T378X2D	encounter
T378X2S	Poisoning by other specified systemic anti-infectives and antiparasitics, intentional self-harm, sequela
T3792XA	Poisoning by unspecified systemic anti-infective and antiparasitics, intentional self-harm, initial encounter
T3792XD	Poisoning by unspecified systemic anti-infective and antiparasitics, intentional self-harm, subsequent encounter
T3792XS	Poisoning by unspecified systemic anti-infective and antiparasitics, intentional self-harm, sequela
T380X2A	Poisoning by glucocorticoids and synthetic analogues, intentional self-harm, initial encounter
T380X2D	Poisoning by glucocorticoids and synthetic analogues, intentional self-harm, subsequent encounter
T380X2S	Poisoning by glucocorticoids and synthetic analogues, intentional self-harm, sequela
T381X2A	Poisoning by thyroid hormones and substitutes, intentional self-harm, initial encounter
T381X2D	Poisoning by thyroid hormones and substitutes, intentional self-harm, subsequent encounter
T381X2S	Poisoning by thyroid hormones and substitutes, intentional self-harm, sequela
T382X2A	Poisoning by antithyroid drugs, intentional self-harm, initial encounter
T382X2D	Poisoning by antithyroid drugs, intentional self-harm, subsequent encounter
T382X2S	Poisoning by antithyroid drugs, intentional self-harm, sequela
T383X2A	Poisoning by insulin and oral hypoglycemic [antidiabetic] drugs, intentional self-harm, initial encounter
T383X2D	Poisoning by insulin and oral hypoglycemic [antidiabetic] drugs, intentional self-harm, subsequent encounter
T383X2S	Poisoning by insulin and oral hypoglycemic [antidiabetic] drugs, intentional self-harm, sequela
T384X2A	Poisoning by oral contraceptives, intentional self-harm, initial encounter
T384X2D	Poisoning by oral contraceptives, intentional self-harm, subsequent encounter
T384X2S	Poisoning by oral contraceptives, intentional self-harm, sequela
T385X2A	Poisoning by other estrogens and progestogens, intentional self-harm, initial encounter
T385X2A	Poisoning by other estrogens and progestogens, intentional self-harm, subsequent encounter
T385X2S	Poisoning by other estrogens and progestogens, intentional self-harm, sequela
	Poisoning by other estrogens and progestogens, intentional sent-narm, sequena  Poisoning by antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified, intentional self-harm,
T386X2A	initial encounter
T386X2D	Poisoning by antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified, intentional self-harm, subsequent encounter

Code	Shortened Description
T386X2S	Poisoning by antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified, intentional self-harm,
1360A23	sequela
T387X2A	Poisoning by androgens and anabolic congeners, intentional self-harm, initial encounter
T387X2D	Poisoning by androgens and anabolic congeners, intentional self-harm, subsequent encounter
T387X2S	Poisoning by androgens and anabolic congeners, intentional self-harm, sequela
T38802A	Poisoning by unspecified hormones and synthetic substitutes, intentional self-harm, initial encounter
T38802D	Poisoning by unspecified hormones and synthetic substitutes, intentional self-harm, subsequent encounter
T38802S	Poisoning by unspecified hormones and synthetic substitutes, intentional self-harm, sequela
T38812A	Poisoning by anterior pituitary [adenohypophyseal] hormones, intentional self-harm, initial encounter
T38812D	Poisoning by anterior pituitary [adenohypophyseal] hormones, intentional self-harm, subsequent encounter
T38812S	Poisoning by anterior pituitary [adenohypophyseal] hormones, intentional self-harm, sequela
T38892A	Poisoning by other hormones and synthetic substitutes, intentional self-harm, initial encounter
T38892D	Poisoning by other hormones and synthetic substitutes, intentional self-harm, subsequent encounter
T38892S	Poisoning by other hormones and synthetic substitutes, intentional self-harm, sequela
T38902A	Poisoning by unspecified hormone antagonists, intentional self-harm, initial encounter
T38902D	Poisoning by unspecified hormone antagonists, intentional self-harm, subsequent encounter
T38902S	Poisoning by unspecified hormone antagonists, intentional self-harm, sequela
T38992A	Poisoning by other hormone antagonists, intentional self-harm, initial encounter
T38992D	Poisoning by other hormone antagonists, intentional self-harm, subsequent encounter
T38992S	Poisoning by other hormone antagonists, intentional self-harm, sequela
T39012A	Poisoning by aspirin, intentional self-harm, initial encounter
T39012D	Poisoning by aspirin, intentional self-harm, subsequent encounter
T39012S	Poisoning by aspirin, intentional self-harm, sequela
T39092A	Poisoning by salicylates, intentional self-harm, initial encounter
T39092D	Poisoning by salicylates, intentional self-harm, subsequent encounter
T39092S	Poisoning by salicylates, intentional self-harm, sequela
T391X2A	Poisoning by 4-Aminophenol derivatives, intentional self-harm, initial encounter
T391X2D	Poisoning by 4-Aminophenol derivatives, intentional self-harm, subsequent encounter
T391X2S	Poisoning by 4-Aminophenol derivatives, intentional self-harm, sequela
T392X2A	Poisoning by pyrazolone derivatives, intentional self-harm, initial encounter
T392X2D	Poisoning by pyrazolone derivatives, intentional self-harm, subsequent encounter
T392X2S	Poisoning by pyrazolone derivatives, intentional self-harm, sequela
T39312A	Poisoning by propionic acid derivatives, intentional self-harm, initial encounter
T39312D	Poisoning by propionic acid derivatives, intentional self-harm, subsequent encounter
T39312S	Poisoning by propionic acid derivatives, intentional self-harm, sequela
T39392A	Poisoning by other nonsteroidal anti-inflammatory drugs [NSAID], intentional self-harm, initial encounter
T39392D	Poisoning by other nonsteroidal anti-inflammatory drugs [NSAID], intentional self-harm, subsequent encounter
T39392S	Poisoning by other nonsteroidal anti-inflammatory drugs [NSAID], intentional self-harm, sequela
T394X2A	Poisoning by antirheumatics, not elsewhere classified, intentional self-harm, initial encounter
T394X2D	Poisoning by antirheumatics, not elsewhere classified, intentional self-harm, subsequent encounter
T394X2S	Poisoning by antirheumatics, not elsewhere classified, intentional self-harm, sequela
T398X2A	Poisoning by other nonopioid analgesics and antipyretics, not elsewhere classified, intentional self-harm, initial encounter
T398X2D	Poisoning by other nonopioid analgesics and antipyretics, not elsewhere classified, intentional self-harm, subsequent encounter
T398X2S	Poisoning by other nonopioid analgesics and antipyretics, not elsewhere classified, intentional self-harm, sequela
T3992XA	Poisoning by unspecified nonopioid analgesic, antipyretic and antirheumatic, intentional self-harm, initial encounter
T3992XD	Poisoning by unspecified nonopioid analgesic, antipyretic and antirheumatic, intentional self-harm, subsequent encounter
T3992XS	Poisoning by unspecified nonopioid analgesic, antipyretic and antirheumatic, intentional self-harm, sequela
T400X2A	Poisoning by opium, intentional self-harm, initial encounter
T400X2D	Poisoning by opium, intentional self-harm, subsequent encounter

Code	Shortened Description
T400X2S	Poisoning by opium, intentional self-harm, sequela
T401X2A	Poisoning by heroin, intentional self-harm, initial encounter
T401X2D	Poisoning by heroin, intentional self-harm, subsequent encounter
T401X2S	Poisoning by heroin, intentional self-harm, sequela
T402X2A	Poisoning by other opioids, intentional self-harm, initial encounter
T402X2D	Poisoning by other opioids, intentional self-harm, subsequent encounter
T402X2S	Poisoning by other opioids, intentional self-harm, sequela
T403X2A	Poisoning by methadone, intentional self-harm, initial encounter
T403X2D	Poisoning by methadone, intentional self-harm, subsequent encounter
T403X2S	Poisoning by methadone, intentional self-harm, sequela
T404X2A	Poisoning by other synthetic narcotics, intentional self-harm, initial encounter
T404X2D	Poisoning by other synthetic narcotics, intentional self-harm, subsequent encounter
T404X2S	Poisoning by other synthetic narcotics, intentional self-harm, sequela
T405X2A	Poisoning by cocaine, intentional self-harm, initial encounter
T405X2D	Poisoning by cocaine, intentional self-harm, subsequent encounter
T405X2S	Poisoning by cocaine, intentional self-harm, sequela
T40602A	Poisoning by unspecified narcotics, intentional self-harm, initial encounter
T40602D	Poisoning by unspecified narcotics, intentional self-harm, subsequent encounter
T40602S	Poisoning by unspecified narcotics, intentional self-harm, sequela
T40692A	Poisoning by other narcotics, intentional self-harm, initial encounter
T40692D	Poisoning by other narcotics, intentional self-harm, subsequent encounter
T40692S	Poisoning by other narcotics, intentional self-harm, sequela
T407X2A	Poisoning by cannabis (derivatives), intentional self-harm, initial encounter
T407X2D	Poisoning by cannabis (derivatives), intentional self-harm, subsequent encounter
T407X2S	Poisoning by cannabis (derivatives), intentional self-harm, sequela
T408X2A	Poisoning by lysergide [LSD], intentional self-harm, initial encounter
T408X2D	Poisoning by lysergide [LSD], intentional self-harm, subsequent encounter
T408X2S	Poisoning by lysergide [LSD], intentional self-harm, sequela
T40902A	Poisoning by unspecified psychodysleptics [hallucinogens], intentional self-harm, initial encounter
T40902D	Poisoning by unspecified psychodysleptics [hallucinogens], intentional self-harm, subsequent encounter
T40902S	Poisoning by unspecified psychodysleptics [hallucinogens], intentional self-harm, sequela
T40992A	Poisoning by other psychodysleptics [hallucinogens], intentional self-harm, initial encounter
T40992D	Poisoning by other psychodysleptics [hallucinogens], intentional self-harm, subsequent encounter
T40992S	Poisoning by other psychodysleptics [hallucinogens], intentional self-harm, sequela
T410X2A	Poisoning by inhaled anesthetics, intentional self-harm, initial encounter
T410X2D	Poisoning by inhaled anesthetics, intentional self-harm, subsequent encounter
T410X2S	Poisoning by inhaled anesthetics, intentional self-harm, sequela
T411X2A	Poisoning by intravenous anesthetics, intentional self-harm, initial encounter
T411X2D	Poisoning by intravenous anesthetics, intentional self-harm, subsequent encounter
T411X2S	Poisoning by intravenous anesthetics, intentional self-harm, sequela
T41202A	Poisoning by unspecified general anesthetics, intentional self-harm, initial encounter
T41202D	Poisoning by unspecified general anesthetics, intentional self-harm, subsequent encounter
T41202S	Poisoning by unspecified general anesthetics, intentional self-harm, sequela
T41292A	Poisoning by other general anesthetics, intentional self-harm, initial encounter
T41292D	Poisoning by other general anesthetics, intentional self-harm, subsequent encounter
T41292S	Poisoning by dother general anesthetics, intentional self-harm, sequela
T413X2A T413X2D	Poisoning by local anesthetics, intentional self-harm, initial encounter
	Poisoning by local anesthetics, intentional self-harm, subsequent encounter
T413X2S	Poisoning by unspecified anotheric, intentional self-harm, sequela
T4142XA	Poisoning by unspecified anesthetic, intentional self-harm, initial encounter
T4142XD	Poisoning by unspecified anesthetic, intentional self-harm, subsequent encounter  Poisoning by unspecified anesthetic, intentional self-harm, sequela
T4142XS T415X2A	
T415X2A	Poisoning by therapeutic gases, intentional self-harm, initial encounter  Poisoning by therapeutic gases, intentional self-harm, subsequent encounter
T415X2D	
1413A28	Poisoning by therapeutic gases, intentional self-harm, sequela

Code	Shortened Description
T420X2A	Poisoning by hydantoin derivatives, intentional self-harm, initial encounter
T420X2D	Poisoning by hydantoin derivatives, intentional self-harm, subsequent encounter
T420X2S	Poisoning by hydantoin derivatives, intentional self-harm, sequela
T421X2A	Poisoning by iminostilbenes, intentional self-harm, initial encounter
T421X2D	Poisoning by iminostilbenes, intentional self-harm, subsequent encounter
T421X2S	Poisoning by iminostilbenes, intentional self-harm, sequela
T422X2A	Poisoning by succinimides and oxazolidinediones, intentional self-harm, initial encounter
T422X2D	Poisoning by succinimides and oxazolidinediones, intentional self-harm, subsequent encounter
T422X2S	Poisoning by succinimides and oxazolidinediones, intentional self-harm, sequela
T423X2A	Poisoning by barbiturates, intentional self-harm, initial encounter
T423X2D	Poisoning by barbiturates, intentional self-harm, subsequent encounter
T423X2S	Poisoning by barbiturates, intentional self-harm, sequela
T424X2A	Poisoning by benzodiazepines, intentional self-harm, initial encounter
T424X2D	Poisoning by benzodiazepines, intentional self-harm, subsequent encounter
T424X2S	Poisoning by benzodiazepines, intentional self-harm, sequela
T425X2A	Poisoning by mixed antiepileptics, intentional self-harm, initial encounter
T425X2D	Poisoning by mixed antiepileptics, intentional self-harm, subsequent encounter
T425X2S	Poisoning by mixed antiepileptics, intentional self-harm, sequela
T426X2A	Poisoning by other antiepileptic and sedative-hypnotic drugs, intentional self-harm, initial encounter
T426X2D	Poisoning by other antiepileptic and sedative-hypnotic drugs, intentional self-harm, subsequent encounter
T426X2S	Poisoning by other antiepileptic and sedative-hypnotic drugs, intentional self-harm, sequela
T4272XA	Poisoning by unspecified antiepileptic and sedative-hypnotic drugs, intentional self-harm, initial encounter
T4272XD	Poisoning by unspecified antiepileptic and sedative-hypnotic drugs, intentional self-harm, subsequent encounter
T4272XS	Poisoning by unspecified antiepileptic and sedative-hypnotic drugs, intentional self-harm, sequela
	Poisoning by antiparkinsonism drugs and other central muscle-tone depressants, intentional self-harm, initial
T428X2A	encounter
T428X2D	Poisoning by antiparkinsonism drugs and other central muscle-tone depressants, intentional self-harm, subsequent encounter
T428X2S	1
T43012A	Poisoning by antiparkinsonism drugs and other central muscle-tone depressants, intentional self-harm, sequela
T43012A	Poisoning by tricyclic antidepressants, intentional self-harm, initial encounter  Poisoning by tricyclic antidepressants, intentional self-harm, subsequent encounter
T43012D	Poisoning by tricyclic antidepressants, intentional self-harm, sequela
T430123	Poisoning by tetracyclic antidepressants, intentional self-harm, initial encounter
T43022A	Poisoning by tetracyclic antidepressants, intentional self-harm, subsequent encounter
T43022B	Poisoning by tetracyclic antidepressants, intentional self-harm, sequela
T431X2A	Poisoning by monoamine-oxidase-inhibitor antidepressants, intentional self-harm, initial encounter
T431X2D	Poisoning by monoamine-oxidase-inhibitor antidepressants, intentional self-harm, subsequent encounter
T431X2S	Poisoning by monoamine-oxidase-inhibitor antidepressants, intentional self-harm, sequela
T43202A	Poisoning by unspecified antidepressants, intentional self-harm, initial encounter
T43202D	Poisoning by unspecified antidepressants, intentional self-harm, subsequent encounter
T43202S	Poisoning by unspecified antidepressants, intentional self-harm, sequela
T43212A	Poisoning by selective serotonin and norepinephrine reuptake inhibitors, intentional self-harm, initial encounter
T43212D	Poisoning by selective serotonin and norepinephrine reuptake inhibitors, intentional self-harm, subsequent
T42212C	encounter  Deignating by collective constants and noneningabelia accordate inhibitous intentional colf house goggets.
T43212S T43222A	Poisoning by selective serotonin and norepinephrine reuptake inhibitors, intentional self-harm, sequela  Poisoning by selective serotonin reuptake inhibitors, intentional self-harm, initial encounter
	Poisoning by selective serotonin reuptake inhibitors, intentional self-harm, subsequent encounter
T43222D T43222S	Poisoning by selective serotonin reuptake inhibitors, intentional self-harm, sequela
T43292A	Poisoning by other antidepressants, intentional self-harm, initial encounter
T43292A T43292D	Poisoning by other antidepressants, intentional self-harm, subsequent encounter
T43292D	Poisoning by other antidepressants, intentional self-harm, sequela
T433X2A	Poisoning by other anticepressants, intentional self-narm, sequeta  Poisoning by phenothiazine antipsychotics and neuroleptics, intentional self-harm, initial encounter
T433X2D	Poisoning by phenothiazine antipsychotics and neuroleptics, intentional self-harm, subsequent encounter
T433X2D	Poisoning by phenothiazine antipsychotics and neuroleptics, intentional self-harm, sequela
1455X2S	proisoning by phenothiazine antipsychotics and neuroleptics, intentional self-harm, sequela

Code	Shortened Description
T434X2A	Poisoning by butyrophenone and thiothixene neuroleptics, intentional self-harm, initial encounter
T434X2D	Poisoning by butyrophenone and thiothixene neuroleptics, intentional self-harm, subsequent encounter
T434X2S	Poisoning by butyrophenone and thiothixene neuroleptics, intentional self-harm, sequela
T43502A	Poisoning by unspecified antipsychotics and neuroleptics, intentional self-harm, initial encounter
T43502D	Poisoning by unspecified antipsychotics and neuroleptics, intentional self-harm, subsequent encounter
T43502S	Poisoning by unspecified antipsychotics and neuroleptics, intentional self-harm, sequela
T43592A	Poisoning by other antipsychotics and neuroleptics, intentional self-harm, initial encounter
T43592D	Poisoning by other antipsychotics and neuroleptics, intentional self-harm, subsequent encounter
T43592S	Poisoning by other antipsychotics and neuroleptics, intentional self-harm, sequela
T43602A	Poisoning by unspecified psychostimulants, intentional self-harm, initial encounter
T43602D	Poisoning by unspecified psychostimulants, intentional self-harm, subsequent encounter
T43602S	Poisoning by unspecified psychostimulants, intentional self-harm, sequela
T43612A	Poisoning by caffeine, intentional self-harm, initial encounter
T43612D	Poisoning by caffeine, intentional self-harm, subsequent encounter
T43612S	Poisoning by caffeine, intentional self-harm, sequela
T43622A	Poisoning by amphetamines, intentional self-harm, initial encounter
T43622D	Poisoning by amphetamines, intentional self-harm, subsequent encounter
T43622S	Poisoning by amphetamines, intentional self-harm, sequela
T43632A	Poisoning by methylphenidate, intentional self-harm, initial encounter
T43632D	Poisoning by methylphenidate, intentional self-harm, subsequent encounter
T43632S	Poisoning by methylphenidate, intentional self-harm, sequela
T440X2A	Poisoning by anticholinesterase agents, intentional self-harm, initial encounter
T440X2D	Poisoning by anticholinesterase agents, intentional self-harm, subsequent encounter
T440X2S	Poisoning by anticholinesterase agents, intentional self-harm, sequela
T441X2A	Poisoning by other parasympathomimetics [cholinergics], intentional self-harm, initial encounter
T441X2D	Poisoning by other parasympathomimetics [cholinergics], intentional self-harm, subsequent encounter
T441X2S	Poisoning by other parasympathomimetics [cholinergics], intentional self-harm, sequela
T442X2A	Poisoning by ganglionic blocking drugs, intentional self-harm, initial encounter
T442X2D	Poisoning by ganglionic blocking drugs, intentional self-harm, subsequent encounter
T442X2S	Poisoning by ganglionic blocking drugs, intentional self-harm, sequela
	Poisoning by other parasympatholytics [anticholinergies and antimuscarinics] and spasmolytics, intentional self-
T443X2A	harm, initial encounter
	Poisoning by other parasympatholytics [anticholinergies and antimuscarinies] and spasmolytics, intentional self-
T443X2D	harm, subsequent encounter
	Poisoning by other parasympatholytics [anticholinergies and antimuscarinies] and spasmolytics, intentional self-
T443X2S	harm, sequela
T444X2A	Poisoning by predominantly alpha-adrenoreceptor agonists, intentional self-harm, initial encounter
T444X2D	Poisoning by predominantly alpha-adrenoreceptor agonists, intentional self-harm, subsequent encounter
T444X2S	Poisoning by predominantly alpha-adrenoreceptor agonists, intentional self-harm, sequela
T445X2A	Poisoning by predominantly beta-adrenoreceptor agonists, intentional self-harm, initial encounter
T445X2D	Poisoning by predominantly beta-adrenoreceptor agonists, intentional self-harm, subsequent encounter
T445X2S	Poisoning by predominantly beta-adrenoreceptor agonists, intentional self-harm, sequela
T446X2A	Poisoning by alpha-adrenoreceptor antagonists, intentional self-harm, initial encounter
T446X2D	Poisoning by alpha-adrenoreceptor antagonists, intentional self-harm, subsequent encounter
T446X2S	Poisoning by alpha-adrenoreceptor antagonists, intentional self-harm, sequela
T447X2A	Poisoning by beta-adrenoreceptor antagonists, intentional self-harm, initial encounter
T447X2D	Poisoning by beta-adrenoreceptor antagonists, intentional self-harm, subsequent encounter
T447X2S	Poisoning by beta-adrenoreceptor antagonists, intentional self-harm, sequela
T448X2A	Poisoning by centrally-acting and adrenergic-neuron-blocking agents, intentional self-harm, initial encounter
T448X2D	Poisoning by centrally-acting and adrenergic-neuron-blocking agents, intentional self-harm, subsequent
	encounter
T448X2S	Poisoning by centrally-acting and adrenergic-neuron-blocking agents, intentional self-harm, sequela
1 1 TTU/\4D	1 obothing by containy acting and action glo-nearon-blocking agents, intentional sen-natin, sequeta
	Poisoning by unspecified drugs primarily affecting the autonomic nervous system, intentional self-harm, initial

Code	Shortened Description
	Poisoning by unspecified drugs primarily affecting the autonomic nervous system, intentional self-harm,
T44902D	subsequent encounter
	Poisoning by unspecified drugs primarily affecting the autonomic nervous system, intentional self-harm,
T44902S	sequela
	Poisoning by other drug primarily affecting the autonomic nervous system, intentional self-harm, initial
T44992A	encounter
	Poisoning by other drug primarily affecting the autonomic nervous system, intentional self-harm, subsequent
T44992D	encounter
T44992S	Poisoning by other drug primarily affecting the autonomic nervous system, intentional self-harm, sequela
T450X2A	Poisoning by antiallergic and antiemetic drugs, intentional self-harm, initial encounter
T450X2D	Poisoning by antiallergic and antiemetic drugs, intentional self-harm, subsequent encounter
T450X2S	Poisoning by antiallergic and antiemetic drugs, intentional self-harm, sequela
T451X2A	Poisoning by antineoplastic and immunosuppressive drugs, intentional self-harm, initial encounter
T451X2A	Poisoning by antineoplastic and immunosuppressive drugs, intentional self-harm, subsequent encounter
T451X2S	Poisoning by antineoplastic and immunosuppressive drugs, intentional self-harm, sequela
T452X2A	Poisoning by vitamins, intentional self-harm, initial encounter
T452X2D	Poisoning by vitamins, intentional self-harm, subsequent encounter
T452X2S	Poisoning by vitamins, intentional self-harm, sequela
T453X2A	Poisoning by enzymes, intentional self-harm, initial encounter
T453X2A	Poisoning by enzymes, intentional self-harm, subsequent encounter
T453X2D	Poisoning by enzymes, intentional self-harm, sequela
T454X2A	Poisoning by iron and its compounds, intentional self-harm, initial encounter
T454X2A T454X2D	Poisoning by iron and its compounds, intentional self-harm, subsequent encounter
T454X2D	Poisoning by iron and its compounds, intentional self-harm, sequela
T454A2S	Poisoning by anticoagulants, intentional self-harm, initial encounter
T45512A	Poisoning by anticoagulants, intentional self-harm, subsequent encounter
T45512B	Poisoning by anticoagulants, intentional self-harm, sequela
T45512S	Poisoning by antitrombotic drugs, intentional self-harm, initial encounter
T45522A T45522D	
T45522S	Poisoning by antithrombotic drugs, intentional self-harm, subsequent encounter
	Poisoning by antithrombotic drugs, intentional self-harm, sequela
T45602A	Poisoning by unspecified fibrinolysis-affecting drugs, intentional self-harm, initial encounter
T45602D	Poisoning by unspecified fibrinolysis-affecting drugs, intentional self-harm, subsequent encounter
T45602S	Poisoning by unspecified fibrinolysis-affecting drugs, intentional self-harm, sequela
T45612A	Poisoning by thrombolytic drug, intentional self-harm, initial encounter
T45612D	Poisoning by thrombolytic drug, intentional self-harm, subsequent encounter
T45612S	Poisoning by thrombolytic drug, intentional self-harm, sequela
T45622A	Poisoning by hemostatic drug, intentional self-harm, initial encounter
T45622D	Poisoning by hemostatic drug, intentional self-harm, subsequent encounter
T45622S	Poisoning by hemostatic drug, intentional self-harm, sequela
T45692A	Poisoning by other fibrinolysis-affecting drugs, intentional self-harm, initial encounter
T45692D	Poisoning by other fibrinolysis-affecting drugs, intentional self-harm, subsequent encounter
T45692S	Poisoning by other fibrinolysis-affecting drugs, intentional self-harm, sequela
T457X2A	Poisoning by anticoagulant antagonists, vitamin K and other coagulants, intentional self-harm, initial encounter
T457X2D	Poisoning by anticoagulant antagonists, vitamin K and other coagulants, intentional self-harm, subsequent
	encounter
T457X2S	Poisoning by anticoagulant antagonists, vitamin K and other coagulants, intentional self-harm, sequela
T458X2A	Poisoning by other primarily systemic and hematological agents, intentional self-harm, initial encounter
T458X2D	Poisoning by other primarily systemic and hematological agents, intentional self-harm, subsequent encounter
T458X2S	Poisoning by other primarily systemic and hematological agents, intentional self-harm, sequela
T4592XA	Poisoning by unspecified primarily systemic and hematological agent, intentional self-harm, initial encounter
T4592XD	Poisoning by unspecified primarily systemic and hematological agent, intentional self-harm, subsequent encounter
T4592XS	Poisoning by unspecified primarily systemic and hematological agent, intentional self-harm, sequela
T460X2A	Poisoning by cardiac-stimulant glycosides and drugs of similar action, intentional self-harm, initial encounter

Code	Shortened Description
	Poisoning by cardiac-stimulant glycosides and drugs of similar action, intentional self-harm, subsequent
T460X2D	encounter
T460X2S	Poisoning by cardiac-stimulant glycosides and drugs of similar action, intentional self-harm, sequela
T461X2A	Poisoning by calcium-channel blockers, intentional self-harm, initial encounter
T461X2D	Poisoning by calcium-channel blockers, intentional self-harm, subsequent encounter
T461X2S	Poisoning by calcium-channel blockers, intentional self-harm, sequela
T462X2A	Poisoning by other antidysrhythmic drugs, intentional self-harm, initial encounter
T462X2D	Poisoning by other antidysrhythmic drugs, intentional self-harm, subsequent encounter
T462X2S	Poisoning by other antidysrhythmic drugs, intentional self-harm, sequela
T463X2A	Poisoning by coronary vasodilators, intentional self-harm, initial encounter
T463X2D	Poisoning by coronary vasodilators, intentional self-harm, subsequent encounter
T463X2S	Poisoning by coronary vasodilators, intentional self-harm, sequela
T464X2A	Poisoning by angiotensin-converting-enzyme inhibitors, intentional self-harm, initial encounter
T464X2D	Poisoning by angiotensin-converting-enzyme inhibitors, intentional self-harm, subsequent encounter
T464X2S	Poisoning by angiotensin-converting-enzyme inhibitors, intentional self-harm, sequela
T465X2A	Poisoning by other antihypertensive drugs, intentional self-harm, initial encounter
T465X2D	Poisoning by other antihypertensive drugs, intentional self-harm, subsequent encounter
T465X2S	Poisoning by other antihypertensive drugs, intentional self-harm, sequela
T466X2A	Poisoning by antihyperlipidemic and antiarteriosclerotic drugs, intentional self-harm, initial encounter
T466X2D	Poisoning by antihyperlipidemic and antiarteriosclerotic drugs, intentional self-harm, subsequent encounter
T466X2S	Poisoning by antihyperlipidemic and antiarteriosclerotic drugs, intentional self-harm, sequela
T467X2A	Poisoning by peripheral vasodilators, intentional self-harm, initial encounter
T467X2D	Poisoning by peripheral vasodilators, intentional self-harm, subsequent encounter
T467X2S	Poisoning by peripheral vasodilators, intentional self-harm, sequela
T468X2A	Poisoning by antivaricose drugs, including sclerosing agents, intentional self-harm, initial encounter
T468X2D	Poisoning by antivaricose drugs, including sclerosing agents, intentional self-harm, subsequent encounter
T468X2S	Poisoning by antivaricose drugs, including sclerosing agents, intentional self-harm, sequela
T46902A	Poisoning by unspecified agents primarily affecting the cardiovascular system, intentional self-harm, initial encounter
T46902D	Poisoning by unspecified agents primarily affecting the cardiovascular system, intentional self-harm, subsequent encounter
T46902S	Poisoning by unspecified agents primarily affecting the cardiovascular system, intentional self-harm, sequela
T46992A	Poisoning by other agents primarily affecting the cardiovascular system, intentional self-harm, initial encounter
T46992D	Poisoning by other agents primarily affecting the cardiovascular system, intentional self-harm, subsequent encounter
T46992S	Poisoning by other agents primarily affecting the cardiovascular system, intentional self-harm, sequela
T470X2A	Poisoning by histamine H2-receptor blockers, intentional self-harm, initial encounter
T470X2D	Poisoning by histamine H2-receptor blockers, intentional self-harm, subsequent encounter
T470X2S	Poisoning by histamine H2-receptor blockers, intentional self-harm, sequela
T471X2A	Poisoning by other antacids and anti-gastric-secretion drugs, intentional self-harm, initial encounter
T471X2D	Poisoning by other antacids and anti-gastric-secretion drugs, intentional self-harm, subsequent encounter
T471X2S	Poisoning by other antacids and anti-gastric-secretion drugs, intentional self-harm, sequela
T472X2A	Poisoning by stimulant laxatives, intentional self-harm, initial encounter
T472X2D	Poisoning by stimulant laxatives, intentional self-harm, subsequent encounter
T472X2S	Poisoning by stimulant laxatives, intentional self-harm, sequela
T473X2A	Poisoning by saline and osmotic laxatives, intentional self-harm, initial encounter
T473X2D	Poisoning by saline and osmotic laxatives, intentional self-harm, subsequent encounter
T473X2S	Poisoning by saline and osmotic laxatives, intentional self-harm, sequela
T474X2A	Poisoning by other laxatives, intentional self-harm, initial encounter
T474X2D	Poisoning by other laxatives, intentional self-harm, subsequent encounter
T474X2S	Poisoning by other laxatives, intentional self-harm, sequela
T475X2A	Poisoning by digestants, intentional self-harm, initial encounter
T475X2D	Poisoning by digestants, intentional self-harm, subsequent encounter
T475X2S	Poisoning by digestants, intentional self-harm, sequela
T476X2A	Poisoning by antidiarrheal drugs, intentional self-harm, initial encounter

Code	Shortened Description
T476X2D	Poisoning by antidiarrheal drugs, intentional self-harm, subsequent encounter
T476X2S	Poisoning by antidiarrheal drugs, intentional self-harm, sequela
T477X2A	Poisoning by emetics, intentional self-harm, initial encounter
T477X2D	Poisoning by emetics, intentional self-harm, subsequent encounter
T477X2S	Poisoning by emetics, intentional self-harm, sequela
T478X2A	Poisoning by other agents primarily affecting gastrointestinal system, intentional self-harm, initial encounter
14/0/12/1	Poisoning by other agents primarily affecting gastrointestinal system, intentional self-harm, subsequent
T478X2D	encounter
T478X2S	Poisoning by other agents primarily affecting gastrointestinal system, intentional self-harm, sequela
T4792XA	Poisoning by unspecified agents primarily affecting the gastrointestinal system, intentional self-harm, initial encounter
T4792XD	Poisoning by unspecified agents primarily affecting the gastrointestinal system, intentional self-harm, subsequent encounter
T4792XS	Poisoning by unspecified agents primarily affecting the gastrointestinal system, intentional self-harm, sequela
T480X2A	Poisoning by oxytocic drugs, intentional self-harm, initial encounter
T480X2D	Poisoning by oxytocic drugs, intentional self-harm, subsequent encounter
T480X2S	Poisoning by oxytocic drugs, intentional self-harm, sequela
T481X2A	Poisoning by skeletal muscle relaxants [neuromuscular blocking agents], intentional self-harm, initial encounter
T481X2D	Poisoning by skeletal muscle relaxants [neuromuscular blocking agents], intentional self-harm, subsequent encounter
T481X2S	Poisoning by skeletal muscle relaxants [neuromuscular blocking agents], intentional self-harm, sequela
T48202A	Poisoning by unspecified drugs acting on muscles, intentional self-harm, initial encounter
T48202D	Poisoning by unspecified drugs acting on muscles, intentional self-harm, subsequent encounter
T48202S	Poisoning by unspecified drugs acting on muscles, intentional self-harm, sequela
T48292A	Poisoning by other drugs acting on muscles, intentional self-harm, initial encounter
T48292A	
	Poisoning by other drugs acting on muscles, intentional self-harm, subsequent encounter
T48292S	Poisoning by other drugs acting on muscles, intentional self-harm, sequela
T483X2A	Poisoning by antitussives, intentional self-harm, initial encounter
T483X2D	Poisoning by antitussives, intentional self-harm, subsequent encounter
T483X2S	Poisoning by antitussives, intentional self-harm, sequela
T484X2A	Poisoning by expectorants, intentional self-harm, initial encounter
T484X2D	Poisoning by expectorants, intentional self-harm, subsequent encounter
T484X2S	Poisoning by expectorants, intentional self-harm, sequela
T485X2A	Poisoning by other anti-common-cold drugs, intentional self-harm, initial encounter
T485X2D	Poisoning by other anti-common-cold drugs, intentional self-harm, subsequent encounter
T485X2S	Poisoning by other anti-common-cold drugs, intentional self-harm, sequela
T486X2A	Poisoning by antiasthmatics, intentional self-harm, initial encounter
T486X2D	Poisoning by antiasthmatics, intentional self-harm, subsequent encounter
T486X2S	Poisoning by antiasthmatics, intentional self-harm, sequela
T48902A	Poisoning by unspecified agents primarily acting on the respiratory system, intentional self-harm, initial encounter
T48902D	Poisoning by unspecified agents primarily acting on the respiratory system, intentional self-harm, subsequent encounter
T48902S	Poisoning by unspecified agents primarily acting on the respiratory system, intentional self-harm, sequela
T48992A	Poisoning by other agents primarily acting on the respiratory system, intentional self-harm, initial encounter
T48992D	Poisoning by other agents primarily acting on the respiratory system, intentional self-harm, subsequent encounter
T48992S	Poisoning by other agents primarily acting on the respiratory system, intentional self-harm, sequela
T490X2A	Poisoning by local antifungal, anti-infective and anti-inflammatory drugs, intentional self-harm, initial
	Poisoning by local antifungal, anti-infective and anti-inflammatory drugs, intentional self-harm, subsequent
T490X2D T490X2S	encounter
	Poisoning by local antifungal, anti-infective and anti-inflammatory drugs, intentional self-harm, sequela
T491X2A	Poisoning by antiprurities, intentional self-harm, initial encounter
T491X2D	Poisoning by antipruritics, intentional self-harm, subsequent encounter

Code	Shortened Description
T491X2S	Poisoning by antipruritics, intentional self-harm, sequela
T492X2A	Poisoning by local astringents and local detergents, intentional self-harm, initial encounter
T492X2D	Poisoning by local astringents and local detergents, intentional self-harm, subsequent encounter
T492X2S	Poisoning by local astringents and local detergents, intentional self-harm, sequela
T493X2A	Poisoning by emollients, demulcents and protectants, intentional self-harm, initial encounter
T493X2D	Poisoning by emollients, demulcents and protectants, intentional self-harm, subsequent encounter
T493X2S	Poisoning by emollients, demulcents and protectants, intentional self-harm, sequela
1493723	Poisoning by keratolytics, keratoplastics, and other hair treatment drugs and preparations, intentional self-harm,
T494X2A	initial encounter
	Poisoning by keratolytics, keratoplastics, and other hair treatment drugs and preparations, intentional self-harm,
T494X2D	
	subsequent encounter
T494X2S	Poisoning by keratolytics, keratoplastics, and other hair treatment drugs and preparations, intentional self-harm,
	sequela
T495X2A	Poisoning by ophthalmological drugs and preparations, intentional self-harm, initial encounter
T495X2D	Poisoning by ophthalmological drugs and preparations, intentional self-harm, subsequent encounter
T495X2S	Poisoning by ophthalmological drugs and preparations, intentional self-harm, sequela
T496X2A	Poisoning by otorhinolaryngological drugs and preparations, intentional self-harm, initial encounter
T496X2D	Poisoning by otorhinolaryngological drugs and preparations, intentional self-harm, subsequent encounter
T496X2S	Poisoning by otorhinolaryngological drugs and preparations, intentional self-harm, sequela
T497X2A	Poisoning by dental drugs, topically applied, intentional self-harm, initial encounter
T497X2D	Poisoning by dental drugs, topically applied, intentional self-harm, subsequent encounter
T497X2S	Poisoning by dental drugs, topically applied, intentional self-harm, sequela
T498X2A	Poisoning by other topical agents, intentional self-harm, initial encounter
T498X2D	Poisoning by other topical agents, intentional self-harm, subsequent encounter
T498X2S	Poisoning by other topical agents, intentional self-harm, sequela
T4992XA	Poisoning by unspecified topical agent, intentional self-harm, initial encounter
T4992XD	Poisoning by unspecified topical agent, intentional self-harm, subsequent encounter
T4992XS	Poisoning by unspecified topical agent, intentional self-harm, sequela
T500X2A	Poisoning by mineralocorticoids and their antagonists, intentional self-harm, initial encounter
T500X2D	Poisoning by mineralocorticoids and their antagonists, intentional self-harm, subsequent encounter
T500X2S	Poisoning by mineralocorticoids and their antagonists, intentional self-harm, sequela
T501X2A	Poisoning by loop [high-ceiling] diuretics, intentional self-harm, initial encounter
T501X2D	Poisoning by loop [high-ceiling] diuretics, intentional self-harm, subsequent encounter
T501X2S	Poisoning by loop [high-ceiling] diuretics, intentional self-harm, sequela
	Poisoning by carbonic-anhydrase inhibitors, benzothiadiazides and other diuretics, intentional self-harm, initial
T502X2A	encounter
	Poisoning by carbonic-anhydrase inhibitors, benzothiadiazides and other diuretics, intentional self-harm,
T502X2D	subsequent encounter
	Poisoning by carbonic-anhydrase inhibitors, benzothiadiazides and other diuretics, intentional self-harm,
T502X2S	sequela
T503X2A	Poisoning by electrolytic, caloric and water-balance agents, intentional self-harm, initial encounter
T503X2D	Poisoning by electrolytic, caloric and water-balance agents, intentional self-harm, subsequent encounter
T503X2S	Poisoning by electrolytic, caloric and water-balance agents, intentional self-harm, sequela
T504X2A	Poisoning by drugs affecting uric acid metabolism, intentional self-harm, initial encounter
T504X2D	Poisoning by drugs affecting uric acid metabolism, intentional self-harm, subsequent encounter
T504X2D	
T505X2A	Poisoning by drugs affecting uric acid metabolism, intentional self-harm, sequela  Poisoning by appetite depressants, intentional self-harm, initial encounter
	Poisoning by appetite depressants, intentional self-harm, subsequent encounter  Poisoning by appetite depressants, intentional self-harm, subsequent encounter
T505X2D	
T505X2S	Poisoning by appetite depressants, intentional self-harm, sequela
T506X2A	Poisoning by antidotes and chelating agents, intentional self-harm, initial encounter
T506X2D	Poisoning by antidotes and chelating agents, intentional self-harm, subsequent encounter
T506X2S	Poisoning by antidotes and chelating agents, intentional self-harm, sequela
T507X2A	Poisoning by analeptics and opioid receptor antagonists, intentional self-harm, initial encounter
T507X2D	Poisoning by analeptics and opioid receptor antagonists, intentional self-harm, subsequent encounter
T507X2S	Poisoning by analeptics and opioid receptor antagonists, intentional self-harm, sequela

T508X2A Poisoning by diagnostic agents, intentional self-harm, initial encounter T508X2D Poisoning by diagnostic agents, intentional self-harm, subsequent encounter T508X2S Poisoning by diagnostic agents, intentional self-harm, subsequent encounter T50902A Poisoning by unspecified drugs, medicaments and biological substances, intentional self-harm, initial encounter T50902D Poisoning by unspecified drugs, medicaments and biological substances, intentional self-harm, subsequent encounter T50902S Poisoning by unspecified drugs, medicaments and biological substances, intentional self-harm, sequela T50912A Poisoning by multiple unspecified drugs, medicaments and biological substances, intentional self-harm, initial encounter T50912D Poisoning by multiple unspecified drugs, medicaments and biological substances, intentional self-harm, subsequent encounter T50912S Poisoning by multiple unspecified drugs, medicaments and biological substances, intentional self-harm, sequela T50992A Poisoning by other drugs, medicaments and biological substances, intentional self-harm, initial encounter T50992D Poisoning by other drugs, medicaments and biological substances, intentional self-harm, subsequent encounter T50992D Poisoning by other drugs, medicaments and biological substances, intentional self-harm, subsequent encounter T50912A Poisoning by pertussis vaccine, including combinations with a pertussis component, intentional self-harm, initial encounter T50A12A Poisoning by pertussis vaccine, including combinations with a pertussis component, intentional self-harm, sequela T50A12A Poisoning by mixed bacterial vaccines without a pertussis component, intentional self-harm, initial encounter T50A22A Poisoning by mixed bacterial vaccines without a pertussis component, intentional self-harm, initial encounter	Code	Shortened Description
Fossoning by diagnostic agents, intentional self-harm, subsequent encounter	T508X2A	*
ISONAUS Poisoning by diagnostic agents, intentional self-harm, sequela ISO902A Poisoning by unspecified drugs, medicaments and biological substances, intentional self-harm, subsequent recounter Poisoning by unspecified drugs, medicaments and biological substances, intentional self-harm, subsequent recounter Poisoning by muspecified drugs, medicaments and biological substances, intentional self-harm, subsequent recounter Poisoning by multiple unspecified drugs, medicaments and biological substances, intentional self-harm, initial recounter Poisoning by multiple unspecified drugs, medicaments and biological substances, intentional self-harm, subsequent recounter Poisoning by multiple unspecified drugs, medicaments and biological substances, intentional self-harm, support recounter Poisoning by multiple unspecified drugs, medicaments and biological substances, intentional self-harm, sequela Poisoning by other drugs, medicaments and biological substances, intentional self-harm, subsequent recounter Poisoning by other drugs, medicaments and biological substances, intentional self-harm, subsequent recounter Poisoning by pertursis vaccine, including combinations with a pertussis component, intentional self-harm, subsequent recounter Poisoning by pertursis vaccine, including combinations with a pertussis component, intentional self-harm, subsequent recounter Poisoning by pertursis vaccine, including combinations with a pertussis component, intentional self-harm, subsequent recounter Poisoning by mixed bacterial vaccines without a pertussis component, intentional self-harm, sequela Poisoning by mixed bacterial vaccines without a pertussis component, intentional self-harm, mixed recounter Poisoning by mixed bacterial vaccines without a pertussis component, intentional self-harm, mixed recounter Poisoning by mixed bacterial vaccines, intentional self-harm, intentional self-harm, sequela Poisoning by mixed bacterial vaccines, intentional self-harm, intentional self-harm, subsequent recounter Poisoning by other bacterial va		
Poisoning by unspecified drugs, medicaments and biological substances, intentional self-harm, subsequent encounter		
Poisoning by unspecified drugs, medicaments and biological substances, intentional self-harm, subsequent encounter		
Ts0902S	T50902D	Poisoning by unspecified drugs, medicaments and biological substances, intentional self-harm, subsequent
Poisoning by multiple unspecified drugs, medicaments and biological substances, intentional self-harm, initial encounter	T50902S	
Poisoning by multiple unspecified drugs, medicaments and biological substances, intentional self-harm, subsequent encounter  Fosioning by multiple unspecified drugs, medicaments and biological substances, intentional self-harm, initial encounter  Fosioning by other drugs, medicaments and biological substances, intentional self-harm, initial encounter  Fosioning by other drugs, medicaments and biological substances, intentional self-harm, initial encounter  Fosioning by other drugs, medicaments and biological substances, intentional self-harm, sequela  Fosioning by other drugs, medicaments and biological substances, intentional self-harm, sequela  Fosioning by pertussis vaccine, including combinations with a pertussis component, intentional self-harm, subsequent encounter  Fosioning by pertussis vaccine, including combinations with a pertussis component, intentional self-harm, sequela  Fosioning by pertussis vaccine, including combinations with a pertussis component, intentional self-harm, sequela  Fosioning by mixed bacterial vaccines without a pertussis component, intentional self-harm, sequela  Fosioning by mixed bacterial vaccines without a pertussis component, intentional self-harm, subsequent encounter  Fosionipa by mixed bacterial vaccines without a pertussis component, intentional self-harm, subsequent  Fosionipa by mixed bacterial vaccines without a pertussis component, intentional self-harm, sequela  Fosioning by mixed bacterial vaccines, intentional self-harm, unitial encounter  Fosionipa by mixed bacterial vaccines, intentional self-harm, subsequent encounter  Fosionipa by other bacterial vaccines, intentional self-harm, subsequent encounter  Fosionipa by other bacterial vaccines, intentional self-harm, initial encounter  Fosionipa by other vaccines, intentional self-harm, initial encounter  Fosionipa by other viral vaccines, intentional self-harm, sequela  Fosionipa by other viral vaccines, intentional self-harm, sequela  Fosioning by other viral vaccines, intentional self-harm, sequela  Fosioning b	T50912A	Poisoning by multiple unspecified drugs, medicaments and biological substances, intentional self-harm, initial
Tsop12S	T50912D	Poisoning by multiple unspecified drugs, medicaments and biological substances, intentional self-harm,
T50992A   Poisoning by other drugs, medicaments and biological substances, intentional self-harm, subsequent encounter   T50992B   Poisoning by other drugs, medicaments and biological substances, intentional self-harm, subsequent encounter   T5092B   Poisoning by pertussis vaccine, including combinations with a pertussis component, intentional self-harm, initial encounter   Poisoning by pertussis vaccine, including combinations with a pertussis component, intentional self-harm, subsequent encounter   Poisoning by pertussis vaccine, including combinations with a pertussis component, intentional self-harm, subsequent encounter   Poisoning by pertussis vaccine, including combinations with a pertussis component, intentional self-harm, sequela   Poisoning by mixed bacterial vaccines without a pertussis component, intentional self-harm, sequela   Poisoning by mixed bacterial vaccines without a pertussis component, intentional self-harm, subsequent encounter   Poisoning by mixed bacterial vaccines without a pertussis component, intentional self-harm, subsequent encounter   Poisoning by mixed bacterial vaccines, intentional self-harm, initial encounter   Poisoning by other bacterial vaccines, intentional self-harm, sequela   Poisoning by other bacterial vaccines, intentional self-harm, subsequent encounter   Poisoning by smallpox vaccines, intentional self-harm, subsequent encounter   Poisoning by smallpox vaccines, intentional self-harm, subsequent encounter   Poisoning by other viral vaccines, intentional self-harm, subsequent encounter   Poisoning by other viral vaccines, intentional self-harm, subsequent encounter   Poisoning by other viral vaccines, intentional self-harm, subsequent encounter   Poisoning by other viral vaccines, intentional self-harm, subsequent encounter   Poisoning by other viral vaccines, intentional self-harm, subsequent encounter   Poisoning by other vaccines and biological substances, intentional self-harm, initial encounter   Poisoning by other vaccines and biological substances, intentio	T50912S	1
Poisoning by other drugs, medicaments and biological substances, intentional self-harm, subsequent encounter Poisoning by other drugs, medicaments and biological substances, intentional self-harm, sequela Poisoning by pertussis vaccine, including combinations with a pertussis component, intentional self-harm, initial encounter		
T509128		
Poisoning by pertussis vaccine, including combinations with a pertussis component, intentional self-harm, initial encounter		
Poisoning by pertussis vaccine, including combinations with a pertussis component, intentional self-harm, subsequent encounter	T50A12A	Poisoning by pertussis vaccine, including combinations with a pertussis component, intentional self-harm,
Source   Poisoning by mixed bacterial vaccines without a pertussis component, intentional self-harm, initial encounter	T50A12D	Poisoning by pertussis vaccine, including combinations with a pertussis component, intentional self-harm,
Poisoning by mixed bacterial vaccines without a pertussis component, intentional self-harm, subsequent encounter  T50A22S Poisoning by mixed bacterial vaccines without a pertussis component, intentional self-harm, sequela  T50A92D Poisoning by other bacterial vaccines, intentional self-harm, initial encounter  T50A92S Poisoning by other bacterial vaccines, intentional self-harm, subsequent encounter  T50A92C Poisoning by other bacterial vaccines, intentional self-harm, subsequent encounter  T50B12D Poisoning by smallpox vaccines, intentional self-harm, initial encounter  T50B12D Poisoning by smallpox vaccines, intentional self-harm, subsequent encounter  T50B12S Poisoning by smallpox vaccines, intentional self-harm, sequela  T50B12S Poisoning by other viral vaccines, intentional self-harm, subsequent encounter  T50B12D Poisoning by other viral vaccines, intentional self-harm, subsequent encounter  T50B12D Poisoning by other viral vaccines, intentional self-harm, subsequent encounter  T50B12D Poisoning by immunoglobulin, intentional self-harm, subsequent encounter  T50Z12A Poisoning by immunoglobulin, intentional self-harm, sequela  T50Z12D Poisoning by immunoglobulin, intentional self-harm, sequela  T50Z92A Poisoning by other vaccines and biological substances, intentional self-harm, initial encounter  T50Z92D Poisoning by other vaccines and biological substances, intentional self-harm, subsequent encounter  T510X2D Toxic effect of ethanol, intentional self-harm, subsequent encounter  T510X2D Toxic effect of ethanol, intentional self-harm, subsequent encounter  T511X2D Toxic effect of methanol, intentional self-harm, subsequent encounter  T512X2A Toxic effect of methanol, intentional self-harm, subsequent encounter  T512X2A Toxic effect of methanol, intentional self-harm, subsequent encounter  T513X2A Toxic effect of fusel oil, intentional self-harm, sequela  T513X2A Toxic effect of fusel oil, intentional self-harm, subsequent encounter  T513X2D Toxic effect of fusel oil, intentional self-harm, subsequent encou	T50A12S	
Poisoning by mixed bacterial vaccines without a pertussis component, intentional self-harm, sequela	T50A22A	Poisoning by mixed bacterial vaccines without a pertussis component, intentional self-harm, initial encounter
Poisoning by other bacterial vaccines, intentional self-harm, initial encounter T50A92D Poisoning by other bacterial vaccines, intentional self-harm, subsequent encounter T50B12A Poisoning by smallpox vaccines, intentional self-harm, initial encounter T50B12D Poisoning by smallpox vaccines, intentional self-harm, initial encounter T50B12B Poisoning by smallpox vaccines, intentional self-harm, subsequent encounter T50B12C Poisoning by smallpox vaccines, intentional self-harm, subsequent encounter T50B12C Poisoning by other viral vaccines, intentional self-harm, subsequent encounter T50B12C Poisoning by other viral vaccines, intentional self-harm, subsequent encounter T50B12C Poisoning by other viral vaccines, intentional self-harm, sequela T50Z12A Poisoning by immunoglobulin, intentional self-harm, subsequent encounter T50Z12D Poisoning by immunoglobulin, intentional self-harm, subsequent encounter T50Z12C Poisoning by other vaccines and biological substances, intentional self-harm, initial encounter T50Z92A Poisoning by other vaccines and biological substances, intentional self-harm, sequela T50Z92C Poisoning by other vaccines and biological substances, intentional self-harm, sequela T50Z92C Poisoning by other vaccines and biological substances, intentional self-harm, sequela T50Z92C Poisoning by other vaccines and biological substances, intentional self-harm, sequela T510X2A Toxic effect of ethanol, intentional self-harm, subsequent encounter T510X2D Toxic effect of ethanol, intentional self-harm, subsequent encounter T511X2D Toxic effect of methanol, intentional self-harm, subsequent encounter T511X2D Toxic effect of methanol, intentional self-harm, subsequent encounter T512X2D Toxic effect of Propanol, intentional self-harm, subsequent encounter T512X2D Toxic effect of 2-Propanol, intentional self-harm, subsequent encounter T513X2A Toxic effect of fusel oil, intentional self-harm, sequela T513X2A Toxic effect of fusel oil, intentional self-harm, subsequent encounter T513X2D Toxic effect of fusel oil, intenti	T50A22D	
Poisoning by other bacterial vaccines, intentional self-harm, initial encounter T50A92D Poisoning by other bacterial vaccines, intentional self-harm, subsequent encounter T50B12A Poisoning by smallpox vaccines, intentional self-harm, sequela T50B12D Poisoning by smallpox vaccines, intentional self-harm, initial encounter T50B12D Poisoning by smallpox vaccines, intentional self-harm, subsequent encounter T50B12S Poisoning by smallpox vaccines, intentional self-harm, sequela T50B92A Poisoning by other viral vaccines, intentional self-harm, sequela T50B92D Poisoning by other viral vaccines, intentional self-harm, sequela T50B92D Poisoning by other viral vaccines, intentional self-harm, sequela T50B12A Poisoning by immunoglobulin, intentional self-harm, subsequent encounter T50B12B Poisoning by immunoglobulin, intentional self-harm, subsequent encounter T50Z12D Poisoning by immunoglobulin, intentional self-harm, sequela T50Z12D Poisoning by other vaccines and biological substances, intentional self-harm, initial encounter T50Z92D Poisoning by other vaccines and biological substances, intentional self-harm, sequela T50Z92S Poisoning by other vaccines and biological substances, intentional self-harm, sequela T50Z92S Poisoning by other vaccines and biological substances, intentional self-harm, sequela T510X2A Toxic effect of ethanol, intentional self-harm, initial encounter T510X2D Toxic effect of ethanol, intentional self-harm, subsequent encounter T511X2D Toxic effect of methanol, intentional self-harm, subsequent encounter T511X2D Toxic effect of methanol, intentional self-harm, subsequent encounter T512X2D Toxic effect of Propanol, intentional self-harm, subsequent encounter T512X2D Toxic effect of Propanol, intentional self-harm, subsequent encounter T512X2D Toxic effect of Propanol, intentional self-harm, subsequent encounter T513X2A Toxic effect of fusel oil, intentional self-harm, subsequent encounter T513X2D Toxic effect of fusel oil, intentional self-harm, subsequent encounter T513X2D Toxic effect of fusel o	T50A22S	Poisoning by mixed bacterial vaccines without a pertussis component, intentional self-harm, sequela
Poisoning by other bacterial vaccines, intentional self-harm, subsequent encounter T50A92S Poisoning by other bacterial vaccines, intentional self-harm, sequela T50B12A Poisoning by smallpox vaccines, intentional self-harm, initial encounter T50B12B Poisoning by smallpox vaccines, intentional self-harm, subsequent encounter T50B12S Poisoning by smallpox vaccines, intentional self-harm, subsequent encounter T50B92A Poisoning by other viral vaccines, intentional self-harm, sequela T50B92B Poisoning by other viral vaccines, intentional self-harm, subsequent encounter T50B92B Poisoning by other viral vaccines, intentional self-harm, subsequent encounter T50B92C Poisoning by immunoglobulin, intentional self-harm, subsequent encounter T50Z12D Poisoning by immunoglobulin, intentional self-harm, subsequent encounter T50Z12D Poisoning by immunoglobulin, intentional self-harm, sequela T50Z92A Poisoning by other vaccines and biological substances, intentional self-harm, subsequent encounter T50Z92B Poisoning by other vaccines and biological substances, intentional self-harm, sequela T510X2A Toxic effect of ethanol, intentional self-harm, initial encounter T510X2D Toxic effect of ethanol, intentional self-harm, subsequent encounter T510X2S Toxic effect of ethanol, intentional self-harm, subsequent encounter T511X2D Toxic effect of methanol, intentional self-harm, subsequent encounter T511X2D Toxic effect of methanol, intentional self-harm, subsequent encounter T511X2S Toxic effect of Propanol, intentional self-harm, subsequent encounter T512X2D Toxic effect of 2-Propanol, intentional self-harm, subsequent encounter T513X2A Toxic effect of Sel oil, intentional self-harm, initial encounter T513X2A Toxic effect of fusel oil, intentional self-harm, sequela T513X2A Toxic effect of Sel oil, intentional self-harm, initial encounter T513X2B Toxic effect of fusel oil, intentional self-harm, subsequent encounter T513X2B Toxic effect of fusel oil, intentional self-harm, subsequent encounter T513X2D Toxic effect of fusel oil, intentio	T50A92A	
Poisoning by other bacterial vaccines, intentional self-harm, sequela		
T50B12A Poisoning by smallpox vaccines, intentional self-harm, initial encounter T50B12B Poisoning by smallpox vaccines, intentional self-harm, subsequent encounter T50B12B Poisoning by other viral vaccines, intentional self-harm, subsequent encounter T50B92A Poisoning by other viral vaccines, intentional self-harm, initial encounter T50B92B Poisoning by other viral vaccines, intentional self-harm, subsequent encounter T50B92B Poisoning by other viral vaccines, intentional self-harm, subsequent encounter T50B12A Poisoning by immunoglobulin, intentional self-harm, subsequent encounter T50Z12B Poisoning by immunoglobulin, intentional self-harm, subsequent encounter T50Z12B Poisoning by other vaccines and biological substances, intentional self-harm, initial encounter T50Z92B Poisoning by other vaccines and biological substances, intentional self-harm, subsequent encounter T50Z92B Poisoning by other vaccines and biological substances, intentional self-harm, sequela T510X2A Toxic effect of ethanol, intentional self-harm, initial encounter T510X2B Toxic effect of ethanol, intentional self-harm, subsequent encounter T510X2B Toxic effect of ethanol, intentional self-harm, sequela T511X2A Toxic effect of methanol, intentional self-harm, subsequent encounter T511X2D Toxic effect of methanol, intentional self-harm, subsequent encounter T512X2D Toxic effect of P-Propanol, intentional self-harm, initial encounter T512X2D Toxic effect of 2-Propanol, intentional self-harm, subsequent encounter T512X2D Toxic effect of 12-Propanol, intentional self-harm, sequela T513X2A Toxic effect of fusel oil, intentional self-harm, subsequent encounter T513X2D Toxic effect of fusel oil, intentional self-harm, initial encounter T513X2D Toxic effect of fusel oil, intentional self-harm, initial encounter T513X2D Toxic effect of fusel oil, intentional self-harm, subsequent encounter T513X2D Toxic effect of other alcohols, intentional self-harm, initial encounter		
T50B12D Poisoning by smallpox vaccines, intentional self-harm, subsequent encounter T50B12S Poisoning by smallpox vaccines, intentional self-harm, sequela T50B92A Poisoning by other viral vaccines, intentional self-harm, initial encounter T50B92D Poisoning by other viral vaccines, intentional self-harm, subsequent encounter T50B92S Poisoning by other viral vaccines, intentional self-harm, sequela T50Z12A Poisoning by immunoglobulin, intentional self-harm, initial encounter T50Z12D Poisoning by immunoglobulin, intentional self-harm, subsequent encounter T50Z12S Poisoning by immunoglobulin, intentional self-harm, sequela T50Z92A Poisoning by other vaccines and biological substances, intentional self-harm, initial encounter T50Z92D Poisoning by other vaccines and biological substances, intentional self-harm, subsequent encounter T50Z92S Poisoning by other vaccines and biological substances, intentional self-harm, sequela T510X2A Toxic effect of ethanol, intentional self-harm, initial encounter T510X2D Toxic effect of ethanol, intentional self-harm, subsequent encounter T511X2A Toxic effect of methanol, intentional self-harm, initial encounter T511X2D Toxic effect of methanol, intentional self-harm, subsequent encounter T511X2D Toxic effect of methanol, intentional self-harm, subsequent encounter T511X2D Toxic effect of 2-Propanol, intentional self-harm, subsequent encounter T512X2D Toxic effect of 2-Propanol, intentional self-harm, subsequent encounter T512X2D Toxic effect of 2-Propanol, intentional self-harm, subsequent encounter T512X2D Toxic effect of fusel oil, intentional self-harm, subsequent encounter T513X2A Toxic effect of fusel oil, intentional self-harm, subsequent encounter T513X2D Toxic effect of fusel oil, intentional self-harm, subsequent encounter T513X2D Toxic effect of ther alcohols, intentional self-harm, initial encounter		
T50B12S Poisoning by smallpox vaccines, intentional self-harm, sequela T50B92A Poisoning by other viral vaccines, intentional self-harm, initial encounter T50B92B Poisoning by other viral vaccines, intentional self-harm, subsequent encounter T50B92S Poisoning by other viral vaccines, intentional self-harm, sequela T50B12A Poisoning by immunoglobulin, intentional self-harm, initial encounter T50Z12D Poisoning by immunoglobulin, intentional self-harm, subsequent encounter T50Z12D Poisoning by immunoglobulin, intentional self-harm, sequela T50Z92A Poisoning by other vaccines and biological substances, intentional self-harm, initial encounter T50Z92D Poisoning by other vaccines and biological substances, intentional self-harm, subsequent encounter T50Z92S Poisoning by other vaccines and biological substances, intentional self-harm, subsequent encounter T50Z92S Poisoning by other vaccines and biological substances, intentional self-harm, sequela T510X2A Toxic effect of ethanol, intentional self-harm, subsequent encounter T510X2D Toxic effect of ethanol, intentional self-harm, subsequent encounter T511X2D Toxic effect of methanol, intentional self-harm, subsequent encounter T511X2D Toxic effect of methanol, intentional self-harm, subsequent encounter T512X2A Toxic effect of 2-Propanol, intentional self-harm, subsequent encounter T512X2D Toxic effect of 2-Propanol, intentional self-harm, subsequent encounter T512X2D Toxic effect of fusel oil, intentional self-harm, subsequent encounter T513X2D Toxic effect of fusel oil, intentional self-harm, subsequent encounter T513X2D Toxic effect of fusel oil, intentional self-harm, subsequent encounter T513X2D Toxic effect of fusel oil, intentional self-harm, subsequent encounter T513X2D Toxic effect of fusel oil, intentional self-harm, subsequent encounter T513X2D Toxic effect of fusel oil, intentional self-harm, subsequent encounter T513X2D Toxic effect of other alcohols, intentional self-harm, subsequent encounter		
T50B92A Poisoning by other viral vaccines, intentional self-harm, initial encounter T50B92B Poisoning by other viral vaccines, intentional self-harm, subsequent encounter T50B92C Poisoning by other viral vaccines, intentional self-harm, sequela T50Z12A Poisoning by immunoglobulin, intentional self-harm, initial encounter T50Z12D Poisoning by immunoglobulin, intentional self-harm, subsequent encounter T50Z12S Poisoning by immunoglobulin, intentional self-harm, sequela T50Z92A Poisoning by other vaccines and biological substances, intentional self-harm, initial encounter T50Z92D Poisoning by other vaccines and biological substances, intentional self-harm, subsequent encounter T50Z92S Poisoning by other vaccines and biological substances, intentional self-harm, subsequent encounter T50Z92S Poisoning by other vaccines and biological substances, intentional self-harm, sequela T510X2A Toxic effect of ethanol, intentional self-harm, initial encounter T510X2D Toxic effect of ethanol, intentional self-harm, subsequent encounter T511X2A Toxic effect of methanol, intentional self-harm, initial encounter T511X2D Toxic effect of methanol, intentional self-harm, subsequent encounter T512X2A Toxic effect of methanol, intentional self-harm, subsequent encounter T512X2D Toxic effect of 2-Propanol, intentional self-harm, subsequent encounter T512X2B Toxic effect of 2-Propanol, intentional self-harm, subsequent encounter T513X2A Toxic effect of fusel oil, intentional self-harm, subsequent encounter T513X2D Toxic effect of fusel oil, intentional self-harm, subsequent encounter T513X2D Toxic effect of fusel oil, intentional self-harm, subsequent encounter T513X2D Toxic effect of fusel oil, intentional self-harm, subsequent encounter T513X2D Toxic effect of fusel oil, intentional self-harm, subsequent encounter T513X2D Toxic effect of fusel oil, intentional self-harm, subsequent encounter		
Poisoning by other viral vaccines, intentional self-harm, subsequent encounter		
Poisoning by other viral vaccines, intentional self-harm, sequela T50Z12A Poisoning by immunoglobulin, intentional self-harm, initial encounter T50Z12D Poisoning by immunoglobulin, intentional self-harm, subsequent encounter T50Z12S Poisoning by immunoglobulin, intentional self-harm, sequela T50Z12A Poisoning by other vaccines and biological substances, intentional self-harm, initial encounter T50Z92D Poisoning by other vaccines and biological substances, intentional self-harm, subsequent encounter T50Z92D Poisoning by other vaccines and biological substances, intentional self-harm, subsequent encounter T50Z92S Poisoning by other vaccines and biological substances, intentional self-harm, sequela T510X2A Toxic effect of ethanol, intentional self-harm, initial encounter T510X2D Toxic effect of ethanol, intentional self-harm, subsequent encounter T510X2D Toxic effect of ethanol, intentional self-harm, sequela T511X2A Toxic effect of methanol, intentional self-harm, subsequent encounter T511X2D Toxic effect of methanol, intentional self-harm, sequela T512X2A Toxic effect of 2-Propanol, intentional self-harm, initial encounter T512X2D Toxic effect of 2-Propanol, intentional self-harm, subsequent encounter T512X2S Toxic effect of 12-Propanol, intentional self-harm, sequela T513X2A Toxic effect of fusel oil, intentional self-harm, sequela T513X2D Toxic effect of fusel oil, intentional self-harm, subsequent encounter T513X2D Toxic effect of fusel oil, intentional self-harm, subsequent encounter T513X2D Toxic effect of other alcohols, intentional self-harm, initial encounter T518X2D Toxic effect of other alcohols, intentional self-harm, subsequent encounter		
Poisoning by immunoglobulin, intentional self-harm, initial encounter T50Z12D Poisoning by immunoglobulin, intentional self-harm, subsequent encounter T50Z12S Poisoning by immunoglobulin, intentional self-harm, sequela T50Z92A Poisoning by other vaccines and biological substances, intentional self-harm, initial encounter T50Z92D Poisoning by other vaccines and biological substances, intentional self-harm, subsequent encounter T50Z92S Poisoning by other vaccines and biological substances, intentional self-harm, sequela T510X2A Toxic effect of ethanol, intentional self-harm, initial encounter T510X2D Toxic effect of ethanol, intentional self-harm, subsequent encounter T510X2C Toxic effect of ethanol, intentional self-harm, sequela T511X2A Toxic effect of methanol, intentional self-harm, initial encounter T511X2D Toxic effect of methanol, intentional self-harm, subsequent encounter T511X2S Toxic effect of methanol, intentional self-harm, sequela T512X2A Toxic effect of 2-Propanol, intentional self-harm, initial encounter T512X2D Toxic effect of 2-Propanol, intentional self-harm, subsequent encounter T512X2D Toxic effect of 5-Propanol, intentional self-harm, sequela T513X2A Toxic effect of fusel oil, intentional self-harm, initial encounter T513X2D Toxic effect of fusel oil, intentional self-harm, subsequent encounter T513X2D Toxic effect of fusel oil, intentional self-harm, subsequent encounter T513X2D Toxic effect of fusel oil, intentional self-harm, subsequent encounter T513X2D Toxic effect of other alcohols, intentional self-harm, initial encounter T518X2D Toxic effect of other alcohols, intentional self-harm, subsequent encounter		
Poisoning by immunoglobulin, intentional self-harm, subsequent encounter T50Z12S Poisoning by immunoglobulin, intentional self-harm, sequela T50Z92A Poisoning by other vaccines and biological substances, intentional self-harm, initial encounter T50Z92D Poisoning by other vaccines and biological substances, intentional self-harm, subsequent encounter T50Z92S Poisoning by other vaccines and biological substances, intentional self-harm, subsequent encounter T50Z92S Poisoning by other vaccines and biological substances, intentional self-harm, sequela T510X2A Toxic effect of ethanol, intentional self-harm, initial encounter T510X2D Toxic effect of ethanol, intentional self-harm, subsequent encounter T510X2S Toxic effect of methanol, intentional self-harm, subsequent encounter T511X2A Toxic effect of methanol, intentional self-harm, subsequent encounter T511X2D Toxic effect of methanol, intentional self-harm, sequela T512X2A Toxic effect of 2-Propanol, intentional self-harm, initial encounter T512X2D Toxic effect of 2-Propanol, intentional self-harm, subsequent encounter T513X2A Toxic effect of fusel oil, intentional self-harm, initial encounter T513X2D Toxic effect of fusel oil, intentional self-harm, subsequent encounter T513X2S Toxic effect of fusel oil, intentional self-harm, subsequent encounter T513X2A Toxic effect of fusel oil, intentional self-harm, subsequent encounter T513X2B Toxic effect of fusel oil, intentional self-harm, subsequent encounter T518X2A Toxic effect of other alcohols, intentional self-harm, initial encounter		
Poisoning by immunoglobulin, intentional self-harm, sequela Poisoning by other vaccines and biological substances, intentional self-harm, initial encounter Poisoning by other vaccines and biological substances, intentional self-harm, subsequent encounter Poisoning by other vaccines and biological substances, intentional self-harm, subsequent encounter Poisoning by other vaccines and biological substances, intentional self-harm, sequela Poisoning by other vaccines and biological substances, intentional self-harm, sequela Poisoning by other vaccines and biological substances, intentional self-harm, sequela Poisoning by other vaccines and biological substances, intentional self-harm, sequela Poisoning by other vaccines and biological substances, intentional self-harm, sequela Poisoning by other vaccines and biological substances, intentional self-harm, subsequent encounter Poisoning by other vaccines and biological substances, intentional self-harm, subsequent encounter Poisoning by other vaccines and biological substances, intentional self-harm, sequela Poisoning by other vaccines and biological substances, intentional self-harm, sequela Poisoning by other vaccines and biological substances, intentional self-harm, sequela Poisoning by other vaccines and biological substances, intentional self-harm, sequela Poisoning by other vaccines and biological substances, intentional self-harm, subsequent encounter Poisoning by other vaccines and biological substances, intentional self-harm, sequela Poisoning by other vaccines and biological substances, intentional self-harm, sequela Poisoning by other vaccines and biological substances, intentional self-harm, sequela Poisoning by other vaccines and biological substances, intentional self-harm, subsequent encounter Poisoning by other vaccines and biological substances, intentional self-harm, subsequent encounter Poisoning by other vaccines and biological substances, intentional self-harm, sequela Poisoning by other vaccines and biological substances, intentional self-harm, s		
Poisoning by other vaccines and biological substances, intentional self-harm, initial encounter Poisoning by other vaccines and biological substances, intentional self-harm, subsequent encounter Poisoning by other vaccines and biological substances, intentional self-harm, sequela Poisoning by other vaccines and biological substances, intentional self-harm, sequela Touci effect of ethanol, intentional self-harm, initial encounter Touci effect of ethanol, intentional self-harm, subsequent encounter Touci effect of ethanol, intentional self-harm, sequela Touci effect of methanol, intentional self-harm, subsequent encounter Touci effect of methanol, intentional self-harm, sequela Touci effect of methanol, intentional self-harm, sequela Touci effect of 2-Propanol, intentional self-harm, initial encounter Touci effect of 2-Propanol, intentional self-harm, subsequent encounter Touci effect of 2-Propanol, intentional self-harm, subsequent encounter Touci effect of 10, intentional self-harm, sequela Touci effect of 10, intentional self-harm, initial encounter Touci effect of fusel oil, intentional self-harm, subsequent encounter Touci effect of fusel oil, intentional self-harm, subsequent encounter Touci effect of fusel oil, intentional self-harm, subsequent encounter Touci effect of fusel oil, intentional self-harm, subsequent encounter Touci effect of other alcohols, intentional self-harm, initial encounter Touci effect of other alcohols, intentional self-harm, initial encounter		
Poisoning by other vaccines and biological substances, intentional self-harm, subsequent encounter  T50Z92S Poisoning by other vaccines and biological substances, intentional self-harm, sequela  T510X2A Toxic effect of ethanol, intentional self-harm, initial encounter  T510X2D Toxic effect of ethanol, intentional self-harm, subsequent encounter  T510X2S Toxic effect of methanol, intentional self-harm, sequela  T511X2A Toxic effect of methanol, intentional self-harm, subsequent encounter  T511X2D Toxic effect of methanol, intentional self-harm, subsequent encounter  T511X2S Toxic effect of methanol, intentional self-harm, sequela  T512X2A Toxic effect of 2-Propanol, intentional self-harm, subsequent encounter  T512X2D Toxic effect of 2-Propanol, intentional self-harm, subsequent encounter  T512X2S Toxic effect of 2-Propanol, intentional self-harm, sequela  T513X2A Toxic effect of fusel oil, intentional self-harm, initial encounter  T513X2D Toxic effect of fusel oil, intentional self-harm, subsequent encounter  T513X2D Toxic effect of fusel oil, intentional self-harm, sequela  T518X2A Toxic effect of other alcohols, intentional self-harm, initial encounter  T518X2D Toxic effect of other alcohols, intentional self-harm, initial encounter		
T50Z92S Poisoning by other vaccines and biological substances, intentional self-harm, sequela T510X2A Toxic effect of ethanol, intentional self-harm, initial encounter T510X2B Toxic effect of ethanol, intentional self-harm, subsequent encounter T510X2S Toxic effect of methanol, intentional self-harm, sequela T511X2A Toxic effect of methanol, intentional self-harm, initial encounter T511X2D Toxic effect of methanol, intentional self-harm, subsequent encounter T511X2S Toxic effect of methanol, intentional self-harm, sequela T512X2A Toxic effect of 2-Propanol, intentional self-harm, initial encounter T512X2D Toxic effect of 2-Propanol, intentional self-harm, subsequent encounter T512X2S Toxic effect of 2-Propanol, intentional self-harm, sequela T513X2A Toxic effect of fusel oil, intentional self-harm, initial encounter T513X2D Toxic effect of fusel oil, intentional self-harm, subsequent encounter T513X2A Toxic effect of fusel oil, intentional self-harm, subsequent encounter T513X2A Toxic effect of fusel oil, intentional self-harm, sequela T518X2A Toxic effect of other alcohols, intentional self-harm, initial encounter T518X2D Toxic effect of other alcohols, intentional self-harm, subsequent encounter		
TS10X2A Toxic effect of ethanol, intentional self-harm, initial encounter TS10X2D Toxic effect of ethanol, intentional self-harm, subsequent encounter TS10X2S Toxic effect of ethanol, intentional self-harm, sequela TS11X2A Toxic effect of methanol, intentional self-harm, initial encounter TS11X2D Toxic effect of methanol, intentional self-harm, subsequent encounter TS11X2S Toxic effect of methanol, intentional self-harm, sequela TS12X2A Toxic effect of 2-Propanol, intentional self-harm, initial encounter TS12X2D Toxic effect of 2-Propanol, intentional self-harm, subsequent encounter TS12X2S Toxic effect of 2-Propanol, intentional self-harm, sequela TS13X2A Toxic effect of fusel oil, intentional self-harm, initial encounter TS13X2D Toxic effect of fusel oil, intentional self-harm, subsequent encounter TS13X2S Toxic effect of fusel oil, intentional self-harm, sequela TS13X2A Toxic effect of fusel oil, intentional self-harm, sequela TS13X2B Toxic effect of fusel oil, intentional self-harm, initial encounter TS13X2A Toxic effect of other alcohols, intentional self-harm, initial encounter TS13X2A Toxic effect of other alcohols, intentional self-harm, subsequent encounter		
Toxic effect of ethanol, intentional self-harm, subsequent encounter T510X2S Toxic effect of ethanol, intentional self-harm, sequela T511X2A Toxic effect of methanol, intentional self-harm, initial encounter T511X2D Toxic effect of methanol, intentional self-harm, subsequent encounter T511X2S Toxic effect of methanol, intentional self-harm, sequela T512X2A Toxic effect of 2-Propanol, intentional self-harm, initial encounter T512X2D Toxic effect of 2-Propanol, intentional self-harm, subsequent encounter T512X2S Toxic effect of 2-Propanol, intentional self-harm, sequela T513X2A Toxic effect of fusel oil, intentional self-harm, initial encounter T513X2D Toxic effect of fusel oil, intentional self-harm, subsequent encounter T513X2S Toxic effect of fusel oil, intentional self-harm, sequela T518X2A Toxic effect of other alcohols, intentional self-harm, initial encounter T518X2D Toxic effect of other alcohols, intentional self-harm, subsequent encounter		
T510X2S Toxic effect of ethanol, intentional self-harm, sequela T511X2A Toxic effect of methanol, intentional self-harm, initial encounter T511X2D Toxic effect of methanol, intentional self-harm, subsequent encounter T511X2S Toxic effect of methanol, intentional self-harm, sequela T512X2A Toxic effect of 2-Propanol, intentional self-harm, initial encounter T512X2D Toxic effect of 2-Propanol, intentional self-harm, subsequent encounter T512X2S Toxic effect of 2-Propanol, intentional self-harm, sequela T513X2A Toxic effect of fusel oil, intentional self-harm, initial encounter T513X2D Toxic effect of fusel oil, intentional self-harm, subsequent encounter T513X2S Toxic effect of fusel oil, intentional self-harm, sequela T518X2A Toxic effect of other alcohols, intentional self-harm, initial encounter T518X2D Toxic effect of other alcohols, intentional self-harm, subsequent encounter		
T511X2A Toxic effect of methanol, intentional self-harm, initial encounter T511X2D Toxic effect of methanol, intentional self-harm, subsequent encounter T511X2S Toxic effect of methanol, intentional self-harm, sequela T512X2A Toxic effect of 2-Propanol, intentional self-harm, initial encounter T512X2D Toxic effect of 2-Propanol, intentional self-harm, subsequent encounter T512X2S Toxic effect of 2-Propanol, intentional self-harm, sequela T513X2A Toxic effect of fusel oil, intentional self-harm, initial encounter T513X2D Toxic effect of fusel oil, intentional self-harm, subsequent encounter T513X2S Toxic effect of fusel oil, intentional self-harm, sequela T518X2A Toxic effect of other alcohols, intentional self-harm, initial encounter T518X2D Toxic effect of other alcohols, intentional self-harm, subsequent encounter		
T511X2D Toxic effect of methanol, intentional self-harm, subsequent encounter T511X2S Toxic effect of methanol, intentional self-harm, sequela T512X2A Toxic effect of 2-Propanol, intentional self-harm, initial encounter T512X2D Toxic effect of 2-Propanol, intentional self-harm, subsequent encounter T512X2S Toxic effect of 2-Propanol, intentional self-harm, sequela T513X2A Toxic effect of fusel oil, intentional self-harm, initial encounter T513X2D Toxic effect of fusel oil, intentional self-harm, subsequent encounter T513X2S Toxic effect of fusel oil, intentional self-harm, sequela T518X2A Toxic effect of other alcohols, intentional self-harm, initial encounter T518X2D Toxic effect of other alcohols, intentional self-harm, subsequent encounter		
T511X2S Toxic effect of methanol, intentional self-harm, sequela T512X2A Toxic effect of 2-Propanol, intentional self-harm, initial encounter T512X2D Toxic effect of 2-Propanol, intentional self-harm, subsequent encounter T512X2S Toxic effect of 2-Propanol, intentional self-harm, sequela T513X2A Toxic effect of fusel oil, intentional self-harm, initial encounter T513X2D Toxic effect of fusel oil, intentional self-harm, subsequent encounter T513X2S Toxic effect of fusel oil, intentional self-harm, sequela T518X2A Toxic effect of other alcohols, intentional self-harm, initial encounter T518X2D Toxic effect of other alcohols, intentional self-harm, subsequent encounter		
T512X2A Toxic effect of 2-Propanol, intentional self-harm, initial encounter T512X2D Toxic effect of 2-Propanol, intentional self-harm, subsequent encounter T512X2S Toxic effect of 2-Propanol, intentional self-harm, sequela T513X2A Toxic effect of fusel oil, intentional self-harm, initial encounter T513X2D Toxic effect of fusel oil, intentional self-harm, subsequent encounter T513X2S Toxic effect of fusel oil, intentional self-harm, sequela T518X2A Toxic effect of other alcohols, intentional self-harm, initial encounter T518X2D Toxic effect of other alcohols, intentional self-harm, subsequent encounter		
T512X2D Toxic effect of 2-Propanol, intentional self-harm, subsequent encounter T512X2S Toxic effect of 2-Propanol, intentional self-harm, sequela T513X2A Toxic effect of fusel oil, intentional self-harm, initial encounter T513X2D Toxic effect of fusel oil, intentional self-harm, subsequent encounter T513X2S Toxic effect of fusel oil, intentional self-harm, sequela T518X2A Toxic effect of other alcohols, intentional self-harm, initial encounter T518X2D Toxic effect of other alcohols, intentional self-harm, subsequent encounter		
T512X2S Toxic effect of 2-Propanol, intentional self-harm, sequela T513X2A Toxic effect of fusel oil, intentional self-harm, initial encounter T513X2D Toxic effect of fusel oil, intentional self-harm, subsequent encounter T513X2S Toxic effect of fusel oil, intentional self-harm, sequela T518X2A Toxic effect of other alcohols, intentional self-harm, initial encounter T518X2D Toxic effect of other alcohols, intentional self-harm, subsequent encounter		
T513X2A Toxic effect of fusel oil, intentional self-harm, initial encounter T513X2D Toxic effect of fusel oil, intentional self-harm, subsequent encounter T513X2S Toxic effect of fusel oil, intentional self-harm, sequela T518X2A Toxic effect of other alcohols, intentional self-harm, initial encounter T518X2D Toxic effect of other alcohols, intentional self-harm, subsequent encounter		
T513X2D Toxic effect of fusel oil, intentional self-harm, subsequent encounter T513X2S Toxic effect of fusel oil, intentional self-harm, sequela T518X2A Toxic effect of other alcohols, intentional self-harm, initial encounter T518X2D Toxic effect of other alcohols, intentional self-harm, subsequent encounter		
T513X2S Toxic effect of fusel oil, intentional self-harm, sequela T518X2A Toxic effect of other alcohols, intentional self-harm, initial encounter T518X2D Toxic effect of other alcohols, intentional self-harm, subsequent encounter		
T518X2A Toxic effect of other alcohols, intentional self-harm, initial encounter T518X2D Toxic effect of other alcohols, intentional self-harm, subsequent encounter		
T518X2D Toxic effect of other alcohols, intentional self-harm, subsequent encounter		
T518X2S Toxic effect of other alcohols, intentional self-harm, sequela		
	T518X2S	Toxic effect of other alcohols, intentional self-harm, sequela

Code	Shortened Description
T5192XA	Toxic effect of unspecified alcohol, intentional self-harm, initial encounter
T5192XD	Toxic effect of unspecified alcohol, intentional self-harm, subsequent encounter
T5192XS	Toxic effect of unspecified alcohol, intentional self-harm, sequela
T520X2A	Toxic effect of petroleum products, intentional self-harm, initial encounter
T520X2D	Toxic effect of petroleum products, intentional self-harm, subsequent encounter
T520X2S	Toxic effect of petroleum products, intentional self-harm, sequela
T521X2A	Toxic effect of benzene, intentional self-harm, initial encounter
T521X2D	Toxic effect of benzene, intentional self-harm, subsequent encounter
T521X2S	Toxic effect of benzene, intentional self-harm, sequela
T522X2A	Toxic effect of homologues of benzene, intentional self-harm, initial encounter
T522X2D	Toxic effect of homologues of benzene, intentional self-harm, subsequent encounter
T522X2S	Toxic effect of homologues of benzene, intentional self-harm, sequela
T523X2A	Toxic effect of glycols, intentional self-harm, initial encounter
T523X2D	Toxic effect of glycols, intentional self-harm, subsequent encounter
T523X2S	Toxic effect of glycols, intentional self-harm, sequela
T524X2A	Toxic effect of ketones, intentional self-harm, initial encounter
T524X2D	Toxic effect of ketones, intentional self-harm, subsequent encounter
T524X2S	Toxic effect of ketones, intentional self-harm, sequela
T528X2A	Toxic effect of other organic solvents, intentional self-harm, initial encounter
T528X2D	Toxic effect of other organic solvents, intentional self-harm, subsequent encounter
T528X2S	Toxic effect of other organic solvents, intentional self-harm, sequela
T550X2A	Toxic effect of soaps, intentional self-harm, initial encounter
T550X2D	Toxic effect of soaps, intentional self-harm, subsequent encounter
T550X2S	Toxic effect of soaps, intentional self-harm, sequela
T551X2A	Toxic effect of detergents, intentional self-harm, initial encounter
T551X2D	Toxic effect of detergents, intentional self-harm, subsequent encounter
T551X2S	Toxic effect of detergents, intentional self-harm, sequela
T560X2A	Toxic effect of lead and its compounds, intentional self-harm, initial encounter
T560X2D	Toxic effect of lead and its compounds, intentional self-harm, subsequent encounter
T560X2S	Toxic effect of lead and its compounds, intentional self-harm, sequela
T561X2A	Toxic effect of mercury and its compounds, intentional self-harm, initial encounter
T561X2D	Toxic effect of mercury and its compounds, intentional self-harm, subsequent encounter
T561X2S	Toxic effect of mercury and its compounds, intentional self-harm, sequela
T562X2A	Toxic effect of chromium and its compounds, intentional self-harm, initial encounter
T562X2D	Toxic effect of chromium and its compounds, intentional self-harm, subsequent encounter
T562X2S	Toxic effect of chromium and its compounds, intentional self-harm, sequela
T563X2A	Toxic effect of cadmium and its compounds, intentional self-harm, initial encounter
T563X2D	Toxic effect of cadmium and its compounds, intentional self-harm, subsequent encounter
T563X2S	Toxic effect of cadmium and its compounds, intentional self-harm, sequela
T564X2A	Toxic effect of copper and its compounds, intentional self-harm, initial encounter
T564X2D	Toxic effect of copper and its compounds, intentional self-harm, subsequent encounter
T564X2S	Toxic effect of copper and its compounds, intentional self-harm, sequela
T565X2A	Toxic effect of zinc and its compounds, intentional self-harm, initial encounter
T565X2D	Toxic effect of zinc and its compounds, intentional self-harm, subsequent encounter
T565X2S T566X2A	Toxic effect of zinc and its compounds, intentional self-harm, sequela  Toxic effect of tin and its compounds, intentional self-harm, initial encounter
T566X2D	Toxic effect of tin and its compounds, intentional self-narm, initial encounter  Toxic effect of tin and its compounds, intentional self-harm, subsequent encounter
T566X2S	Toxic effect of tin and its compounds, intentional self-harm, sequela
T567X2A	Toxic effect of thi and its compounds, intentional self-harm, initial encounter
T567X2D	Toxic effect of beryllium and its compounds, intentional self-harm, subsequent encounter
T567X2S	Toxic effect of beryllium and its compounds, intentional self-harm, sequela
T56812A	Toxic effect of thallium, intentional self-harm, initial encounter
T56812D	Toxic effect of thallium, intentional self-harm, subsequent encounter
T56812S	Toxic effect of thallium, intentional self-harm, sequela
T56892A	Toxic effect of other metals, intentional self-harm, initial encounter
	1,

Code	Shortened Description
T56892D	Toxic effect of other metals, intentional self-harm, subsequent encounter
T56892S	Toxic effect of other metals, intentional self-harm, sequela
T5692XA	Toxic effect of unspecified metal, intentional self-harm, initial encounter
T5692XD	Toxic effect of unspecified metal, intentional self-harm, subsequent encounter
T5692XS	Toxic effect of unspecified metal, intentional self-harm, sequela
T570X2A	Toxic effect of arsenic and its compounds, intentional self-harm, initial encounter
T570X2D	Toxic effect of arsenic and its compounds, intentional self-harm, subsequent encounter
T570X2S	Toxic effect of arsenic and its compounds, intentional self-harm, sequela
T571X2A	Toxic effect of phosphorus and its compounds, intentional self-harm, initial encounter
T571X2D	Toxic effect of phosphorus and its compounds, intentional self-harm, subsequent encounter
T571X2S	Toxic effect of phosphorus and its compounds, intentional self-harm, sequela
T572X2A	Toxic effect of manganese and its compounds, intentional self-harm, initial encounter
T572X2D	Toxic effect of manganese and its compounds, intentional self-harm, subsequent encounter
T572X2S	Toxic effect of manganese and its compounds, intentional self-harm, sequela
T573X2A	Toxic effect of hydrogen cyanide, intentional self-harm, initial encounter
T573X2D	Toxic effect of hydrogen cyanide, intentional self-harm, subsequent encounter
T573X2B	Toxic effect of hydrogen cyanide, intentional self-harm, sequela
T578X2A	Toxic effect of other specified inorganic substances, intentional self-harm, initial encounter
T578X2D	Toxic effect of other specified inorganic substances, intentional self-harm, subsequent encounter
T578X2S	Toxic effect of other specified inorganic substances, intentional self-harm, sequela
T5792XA	Toxic effect of unspecified inorganic substance, intentional self-harm, initial encounter
T5792XA	Toxic effect of unspecified inorganic substance, intentional self-harm, subsequent encounter
T5792XS	Toxic effect of unspecified inorganic substance, intentional self-harm, sequela
T5802XA	Toxic effect of carbon monoxide from motor vehicle exhaust, intentional self-harm, initial encounter
T5802XA	Toxic effect of carbon monoxide from motor vehicle exhaust, intentional self-harm, subsequent encounter
T5802XD	Toxic effect of carbon monoxide from motor vehicle exhaust, intentional self-harm, sequela
T5812XA	Toxic effect of carbon monoxide from utility gas, intentional self-harm, initial encounter
T5812XA	Toxic effect of carbon monoxide from utility gas, intentional self-harm, subsequent encounter
T5812XS	Toxic effect of carbon monoxide from utility gas, intentional self-harm, sequela
13612A3	Toxic effect of carbon monoxide from incomplete combustion of other domestic fuels, intentional self-harm,
T582X2A	initial encounter
	Toxic effect of carbon monoxide from incomplete combustion of other domestic fuels, intentional self-harm,
T582X2D	subsequent encounter
	Toxic effect of carbon monoxide from incomplete combustion of other domestic fuels, intentional self-harm,
T582X2S	
T588X2A	sequela  Toxic effect of carbon monoxide from other source, intentional self-harm, initial encounter
T588X2D	
	Toxic effect of carbon monoxide from other source, intentional self-harm, subsequent encounter
T588X2S T5892XA	Toxic effect of carbon monoxide from other source, intentional self-harm, sequela  Toxic effect of carbon monoxide from unspecified source, intentional self-harm, initial encounter
T5892XA	Toxic effect of carbon monoxide from unspecified source, intentional self-harm, subsequent encounter
T5892XD	Toxic effect of carbon monoxide from unspecified source, intentional self-harm, sequela
T590X2A	Toxic effect of carbon monoxide from unspectified source, intentional self-narm, sequera  Toxic effect of nitrogen oxides, intentional self-harm, initial encounter
T590X2A	Toxic effect of nitrogen oxides, intentional self-harm, subsequent encounter
T590X2D	Toxic effect of nitrogen oxides, intentional self-harm, sequela
T591X2A	Toxic effect of introgen oxides, intentional self-harm, initial encounter
T591X2A	Toxic effect of sulfur dioxide, intentional self-harm, subsequent encounter
T591X2D	Toxic effect of sulfur dioxide, intentional self-harm, sequela
T592X2A	Toxic effect of formaldehyde, intentional self-harm, initial encounter
T592X2A	Toxic effect of formaldehyde, intentional self-harm, subsequent encounter
T592X2D	Toxic effect of formaldehyde, intentional self-harm, squela
	Toxic effect of lacrimogenic gas, intentional self-harm, initial encounter
T593X2A T593X2D	Toxic effect of lacrimogenic gas, intentional self-harm, subsequent encounter
T593X2D T593X2S	Toxic effect of lacrimogenic gas, intentional self-harm, subsequent encounter  Toxic effect of lacrimogenic gas, intentional self-harm, sequela
T594X2A	Toxic effect of chlorine gas, intentional self-harm, initial encounter
T594X2D	Toxic effect of chlorine gas, intentional self-harm, subsequent encounter

Code	Shortened Description
T594X2S	Toxic effect of chlorine gas, intentional self-harm, sequela
T595X2A	Toxic effect of fluorine gas and hydrogen fluoride, intentional self-harm, initial encounter
T595X2D	Toxic effect of fluorine gas and hydrogen fluoride, intentional self-harm, subsequent encounter
T595X2S	Toxic effect of fluorine gas and hydrogen fluoride, intentional self-harm, sequela
T600X2A	Toxic effect of organophosphate and carbamate insecticides, intentional self-harm, initial encounter
T600X2D	Toxic effect of organophosphate and carbamate insecticides, intentional self-harm, subsequent encounter
T600X2S	Toxic effect of organophosphate and carbamate insecticides, intentional self-harm, sequela
T601X2A	Toxic effect of halogenated insecticides, intentional self-harm, initial encounter
T601X2D	Toxic effect of halogenated insecticides, intentional self-harm, subsequent encounter
T601X2S	Toxic effect of halogenated insecticides, intentional self-harm, sequela
T602X2A	Toxic effect of other insecticides, intentional self-harm, initial encounter
T602X2D	Toxic effect of other insecticides, intentional self-harm, subsequent encounter
T602X2S	Toxic effect of other insecticides, intentional self-harm, sequela
T603X2A	Toxic effect of herbicides and fungicides, intentional self-harm, initial encounter
T603X2D	Toxic effect of herbicides and fungicides, intentional self-harm, subsequent encounter
T603X2S	Toxic effect of herbicides and fungicides, intentional self-harm, sequela
T604X2A	Toxic effect of rodenticides, intentional self-harm, initial encounter
T604X2D	Toxic effect of rodenticides, intentional self-harm, subsequent encounter
T604X2S	Toxic effect of rodenticides, intentional self-harm, sequela
T608X2A	Toxic effect of other pesticides, intentional self-harm, initial encounter
T608X2D	Toxic effect of other pesticides, intentional self-harm, subsequent encounter
T608X2S	Toxic effect of other pesticides, intentional self-harm, sequela
T6092XA	Toxic effect of unspecified pesticide, intentional self-harm, initial encounter
T6092XD	Toxic effect of unspecified pesticide, intentional self-harm, subsequent encounter
T6092XS	Toxic effect of unspecified pesticide, intentional self-harm, sequela
T6102XA	Ciguatera fish poisoning, intentional self-harm, initial encounter
T6102XD	Ciguatera fish poisoning, intentional self-harm, subsequent encounter
T6102XS	Ciguatera fish poisoning, intentional self-harm, sequela
T6112XA	Scombroid fish poisoning, intentional self-harm, initial encounter
T6112XD	Scombroid fish poisoning, intentional self-harm, subsequent encounter
T6112XS	Scombroid fish poisoning, intentional self-harm, sequela
T61772A	Other fish poisoning, intentional self-harm, initial encounter
T61772D	Other fish poisoning, intentional self-harm, subsequent encounter
T61772S	Other fish poisoning, intentional self-harm, sequela
T61782A	Other shellfish poisoning, intentional self-harm, initial encounter
T61782D	Other shellfish poisoning, intentional self-harm, subsequent encounter
T61782S	Other shellfish poisoning, intentional self-harm, sequela
T618X2A	Toxic effect of other seafood, intentional self-harm, initial encounter
T618X2D	Toxic effect of other seafood, intentional self-harm, subsequent encounter
T618X2S	Toxic effect of other seafood, intentional self-harm, sequela
T6192XA	Toxic effect of unspecified seafood, intentional self-harm, initial encounter
T6192XD	Toxic effect of unspecified seafood, intentional self-harm, subsequent encounter
T6192XS	Toxic effect of unspecified seafood, intentional self-harm, sequela
T620X2A	Toxic effect of ingested mushrooms, intentional self-harm, initial encounter
T620X2D	Toxic effect of ingested mushrooms, intentional self-harm, subsequent encounter
T620X2S	Toxic effect of ingested mushrooms, intentional self-harm, sequela
T621X2A	Toxic effect of ingested berries, intentional self-harm, initial encounter
T621X2D	Toxic effect of ingested berries, intentional self-harm, subsequent encounter
T621X2S	Toxic effect of ingested berries, intentional self-harm, sequela
T622X2A	Toxic effect of other ingested (parts of) plant(s), intentional self-harm, initial encounter
T622X2D	Toxic effect of other ingested (parts of) plant(s), intentional self-harm, subsequent encounter
T622X2S	Toxic effect of other ingested (parts of) plant(s), intentional self-harm, sequela
T628X2A	Toxic effect of other specified noxious substances eaten as food, intentional self-harm, initial encounter
T628X2D	Toxic effect of other specified noxious substances eaten as food, intentional self-harm, subsequent encounter
T628X2S	Toxic effect of other specified noxious substances eaten as food, intentional self-harm, sequela

Code	Shortened Description
T6292XA	Toxic effect of unspecified noxious substance eaten as food, intentional self-harm, initial encounter
T6292XD	Toxic effect of unspecified noxious substance eaten as food, intentional self-harm, subsequent encounter
T6292XS	Toxic effect of unspecified noxious substance eaten as food, intentional self-harm, sequela
T63002A	Toxic effect of unspecified snake venom, intentional self-harm, initial encounter
T63002D	Toxic effect of unspecified snake venom, intentional self-harm, subsequent encounter
T63002S	Toxic effect of unspecified snake venom, intentional self-harm, sequela
T63012A	Toxic effect of rattlesnake venom, intentional self-harm, initial encounter
T63012D	Toxic effect of rattlesnake venom, intentional self-harm, subsequent encounter
T63012S	Toxic effect of rattlesnake venom, intentional self-harm, sequela
T63022A	Toxic effect of coral snake venom, intentional self-harm, initial encounter
T63022D	Toxic effect of coral snake venom, intentional self-harm, subsequent encounter
T63022S	Toxic effect of coral snake venom, intentional self-harm, sequela
T63032A	Toxic effect of taipan venom, intentional self-harm, initial encounter
T63032D	Toxic effect of taipan venom, intentional self-harm, subsequent encounter
T63032S	Toxic effect of taipan venom, intentional self-harm, sequela
T63042A	Toxic effect of cobra venom, intentional self-harm, initial encounter
T63042D	Toxic effect of cobra venom, intentional self-harm, subsequent encounter
T63042S	Toxic effect of cobra venom, intentional self-harm, sequela
T63062A	Toxic effect of venom of other North and South American snake, intentional self-harm, initial encounter
T63062D	Toxic effect of venom of other North and South American snake, intentional self-harm, subsequent encounter
T63062S	Toxic effect of venom of other North and South American snake, intentional self-harm, sequela
T63072A	Toxic effect of venom of other Australian snake, intentional self-harm, initial encounter
T63072D	Toxic effect of venom of other Australian snake, intentional self-harm, subsequent encounter
T63072S	Toxic effect of venom of other Australian snake, intentional self-harm, sequela
T63082A	Toxic effect of venom of other African and Asian snake, intentional self-harm, initial encounter
T63082D	Toxic effect of venom of other African and Asian snake, intentional self-harm, subsequent encounter
T63082S	Toxic effect of venom of other African and Asian snake, intentional self-harm, sequela
T63092A	Toxic effect of venom of other snake, intentional self-harm, initial encounter
T63092D	Toxic effect of venom of other snake, intentional self-harm, subsequent encounter
T63092S	Toxic effect of venom of other snake, intentional self-harm, sequela
T63112A	Toxic effect of venom of gila monster, intentional self-harm, initial encounter
T63112D	Toxic effect of venom of gila monster, intentional self-harm, subsequent encounter
T63112S	Toxic effect of venom of gila monster, intentional self-harm, sequela
T63122A	Toxic effect of venom of other venomous lizard, intentional self-harm, initial encounter
T63122D	Toxic effect of venom of other venomous lizard, intentional self-harm, subsequent encounter
T63122S	Toxic effect of venom of other venomous lizard, intentional self-harm, sequela
T63192A	Toxic effect of venom of other reptiles, intentional self-harm, initial encounter
T63192D	Toxic effect of venom of other reptiles, intentional self-harm, subsequent encounter
T63192S	Toxic effect of venom of other reptiles, intentional self-harm, sequela
T632X2A	Toxic effect of venom of scorpion, intentional self-harm, initial encounter
T632X2D	Toxic effect of venom of scorpion, intentional self-harm, subsequent encounter
T632X2S	Toxic effect of venom of scorpion, intentional self-harm, sequela
T63302A	Toxic effect of unspecified spider venom, intentional self-harm, initial encounter
T63302D	Toxic effect of unspecified spider venom, intentional self-harm, subsequent encounter
T63302S	Toxic effect of unspecified spider venom, intentional self-harm, sequela
T63312A	Toxic effect of venom of black widow spider, intentional self-harm, initial encounter
T63312D	Toxic effect of venom of black widow spider, intentional self-harm, subsequent encounter
T63312S	Toxic effect of venom of black widow spider, intentional self-harm, sequela
T63322A	Toxic effect of venom of tarantula, intentional self-harm, initial encounter
T63322D	Toxic effect of venom of tarantula, intentional self-harm, subsequent encounter
T63322S	Toxic effect of venom of tarantula, intentional self-harm, sequela
T63332A	Toxic effect of venom of brown recluse spider, intentional self-harm, initial encounter
T63332D	Toxic effect of venom of brown recluse spider, intentional self-harm, subsequent encounter
T63332S	Toxic effect of venom of brown recluse spider, intentional self-harm, sequela
T63392A	Toxic effect of venom of other spider, intentional self-harm, initial encounter

n, initial encounter n, subsequent encounter n, sequela
n, subsequent encounter n, sequela
n, subsequent encounter n, sequela
n, subsequent encounter n, sequela
ı, sequela
er
-01
ınter
encounter
ounter
t encounter
nter
er
• • • •
initial encounter
subsequent encounter
sequela
counter
ent encounter
ton
ounter
t encounter
ınter
intel
ınter
ınter
unter l encounter
1

CodeShortened DescriptionT63832SToxic effect of contact with other venomous amphibian, intentional self-harm, sequelaT63892AToxic effect of contact with other venomous animals, intentional self-harm, initial encoT63892DToxic effect of contact with other venomous animals, intentional self-harm, subsequentT63892SToxic effect of contact with other venomous animals, intentional self-harm, sequelaT6392XAToxic effect of contact with unspecified venomous animal, intentional self-harm, initialT6392XDToxic effect of contact with unspecified venomous animal, intentional self-harm, subsequentT6402XAToxic effect of aflatoxin, intentional self-harm, initial encounterT6402XDToxic effect of aflatoxin, intentional self-harm, subsequent encounterT6402XSToxic effect of aflatoxin, intentional self-harm, sequelaT6482XAToxic effect of other mycotoxin food contaminants, intentional self-harm, initial encounterT6482XDToxic effect of other mycotoxin food contaminants, intentional self-harm, subsequent encounterT6482XSToxic effect of other mycotoxin food contaminants, intentional self-harm, subsequent encounter	encounter  encounter  quent encounter
Toxic effect of contact with other venomous animals, intentional self-harm, initial enco Toxic effect of contact with other venomous animals, intentional self-harm, subsequent Toxic effect of contact with other venomous animals, intentional self-harm, sequela Toxic effect of contact with unspecified venomous animal, intentional self-harm, initial Toxic effect of contact with unspecified venomous animal, intentional self-harm, subsective of toxic effect of contact with unspecified venomous animal, intentional self-harm, sequel Toxic effect of aflatoxin, intentional self-harm, initial encounter Toxic effect of aflatoxin, intentional self-harm, subsequent encounter Toxic effect of aflatoxin, intentional self-harm, sequela Toxic effect of aflatoxin, intentional self-harm, sequela Toxic effect of other mycotoxin food contaminants, intentional self-harm, initial encounter Toxic effect of other mycotoxin food contaminants, intentional self-harm, subsequent encounter Toxic effect of other mycotoxin food contaminants, intentional self-harm, subsequent encounter Toxic effect of other mycotoxin food contaminants, intentional self-harm, subsequent encounter Toxic effect of other mycotoxin food contaminants, intentional self-harm, subsequent encounter	encounter  encounter  quent encounter
Toxic effect of contact with other venomous animals, intentional self-harm, subsequent Toxic effect of contact with other venomous animals, intentional self-harm, sequela Toxic effect of contact with unspecified venomous animal, intentional self-harm, initial Toxic effect of contact with unspecified venomous animal, intentional self-harm, subsect Toxic effect of contact with unspecified venomous animal, intentional self-harm, subsect Toxic effect of contact with unspecified venomous animal, intentional self-harm, sequel Toxic effect of aflatoxin, intentional self-harm, initial encounter Toxic effect of aflatoxin, intentional self-harm, subsequent encounter Toxic effect of aflatoxin, intentional self-harm, sequela Toxic effect of other mycotoxin food contaminants, intentional self-harm, initial encounter Toxic effect of other mycotoxin food contaminants, intentional self-harm, subsequent encounter Toxic effect of other mycotoxin food contaminants, intentional self-harm, subsequent encounter Toxic effect of other mycotoxin food contaminants, intentional self-harm, subsequent encounter	encounter l encounter quent encounter
T63892S Toxic effect of contact with other venomous animals, intentional self-harm, sequela T6392XA Toxic effect of contact with unspecified venomous animal, intentional self-harm, initial T6392XD Toxic effect of contact with unspecified venomous animal, intentional self-harm, subset T6392XS Toxic effect of contact with unspecified venomous animal, intentional self-harm, seque T6402XA Toxic effect of aflatoxin, intentional self-harm, initial encounter T6402XD Toxic effect of aflatoxin, intentional self-harm, subsequent encounter T6402XS Toxic effect of aflatoxin, intentional self-harm, sequela T6482XA Toxic effect of other mycotoxin food contaminants, intentional self-harm, initial encounter T6482XD Toxic effect of other mycotoxin food contaminants, intentional self-harm, subsequent encounter	l encounter quent encounter
Toxic effect of contact with unspecified venomous animal, intentional self-harm, initial Tosayaxa Toxic effect of contact with unspecified venomous animal, intentional self-harm, subsect Toxic effect of contact with unspecified venomous animal, intentional self-harm, seque Toxic effect of aflatoxin, intentional self-harm, initial encounter Toxic effect of aflatoxin, intentional self-harm, subsequent encounter Toxic effect of aflatoxin, intentional self-harm, sequela Toxic effect of aflatoxin, intentional self-harm, sequela Toxic effect of other mycotoxin food contaminants, intentional self-harm, initial encounter Toxic effect of other mycotoxin food contaminants, intentional self-harm, subsequent encounter Toxic effect of other mycotoxin food contaminants, intentional self-harm, subsequent encounter Toxic effect of other mycotoxin food contaminants, intentional self-harm, subsequent encounter Toxic effect of other mycotoxin food contaminants, intentional self-harm, subsequent encounter Toxic effect of other mycotoxin food contaminants, intentional self-harm, subsequent encounter Toxic effect of other mycotoxin food contaminants, intentional self-harm, subsequent encounter Toxic effect of other mycotoxin food contaminants, intentional self-harm, subsequent encounter Toxic effect of other mycotoxin food contaminants, intentional self-harm, subsequent encounter Toxic effect of other mycotoxin food contaminants, intentional self-harm, subsequent encounter Toxic effect of other mycotoxin food contaminants, intentional self-harm, subsequent encounter Toxic effect of other mycotoxin food contaminants, intentional self-harm, subsequent encounter Toxic effect of other mycotoxin food contaminants.	quent encounter
T6392XD Toxic effect of contact with unspecified venomous animal, intentional self-harm, subset T6392XS Toxic effect of contact with unspecified venomous animal, intentional self-harm, seque T6402XA Toxic effect of aflatoxin, intentional self-harm, initial encounter T6402XD Toxic effect of aflatoxin, intentional self-harm, subsequent encounter T6402XS Toxic effect of aflatoxin, intentional self-harm, sequela Toxic effect of other mycotoxin food contaminants, intentional self-harm, initial encounter T6482XA Toxic effect of other mycotoxin food contaminants, intentional self-harm, subsequent encounter Toxic effect of other mycotoxin food contaminants, intentional self-harm, subsequent encounter Toxic effect of other mycotoxin food contaminants, intentional self-harm, subsequent encounter Toxic effect of other mycotoxin food contaminants, intentional self-harm, subsequent encounter Toxic effect of other mycotoxin food contaminants, intentional self-harm, subsequent encounter Toxic effect of other mycotoxin food contaminants, intentional self-harm, subsequent encounter Toxic effect of other mycotoxin food contaminants, intentional self-harm, subsequent encounter Toxic effect of other mycotoxin food contaminants, intentional self-harm, subsequent encounter Toxic effect of other mycotoxin food contaminants.	quent encounter
Toxic effect of contact with unspecified venomous animal, intentional self-harm, seque Toxic effect of aflatoxin, intentional self-harm, initial encounter Toxic effect of aflatoxin, intentional self-harm, subsequent encounter Toxic effect of aflatoxin, intentional self-harm, sequela Toxic effect of aflatoxin, intentional self-harm, sequela Toxic effect of other mycotoxin food contaminants, intentional self-harm, initial encounter Toxic effect of other mycotoxin food contaminants, intentional self-harm, subsequent encounter Toxic effect of other mycotoxin food contaminants, intentional self-harm, subsequent encounter Toxic effect of other mycotoxin food contaminants, intentional self-harm, subsequent encounter Toxic effect of other mycotoxin food contaminants, intentional self-harm, subsequent encounter Toxic effect of other mycotoxin food contaminants, intentional self-harm, subsequent encounter Toxic effect of other mycotoxin food contaminants, intentional self-harm, subsequent encounter Toxic effect of other mycotoxin food contaminants, intentional self-harm, subsequent encounter Toxic effect of other mycotoxin food contaminants, intentional self-harm, subsequent encounter Toxic effect of other mycotoxin food contaminants, intentional self-harm, subsequent encounter Toxic effect of other mycotoxin food contaminants.	
T6402XAToxic effect of aflatoxin, intentional self-harm, initial encounterT6402XDToxic effect of aflatoxin, intentional self-harm, subsequent encounterT6402XSToxic effect of aflatoxin, intentional self-harm, sequelaT6482XAToxic effect of other mycotoxin food contaminants, intentional self-harm, initial encounterT6482XDToxic effect of other mycotoxin food contaminants, intentional self-harm, subsequent encounter	
T6402XDToxic effect of aflatoxin, intentional self-harm, subsequent encounterT6402XSToxic effect of aflatoxin, intentional self-harm, sequelaT6482XAToxic effect of other mycotoxin food contaminants, intentional self-harm, initial encounterT6482XDToxic effect of other mycotoxin food contaminants, intentional self-harm, subsequent encounter	
T6402XS Toxic effect of aflatoxin, intentional self-harm, sequela  T6482XA Toxic effect of other mycotoxin food contaminants, intentional self-harm, initial encour  T6482XD Toxic effect of other mycotoxin food contaminants, intentional self-harm, subsequent en	
T6482XA Toxic effect of other mycotoxin food contaminants, intentional self-harm, initial encour T6482XD Toxic effect of other mycotoxin food contaminants, intentional self-harm, subsequent en	
T6482XD Toxic effect of other mycotoxin food contaminants, intentional self-harm, subsequent en	 nter
	neounter
T650X2A Toxic effect of cyanides, intentional self-harm, initial encounter	
T650X2D Toxic effect of cyanides, intentional self-harm, subsequent encounter	
T650X2S Toxic effect of cyanides, intentional self-harm, sequela	
	_
T651X2A Toxic effect of strychnine and its salts, intentional self-harm, initial encounter	
T651X2D Toxic effect of strychnine and its salts, intentional self-harm, subsequent encounter T651X2S Toxic effect of strychnine and its salts, intentional self-harm, sequela	
T65212A Toxic effect of chewing tobacco, intentional self-harm, initial encounter T65212D Toxic effect of chewing tobacco, intentional self-harm, subsequent encounter	
T65212S Toxic effect of chewing tobacco, intentional self-harm, sequela	
T65222A Toxic effect of tobacco cigarettes, intentional self-harm, initial encounter	
T65222D Toxic effect of tobacco cigarettes, intentional self-harm, subsequent encounter	
T65222S Toxic effect of tobacco cigarettes, intentional self-harm, sequela	
T65292A Toxic effect of other tobacco and nicotine, intentional self-harm, initial encounter	
T65292D Toxic effect of other tobacco and nicotine, intentional self-harm, subsequent encounter	
T65292S Toxic effect of other tobacco and nicotine, intentional self-harm, sequela	1 101
Toxic effect of nitroderivatives and aminoderivatives of benzene and its homologues, in	itentional self-harm,
initial encounter	
Toxic effect of nitroderivatives and aminoderivatives of benzene and its homologues, in	itentional self-harm,
subsequent encounter	
Toxic effect of nitroderivatives and aminoderivatives of benzene and its homologues, in	ntentional self-harm,
sequela	
T654X2A Toxic effect of carbon disulfide, intentional self-harm, initial encounter	
T654X2D Toxic effect of carbon disulfide, intentional self-harm, subsequent encounter	
T654X2S Toxic effect of carbon disulfide, intentional self-harm, sequela	
T655X2A Toxic effect of nitroglycerin and other nitric acids and esters, intentional self-harm, init	
T655X2D Toxic effect of nitroglycerin and other nitric acids and esters, intentional self-harm, sub	
T655X2S Toxic effect of nitroglycerin and other nitric acids and esters, intentional self-harm, seq	
T656X2A Toxic effect of paints and dyes, not elsewhere classified, intentional self-harm, initial en	
T656X2D Toxic effect of paints and dyes, not elsewhere classified, intentional self-harm, subsequ	ent encounter
T656X2S Toxic effect of paints and dyes, not elsewhere classified, intentional self-harm, sequela	
T65812A Toxic effect of latex, intentional self-harm, initial encounter	
T65812D Toxic effect of latex, intentional self-harm, subsequent encounter	
T65812S Toxic effect of latex, intentional self-harm, sequela	
T65822A Toxic effect of harmful algae and algae toxins, intentional self-harm, initial encounter	
T65822D Toxic effect of harmful algae and algae toxins, intentional self-harm, subsequent encountries and algae toxins are self-harm.	nter
T65822S Toxic effect of harmful algae and algae toxins, intentional self-harm, sequela	
T65832A Toxic effect of fiberglass, intentional self-harm, initial encounter	
T65832D Toxic effect of fiberglass, intentional self-harm, subsequent encounter	
T65832S Toxic effect of fiberglass, intentional self-harm, sequela	
T65892A Toxic effect of other specified substances, intentional self-harm, initial encounter	
T65892D Toxic effect of other specified substances, intentional self-harm, subsequent encounter	

Code	Shortened Description
T6592XA	Toxic effect of unspecified substance, intentional self-harm, initial encounter
T6592XD	Toxic effect of unspecified substance, intentional self-harm, subsequent encounter
T6592XS	Toxic effect of unspecified substance, intentional self-harm, sequela
X710XXA	Intentional self-harm by drowning and submersion while in bathtub, initial encounter
X710XXD	Intentional self-harm by drowning and submersion while in bathtub, subsequent encounter
X710XXS	Intentional self-harm by drowning and submersion while in bathtub, sequela
X711XXA	Intentional self-harm by drowning and submersion while in swimming pool, initial encounter
X711XXD	Intentional self-harm by drowning and submersion while in swimming pool, subsequent encounter
X711XXS	Intentional self-harm by drowning and submersion while in swimming pool, sequela
X712XXA	Intentional self-harm by drowning and submersion after jump into swimming pool, initial encounter
X712XXD	Intentional self-harm by drowning and submersion after jump into swimming pool, subsequent encounter
X712XXS	Intentional self-harm by drowning and submersion after jump into swimming pool, sequela
X713XXA	Intentional self-harm by drowning and submersion in natural water, initial encounter
X713XXD	Intentional self-harm by drowning and submersion in natural water, subsequent encounter
X713XXS	Intentional self-harm by drowning and submersion in natural water, sequela
X718XXA	Other intentional self-harm by drowning and submersion, initial encounter
X718XXD	Other intentional self-harm by drowning and submersion, subsequent encounter
X718XXS	Other intentional self-harm by drowning and submersion, sequela
X719XXA	Intentional self-harm by drowning and submersion, unspecified, initial encounter
X719XXD	Intentional self-harm by drowning and submersion, unspecified, subsequent encounter
X719XXS	Intentional self-harm by drowning and submersion, unspecified, sequela
X72XXXA	Intentional self-harm by handgun discharge, initial encounter
X72XXXD	Intentional self-harm by handgun discharge, subsequent encounter
X72XXXS	Intentional self-harm by handgun discharge, sequela
X730XXA	Intentional self-harm by shotgun discharge, initial encounter
X730XXD	Intentional self-harm by shotgun discharge, subsequent encounter
X730XXS	Intentional self-harm by shotgun discharge, sequela
X731XXA	Intentional self-harm by hunting rifle discharge, initial encounter
X731XXD	Intentional self-harm by hunting rifle discharge, subsequent encounter
X731XXS	Intentional self-harm by hunting rifle discharge, sequela
X732XXA	Intentional self-harm by machine gun discharge, initial encounter
X732XXD	Intentional self-harm by machine gun discharge, subsequent encounter
X732XXS	Intentional self-harm by machine gun discharge, sequela
X738XXA	Intentional self-harm by other larger firearm discharge, initial encounter
X738XXD	Intentional self-harm by other larger firearm discharge, subsequent encounter
X738XXS	Intentional self-harm by other larger firearm discharge, sequela
X739XXA	Intentional self-harm by unspecified larger firearm discharge, initial encounter
X739XXD	Intentional self-harm by unspecified larger firearm discharge, subsequent encounter
X739XXS	Intentional self-harm by unspecified larger firearm discharge, sequela
X7401XA	Intentional self-harm by airgun, initial encounter
X7401XD	Intentional self-harm by airgun, subsequent encounter
X7401XS	Intentional self-harm by airgun, sequela
X7402XA	Intentional self-harm by paintball gun, initial encounter
X7402XD	Intentional self-harm by paintball gun, subsequent encounter
X7402XS	Intentional self-harm by paintball gun, sequela
X7409XA	Intentional self-harm by other gas, air or spring-operated gun, initial encounter
X7409XD	Intentional self-harm by other gas, air or spring-operated gun, subsequent encounter
X7409XS	Intentional self-harm by other gas, air or spring-operated gun, sequela
X748XXA	Intentional self-harm by other firearm discharge, initial encounter
X748XXD	Intentional self-harm by other firearm discharge, subsequent encounter
X748XXS	Intentional self-harm by other firearm discharge, sequela
X749XXA	Intentional self-harm by unspecified firearm discharge, initial encounter
X749XXD	Intentional self-harm by unspecified firearm discharge, subsequent encounter
X749XXS	Intentional self-harm by unspecified firearm discharge, sequela
X75XXXA	Intentional self-harm by explosive material, initial encounter

Code	Shortened Description
X75XXXD	Intentional self-harm by explosive material, subsequent encounter
X75XXXS	Intentional self-harm by explosive material, sequela
X76XXXA	Intentional self-harm by smoke, fire and flames, initial encounter
X76XXXD	Intentional self-harm by smoke, fire and flames, subsequent encounter
X76XXXS	Intentional self-harm by smoke, fire and flames, sequela
X770XXA	Intentional self-harm by steam or hot vapors, initial encounter
X770XXD	Intentional self-harm by steam or hot vapors, subsequent encounter
X770XXS	Intentional self-harm by steam or hot vapors, sequela
X771XXA	Intentional self-harm by hot tap water, initial encounter
X771XXX X771XXD	Intentional self-harm by hot tap water, subsequent encounter
X771XXS	Intentional self-harm by hot tap water, sequela
X772XXA	Intentional self-harm by other hot fluids, initial encounter
X772XXD	Intentional self-harm by other hot fluids, subsequent encounter
X772XXS	Intentional self-harm by other hot fluids, sequela
X773XXA	Intentional self-harm by hot household appliances, initial encounter
X773XXD	Intentional self-harm by hot household appliances, subsequent encounter
X773XXS	Intentional self-harm by hot household appliances, sequela
X778XXA	Intentional self-harm by other hot objects, initial encounter
X778XXD	Intentional self-harm by other hot objects, subsequent encounter
X778XXS	Intentional self-harm by other hot objects, sequela
X779XXA	Intentional self-harm by unspecified hot objects, initial encounter
X779XXD	Intentional self-harm by unspecified hot objects, subsequent encounter
X779XXS	Intentional self-harm by unspecified hot objects, sequela
X780XXA	Intentional self-harm by sharp glass, initial encounter
X780XXD	Intentional self-harm by sharp glass, subsequent encounter
X780XXS	Intentional self-harm by sharp glass, sequela
X781XXA	Intentional self-harm by knife, initial encounter
X781XXD	Intentional self-harm by knife, subsequent encounter
X781XXS	Intentional self-harm by knife, sequela
X782XXA	Intentional self-harm by sword or dagger, initial encounter
X782XXD	Intentional self-harm by sword or dagger, subsequent encounter
X782XXS	Intentional self-harm by sword or dagger, sequela
X782XXA	Intentional self-harm by other sharp object, initial encounter
	Intentional self-harm by other sharp object, initial encounter
X788XXD	, , , , ,
X788XXS	Intentional self-harm by other sharp object, sequela
X789XXA	Intentional self-harm by unspecified sharp object, initial encounter
X789XXD	Intentional self-harm by unspecified sharp object, subsequent encounter
X789XXS	Intentional self-harm by unspecified sharp object, sequela
X79XXXA	Intentional self-harm by blunt object, initial encounter
X79XXXD	Intentional self-harm by blunt object, subsequent encounter
X79XXXS	Intentional self-harm by blunt object, sequela
X80XXXA	Intentional self-harm by jumping from a high place, initial encounter
X80XXXD	Intentional self-harm by jumping from a high place, subsequent encounter
X80XXXS	Intentional self-harm by jumping from a high place, sequela
X810XXA	Intentional self-harm by jumping or lying in front of motor vehicle, initial encounter
X810XXD	Intentional self-harm by jumping or lying in front of motor vehicle, subsequent encounter
X810XXS	Intentional self-harm by jumping or lying in front of motor vehicle, sequela
X811XXA	Intentional self-harm by jumping or lying in front of (subway) train, initial encounter
X811XXD	Intentional self-harm by jumping or lying in front of (subway) train, subsequent encounter
X811XXS	Intentional self-harm by jumping or lying in front of (subway) train, sequela
X818XXA	Intentional self-harm by jumping or lying in front of other moving object, initial encounter
X818XXD	Intentional self-harm by jumping or lying in front of other moving object, subsequent encounter
2 X O 1 O 2 X 2 X X D	
XX18XXC	Intentional self-harm by jumning or lying in front of other moving object, sequels
X818XXS X820XXA	Intentional self-harm by jumping or lying in front of other moving object, sequela  Intentional collision of motor vehicle with other motor vehicle, initial encounter

C	
Code	Shortened Description
X820XXS	Intentional collision of motor vehicle with other motor vehicle, sequela
X821XXA	Intentional collision of motor vehicle with train, initial encounter
X821XXD	Intentional collision of motor vehicle with train, subsequent encounter
X821XXS	Intentional collision of motor vehicle with train, sequela
X822XXA	Intentional collision of motor vehicle with tree, initial encounter
X822XXD	Intentional collision of motor vehicle with tree, subsequent encounter
X822XXS	Intentional collision of motor vehicle with tree, sequela
X828XXA	Other intentional self-harm by crashing of motor vehicle, initial encounter
X828XXD	Other intentional self-harm by crashing of motor vehicle, subsequent encounter
X828XXS	Other intentional self-harm by crashing of motor vehicle, sequela
X830XXA	Intentional self-harm by crashing of aircraft, initial encounter
X830XXD	Intentional self-harm by crashing of aircraft, subsequent encounter
X830XXS	Intentional self-harm by crashing of aircraft, sequela
X831XXA	Intentional self-harm by electrocution, initial encounter
X831XXD	Intentional self-harm by electrocution, subsequent encounter
X831XXS	Intentional self-harm by electrocution, sequela
X832XXA	Intentional self-harm by exposure to extremes of cold, initial encounter
X832XXD	Intentional self-harm by exposure to extremes of cold, subsequent encounter
X832XXS	Intentional self-harm by exposure to extremes of cold, sequela
X838XXA	Intentional self-harm by other specified means, initial encounter
X838XXD	Intentional self-harm by other specified means, subsequent encounter
X838XXS	Intentional self-harm by other specified means, sequela
Z554	Educational maladjustement and discord with teachers and classmates
Z563	Stressful work schedule
Z564	Discord with boss and workmates
Z5681	Sexual harassment on the job
Z592	Discord with neighbors, lodgers and landlord
Z600	Problems of adjustment to life-cycle transitions
Z603	Acculturation difficulty
Z604	Social exclusion and rejection
Z605	Target of (perceived) adverse discrimination and persecution
Z620	Inadequate parental supervision and control
Z621	Parental overprotection
Z6222	Institutional upbringing
Z6229	Other upbringing away from parents
Z623	Hostility towards and scapegoating of child
Z626	Inappropriate (excessive) parental pressure
Z62810	Personal history of physical and sexual abuse in childhood
Z62811	Personal history or psychological abuse in childhood
Z62812	Personal history of neglect in childhood
Z62813	Personal history of forced labor or sexual exploitation in childhood
Z62819	Personal history of unspecified abuse in childhood
Z62820	Parent-biological child conflict
Z62821	Parent-adopted child conflict
Z62822	Parent-foster child conflict
Z62890	Parent-child estrangement NEC
Z62891	Sibling rivalry
Z62898	Other specified problems related to upbringing
Z629	Problem related to upbringing, unspecified
Z630	Problems in relationship with spouse or partner
Z631	Problems in relationship with in-laws
Z634	Disappearance and death of family member
Z635	Disruption of family by separation and divorce
Z6371	Stress on family due to return of family member from military deployment
Z6372	Alcoholism and drug addiction in family
_00/2	1

Code	Shortened Description
Z6379	Other stressful life events affecting family and household
Z638	Other specified problems related to primary support group
Z644	Discord with counselors
Z658	Other specified problems related to psychosocial circumstances
Z69010	Encounter for mental health services for victim of parental child abuse
Z69011	Encounter for mental health services for perpetrator of parental child abuse
Z69020	Encounter for mental health services for victim of non-parental child abuse
Z69021	Encounter for mental health services for perpetrator of non-parental child abuse
Z6911	Encounter for mental health services for victim of spousal or partner abuse
Z6912	Encounter for mental health services for perpetrator of spousal or partner abuse
Z6981	Encounter for mental health services for victim of other abuse
Z6982	Encounter for mental health services for perpetrator of other abuse
Z700	Counseling related to sexual attitude
Z701	Counseling related to sexual attitude  Counseling related to patient's sexual behavior and orientation
Z702	Counseling related to sexual behavior and orientation of third party
Z703	Counseling related to combined concerns regarding sexual attitude, behavior and orientation
Z708	Other sex counseling
Z709	Sex counseling, unspecified
Z7141	Alcohol abuse counseling and surveillance of alcoholic
Z7142	Counseling for family member of alcoholic
Z7151	Drug abuse counseling and surveillance of drug abuser
Z7151 Z7152	Counseling for family member of drug abuser
Z7189	Other specified counseling
Z7251	High risk heterosexual behavior
Z7252	High risk homosexual behavior
Z7253	High risk bisexual behavior
Z726	Gambling and betting
Z72810	Child and adolescent antisocial behavior
Z72811	Adult antisocial behavior
Z72820	Sleep deprivation
Z7289	Other problems related to lifestyle
Z730	Burn-out
Z731	Type A behavior pattern
Z733	Stress, not elsewhere classified
Z734	Inadequate social skills, not elsewhere classified
Z735	Social role conflict, not elsewhere classified
Z73810	Behavioral insomnia of childhood, sleep-onset association type
Z73810 Z73811	Behavioral insomnia of childhood, limit setting type
Z73812	Behavioral insomnia of childhood, combined type
Z73819	Behavioral insomnia of childhood, unspecified type
Z73819 Z7389	Other problems related to life management difficulty
Z8651	Personal history of combat and operational stress reaction
Z8659	Personal history of other mental and behavioral disorders
Z87820	Personal history of traumatic brain injury
Z91410	Personal history of adult physical and sexual abuse
Z91410 Z91411	Personal history of adult psychological abuse
Z91411 Z91412	Personal history of adult neglect
Z91412 Z91419	Personal history of unspecified adult abuse
Z91419 Z9142	Personal history of forced labor or sexual exploitation
Z9142 Z9149	Other personal history of psychological trauma, not elsewhere classified
Z9149 Z915	Personal history of self-harm
<b>ム</b> フ1フ	ji Gisonai misiory of sen-natin

**OP Table 8.0: Ischemic Hemorrhagic Stroke** 

Shortean Description  Montraumatic subarachnoid hemorrhage from unspecified carotid siphon and bifurcation  Montraumatic subarachnoid hemorrhage from fight carotid siphon and bifurcation  Montraumatic subarachnoid hemorrhage from len carotid siphon and bifurcation  Montraumatic subarachnoid hemorrhage from unspecified middle cerebral artery  Montraumatic subarachnoid hemorrhage from gipht carotid siphon and bifurcation  Montraumatic subarachnoid hemorrhage from len middle cerebral artery  Montraumatic subarachnoid hemorrhage from self posterior communicating artery  Montraumatic subarachnoid hemorrhage from self posterior communicating artery  Montraumatic subarachnoid hemorrhage from pight posterior communicating artery  Montraumatic subarachnoid hemorrhage from pight posterior communicating artery  Montraumatic subarachnoid hemorrhage from pight vertebral artery  Montraumatic subarachnoid hemorrhage from pight vertebral artery  Montraumatic subarachnoid hemorrhage from other intracranial arteries  Montraumatic subarachnoid hemorrhage from other intracranial arteries  Montraumatic subarachnoid hemorrhage from other intracranial artery  Montraumatic subarachnoid hemorrhage from other intracranial artery  Montraumatic subarachnoid hemorrhage from subspecified  Nontraumatic intracerebral hemorrhage in hemisphere, subcortical  Montraumatic intracerebral hemorrhage in hemisphere, subcortical  Montraumatic intracerebral hemorrhage in hemisphere, unspecified  Nontraumatic intracerebral hemorrhage in hemisphere, unspecified  Nontraumatic intracerebral hemorrhage in propertical artery  Montraumatic intracerebral hemorrhage in propertical artery  Montraumatic intracerebral hemorrhage, intravertical artery  Montraumatic intracerebral hemorrhage, intravertical artery  Montraumatic intracerebral hemorrhage, intrav	C. I.	OP Table 8.0: Ischemic Hemorrhagic Stroke
Montraumatic subarachmoid hemorrhage from right carotid siphon and bifurcation	Code	Shortened Description
Nontraumatic subarachnoid hemorrhage from left carotid sipton and bifurcation		· · · · · · · · · · · · · · · · · · ·
Nontraumatic subarachnoid hemorrhage from unspecified middle cerebral artery		i i
Nontraumatic subarachnoid hemorrhage from right middle cerebral artery		
Nontraumatic subarachnoid hemorrhage from left middle cerebral artery		
Nontraumatic subarachnoid hemorrhage from anterior communicating artery		
Nontraumatic subarachnoid hemorrhage from unspecified posterior communicating artery		- :
Nontraumatic subarachnoid hemorrhage from right posterior communicating artery		, ,
Nontraumatic subarachnoid hemorrhage from left posterior communicating artery		
Nontraumatic subarachnoid hemorrhage from basilar artery		
Nontraumatic subarachnoid bemorrhage from unspecified vertebral artery		
Nontraumatic subarachnoid hemorrhage from right vertebral artery		
Nontraumatic subarachnoid hemorrhage from left vertebral artery		
Nontraumatic subarachnoid hemorrhage from other intracranial arteries		· · ·
Nontraumatic subarachnoid hemorrhage from unspecified intracranial artery		
Other nontraumatic subarachnoid hemorrhage, unspecified		-
Nontraumatic subarachnoid hemorrhage, unspecified		
Nontraumatic intracerebral hemorrhage in hemisphere, subcortical		
Nontraumatic intracerebral hemorrhage in hemisphere, cortical		
Nontraumatic intracerebral hemorrhage in brain stem		
Nontraumatic intracerebral hemorrhage in brain stem		
1614         Nontraumatic intracerebral hemorrhage in cerebellum           1615         Nontraumatic intracerebral hemorrhage, intraventricular           1616         Nontraumatic intracerebral hemorrhage, multiple localized           1618         Other nontraumatic intracerebral hemorrhage           1619         Nontraumatic intracerebral hemorrhage, unspecified           1629         Nontraumatic intracerabial hemorrhage, unspecified           16300         Cerebral infarction due to thrombosis of unspecified precerebral artery           163011         Cerebral infarction due to thrombosis of pith vertebral artery           163012         Cerebral infarction due to thrombosis of pith vertebral artery           163013         Cerebral infarction due to thrombosis of bilateral vertebral artery           163019         Cerebral infarction due to thrombosis of basilar artery           16302         Cerebral infarction due to thrombosis of right carotid artery           163031         Cerebral infarction due to thrombosis of left carotid artery           163032         Cerebral infarction due to thrombosis of bilateral carotid artery           163033         Cerebral infarction due to thrombosis of unspecified arotid artery           163039         Cerebral infarction due to moblosis of other precerebral artery           16310         Cerebral infarction due to embolism of unspecified precerebral artery		
Nontraumatic intracerebral hemorrhage, intraventricular		-
1616         Nontraumatic intracerebral hemorrhage, multiple localized           1618         Other nontraumatic intracerebral hemorrhage           1619         Nontraumatic intracerebral hemorrhage, unspecified           1629         Nontraumatic intracerial hemorrhage, unspecified           16300         Cerebral infarction due to thrombosis of unspecified precerebral artery           163011         Cerebral infarction due to thrombosis of right vertebral artery           163012         Cerebral infarction due to thrombosis of bilateral vertebral artery           163013         Cerebral infarction due to thrombosis of bilateral vertebral artery           163019         Cerebral infarction due to thrombosis of unspecified vertebral artery           16302         Cerebral infarction due to thrombosis of left carotid artery           163031         Cerebral infarction due to thrombosis of left carotid artery           163032         Cerebral infarction due to thrombosis of bilateral carotid artery           163039         Cerebral infarction due to thrombosis of unspecified carotid artery           16310         Cerebral infarction due to embolism of unspecified precerebral artery           16311         Cerebral infarction due to embolism of pight vertebral artery           163112         Cerebral infarction due to embolism of bilateral vertebral artery           16312         Cerebral infarction due to embolism of bilateral verte		-
1618         Other nontraumatic intracerebral hemorrhage           1619         Nontraumatic intracerebral hemorrhage, unspecified           1620         Nontraumatic intracranial hemorrhage, unspecified           16300         Cerebral infarction due to thrombosis of unspecified precerebral artery           163011         Cerebral infarction due to thrombosis of left vertebral artery           163012         Cerebral infarction due to thrombosis of belf vertebral artery           163013         Cerebral infarction due to thrombosis of bilateral vertebral artery           163019         Cerebral infarction due to thrombosis of basilar artery           163020         Cerebral infarction due to thrombosis of basilar artery           163031         Cerebral infarction due to thrombosis of left carotid artery           163032         Cerebral infarction due to thrombosis of left carotid artery           163033         Cerebral infarction due to thrombosis of bilateral carotid artery           163030         Cerebral infarction due to thrombosis of unspecified carotid artery           163031         Cerebral infarction due to thrombosis of unspecified carotid artery           163039         Cerebral infarction due to embolism of unspecified precerebral artery           16310         Cerebral infarction due to embolism of pight vertebral artery           163111         Cerebral infarction due to embolism of left vertebral artery		
Nontraumatic intracerebral hemorrhage, unspecified		
1629   Nontraumatic intracranial hemorrhage, unspecified   16300   Cerebral infarction due to thrombosis of unspecified precerebral artery   163011   Cerebral infarction due to thrombosis of left vertebral artery   163012   Cerebral infarction due to thrombosis of left vertebral arteries   163013   Cerebral infarction due to thrombosis of bilateral vertebral arteries   163019   Cerebral infarction due to thrombosis of unspecified vertebral artery   16302   Cerebral infarction due to thrombosis of unspecified vertebral artery   163031   Cerebral infarction due to thrombosis of right carotid artery   163032   Cerebral infarction due to thrombosis of left carotid artery   163033   Cerebral infarction due to thrombosis of bilateral carotid arteries   163039   Cerebral infarction due to thrombosis of bilateral carotid artery   16309   Cerebral infarction due to thrombosis of unspecified carotid artery   16310   Cerebral infarction due to embolism of unspecified precerebral artery   163111   Cerebral infarction due to embolism of unspecified precerebral artery   163112   Cerebral infarction due to embolism of left vertebral artery   163113   Cerebral infarction due to embolism of bilateral vertebral artery   163110   Cerebral infarction due to embolism of unspecified vertebral artery   163111   Cerebral infarction due to embolism of bilateral vertebral artery   163112   Cerebral infarction due to embolism of unspecified vertebral artery   163131   Cerebral infarction due to embolism of bilateral vertebral artery   163132   Cerebral infarction due to embolism of bilateral carotid artery   163133   Cerebral infarction due to embolism of left carotid artery   163134   Cerebral infarction due to embolism of bilateral carotid artery   163135   Cerebral infarction due to embolism of bilateral carotid arteries   163139   Cerebral infarction due to embolism of bilateral carotid arteries   163139   Cerebral infarction due to embolism of bilateral carotid artery   163139   Cerebral infarction due to embolism of bilateral car		
I6300       Cerebral infarction due to thrombosis of unspecified precerebral artery         I63011       Cerebral infarction due to thrombosis of left vertebral artery         I63012       Cerebral infarction due to thrombosis of left vertebral artery         I63013       Cerebral infarction due to thrombosis of bilateral vertebral arteries         I63019       Cerebral infarction due to thrombosis of unspecified vertebral artery         I6302       Cerebral infarction due to thrombosis of basilar artery         I63031       Cerebral infarction due to thrombosis of right carotid artery         I63032       Cerebral infarction due to thrombosis of left carotid artery         I63033       Cerebral infarction due to thrombosis of bilateral carotid artery         I6309       Cerebral infarction due to thrombosis of unspecified carotid artery         I6310       Cerebral infarction due to embolism of unspecified precerebral artery         I63111       Cerebral infarction due to embolism of right vertebral artery         I63112       Cerebral infarction due to embolism of bilateral vertebral arteries         I63119       Cerebral infarction due to embolism of basilar artery         I6312       Cerebral infarction due to embolism of basilar artery         I6313       Cerebral infarction due to embolism of fight carotid artery         I63130       Cerebral infarction due to embolism of lateral carotid artery <tr< td=""><td></td><td></td></tr<>		
163011 Cerebral infarction due to thrombosis of right vertebral artery 163012 Cerebral infarction due to thrombosis of left vertebral artery 163013 Cerebral infarction due to thrombosis of bilateral vertebral arteries 163019 Cerebral infarction due to thrombosis of unspecified vertebral artery 16302 Cerebral infarction due to thrombosis of basilar artery 163031 Cerebral infarction due to thrombosis of right carotid artery 163032 Cerebral infarction due to thrombosis of left carotid artery 163033 Cerebral infarction due to thrombosis of left carotid arteries 163039 Cerebral infarction due to thrombosis of bilateral carotid artery 16310 Cerebral infarction due to thrombosis of other precerebral artery 16311 Cerebral infarction due to embolism of unspecified precerebral artery 16311 Cerebral infarction due to embolism of right vertebral artery 16311 Cerebral infarction due to embolism of bilateral vertebral arteries 16311 Cerebral infarction due to embolism of bilateral vertebral arteries 16311 Cerebral infarction due to embolism of bilateral vertebral arteries 163110 Cerebral infarction due to embolism of bilateral vertebral arteries 163111 Cerebral infarction due to embolism of bilateral vertebral arteries 163112 Cerebral infarction due to embolism of bilateral vertebral artery 16312 Cerebral infarction due to embolism of bilateral vertebral artery 16313 Cerebral infarction due to embolism of right carotid artery 16313 Cerebral infarction due to embolism of left carotid artery 16313 Cerebral infarction due to embolism of left carotid artery 16313 Cerebral infarction due to embolism of left carotid artery 16313 Cerebral infarction due to embolism of bilateral carotid artery 16313 Cerebral infarction due to embolism of bilateral carotid artery 16314 Cerebral infarction due to embolism of bilateral carotid artery 16315 Cerebral infarction due to embolism of bilateral carotid artery 16316 Cerebral infarction due to embolism of the precerebral artery		
163012       Cerebral infarction due to thrombosis of left vertebral artery         163013       Cerebral infarction due to thrombosis of bilateral vertebral arteries         163019       Cerebral infarction due to thrombosis of unspecified vertebral artery         16302       Cerebral infarction due to thrombosis of basilar artery         163031       Cerebral infarction due to thrombosis of right carotid artery         163032       Cerebral infarction due to thrombosis of left carotid artery         163033       Cerebral infarction due to thrombosis of bilateral carotid arteries         163039       Cerebral infarction due to thrombosis of other precerebral artery         16310       Cerebral infarction due to embolism of unspecified precerebral artery         163111       Cerebral infarction due to embolism of right vertebral artery         163112       Cerebral infarction due to embolism of bilateral vertebral arteries         163119       Cerebral infarction due to embolism of unspecified vertebral artery         16312       Cerebral infarction due to embolism of basilar artery         16313       Cerebral infarction due to embolism of pright carotid artery         16313       Cerebral infarction due to embolism of left carotid artery         16313       Cerebral infarction due to embolism of left carotid artery         163139       Cerebral infarction due to embolism of unspecified carotid artery      <		
163013       Cerebral infarction due to thrombosis of bilateral vertebral arteries         163019       Cerebral infarction due to thrombosis of unspecified vertebral artery         16302       Cerebral infarction due to thrombosis of basilar artery         163031       Cerebral infarction due to thrombosis of left carotid artery         163032       Cerebral infarction due to thrombosis of left carotid artery         163033       Cerebral infarction due to thrombosis of bilateral carotid artery         16309       Cerebral infarction due to thrombosis of unspecified artery         16310       Cerebral infarction due to embolism of unspecified precerebral artery         163111       Cerebral infarction due to embolism of right vertebral artery         163112       Cerebral infarction due to embolism of bilateral vertebral arteries         163119       Cerebral infarction due to embolism of busilateral vertebral artery         16312       Cerebral infarction due to embolism of basilar artery         16313       Cerebral infarction due to embolism of basilar artery         16313       Cerebral infarction due to embolism of left carotid artery         16313       Cerebral infarction due to embolism of left carotid artery         163130       Cerebral infarction due to embolism of left carotid artery         163131       Cerebral infarction due to embolism of bilateral carotid artery         163132 <td></td> <td>·</td>		·
Cerebral infarction due to thrombosis of unspecified vertebral artery     16302   Cerebral infarction due to thrombosis of basilar artery     163031   Cerebral infarction due to thrombosis of right carotid artery     163032   Cerebral infarction due to thrombosis of left carotid artery     163033   Cerebral infarction due to thrombosis of bilateral carotid arteries     16304   Cerebral infarction due to thrombosis of unspecified carotid artery     16309   Cerebral infarction due to thrombosis of other precerebral artery     16310   Cerebral infarction due to embolism of unspecified precerebral artery     163111   Cerebral infarction due to embolism of right vertebral artery     163112   Cerebral infarction due to embolism of bilateral vertebral arteries     163113   Cerebral infarction due to embolism of bilateral vertebral artery     16312   Cerebral infarction due to embolism of basilar artery     16313   Cerebral infarction due to embolism of pasilar artery     16313   Cerebral infarction due to embolism of left carotid artery     16313   Cerebral infarction due to embolism of bilateral carotid artery     16313   Cerebral infarction due to embolism of bilateral carotid artery     16313   Cerebral infarction due to embolism of bilateral carotid artery     16313   Cerebral infarction due to embolism of bilateral carotid artery     16313   Cerebral infarction due to embolism of bilateral carotid artery     16314   Cerebral infarction due to embolism of bilateral carotid artery     16315   Cerebral infarction due to embolism of unspecified carotid artery     16316   Cerebral infarction due to embolism of unspecified carotid artery     16317   Cerebral infarction due to embolism of unspecified carotid artery     16318   Cerebral infarction due to embolism of other precerebral artery		•
16302       Cerebral infarction due to thrombosis of basilar artery         163031       Cerebral infarction due to thrombosis of right carotid artery         163032       Cerebral infarction due to thrombosis of left carotid artery         163033       Cerebral infarction due to thrombosis of bilateral carotid artery         16309       Cerebral infarction due to thrombosis of other precerebral artery         16310       Cerebral infarction due to embolism of unspecified precerebral artery         163111       Cerebral infarction due to embolism of right vertebral artery         163112       Cerebral infarction due to embolism of left vertebral artery         163113       Cerebral infarction due to embolism of bilateral vertebral arteries         163119       Cerebral infarction due to embolism of basilar artery         16312       Cerebral infarction due to embolism of basilar artery         163131       Cerebral infarction due to embolism of right carotid artery         163132       Cerebral infarction due to embolism of left carotid artery         163133       Cerebral infarction due to embolism of bilateral carotid arteries         163139       Cerebral infarction due to embolism of unspecified carotid artery         16319       Cerebral infarction due to embolism of other precerebral artery		
163031Cerebral infarction due to thrombosis of right carotid artery163032Cerebral infarction due to thrombosis of left carotid artery163033Cerebral infarction due to thrombosis of bilateral carotid arteries163039Cerebral infarction due to thrombosis of unspecified carotid artery16309Cerebral infarction due to embolism of unspecified precerebral artery16310Cerebral infarction due to embolism of unspecified precerebral artery163111Cerebral infarction due to embolism of right vertebral artery163112Cerebral infarction due to embolism of left vertebral artery163113Cerebral infarction due to embolism of bilateral vertebral arteries163119Cerebral infarction due to embolism of unspecified vertebral artery16312Cerebral infarction due to embolism of basilar artery163131Cerebral infarction due to embolism of right carotid artery163132Cerebral infarction due to embolism of left carotid artery163133Cerebral infarction due to embolism of bilateral carotid arteries163139Cerebral infarction due to embolism of unspecified carotid artery16319Cerebral infarction due to embolism of other precerebral artery		
I63032Cerebral infarction due to thrombosis of left carotid arteryI63033Cerebral infarction due to thrombosis of bilateral carotid arteriesI6309Cerebral infarction due to thrombosis of other precerebral arteryI6310Cerebral infarction due to embolism of unspecified precerebral arteryI6311Cerebral infarction due to embolism of right vertebral arteryI63112Cerebral infarction due to embolism of left vertebral arteryI63113Cerebral infarction due to embolism of bilateral vertebral arteriesI63119Cerebral infarction due to embolism of unspecified vertebral arteryI6312Cerebral infarction due to embolism of basilar arteryI63131Cerebral infarction due to embolism of right carotid arteryI63132Cerebral infarction due to embolism of left carotid arteryI63133Cerebral infarction due to embolism of bilateral carotid arteriesI63139Cerebral infarction due to embolism of unspecified carotid arteryI6319Cerebral infarction due to embolism of other precerebral artery		·
I63033Cerebral infarction due to thrombosis of bilateral carotid arteriesI63039Cerebral infarction due to thrombosis of unspecified carotid arteryI6309Cerebral infarction due to thrombosis of other precerebral arteryI6310Cerebral infarction due to embolism of unspecified precerebral arteryI63111Cerebral infarction due to embolism of right vertebral arteryI63112Cerebral infarction due to embolism of bilateral vertebral arteriesI63113Cerebral infarction due to embolism of unspecified vertebral arteryI63119Cerebral infarction due to embolism of basilar arteryI6312Cerebral infarction due to embolism of right carotid arteryI63131Cerebral infarction due to embolism of left carotid arteryI63132Cerebral infarction due to embolism of bilateral carotid arteriesI63133Cerebral infarction due to embolism of bilateral carotid arteriesI63139Cerebral infarction due to embolism of other precerebral arteryI6319Cerebral infarction due to embolism of other precerebral artery		
I63039Cerebral infarction due to thrombosis of unspecified carotid arteryI6309Cerebral infarction due to thrombosis of other precerebral arteryI6310Cerebral infarction due to embolism of unspecified precerebral arteryI63111Cerebral infarction due to embolism of right vertebral arteryI63112Cerebral infarction due to embolism of belt vertebral arteryI63113Cerebral infarction due to embolism of bilateral vertebral arteriesI63119Cerebral infarction due to embolism of unspecified vertebral arteryI6312Cerebral infarction due to embolism of basilar arteryI63131Cerebral infarction due to embolism of right carotid arteryI63132Cerebral infarction due to embolism of belft carotid arteryI63133Cerebral infarction due to embolism of bilateral carotid arteriesI63139Cerebral infarction due to embolism of unspecified carotid arteryI6319Cerebral infarction due to embolism of other precerebral artery		
I6309Cerebral infarction due to thrombosis of other precerebral arteryI6310Cerebral infarction due to embolism of unspecified precerebral arteryI63111Cerebral infarction due to embolism of right vertebral arteryI63112Cerebral infarction due to embolism of left vertebral arteryI63113Cerebral infarction due to embolism of bilateral vertebral arteriesI63119Cerebral infarction due to embolism of unspecified vertebral arteryI6312Cerebral infarction due to embolism of basilar arteryI63131Cerebral infarction due to embolism of right carotid arteryI63132Cerebral infarction due to embolism of left carotid arteryI63133Cerebral infarction due to embolism of bilateral carotid arteriesI63139Cerebral infarction due to embolism of unspecified carotid arteryI6319Cerebral infarction due to embolism of other precerebral artery		
I6310Cerebral infarction due to embolism of unspecified precerebral arteryI63111Cerebral infarction due to embolism of right vertebral arteryI63112Cerebral infarction due to embolism of left vertebral arteryI63113Cerebral infarction due to embolism of bilateral vertebral arteriesI63119Cerebral infarction due to embolism of unspecified vertebral arteryI6312Cerebral infarction due to embolism of basilar arteryI63131Cerebral infarction due to embolism of right carotid arteryI63132Cerebral infarction due to embolism of left carotid arteryI63133Cerebral infarction due to embolism of bilateral carotid arteriesI63139Cerebral infarction due to embolism of unspecified carotid arteryI6319Cerebral infarction due to embolism of other precerebral artery		
I63111Cerebral infarction due to embolism of right vertebral arteryI63112Cerebral infarction due to embolism of left vertebral arteryI63113Cerebral infarction due to embolism of bilateral vertebral arteriesI63119Cerebral infarction due to embolism of unspecified vertebral arteryI6312Cerebral infarction due to embolism of basilar arteryI63131Cerebral infarction due to embolism of right carotid arteryI63132Cerebral infarction due to embolism of left carotid arteryI63133Cerebral infarction due to embolism of bilateral carotid arteriesI63139Cerebral infarction due to embolism of unspecified carotid arteryI6319Cerebral infarction due to embolism of other precerebral artery		. · · · · ·
I63112Cerebral infarction due to embolism of left vertebral arteryI63113Cerebral infarction due to embolism of bilateral vertebral arteriesI63119Cerebral infarction due to embolism of unspecified vertebral arteryI6312Cerebral infarction due to embolism of basilar arteryI63131Cerebral infarction due to embolism of right carotid arteryI63132Cerebral infarction due to embolism of left carotid arteryI63133Cerebral infarction due to embolism of bilateral carotid arteriesI63139Cerebral infarction due to embolism of unspecified carotid arteryI6319Cerebral infarction due to embolism of other precerebral artery		
I63113Cerebral infarction due to embolism of bilateral vertebral arteriesI63119Cerebral infarction due to embolism of unspecified vertebral arteryI6312Cerebral infarction due to embolism of basilar arteryI63131Cerebral infarction due to embolism of right carotid arteryI63132Cerebral infarction due to embolism of left carotid arteryI63133Cerebral infarction due to embolism of bilateral carotid arteriesI63139Cerebral infarction due to embolism of unspecified carotid arteryI6319Cerebral infarction due to embolism of other precerebral artery		- · ·
I63119Cerebral infarction due to embolism of unspecified vertebral arteryI6312Cerebral infarction due to embolism of basilar arteryI63131Cerebral infarction due to embolism of right carotid arteryI63132Cerebral infarction due to embolism of left carotid arteryI63133Cerebral infarction due to embolism of bilateral carotid arteriesI63139Cerebral infarction due to embolism of unspecified carotid arteryI6319Cerebral infarction due to embolism of other precerebral artery		
I6312       Cerebral infarction due to embolism of basilar artery         I63131       Cerebral infarction due to embolism of right carotid artery         I63132       Cerebral infarction due to embolism of left carotid artery         I63133       Cerebral infarction due to embolism of bilateral carotid arteries         I63139       Cerebral infarction due to embolism of unspecified carotid artery         I6319       Cerebral infarction due to embolism of other precerebral artery	I63113	
I63131       Cerebral infarction due to embolism of right carotid artery         I63132       Cerebral infarction due to embolism of left carotid artery         I63133       Cerebral infarction due to embolism of bilateral carotid arteries         I63139       Cerebral infarction due to embolism of unspecified carotid artery         I6319       Cerebral infarction due to embolism of other precerebral artery		· · · · · · · · · · · · · · · · · · ·
I63132       Cerebral infarction due to embolism of left carotid artery         I63133       Cerebral infarction due to embolism of bilateral carotid arteries         I63139       Cerebral infarction due to embolism of unspecified carotid artery         I6319       Cerebral infarction due to embolism of other precerebral artery		·
I63133       Cerebral infarction due to embolism of bilateral carotid arteries         I63139       Cerebral infarction due to embolism of unspecified carotid artery         I6319       Cerebral infarction due to embolism of other precerebral artery		·
I63139 Cerebral infarction due to embolism of unspecified carotid artery I6319 Cerebral infarction due to embolism of other precerebral artery	I63132	Cerebral infarction due to embolism of left carotid artery
I6319 Cerebral infarction due to embolism of other precerebral artery	I63133	Cerebral infarction due to embolism of bilateral carotid arteries
·	I63139	Cerebral infarction due to embolism of unspecified carotid artery
I6320 Cerebral infarction due to unspecified occlusion or stenosis of unspecified precerebral arteries		·
	16320	Cerebral infarction due to unspecified occlusion or stenosis of unspecified precerebral arteries

Code	Shortened Description
I63211	Cerebral infarction due to unspecified occlusion or stenosis of right vertebral artery
I63212	Cerebral infarction due to unspecified occlusion or stenosis of left vertebral artery
I63213	Cerebral infarction due to unspecified occlusion or stenosis of bilateral vertebral arteries
I63219	Cerebral infarction due to unspecified occlusion or stenosis of unspecified vertebral artery
I6322	Cerebral infarction due to unspecified occlusion or stenosis of basilar artery
I63231	Cerebral infarction due to unspecified occlusion or stenosis of right carotid arteries
I63232	Cerebral infarction due to unspecified occlusion or stenosis of left carotid arteries
I63233	Cerebral infarction due to unspecified occlusion or stenosis of bilateral carotid arteries
I63239	Cerebral infarction due to unspecified occlusion or stenosis of unspecified carotid artery
I6329	Cerebral infarction due to unspecified occlusion or stenosis of other precerebral arteries
I6330	Cerebral infarction due to thrombosis of unspecified cerebral artery
I63311	Cerebral infarction due to thrombosis of right middle cerebral artery
I63312	Cerebral infarction due to thrombosis of left middle cerebral artery
I63313	Cerebral infarction due to thrombosis of bilateral middle cerebral arteries
I63319	Cerebral infarction due to thrombosis of unspecified middle cerebral artery
I63321	Cerebral infarction due to thrombosis of right anterior cerebral artery
I63322	Cerebral infarction due to thrombosis of left anterior cerebral artery
I63323	Cerebral infarction due to thrombosis of bilateral anterior cerebral arteries
I63329	Cerebral infarction due to thrombosis of unspecified anterior cerebral artery
I63331	Cerebral infarction due to thrombosis of right posterior cerebral artery
I63332	Cerebral infarction due to thrombosis of left posterior cerebral artery
I63333	Cerebral infarction due to thrombosis of bilateral posterior cerebral arteries
I63339	Cerebral infarction due to thrombosis of unspecified posterior cerebral artery
I63341	Cerebral infarction due to thrombosis of right cerebellar artery
I63342	Cerebral infarction due to thrombosis of left cerebellar artery
I63343	Cerebral infarction due to thrombosis of bilateral cerebellar arteries
I63349	Cerebral infarction due to thrombosis of unspecified cerebellar artery
I6339	Cerebral infarction due to thrombosis of other cerebral artery
I6340	Cerebral infarction due to embolism of unspecified cerebral artery
I63411	Cerebral infarction due to embolism of right middle cerebral artery
I63412	Cerebral infarction due to embolism of left middle cerebral artery
I63413	Cerebral infarction due to embolism of bilateral middle cerebral arteries
I63419	Cerebral infarction due to embolism of unspecified middle cerebral artery
I63421	Cerebral infarction due to embolism of right anterior cerebral artery
I63422	Cerebral infarction due to embolism of left anterior cerebral artery
I63423	Cerebral infarction due to embolism of bilateral anterior cerebral arteries
I63429	Cerebral infarction due to embolism of unspecified anterior cerebral artery
I63431	Cerebral infarction due to embolism of right posterior cerebral artery
I63432	Cerebral infarction due to embolism of left posterior cerebral artery
I63433	Cerebral infarction due to embolism of bilateral posterior cerebral arteries
I63439	Cerebral infarction due to embolism of unspecified posterior cerebral artery
I63441	Cerebral infarction due to embolism of right cerebellar artery
I63442	Cerebral infarction due to embolism of left cerebellar artery
I63443	Cerebral infarction due to embolism of bilateral cerebellar arteries
I63449	Cerebral infarction due to embolism of unspecified cerebellar artery
I6349	Cerebral infarction due to embolism of other cerebral artery
I6350	Cerebral infarction due to unspecified occlusion or stenosis of unspecified cerebral artery
I63511	Cerebral infarction due to unspecified occlusion or stenosis of right middle cerebral artery
I63512	Cerebral infarction due to unspecified occlusion or stenosis of left middle cerebral artery
I63513	Cerebral infarction due to unspecified occlusion or stenosis of bilateral middle cerebral arteries
I63519	Cerebral infarction due to unspecified occlusion or stenosis of unspecified middle cerebral artery
I63521	Cerebral infarction due to unspecified occlusion or stenosis of right anterior cerebral artery
100021	

Code	Shortened Description	
I63522	Cerebral infarction due to unspecified occlusion or stenosis of left anterior cerebral artery	
I63523	Cerebral infarction due to unspecified occlusion or stenosis of bilateral anterior cerebral arteries	
I63529	Cerebral infarction due to unspecified occlusion or stenosis of unspecified anterior cerebral artery	
I63531	Cerebral infarction due to unspecified occlusion or stenosis of right posterior cerebral artery	
I63532	Cerebral infarction due to unspecified occlusion or stenosis of left posterior cerebral artery	
I63533	Cerebral infarction due to unspecified occlusion or stenosis of bilateral posterior cerebral arteries	
I63539	Cerebral infarction due to unspecified occlusion or stenosis of unspecified posterior cerebral artery	
I63541	Cerebral infarction due to unspecified occlusion or stenosis of right cerebellar artery	
I63542	Cerebral infarction due to unspecified occlusion or stenosis of left cerebellar artery	
I63543	Cerebral infarction due to unspecified occlusion or stenosis of bilateral cerebellar arteries	
I63549	Cerebral infarction due to unspecified occlusion or stenosis of unspecified cerebellar artery	
I6359	Cerebral infarction due to unspecified occlusion or stenosis of other cerebral artery	
I636	Cerebral infarction due to cerebral venous thrombosis, nonpyogenic	
I6381	Other cerebral infarction due to occlusion or stenosis of small artery	
I6389	Other cerebral infarction	
I639	Cerebral infarction, unspecified	

#### Appendix B Glossary of Terms

accuracy (of data) The extent to which data are free of identifiable errors.

**acute myocardial infarction (AMI)** Death of heart muscle resulting from insufficient blood supply to the heart. For purposes of this measure, acute myocardial infarction is identified by the ICD-10-CM codes in Appendix A, Table 1.1.

administrative/billing data (data source) Data that generally reflects the content of discharge abstracts (for example, demographic information on patients such as age, sex, ZIP code; information about the episode of care such as admission source, length of stay, charges, discharge status; and diagnostic and procedural codes). Namely, the Uniform Hospital Discharge Data Set and the Uniform Bill of the Health Care Financing Administration (UB-04) provide specifications for the abstraction of administrative/billing data.

**algorithm** An ordered sequence of data element retrieval and aggregation through which numerator and denominator events or continuous variable values are identified by a measure. The algorithms are depicted using flowcharting symbols.

allowable values A list of acceptable responses for a data element.

**ANSI X12** The American National Standards Institute's standard for transmitting data electronically, or electronic data interchange (EDI).

**binary outcome** Events or conditions that occur in one or two possible states often labeled 0 or 1. Such data are frequently encountered in medical research. Common examples include dead or alive, and improved or not improved.

**central tendency** A property of the distribution of a variable, usually measured by statistics such as the mean, median, and mode.

**clinical measures** Measures designed to evaluate the processes or outcomes of care associated with the delivery of clinical services; allow for intra- and inter-organizational comparisons to be used to continuously improve patient health outcomes; may focus on the appropriateness of clinical decision-making and implementation of these decisions; must be condition-specific, procedure-specific, or address important functions of patient care.

**confounding factors** Intervening variables that distort the true relationship between/among the variables of interest. They are related to the outcome of interest, but extraneous to the study question and are non-randomly distributed among the groups being compared. They can hide a true correlation or give the appearance of a correlation when none actually exists.

**continuous variable** An aggregate data measure in which the value of each measurement can fall anywhere along a continuous scale (e.g., the time [in minutes] from emergency department arrival to administration of fibrinolytics).

**continuous variable data elements** Those data elements required to construct the measure as stated in the section labeled "Continuous Variable Statement."

**contraindication** A factor or condition that may render the administration of a drug or agent or the performance of a procedure or other practice inadvisable, improper, and/or undesirable.

Current Procedural Terminology (CPT®) code A listing of descriptive terms and identifying codes for reporting medical services and procedures performed by physicians.

critical access hospital (CAH) Hospitals that offer limited services to include round-the-clock emergency care services and are, by definition, located more than 35 miles from a hospital or another critical access hospital, or are certified by the state as being a necessary provider of healthcare services to residents in the area. They maintain no more than 25 beds for acute (hospital-level) inpatient care, subject to a 96-hour average length of stay for acute care patients. For CAHs with swing bed agreements, any of its beds may be used to furnish either inpatient acute care or swing bed services. Hospitals certified by the Secretary of the Department of Health and Human Services (DHHS) as critical access hospitals are eligible for cost-based reimbursement from Medicare if they meet a specific set of federal Conditions of Participation (COPs).

data collection The act or process of capturing raw or primary data from a single or number of sources; also called "data gathering."

**data collection effort** The availability and accessibility of the required data elements, the relative effort required, and associated cost of abstracting or collecting the data.

data editing The process of correcting erroneous or incomplete existing data, exclusive of data entry input edits.

**data element** A discrete piece of data, such as patient birthdate or principal diagnosis. See also denominator data elements, numerator data elements, and continuous variable data elements.

data entry The process by which data are transcribed or transferred into an electronic format.

**data point** The representation of a value for a set of observations or measurements at a specific time interval (e.g., perioperative mortality rate for the month of June 2019).

data quality The accuracy and completeness of measure data on performance in the context of the analytic purposes for which they will be used.

data sources The primary source document(s) used for data collection (for example, billing or administrative data, encounter form, enrollment forms, and medical record). See also administrative data, clinical survey, medical record, patient survey, provider data, and registry/log data.

data transmission The process by which data are electronically sent from one organization to another.

**denominator** The lower part of a fraction used to calculate a rate, proportion, or ratio. Also, the population for a rate-based measure.

denominator data elements Those data elements required to construct the denominator.

discrete variable See rate-based measure.

**electronic data interchange (EDI)** An instance of data being sent electronically between parties, normally according to predefined industry standards.

electrocardiogram (ECG) A graphic tracing of the heart's electrical impulses.

Hospital OQR Specifications Manual

**emergency department** A department that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment.

episode of care (EOC) A patient or case-level record submitted to the database.

**Evaluation and Management (E/M) codes** Codes used to report evaluation and management services provided in the physician's office, or in an outpatient or other ambulatory facility.

**excluded populations** Detailed information describing the populations that should not be included in the indicator. For example, specific age groups, ICD-10-CM procedure or diagnostic codes, or certain time periods could be excluded from the general population drawn upon by the indicator.

**fibrinolytic therapy** Administration of a pharmacological agent intended to cause lysis of a thrombus (destruction or dissolution of a blood clot). Refer to Appendix C, Table 1.3 for a listing of fibrinolytic agents.

**format** Specifies the character length of a specific data element; the type of information the data element contains: numeric, decimal number, date, time, or alphanumeric; and the frequency with which the data element occurs.

**general data elements** Data elements that must be collected by hospitals for each patient record. These data are patient demographic data, hospital identifiers, and patient identifiers.

**healthcare organization (HCO)** The business entity which is participating in a performance measurement system (e.g., healthcare organization level data describes information about the business entity).

**hospital** A healthcare organization that has a governing body; an organized medical and professional staff and inpatient facilities; and provides medical, nursing, and related services for ill and injured patients 24 hours per day, seven days per week. For licensing purposes, each state has its own definition of a hospital.

**hospitalist** A physician whose main practice provides care for hospitalized patients.

**ICD-10-CM codes** A two-part classification system in current use for coding patient medical information used in abstracting systems and for classifying patients into diagnosis-related groups (DRGs). The first part is a comprehensive list of diseases with corresponding codes compatible with the World Health Organization's list of disease codes. The second part contains procedure codes independent of the disease codes.

**included populations** Detailed information describing the population(s) that the indicator intends to measure. Details could include such information as specific age groups, diagnoses, ICD-10-CM diagnostic and procedure codes, CPT<sup>®</sup> codes, enrollment periods, insurance and health plan groups, etc.

**Inpatient Prospective Payment System (IPPS) Rule** A prospective payment system (PPS) under Medicare for hospital acute inpatient services. Hospitals contract with Medicare to furnish acute inpatient care and are reimbursed through pre-determined payment on a per discharge or per case basis for Medicare beneficiaries with inpatient stays.

**invalid data** Values for data elements that are required for calculating and/or risk adjusting a core measure that fall outside of the acceptable range of values defined for that data element. Refer to the Missing and Invalid Data section for further information.

**mean** A measure of central tendency for a continuous variable measure. The mean is the sum of the values divided by the number of observations.

Hospital OQR Specifications Manual

**measure information form** Tool to provide specific clinical and technical information on a measure. The information contained includes: performance measure name, description, rationale, numerator/denominator/continuous variable statements, included populations, excluded populations, data elements, risk adjustment, sampling, data accuracy, and selected references.

measure of performance See performance measure.

measure-related feedback Measure-related information on performance that is available, on a timely basis, to organizations actively participating in the performance measurement system for use in the organization's ongoing efforts to improve patient care and organizational performance. Feedback can be reflective of information within individual organizations (intra-organizational) and/or across organizations (inter-organizational).

measure-specific data elements Data elements used by one specific measure or several measures in one specific measure set.

**median** The value in a group of ranked observations that divides the data into two equal parts.

missing data No values present for one or more data elements that are required for calculating and/or risk adjusting a national hospital quality measure. Refer to the Missing and Invalid Data section for further information.

**mode** The most frequently occurring response for that data element.

module A set of measures under a common group/topic area (e.g., fibrinolytic module).

**monthly data point** The representation of a value for a set of observations or measurements for a calendar month.

**multivariate analysis** The analysis of the simultaneous relationships among variables.

**national quality measure** A standardized performance measure that meets the Centers for Medicare & Medicaid Services evaluation criteria, has precisely defined specifications, can be uniformly embedded in extant systems, has standardized data collection protocols to permit uniform implementation by healthcare organizations and permit comparisons of healthcare organization performance over time through the establishment of a national comparative database.

**nosocomial infection** An infection acquired by a patient in a healthcare organization, especially a hospital. This infection is not present or incubating before admission to a hospital.

**numerator** The upper portion of a fraction used to calculate a rate, proportion, or ratio.

**numerator data elements** Those data elements necessary or required to construct the numerator.

**observed rate** The observed rate is the measure rate that is based on a hospital's aggregated data for the reporting period. This is calculated as the number of measure numerator cases for the reporting period divided by the number of denominator cases. Observed rates are used to measure hospital performances.

**Outpatient Prospective Payment System (OPPS) Rule** A prospective payment system (PPS) under Medicare for hospital outpatient services, certain Part B services furnished to hospital inpatients that have no Part A coverage, and partial hospitalization services furnished by community mental health centers. All services paid under the PPS are classified into groups called Ambulatory Payment Classifications or APCs.

Hospital OQR Specifications Manual

A payment rate is established for each APC. Depending on the services provided, hospitals may be paid for more than one APC for an encounter.

**outpatient record (data source)** Data obtained from the records or documentation maintained on a patient in the hospital outpatient department setting (for example, hospital-based outpatient surgery, hospital-based clinic, emergency department). Includes automated and paper medical record systems.

**parenteral** Not through the alimentary canal but rather by injection through some other route, such as subcutaneous, intramuscular, intraorbital, intracapsular, intraspinal, intrasternal, intravenous, etc.

**patient factor** A variable describing some characteristic of individual patients that may influence healthcare-related outcomes. Patient factors can include:

- **complications** Conditions arising after the beginning of healthcare observation and treatment that modifies the course of the patient's health or illness and the intervention/care required.
- **co-morbidities** Pre-existing diseases or conditions.
- **severity of illness classifications** Seriousness or stage of illness at the time of the beginning of healthcare observation or treatment (for example, AJCC staging for oncology patients, NYHA class for cardiovascular patients).
- **functional status** Factors related to health status including physical functioning, role disability due to physical-health problems, bodily pain, general health perceptions, vitality, social functioning, role disability due to emotional problems, and general mental health.
- patient demographics Age, ethnicity, gender, location, etc.

**patient-level data** Collection of data elements that depict the healthcare services provided to an individual (patient). Patient-level data are aggregated to generate hospital-level data and comparison group data.

**percentile** A value on a scale of 100 that indicates the percentage of a distribution that is equal to or below it

**performance measure** A quantitative tool (for example, rate, ratio, index, percentage) that provides an indication of an organization's performance in relation to a specified process or outcome. See the process measure and the outcome measure.

**performance measurement system** An entity consisting of an automated database(s) that facilitates performance improvement in healthcare organizations through the collection and dissemination of process and/or outcome measures of performance. Measurement systems must be able to generate internal comparisons of organization performance over time, and external comparisons of performance among participating organizations at comparable times.

performance measure-related feedback See measure-related feedback.

**predicted value** The statistically expected response or outcome for a patient after the risk adjustment model has been applied and the patient's unique set of risk factors have been taken into account.

**process** An interrelated series of events, activities, actions, mechanisms, or steps that transform inputs into outputs.

**proportion measure** A measure which shows the number of occurrences over the entire group within which the occurrence should take place (e.g., patients delivered by cesarean section over all deliveries).

**provider data (data source)** Data obtained from other provider-generated records that are not necessarily contained in the medical record (e.g., pharmacy patient medication profiles, nursing care plans).

**randomization** A technique for selecting or assigning cases such that each case has an equal probability of being selected or assigned. It is done to stimulate chance distribution, reduce the effects of confounding factors, and produce unbiased statistical data.

range A measure of the spread of a data set; the difference between the smallest and largest observation.

**rate-based (measure)** An aggregate data measure in which the value of each measurement is expressed as a proportion or as a ratio. In a proportion, the numerator is expressed as a subset of the denominator (for example, patients with cesarean section, divided by all patients who deliver). In a ratio, the numerator and denominator measure different phenomena (for example, the number of patients with central lines who develop infections divided by the number of central line days).

**ratio** A relationship between two counted sets of data, which may have a value of zero or greater. In a ratio, the numerator is not necessarily a subset of the denominator (e.g., pints of blood transfused to number of patients discharged).

**registry/log data (data source)** Data obtained from local, regional, or national disease or procedure-related registries, data obtained from the healthcare organization's daily recordings (logs). Examples of such data include tumor, trauma, and cardiology registries. Examples of log data include infusion therapy, central line infection, and labor and delivery logs.

**regression coefficients** Synonym for regression weight which is derived from statistical modeling and expresses the change in a patient's response or outcome corresponding to a unit of change in the appropriate explanatory variable (i.e., patient risk factor).

relevance The applicability and/or pertinence of the indicator to its users and customers.

**reliability** The ability of the indicator to accurately and consistently identify the events it was designed to identify across multiple healthcare settings.

**reporting period** The defined time period which describes the patient's end-of-service.

**reperfusion** Re-establishing blood flow in an obstructed coronary artery. It may be accomplished with thrombolytic therapy or percutaneous coronary intervention.

**risk-adjusted measures** Measures that are risk-adjusted using statistical modeling or stratification methods.

**risk-adjusted rate** A rate that takes into account differences in case mix to allow for more valid comparisons between groups.

**sampling frequency** If a hospital chooses to sample, they may sample data on either a monthly or quarterly basis. Refer to the "Sample Size Requirements" discussion in the Population and Sampling Specifications section for further information.

**sampling method** Describes the process used to select a sample. Sampling approaches for national hospital quality measures are simple random sampling and systematic sampling. Refer to the "Sampling Approaches" discussion in the Population and Sampling Specifications section for further information.

**sample size** The number of individuals or particular patients included in a study, usually chosen so that the study has a particular statistical power of detecting an effect of a particular size. Refer to the "Sample Size Requirements" discussion in the Population and Sampling Specifications section for further information.

**score** A rating, usually expressed as a number, and based on the degree to which certain qualities or attributes are present (e.g., Glascow coma, ASA scores).

**severity** The degree of biomedical risk or mortality of medical treatment.

**simple random sample** A process in which a sample of data is selected from the total population in such a way that every case has the same chance of being selected and that the sample size is met. Refer to the "Sampling Approaches" discussion in the Population and Sampling Specifications section for further information.

**standard deviation** A measure of variability that indicates the dispersion, spread, or variation in a distribution.

strata See stratified measure.

**stratification** A form of risk adjustment, which involves classifying data into strata based on one or more characteristics, variables, or other categories.

**stratification-based approach for risk adjustment** The process of dividing or classifying subgroups known as strata in order to facilitate more valid comparisons. For example, a measure's outcome may be divided into type of surgery-specific categories or strata.

**stratified measure** A performance measure that is classified into a number of strata to assist in analysis and interpretation. The overall or un-stratified measure evaluates all of the strata together. The stratified measure or each stratum consists of a subset of the overall measure.

**stratum** See stratified measure.

**structure measure** A measure that assesses whether organizational resources and arrangements are in place to deliver healthcare, such as the number, type, and distribution of medical personnel, equipment, and facilities.

**systematic random sampling** A process in which the starting case is selected randomly, and the next cases are selected according to a fixed interval that is based upon the number of cases in the population. For example, the starting case is the second patient that arrives at the hospital. This patient and every subsequent fifth patient becomes part of the random sample until the sample size is reached. Refer to the "Sampling Approaches" discussion in the Population and Sampling Specifications section for further information.

**test cases** Fictitious patient-level data composed of clinical data elements that yield an expected result for a specific core measure algorithm.

thrombolytic therapy See fibrinolytic therapy.

transmission schedule The schedule of dates on which data are expected to be transmitted.

**unable to be determined (UTD)** Each data element that is applicable per the algorithm for each of the measures within a topic must be "touched" by the abstractor. While there is an expectation that all data elements are collected, it is recognized that in certain situations information may not be available (i.e., dates,

Hospital OQR Specifications Manual

times, codes, etc.). If, after due diligence, the abstractor determines that a value is not documented or is not able to determine the answer value, the abstractor must select "Unable to Determine (UTD)" as the answer.

validation The process by which the integrity and correctness of data are established. Validation processes can occur immediately after a data item is collected or after a complete set of data are collected. The Centers for Medicare & Medicaid Services (CMS) chart-level validation will validate the data at several levels. There are consistency and internal edit checks to assure the integrity of the submitted data, there are external edit checks to verify expectations about the volume of the data received, and there will be chart-level audits to assure the reliability of the submitted data. Information on these procedures is available on http://www.qualitynet.org.

**validity** Ability to identify opportunities for improvement in the quality of care, demonstration that the indicator uses results in improvements in outcomes and/or quality of care.

variance Equal to the square of the standard deviation.

**verification** The process used to ensure consistent implementation of core measure algorithms specified in this manual across disparate measurement systems.

#### **Selected Sources:**

- Babbie ER, The Practice of Social Research, 2<sup>nd</sup> edition, Belmont, CA: Wadsworth Publishing Company, 1979.
- Current Procedural Terminology (CPT®), 4rth edition, American Medical Association, 2007.
- Everitt, BS, The Cambridge Dictionary of Statistics, Cambridge University press, 1998.
- Iezonni LI, Foley SM, Heeran T, Daley J, Duncan CC, Fisher ES, Hughes J. "A Method for Screening the Quality of Hospital Care Uning Administrative Data: Preliminary Validation Results, "Quality Review Bulletin, November, 1992, 361-370.
- Lexikon Second Edition, Oakbrook Terrace, IL: Joint Commission on Accreditation of Healthcare Organizations, 1998.
- McHorney CA, Kosinsk, M, and Ware Jr. JE. "Comparisons of the Cost and Quality of Norms for the SF-36 Health Survey Collected by Mail Versus Telephone Interview: Results From a National Survey," Medical Care, 32, (1994), 551-567.
- Leon-Chisen N. ICD-10-CM and ICD-10-PCS Coding Handbook, 2014 Ed. with Answers Amer Hospital Assn; 2013.
- ORYX® technical Implementation Guide, Oakbrook Terrace, IL: Joint Commission on Accreditation of Healthcare Organizations, current.
- 2006 Accreditation Manual(s), Oakbrook Terrace, IL: Joint Commission in Accreditation of Healthcare Organizations, 2005.

# **Appendix C Medication Tables**

**Note:** The medication tables are not meant to be inclusive lists of all available therapeutic agents. Discrepancies must be reported.

#### Index

Number	Name	Page
Table 1.2	Warfarin	Appendix C-4
Table 1.3	Fibrinolytic Agents	Appendix C-4

#### **OP table 1.2 Warfarin**

Medication Name
Warfarin Sodium
Coumadin
Jantoven
Warfarin

**OP Table 1.3 Fibrinolytic Agents** 

Medication Name		
Activase		
Alteplase		
Anisoylated Plasminogen-Streptokinase Activator Complex		
APSAC		
Kabikinase		
Retavase		
Reteplase		
rPA (RPA)		
Streptase		
Streptokinase		
Tenecteplase		
Tissue plasminogen activator		
TNKase		
tPA (TPA)		

#### **Appendix D: Preview Section**

The Preview Section provides information on new measures. The information provided in this section should not be programmed or submitted. The measure(s) identified in this section are not currently collected.

No new measures have been introduced for the CY 2023 payment determination.

Hospitals that are excluded from payment under the OPPS are not required to report on the Hospital OQR program measures but may do so on a voluntary basis.